

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
7 March 2002 (07.03.2002)

PCT

(10) International Publication Number
WO 02/18557 A2(51) International Patent Classification⁷: C12N 9/00

(21) International Application Number: PCT/US01/27219

(22) International Filing Date: 31 August 2001 (31.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/229,873	31 August 2000 (31.08.2000)	US
60/231,357	8 September 2000 (08.09.2000)	US
60/232,654	14 September 2000 (14.09.2000)	US
60/234,902	22 September 2000 (22.09.2000)	US
60/236,499	29 September 2000 (29.09.2000)	US
60/238,389	6 October 2000 (06.10.2000)	US
60/240,542	13 October 2000 (13.10.2000)	US

(71) Applicant (for all designated States except US): INCYTE GENOMICS, INC. [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). NGUYEN, Danniell, B. [US/US]; 1403 Ridgewood Drive, San Jose, CA 95118 (US). WALIA, Narinder, K. [US/US]; 890 David Street, #205, San Leandro, CA 94577 (US). HAFALIA, April, J., A. [US/US]; 2227 Calle de Primavera, Santa Clara, CA 95054 (US). YAO, Monique, G. [US/US]; 111 Frederick Court, Mountain View, CA 94043 (US). GANDHI, Ameena, R. [US/US]; 837 Roble Avenue #1, Menlo Park, CA 94025 (US). GURURAJAN, Rajagopal [IN/US]; 5591 Dent Avenue, San Jose, CA 95118 (US). DING, Li [CN/US]; 3353 Alma Street #146, Palo Alto, CA 94306 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). TRIBOULEY, Catherine, M. [FR/US]; 1121 Tennessee Street #5, San Francisco, CA 94107 (US). THORNTON, Michael [US/US]; 9 Medway Road, Woodside, CA 94062-2612 (US). ELLIOTT, Vicki, S. [US/US]; 3770 Polton Place Way, San Jose, CA 95121 (US). LU, Yan [CN/US]; 3885 Corrina Way, Palo Alto, CA 94303 (US). ISON, Craig, H. [US/US]; 1242 Weathersfield Way, San Jose, CA 95118 (US). AU-YOUNG, Janice [US/US]; 233

Golden Eagle Lane, Brisbane, CA 94005 (US). TANG, Y., Tom [US/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). AZIMZAI, Yalda [US/US]; 5518 Boulder Canyon Drive, Castro Valley, CA 94552 (US). BURRILL, John, D. [US/US]; 650 Emerald Hill Road, Redwood City, CA 94061 (US). MARCUS, Gregory, A. [US/US]; 73 Maple Way, San Carlos, CA 94070 (US). ZINGLER, Kurt, A. [US/US]; 723 Ashbury Street #C, San Francisco, CA 94117 (US). LU, Dyung, Aina, M. [US/US]; 233 Coy Drive, San Jose, CA 95123 (US). LAL, Preeti, G. [IN/US]; P.O. Box 5142, Santa Clara, CA 95056 (US). RAMKUMAR, Jayalaxmi [IN/US]; 34359 Maybird Circle, Fremont, CA 94555 (US). WARREN, Bridget, A. [US/US]; 10130 Parkwood Drive #2, Cupertino, CA 95014 (US). KEARNEY, Liam [IR/US]; 50 Woodside Avenue, San Francisco, CA 94127 (US). POLICKY, Jennifer, L. [US/US]; 1511 Jarvis Court, San Jose, CA 95118 (US). THANGAVELU, Kavitha [IN/US]; 1950 Montecito Avenue #23, Mountain View, CA 94043 (US). BURFORD, Neil [GB/US]; 105 Wildwood Circle, Durham, CT 06422 (US).

(74) Agents: HAMLET-COX, Diana et al.; Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HUMAN KINASES

(57) Abstract: The invention provides human kinases (PKIN) and polynucleotides which identify and encode PKIN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of PKIN.

HUMAN KINASES

TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of human kinases and to the use of these sequences in the diagnosis, treatment, and prevention of cancer, immune disorders, disorders affecting growth and development, cardiovascular diseases, and lipid disorders, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of human kinases.

BACKGROUND OF THE INVENTION

Kinases comprise the largest known enzyme superfamily and vary widely in their target molecules. Kinases catalyze the transfer of high energy phosphate groups from a phosphate donor to a phosphate acceptor. Nucleotides usually serve as the phosphate donor in these reactions, with most kinases utilizing adenosine triphosphate (ATP). The phosphate acceptor can be any of a variety of molecules, including nucleosides, nucleotides, lipids, carbohydrates, and proteins. Proteins are phosphorylated on hydroxyamino acids. Addition of a phosphate group alters the local charge on the acceptor molecule, causing internal conformational changes and potentially influencing intermolecular contacts. Reversible protein phosphorylation is the primary method for regulating protein activity in eukaryotic cells. In general, proteins are activated by phosphorylation in response to extracellular signals such as hormones, neurotransmitters, and growth and differentiation factors. The activated proteins initiate the cell's intracellular response by way of intracellular signaling pathways and second messenger molecules such as cyclic nucleotides, calcium-calmodulin, inositol, and various mitogens, that regulate protein phosphorylation.

Kinases are involved in all aspects of a cell's function, from basic metabolic processes, such as glycolysis, to cell-cycle regulation, differentiation, and communication with the extracellular environment through signal transduction cascades. Inappropriate phosphorylation of proteins in cells has been linked to changes in cell cycle progression and cell differentiation. Changes in the cell cycle have been linked to induction of apoptosis or cancer. Changes in cell differentiation have been linked to diseases and disorders of the reproductive system, immune system, and skeletal muscle.

There are two classes of protein kinases. One class, protein tyrosine kinases (PTKs), phosphorylates tyrosine residues, and the other class, protein serine/threonine kinases (STKs), phosphorylates serine and threonine residues. Some PTKs and STKs possess structural characteristics of both families and have dual specificity for both tyrosine and serine/threonine residues. Almost all kinases contain a conserved 250-300 amino acid catalytic domain containing

specific residues and sequence motifs characteristic of the kinase family. The protein kinase catalytic domain can be further divided into 11 subdomains. N-terminal subdomains I-IV fold into a two-lobed structure which binds and orients the ATP donor molecule, and subdomain V spans the two lobes. C-terminal subdomains VI-XI bind the protein substrate and transfer the gamma phosphate from ATP to the hydroxyl group of a tyrosine, serine, or threonine residue. Each of the 11 subdomains contains specific catalytic residues or amino acid motifs characteristic of that subdomain. For example, subdomain I contains an 8-amino acid glycine-rich ATP binding consensus motif, subdomain II contains a critical lysine residue required for maximal catalytic activity, and subdomains VI through IX comprise the highly conserved catalytic core. PTKs and STKs also contain distinct sequence motifs in subdomains VI and VIII which may confer hydroxyamino acid specificity.

In addition, kinases may also be classified by additional amino acid sequences, generally between 5 and 100 residues, which either flank or occur within the kinase domain. These additional amino acid sequences regulate kinase activity and determine substrate specificity. (Reviewed in Hardie, G. and S. Hanks (1995) The Protein Kinase Facts Book, Vol I, pp. 17-20 Academic Press, San Diego CA.). In particular, two protein kinase signature sequences have been identified in the kinase domain, the first containing an active site lysine residue involved in ATP binding, and the second containing an aspartate residue important for catalytic activity. If a protein analyzed includes the two protein kinase signatures, the probability of that protein being a protein kinase is close to 100% (PROSITE: PDOC00100, November 1995).

Protein Tyrosine Kinases

Protein tyrosine kinases (PTKs) may be classified as either transmembrane, receptor PTKs or nontransmembrane, nonreceptor PTK proteins. Transmembrane tyrosine kinases function as receptors for most growth factors. Growth factors bind to the receptor tyrosine kinase (RTK), which causes the receptor to phosphorylate itself (autophosphorylation) and specific intracellular second messenger proteins. Growth factors (GF) that associate with receptor PTKs include epidermal GF, platelet-derived GF, fibroblast GF, hepatocyte GF, insulin and insulin-like GFs, nerve GF, vascular endothelial GF, and macrophage colony stimulating factor.

Nontransmembrane, nonreceptor PTKs lack transmembrane regions and, instead, form signaling complexes with the cytosolic domains of plasma membrane receptors. Receptors that function through non-receptor PTKs include those for cytokines and hormones (growth hormone and prolactin), and antigen-specific receptors on T and B lymphocytes.

Many PTKs were first identified as oncogene products in cancer cells in which PTK activation was no longer subject to normal cellular controls. In fact, about one third of the known oncogenes encode PTKs. Furthermore, cellular transformation (oncogenesis) is often accompanied

by increased tyrosine phosphorylation activity (Charbonneau, H. and N.K. Tonks (1992) *Annu. Rev. Cell Biol.* 8:463-493). Regulation of PTK activity may therefore be an important strategy in controlling some types of cancer.

Substrates for tyrosine kinases can be identified using anti-phosphotyrosine antibodies to screen tyrosine-phosphorylated cDNA expression libraries. Fish, so named for tyrosine-phosphorylated in Src-transformed fibroblast, is a tyrosine kinase substrate which has been identified by such a technique. Fish has five SH3 domains and a phospho homology (PX) domain. Fish is suggested to be involved in signalling by tyrosine kinases and have a role in the actin cytoskeleton (Lock, P. et al (1998) *EMBO J.* 17:4346-4357).

SHP-2, an SH2-domain-containing phosphotyrosine phosphatase, is a positive signal transducer for several receptor tyrosine kinases (RTKs) and cytokine receptors. Phosphotyrosine phosphatases are critical positive and negative regulators in the intracellular signalling pathways that result in growth-factor-specific cell responses such as mitosis, migration, differentiation, transformation, survival or death. Signal-regulatory proteins (SIRPs) comprise a new gene family of at least 15 members, consisting of two subtypes distinguished by the presence or absence of a cytoplasmic SHP-2-binding domain. The SIRP-alpha subfamily members have a cytoplasmic SHP2-binding domain and includes SIRP-alpha-1, a transmembrane protein, a substrate of activated RTKs and which binds to SH2 domains. SIRPs have a high degree of homology with immune antigen recognition molecules. The SIRP-beta subfamily lacks the cytoplasmic tail. The SIRP-beta-1 gene encodes a polypeptide of 398 amino acids. SIRP family members are generally involved in regulation of signals which define different physiological and pathological processes (Kharitonov, A. et al (1997) *Nature* 386:181-186). Two possible areas of regulation include determination of brain diversity and genetic individuality (Sano, S et al (1999) *Biochem. J.* 344 Pt 3:667-675) and recognition of self which fails in diseases such as hemolytic anemia (Oldenburg, P.-A et al (2000) *Science* 288:2051-2054).

Protein Serine/Threonine Kinases

Protein serine/threonine kinases (STKs) are nontransmembrane proteins. A subclass of STKs are known as ERKs (extracellular signal regulated kinases) or MAPs (mitogen-activated protein kinases) and are activated after cell stimulation by a variety of hormones and growth factors. Cell stimulation induces a signaling cascade leading to phosphorylation of MEK (MAP/ERK kinase) which, in turn, activates ERK via serine and threonine phosphorylation. A varied number of proteins represent the downstream effectors for the active ERK and implicate it in the control of cell proliferation and differentiation, as well as regulation of the cytoskeleton. Activation of ERK is normally transient, and cells possess dual specificity phosphatases that are responsible for its down-regulation. Also, numerous studies have shown that elevated ERK activity is associated with some

cancers. Other STKs include the second messenger dependent protein kinases such as the cyclic-AMP dependent protein kinases (PKA), calcium-calmodulin (CaM) dependent protein kinases, and the mitogen-activated protein kinases (MAP); the cyclin-dependent protein kinases; checkpoint and cell cycle kinases; Numb-associated kinase (Nak); human Fused (hFu); proliferation-related kinases; 5'-AMP-activated protein kinases; and kinases involved in apoptosis.

The second messenger dependent protein kinases primarily mediate the effects of second messengers such as cyclic AMP (cAMP), cyclic GMP, inositol triphosphate, phosphatidylinositol, 3,4,5-triphosphate, cyclic ADP ribose, arachidonic acid, diacylglycerol and calcium-calmodulin. The PKAs are involved in mediating hormone-induced cellular responses and are activated by cAMP produced within the cell in response to hormone stimulation. cAMP is an intracellular mediator of hormone action in all animal cells that have been studied. Hormone-induced cellular responses include thyroid hormone secretion, cortisol secretion, progesterone secretion, glycogen breakdown, bone resorption, and regulation of heart rate and force of heart muscle contraction. PKA is found in all animal cells and is thought to account for the effects of cAMP in most of these cells. Altered PKA expression is implicated in a variety of disorders and diseases including cancer, thyroid disorders, diabetes, atherosclerosis, and cardiovascular disease (Isselbacher, K.J. et al. (1994) Harrison's Principles of Internal Medicine, McGraw-Hill, New York NY, pp. 416-431, 1887).

The casein kinase I (CKI) gene family is another subfamily of serine/threonine protein kinases. This continuously expanding group of kinases have been implicated in the regulation of numerous cytoplasmic and nuclear processes, including cell metabolism, and DNA replication and repair. CKI enzymes are present in the membranes, nucleus, cytoplasm and cytoskeleton of eukaryotic cells, and on the mitotic spindles of mammalian cells (Fish, K.J. et al. (1995) *J. Biol. Chem.* 270:14875-14883).

The CKI family members all have a short amino-terminal domain of 9-76 amino acids, a highly conserved kinase domain of 284 amino acids, and a variable carboxyl-terminal domain that ranges from 24 to over 200 amino acids in length (Cegielska, A. et al. (1998) *J. Biol. Chem.* 273:1357-1364). The CKI family is comprised of highly related proteins, as seen by the identification of isoforms of casein kinase I from a variety of sources. There are at least five mammalian isoforms, α , β , γ , δ , and ϵ . Fish et al., identified CKI-epsilon from a human placenta cDNA library. It is a basic protein of 416 amino acids and is closest to CKI-delta. Through recombinant expression, it was determined to phosphorylate known CKI substrates and was inhibited by the CKI-specific inhibitor CKI-7. The human gene for CKI-epsilon was able to rescue yeast with a slow-growth phenotype caused by deletion of the yeast CKI locus, HRR250 (Fish et al., *supra*).

The mammalian circadian mutation tau was found to be a semidominant autosomal allele of

CKI-epsilon that markedly shortens period length of circadian rhythms in Syrian hamsters. The tau locus is encoded by casein kinase I-epsilon, which is also a homolog of the *Drosophila* circadian gene double-time. Studies of both the wildtype and tau mutant CKI-epsilon enzyme indicated that the mutant enzyme has a noticeable reduction in the maximum velocity and autophosphorylation state.

- 5 Further, *in vitro*, CKI-epsilon is able to interact with mammalian PERIOD proteins, while the mutant enzyme is deficient in its ability to phosphorylate PERIOD. Lowrey et al., have proposed that CKI-epsilon plays a major role in delaying the negative feedback signal within the transcription-translation-based autoregulatory loop that composes the core of the circadian mechanism. Therefore the CKI-epsilon enzyme is an ideal target for pharmaceutical compounds influencing circadian rhythms, jet-lag and sleep, in addition to other physiologic and metabolic processes under circadian regulation (Lowrey, P.L. et al. (2000) Science 288:483-491).

- Homeodomain-interacting protein kinases (HIPKs) are serine/threonine kinases and novel members of the DYRK kinase subfamily (Hofmann, T.G. et al. (2000) Biochimie 82:1123-1127). HIPKs contain a conserved protein kinase domain separated from a domain that interacts with homeoproteins. HIPKs are nuclear kinases, and HIPK2 is highly expressed in neuronal tissue (Kim, Y.H. et al. (1998) J. Biol. Chem. 273:25875-25879; Wang, Y. et al. (2001) Biochim. Biophys. Acta 1518:168-172). HIPKs act as corepressors for homeodomain transcription factors. This corepressor activity is seen in posttranslational modifications such as ubiquitination and phosphorylation, each of which are important in the regulation of cellular protein function (Kim, Y.H. et al. (1999) Proc. Natl. Acad. Sci. USA 96:12350-12355).

- The UNC-51 serine/threonine kinase of *Caenorhabditis elegans* is required for axon formation. Its murine homolog is expressed in granule cells of the cerebellar cortex (Tomoda, T. et al. (1999) Neuron 24:833-846). The human homolog of UNC-51, ULK1 (UNC-51 (*C. elegans*)-like kinase 1), is highly conserved among vertebrates. It is composed of 1050 amino acids, has a calculated MW of 112.6 kDa and a pI of 8.80. ULK1 is ubiquitously expressed in adult tissues while UNC-51 has been specifically located in the nervous system of *C. elegans*. ULK1 has been mapped to human chromosome 12q24.3 (Kuroyanagi, H. et al. (1998) Genomics 51:76-85).

Calcium-Calmodulin Dependent Protein Kinases

- Calcium-calmodulin dependent (CaM) kinases are involved in regulation of smooth muscle contraction, glycogen breakdown (phosphorylase kinase), and neurotransmission (CaM kinase I and CaM kinase II). CaM dependent protein kinases are activated by calmodulin, an intracellular calcium receptor, in response to the concentration of free calcium in the cell. Many CaM kinases are also activated by phosphorylation. Some CaM kinases are also activated by autophosphorylation or by other regulatory kinases. CaM kinase I phosphorylates a variety of substrates including the

neurotransmitter-related proteins synapsin I and II, the gene transcription regulator, CREB, and the cystic fibrosis conductance regulator protein, CFTR (Haribabu, B. et al. (1995) EMBO J. 14:3679-3686). CaM kinase II also phosphorylates synapsin at different sites and controls the synthesis of catecholamines in the brain through phosphorylation and activation of tyrosine hydroxylase. CaM kinase II controls the synthesis of catecholamines and serotonin, through phosphorylation/activation of tyrosine hydroxylase and tryptophan hydroxylase, respectively (Fujisawa, H. (1990) BioEssays 12:27-29). The mRNA encoding a calmodulin-binding protein kinase-like protein was found to be enriched in mammalian forebrain. This protein is associated with vesicles in both axons and dendrites and accumulates largely postnatally. The amino acid sequence of this protein is similar to CaM-dependent STKs, and the protein binds calmodulin in the presence of calcium (Godbout, M. et al. (1994) J. Neurosci. 14:1-13).

Mitogen-Activated Protein Kinases

The mitogen-activated protein kinases (MAP) which mediate signal transduction from the cell surface to the nucleus via phosphorylation cascades are another STK family that regulates intracellular signaling pathways. Several subgroups have been identified, and each manifests different substrate specificities and responds to distinct extracellular stimuli (Egan, S.E. and R.A. Weinberg (1993) Nature 365:781-2483). There are 3-kinase modules comprising the MAP kinase cascade: MAPK (MAP), MAPK kinase (MAP2K, MAPKK, or MKK), and MKK kinase (MAP3K, MAPKKK, OR MEKK) (Wang, X.S. et al (1998) Biochem. Biophys. Res. Commun. 253:33-37). The extracellular-regulated kinase (ERK) pathway is activated by growth factors and mitogens, for example, epidermal growth factor (EGF), ultraviolet light, hyperosmolar medium, heat shock, endotoxic lipopolysaccharide (LPS). The closely related though distinct parallel pathways, the c-Jun N-terminal kinase (JNK), or stress-activated kinase (SAPK) pathway, and the p38 kinase pathway are activated by stress stimuli and proinflammatory cytokines such as tumor necrosis factor (TNF) and interleukin-1 (IL-1). Altered MAP kinase expression is implicated in a variety of disease conditions including cancer, inflammation, immune disorders, and disorders affecting growth and development. MAP kinase signaling pathways are present in mammalian cells as well as in yeast.

MAPKKK6 (MAP3K6) is one of numerous MAP3Ks identified. Isolated from skeletal muscle, MAP3K6 is 1,280 amino acids in length with 11 kinase subdomains and is detected in several tissues. The highest expression has been found in heart and skeletal muscle. MAP3K6 has 45% amino acid sequence identity with MAP3K5, while their catalytic domains share 82% identity. MAP3K6 interaction with MAP3K5 *in vivo* was confirmed by coimmunoprecipitation. Recombinant MAP3K6 has been shown to weakly activate the JNK but not the p38 kinase or ERK pathways (Wang, X.S. et al. *supra*)

Cyclin-Dependent Protein Kinases

The cyclin-dependent protein kinases (CDKs) are STKs that control the progression of cells through the cell cycle. The entry and exit of a cell from mitosis are regulated by the synthesis and destruction of a family of activating proteins called cyclins. Cyclins are small regulatory proteins that bind to and activate CDKs, which then phosphorylate and activate selected proteins involved in the mitotic process. CDKs are unique in that they require multiple inputs to become activated. In addition to cyclin binding, CDK activation requires the phosphorylation of a specific threonine residue and the dephosphorylation of a specific tyrosine residue on the CDK.

Another family of STKs associated with the cell cycle are the NIMA (never in mitosis)-related kinases (Neks). Both CDKs and Neks are involved in duplication, maturation, and separation of the microtubule organizing center, the centrosome, in animal cells (Fry, A.M. et al. (1998) EMBO J. 17:470-481).

Checkpoint and Cell Cycle Kinases

In the process of cell division, the order and timing of cell cycle transitions are under control of cell cycle checkpoints, which ensure that critical events such as DNA replication and chromosome segregation are carried out with precision. If DNA is damaged, e.g. by radiation, a checkpoint pathway is activated that arrests the cell cycle to provide time for repair. If the damage is extensive, apoptosis is induced. In the absence of such checkpoints, the damaged DNA is inherited by aberrant cells which may cause proliferative disorders such as cancer. Protein kinases play an important role in this process. For example, a specific kinase, checkpoint kinase 1 (Chk1), has been identified in yeast and mammals, and is activated by DNA damage in yeast. Activation of Chk1 leads to the arrest of the cell at the G2/M transition (Sanchez, Y. et al. (1997) Science 277:1497-1501). Specifically, Chk1 phosphorylates the cell division cycle phosphatase CDC25, inhibiting its normal function which is to dephosphorylate and activate the cyclin-dependent kinase Cdc2. Cdc2 activation controls the entry of cells into mitosis (Peng, C.-Y. et al. (1997) Science 277:1501-1505). Thus, activation of Chk1 prevents the damaged cell from entering mitosis. A similar deficiency in a checkpoint kinase, such as Chk1, may also contribute to cancer by failure to arrest cells with damaged DNA at other checkpoints such as G2/M.

Proliferation-Related Kinases

Proliferation-related kinase is a serum/cytokine inducible STK that is involved in regulation of the cell cycle and cell proliferation in human megakaryocytic cells (Li, B. et al. (1996) J. Biol. Chem. 271:19402-19408). Proliferation-related kinase is related to the polo (derived from *Drosophila* polo gene) family of STKs implicated in cell division. Proliferation-related kinase is downregulated in lung tumor tissue and may be a proto-oncogene whose deregulated expression in normal tissue leads to

oncogenic transformation.

5'-AMP-activated protein kinase

A ligand-activated STK protein kinase is 5'-AMP-activated protein kinase (AMPK) (Gao, G. et al. (1996) J. Biol. Chem. 271:8675-8681). Mammalian AMPK is a regulator of fatty acid and sterol synthesis through phosphorylation of the enzymes acetyl-CoA carboxylase and hydroxymethylglutaryl-CoA reductase and mediates responses of these pathways to cellular stresses such as heat shock and depletion of glucose and ATP. AMPK is a heterotrimeric complex comprised of a catalytic alpha subunit and two non-catalytic beta and gamma subunits that are believed to regulate the activity of the alpha subunit. Subunits of AMPK have a much wider distribution in non-lipogenic tissues such as brain, heart, spleen, and lung than expected. This distribution suggests that its role may extend beyond regulation of lipid metabolism alone.

Kinases in Apoptosis

Apoptosis is a highly regulated signaling pathway leading to cell death that plays a crucial role in tissue development and homeostasis. Deregulation of this process is associated with the pathogenesis of a number of diseases including autoimmune disease, neurodegenerative disorders, and cancer. Various STKs play key roles in this process. ZIP kinase is an STK containing a C-terminal leucine zipper domain in addition to its N-terminal protein kinase domain. This C-terminal domain appears to mediate homodimerization and activation of the kinase as well as interactions with transcription factors such as activating transcription factor, ATF4, a member of the cyclic-AMP responsive element binding protein (ATF/CREB) family of transcriptional factors (Sanjo, H. et al. (1998) J. Biol. Chem. 273:29066-29071). DRAK1 and DRAK2 are STKs that share homology with the death-associated protein kinases (DAP kinases), known to function in interferon- γ induced apoptosis (Sanjo et al., *supra*). Like ZIP kinase, DAP kinases contain a C-terminal protein-protein interaction domain, in the form of ankyrin repeats, in addition to the N-terminal kinase domain. ZIP, DAP, and DRAK kinases induce morphological changes associated with apoptosis when transfected into NIH3T3 cells (Sanjo et al., *supra*). However, deletion of either the N-terminal kinase catalytic domain or the C-terminal domain of these proteins abolishes apoptosis activity, indicating that in addition to the kinase activity, activity in the C-terminal domain is also necessary for apoptosis, possibly as an interacting domain with a regulator or a specific substrate.

RICK is another STK recently identified as mediating a specific apoptotic pathway involving the death receptor, CD95 (Inohara, N. et al. (1998) J. Biol. Chem. 273:12296-12300). CD95 is a member of the tumor necrosis factor receptor superfamily and plays a critical role in the regulation and homeostasis of the immune system (Nagata, S. (1997) Cell 88:355-365). The CD95 receptor signaling pathway involves recruitment of various intracellular molecules to a receptor complex

following ligand binding. This process includes recruitment of the cysteine protease caspase-8 which, in turn, activates a caspase cascade leading to cell death. RICK is composed of an N-terminal kinase catalytic domain and a C-terminal "caspase-recruitment" domain that interacts with caspase-like domains, indicating that RICK plays a role in the recruitment of caspase-8. This interpretation is supported by the fact that the expression of RICK in human 293T cells promotes activation of caspase-8 and potentiates the induction of apoptosis by various proteins involved in the CD95 apoptosis pathway (Inohara et al., supra).

Mitochondrial Protein Kinases

A novel class of eukaryotic kinases, related by sequence to prokaryotic histidine protein kinases, are the mitochondrial protein kinases (MPKs) which seem to have no sequence similarity with other eukaryotic protein kinases. These protein kinases are located exclusively in the mitochondrial matrix space and may have evolved from genes originally present in respiration-dependent bacteria which were endocytosed by primitive eukaryotic cells. MPKs are responsible for phosphorylation and inactivation of the branched-chain alpha-ketoacid dehydrogenase and pyruvate dehydrogenase complexes (Harris, R.A. et al. (1995) Adv. Enzyme Regul. 34:147-162). Five MPKs have been identified. Four members correspond to pyruvate dehydrogenase kinase isozymes, regulating the activity of the pyruvate dehydrogenase complex, which is an important regulatory enzyme at the interface between glycolysis and the citric acid cycle. The fifth member corresponds to a branched-chain alpha-ketoacid dehydrogenase kinase, important in the regulation of the pathway for the disposal of branched-chain amino acids. (Harris, R.A. et al. (1997) Adv. Enzyme Regul. 37:271-293). Both starvation and the diabetic state are known to result in a great increase in the activity of the pyruvate dehydrogenase kinase in the liver, heart and muscle of the rat. This increase contributes in both disease states to the phosphorylation and inactivation of the pyruvate dehydrogenase complex and conservation of pyruvate and lactate for gluconeogenesis (Harris (1995) supra).

KINASES WITH NON-PROTEIN SUBSTRATES

Lipid and Inositol kinases

Lipid kinases phosphorylate hydroxyl residues on lipid head groups. A family of kinases involved in phosphorylation of phosphatidylinositol (PI) has been described, each member phosphorylating a specific carbon on the inositol ring (Leervers, S.J. et al. (1999) Curr. Opin. Cell. Biol. 11:219-225). The phosphorylation of phosphatidylinositol is involved in activation of the protein kinase C signaling pathway. The inositol phospholipids (phosphoinositides) intracellular signaling pathway begins with binding of a signaling molecule to a G-protein linked receptor in the plasma membrane.

This leads to the phosphorylation of phosphatidylinositol (PI) residues on the inner side of the plasma membrane by inositol kinases, thus converting PI residues to the biphosphate state (PIP₂). PIP₂ is then cleaved into inositol triphosphate (IP₃) and diacylglycerol. These two products act as mediators for separate signaling pathways. Cellular responses that are mediated by these pathways are

glycogen breakdown in the liver in response to vasopressin, smooth muscle contraction in response to acetylcholine, and thrombin-induced platelet aggregation.

PI 3-kinase (PI3K), which phosphorylates the D3 position of PI and its derivatives, has a central role in growth factor signal cascades involved in cell growth, differentiation, and metabolism. PI3K is a heterodimer consisting of an adapter subunit and a catalytic subunit. The adapter subunit acts as a scaffolding protein, interacting with specific tyrosine-phosphorylated proteins, lipid moieties, and other cytosolic factors. When the adapter subunit binds tyrosine phosphorylated targets, such as the insulin responsive substrate (IRS)-1, the catalytic subunit is activated and converts PI (4,5) biphosphate (PIP₂) to PI (3,4,5) P₃ (PIP₃). PIP₃ then activates a number of other proteins, including PKA, protein kinase B (PKB), protein kinase C (PKC), glycogen synthase kinase (GSK)-3, and p70 ribosomal s6 kinase. PI3K also interacts directly with the cytoskeletal organizing proteins, Rac, rho, and cdc42 (Shepherd, P.R. et al. (1998) Biochem. J. 333:471-490). Animal models for diabetes, such as *obese* and *fat* mice, have altered PI3K adapter subunit levels. Specific mutations in the adapter subunit have also been found in an insulin-resistant Danish population, suggesting a role for PI3K in type-2 diabetes (Shepard, supra).

An example of lipid kinase phosphorylation activity is the phosphorylation of D-erythro-sphingosine to the sphingolipid metabolite, sphingosine-1-phosphate (SPP). SPP has emerged as a novel lipid second-messenger with both extracellular and intracellular actions (Kohama, T. et al. (1998) J. Biol. Chem. 273:23722-23728). Extracellularly, SPP is a ligand for the G-protein coupled receptor EDG-1 (endothelial-derived, G-protein coupled receptor). Intracellularly, SPP regulates cell growth, survival, motility, and cytoskeletal changes. SPP levels are regulated by sphingosine kinases that specifically phosphorylate D-erythro-sphingosine to SPP. The importance of sphingosine kinase in cell signaling is indicated by the fact that various stimuli, including platelet-derived growth factor (PDGF), nerve growth factor, and activation of protein kinase C, increase cellular levels of SPP by activation of sphingosine kinase, and the fact that competitive inhibitors of the enzyme selectively inhibit cell proliferation induced by PDGF (Kohama et al., supra).

Purine Nucleotide Kinases

The purine nucleotide kinases, adenylate kinase (ATP:AMP phosphotransferase, or AdK) and guanylate kinase (ATP:GMP phosphotransferase, or GuK) play a key role in nucleotide metabolism and are crucial to the synthesis and regulation of cellular levels of ATP and GTP, respectively. These

two molecules are precursors in DNA and RNA synthesis in growing cells and provide the primary source of biochemical energy in cells (ATP), and signal transduction pathways (GTP). Inhibition of various steps in the synthesis of these two molecules has been the basis of many antiproliferative drugs for cancer and antiviral therapy (Pillwein, K. et al. (1990) Cancer Res. 50:1576-1579).

5 AdK is found in almost all cell types and is especially abundant in cells having high rates of ATP synthesis and utilization such as skeletal muscle. In these cells AdK is physically associated with mitochondria and myofibrils, the subcellular structures that are involved in energy production and utilization, respectively. Recent studies have demonstrated a major function for AdK in transferring high energy phosphoryls from metabolic processes generating ATP to cellular components consuming
10 ATP (Zelevnikar, R.J. et al. (1995) J. Biol. Chem. 270:7311-7319). Thus AdK may have a pivotal role in maintaining energy production in cells, particularly those having a high rate of growth or metabolism such as cancer cells, and may provide a target for suppression of its activity to treat certain cancers. Alternatively, reduced AdK activity may be a source of various metabolic, muscle-energy disorders that can result in cardiac or respiratory failure and may be treatable by
15 increasing AdK activity.

GuK, in addition to providing a key step in the synthesis of GTP for RNA and DNA synthesis, also fulfills an essential function in signal transduction pathways of cells through the regulation of GDP and GTP. Specifically, GTP binding to membrane associated G proteins mediates the activation of cell receptors, subsequent intracellular activation of adenyl cyclase, and production of the second
20 messenger, cyclic AMP. GDP binding to G proteins inhibits these processes. GDP and GTP levels also control the activity of certain oncogenic proteins such as p21^{ras} known to be involved in control of cell proliferation and oncogenesis (Bos, J.L. (1989) Cancer Res. 49:4682-4689). High ratios of GTP:GDP caused by suppression of GuK cause activation of p21^{ras} and promote oncogenesis. Increasing GuK activity to increase levels of GDP and reduce the GTP:GDP ratio may provide a
25 therapeutic strategy to reverse oncogenesis.

GuK is an important enzyme in the phosphorylation and activation of certain antiviral drugs useful in the treatment of herpes virus infections. These drugs include the guanine homologs acyclovir and bucciclovir (Miller, W.H. and R.L. Miller (1980) J. Biol. Chem. 255:7204-7207; Stenberg, K. et al. (1986) J. Biol. Chem. 261:2134-2139). Increasing GuK activity in infected cells may provide a
30 therapeutic strategy for augmenting the effectiveness of these drugs and possibly for reducing the necessary dosages of the drugs.

Pyrimidine Kinases

The pyrimidine kinases are deoxycytidine kinase and thymidine kinase 1 and 2. Deoxycytidine kinase is located in the nucleus, and thymidine kinase 1 and 2 are found in the cytosol (Johansson, M.

et al. (1997) Proc. Natl. Acad. Sci. USA 94:11941-11945). Phosphorylation of deoxyribonucleosides by pyrimidine kinases provides an alternative pathway for *de novo* synthesis of DNA precursors. The role of pyrimidine kinases, like purine kinases, in phosphorylation is critical to the activation of several chemotherapeutically important nucleoside analogues (Arner E.S. and S. Eriksson (1995) Pharmacol. Ther. 67:155-186).

The discovery of new human kinases, and the polynucleotides encoding them, satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cancer, immune disorders, disorders affecting growth and development, cardiovascular diseases, and lipid disorders, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of human kinases.

SUMMARY OF THE INVENTION

The invention features purified polypeptides, human kinases, referred to collectively as "PKIN" and individually as "PKIN-1," "PKIN-2," "PKIN-3," "PKIN-4," "PKIN-5," "PKIN-6," "PKIN-7," "PKIN-8," "PKIN-9," "PKIN-10," "PKIN-11," "PKIN-12," "PKIN-13," "PKIN-14," "PKIN-15," "PKIN-16," "PKIN-17," "PKIN-18," "PKIN-19," "PKIN-20," "PKIN-21," "PKIN-22," "PKIN-23," and "PKIN-24." In one aspect, the invention provides an isolated polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-24.

The invention further provides an isolated polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24. In one alternative, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:1-24. In another alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:25-48.

• Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.

The invention also provides a method for producing a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24.

The invention further provides an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:25-48, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:25-48, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). In one alternative, the polynucleotide

comprises at least 60 contiguous nucleotides.

Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:25-48, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:25-48, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous nucleotides.

The invention further provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:25-48, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:25-48, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

The invention further provides a composition comprising an effective amount of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-24. The invention additionally provides a method of treating a disease or condition associated with decreased expression of

functional PKIN, comprising administering to a patient in need of such treatment the composition.

The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional PKIN, comprising administering to a patient in need of such treatment the composition.

Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional PKIN, comprising administering to a patient in need of such treatment the composition.

The invention further provides a method of screening for a compound that specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group

consisting of SEQ ID NO:1-24. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.

The invention further provides a method of screening for a compound that modulates the activity of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.

The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO:25-48, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, and b) detecting altered expression of the target polynucleotide.

The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:25-48, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:25-48, iii) a polynucleotide having a sequence complementary to i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:25-48, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a

polynucleotide sequence selected from the group consisting of SEQ ID NO:25-48, iii) a polynucleotide complementary to the polynucleotide of i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Alternatively, the target polynucleotide comprises a fragment of a polynucleotide sequence selected from the group consisting of i)-v) above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

BRIEF DESCRIPTION OF THE TABLES

Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the present invention.

Table 2 shows the GenBank identification number and annotation of the nearest GenBank homolog for polypeptides of the invention. The probability score for the match between each polypeptide and its GenBank homolog is also shown.

Table 3 shows structural features of polypeptide sequences of the invention, including predicted motifs and domains, along with the methods, algorithms, and searchable databases used for analysis of the polypeptides.

Table 4 lists the cDNA and/or genomic DNA fragments which were used to assemble polynucleotide sequences of the invention, along with selected fragments of the polynucleotide sequences.

Table 5 shows the representative cDNA library for polynucleotides of the invention.

Table 6 provides an appendix which describes the tissues and vectors used for construction of the cDNA libraries shown in Table 5.

Table 7 shows the tools, programs, and algorithms used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.

DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an,"

and “the” include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to “a host cell” includes a plurality of such host cells, and a reference to “an antibody” is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

“PKIN” refers to the amino acid sequences of substantially purified PKIN obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term “agonist” refers to a molecule which intensifies or mimics the biological activity of PKIN. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of PKIN either by directly interacting with PKIN or by acting on components of the biological pathway in which PKIN participates.

An “allelic variant” is an alternative form of the gene encoding PKIN. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

“Altered” nucleic acid sequences encoding PKIN include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as PKIN or a polypeptide with at least one functional characteristic of PKIN. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding PKIN, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding PKIN. The encoded protein may also be “altered,” and may contain deletions, insertions, or substitutions of amino

acid residues which produce a silent change and result in a functionally equivalent PKIN. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of PKIN is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where "amino acid sequence" is recited to refer to a sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

The term "antagonist" refers to a molecule which inhibits or attenuates the biological activity of PKIN. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of PKIN either by directly interacting with PKIN or by acting on components of the biological pathway in which PKIN participates.

The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab')₂, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind PKIN polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on

the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "antisense" refers to any composition capable of base-pairing with the "sense" (coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand of a reference DNA molecule.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" or "immunogenic" refers to the capability of the natural, recombinant, or synthetic PKIN, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

"Complementary" describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5'-AGT-3' pairs with its complement, 3'-TCA-5'.

A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding PKIN or fragments of PKIN may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (Applied Biosystems, Foster City CA) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison

WI) or Phrap (University of Washington, Seattle WA). Some sequences have been both extended and assembled to produce the consensus sequence.

“Conservative amino acid substitutions” are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.

	Original Residue	Conservative Substitution
	Ala	Gly, Ser
10	Arg	His, Lys
	Asn	Asp, Gln, His
	Asp	Asn, Glu
	Cys	Ala, Ser
	Gln	Asn, Glu, His
15	Glu	Asp, Gln, His
	Gly	Ala
	His	Asn, Arg, Gln, Glu
	Ile	Leu, Val
	Leu	Ile, Val
20	Lys	Arg, Gln, Glu
	Met	Leu, Ile
	Phe	His, Met, Leu, Trp, Tyr
	Ser	Cys, Thr
	Thr	Ser, Val
25	Trp	Phe, Tyr
	Tyr	His, Phe, Trp
	Val	Ile, Leu, Thr

Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

A “deletion” refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term “derivative” refers to a chemically modified polynucleotide or polypeptide. Chemical modifications of a polynucleotide can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

A “detectable label” refers to a reporter molecule or enzyme that is capable of generating a

measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.

“Differential expression” refers to increased or upregulated; or decreased, downregulated, or absent gene or protein expression, determined by comparing at least two different samples. Such comparisons may be carried out between, for example, a treated and an untreated sample, or a diseased and a normal sample.

“Exon shuffling” refers to the recombination of different coding regions (exons). Since an exon may represent a structural or functional domain of the encoded protein, new proteins may be assembled through the novel reassortment of stable substructures, thus allowing acceleration of the evolution of new protein functions.

A “fragment” is a unique portion of PKIN or the polynucleotide encoding PKIN which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

A fragment of SEQ ID NO:25-48 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:25-48, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:25-48 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:25-48 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:25-48 and the region of SEQ ID NO:25-48 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-24 is encoded by a fragment of SEQ ID NO:25-48. A fragment of SEQ ID NO:1-24 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-24. For example, a fragment of SEQ ID NO:1-24 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-24. The precise length of a fragment of SEQ ID NO:1-24 and the region of SEQ ID NO:1-24 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the

intended purpose for the fragment.

A “full length” polynucleotide sequence is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A “full length” polynucleotide sequence encodes a “full length” polypeptide sequence.

5 “Homology” refers to sequence similarity or, interchangeably, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.

The terms “percent identity” and “% identity,” as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in
10 the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of
15 molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and “diagonals saved”=4. The “weighted” residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the “percent
20 similarity” between aligned polynucleotide sequences.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at

25 <http://www.ncbi.nlm.nih.gov/BLAST/>. The BLAST software suite includes various sequence analysis programs including “blastn,” that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called “BLAST 2 Sequences” that is used for direct pairwise comparison of two nucleotide sequences. “BLAST 2 Sequences” can be accessed and used interactively at <http://www.ncbi.nlm.nih.gov/gorf/bl2.html>. The
30 “BLAST 2 Sequences” tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the “BLAST 2 Sequences” tool Version 2.0.12 (April-21-2000) set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Reward for match: 1

Penalty for mismatch: -2

Open Gap: 5 and Extension Gap: 2 penalties

Gap x drop-off: 50

5 *Expect: 10*

Word Size: 11

Filter: on

Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

15 Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

25 Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) with blastp set at default parameters. Such default parameters may be, for

example:

Matrix: BLOSUM62

Open Gap: 11 and Extension Gap: 1 penalties

Gap x drop-off: 50

Expect: 10

Word Size: 3

Filter: on

Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size and which contain all of the elements required for chromosome replication, segregation and maintenance.

The term "humanized antibody" refers to an antibody molecule in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

"Hybridization" refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the "washing" step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v) SDS, and about 100 µg/ml sheared, denatured salmon sperm DNA.

Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about

5°C to 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating T_m and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et al. (1989)

5 Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration may
10 be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 µg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily
15 apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A
20 hybridization complex may be formed in solution (e.g., C_0t or R_0t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide
25 sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

30 An "immunogenic fragment" is a polypeptide or oligopeptide fragment of PKIN which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide fragment of PKIN which is useful in any of the antibody production methods disclosed herein or known in the art.

The term "microarray" refers to an arrangement of a plurality of polynucleotides,

polypeptides, or other chemical compounds on a substrate.

The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.

The term "modulate" refers to a change in the activity of PKIN. For example, modulation
5 may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of PKIN.

The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the
10 antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where
15 necessary to join two protein coding regions, in the same reading frame.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and
20 may be pegylated to extend their lifespan in the cell.

"Post-translational modification" of an PKIN may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of PKIN.

25 "Probe" refers to nucleic acid sequences encoding PKIN, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. "Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target
30 polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also

be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

5 Methods for preparing and using probes and primers are described in the references, for example Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel, F.M. et al. (1987) Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis, M. et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs
10 can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).

 Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to
15 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase
20 sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may
25 also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved
30 oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques
5 such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a
10 vaccinia virus, that could be used to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

A "regulatory element" refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5' and 3' untranslated regions (UTRs). Regulatory elements interact with host or viral proteins which control transcription,
15 translation, or RNA stability.

"Reporter molecules" are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.

20 An "RNA equivalent," in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The term "sample" is used in its broadest sense. A sample suspected of containing PKIN,
25 nucleic acids encoding PKIN, or fragments thereof may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or
30 synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide comprising the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.

5 A "substitution" refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells,
10 trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

A "transcript image" refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.

"Transformation" describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods
15 well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed cells" includes stably transformed cells in which the inserted DNA is capable of replication either as
20 an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "transgenic organism," as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The
25 nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or *in vitro* fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria,
30 fungi, plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), *supra*.

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having

at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides will generally have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length of one of the polypeptides.

THE INVENTION

The invention is based on the discovery of new human human kinases (PKIN), the polynucleotides encoding PKIN, and the use of these compositions for the diagnosis, treatment, or prevention of cancer, immune disorders, disorders affecting growth and development, cardiovascular diseases, and lipid disorders.

Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the invention. Each polynucleotide and its corresponding polypeptide are correlated to a single Incyte project identification number (Incyte Project ID). Each polypeptide sequence is denoted by both a polypeptide sequence identification number (Polypeptide SEQ ID NO:) and an Incyte

polypeptide sequence number (Incyte Polypeptide ID) as shown. Each polynucleotide sequence is denoted by both a polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and an Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) as shown.

Table 2 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (genpept) database. Columns 1 and 2 show the polypeptide sequence identification number (Polypeptide SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for polypeptides of the invention. Column 3 shows the GenBank identification number (Genbank ID NO:) of the nearest GenBank homolog. Column 4 shows the probability score for the match between each polypeptide and its GenBank homolog. Column 5 shows the annotation of the GenBank homolog along with relevant citations where applicable, all of which are expressly incorporated by reference herein.

Table 3 shows various structural features of the polypeptides of the invention. Columns 1 and 2 show the polypeptide sequence identification number (SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for each polypeptide of the invention. Column 3 shows the number of amino acid residues in each polypeptide. Column 4 shows potential phosphorylation sites, and column 5 shows potential glycosylation sites, as determined by the MOTIFS program of the GCG sequence analysis software package (Genetics Computer Group, Madison WI). Column 6 shows amino acid residues comprising signature sequences, domains, and motifs. Column 7 shows analytical methods for protein structure/function analysis and in some cases, searchable databases to which the analytical methods were applied.

Together, Tables 2 and 3 summarize the properties of polypeptides of the invention, and these properties establish that the claimed polypeptides are human kinases. For example, SEQ ID NO:2 is 95% identical to rat myotonic dystrophy kinase-related Cdc42-binding kinase (GenBank ID g2736151) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 0.0, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:2 also contains kinase active site domains, a phorbol ester binding domain, and a protein-protein interaction domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) BLIMPS, MOTIFS, and PROFILESCAN analyses confirm the presence of these domains and provide further corroborative evidence that SEQ ID NO:2 is a protein kinase. In an alternate example, SEQ ID NO:4 is 79% identical to Rattus norvegicus extracellular signal-regulated kinase 7 (ERK7) (GenBank ID g4220888) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 5.3e-171, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. In another example,

SEQ ID NO:4 is 47% identical to *Leishmania mexicana* MAP-kinase homologue (LMPK) (GenBank ID g2131000) with a probability score of $4.2e-70$ as determined by the BLAST. (See Table 2.) It has been shown that *Leishmania mexicana* mutants, deleted for LMPK, lose the ability to cause a progressive disease in Balb/c mice. These *L. mexicana* mutants were restored to infectivity in

5 complementation experiments, demonstrating that LMPK is essential for the infectivity of *L. mexicana* in an infected host. Additionally, SEQ ID NO:4 is 48% identical to a MAP-kinase homologue from the human malaria parasite, *Plasmodium falciparum* (GenBank ID g1360110) with a probability score of $5.8e-73$ as determined by the BLAST. (See Table 2.) This homologue is closely related to MAP-kinases, which play important roles in eukaryotic adaptive response and signal transduction. SEQ ID

10 NO:4 also contains a eukaryotic protein kinase domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS reveals a tyrosine kinase catalytic domain signature (See Table 3.) Additional data from MOTIFS and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:4 is a protein kinase. SEQ ID NO:5 is 45% identical

15 to *Mus musculus* serine/threonine kinase (GenBank ID g404634) as determined by the BLAST. (See Table 2.) The BLAST probability score is $2.6e-54$. SEQ ID NO:5 also contains a eukaryotic protein kinase domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS_PRINTS reveals a tyrosine kinase catalytic domain signature. BLAST_DOMO data

20 indicates the presence of a protein kinase domain. Additional data from MOTIFS and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:5 is a protein kinase. In an alternate example, SEQ ID NO:7 is 53% identical to chicken qin-induced kinase (Qik), a serine-threonine kinase (GenBank ID g6760436) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is $9.2e-125$, which indicates the

25 probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:7 also contains a eukaryotic protein kinase domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of protein family domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:7 is a protein kinase. In an alternate example, SEQ ID NO:8

30 is 55% identical to human adenylate kinase (GenBank ID g5757703) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 0.0, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:8 also contains a eukaryotic protein kinase domain and a PDZ domain, as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM

database of conserved protein family domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:8 is a protein kinase. In an alternate example, SEQ ID NO:16 is 42% identical to rat serine/threonine protein kinase (GenBank ID g4115429) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is $7.9e-53$, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:16 also contains a eukaryotic protein kinase domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:16 is a protein kinase. In an alternate example, SEQ ID NO:19 is 95% identical to rat nucleoside diphosphate kinase beta isoform (GenBank ID g286232) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is $3.1e-76$, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:19 also contains a nucleoside diphosphate kinase domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:19 is a nucleoside diphosphate kinase. In an alternate example, SEQ ID NO:24 is 52% identical to murine apoptosis associated tyrosine kinase (GenBank ID g2459993) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is $1.5e-153$, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:24 also contains a eukaryotic protein kinase domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:24 is a tyrosine kinase. SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9-15, SEQ ID NO:17-18, and SEQ ID NO:20-23 were analyzed and annotated in a similar manner. The algorithms and parameters for the analysis of SEQ ID NO:1-24 are described in Table 7.

As shown in Table 4, the full length polynucleotide sequences of the present invention were assembled using cDNA sequences or coding (exon) sequences derived from genomic DNA, or any combination of these two types of sequences. Columns 1 and 2 list the polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and the corresponding Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) for each polynucleotide of the invention. Column 3 shows the length of each polynucleotide sequence in basepairs. Column 4 lists fragments of

the polynucleotide sequences which are useful, for example, in hybridization or amplification technologies that identify SEQ ID NO:25-48 or that distinguish between SEQ ID NO:25-48 and related polynucleotide sequences. Column 5 shows identification numbers corresponding to cDNA sequences, coding sequences (exons) predicted from genomic DNA, and/or sequence assemblages comprised of both cDNA and genomic DNA. These sequences were used to assemble the full length polynucleotide sequences of the invention. Columns 6 and 7 of Table 4 show the nucleotide start (5') and stop (3') positions of the cDNA and/or genomic sequences in column 5 relative to their respective full length sequences.

The identification numbers in Column 5 of Table 4 may refer specifically, for example, to Incyte cDNAs along with their corresponding cDNA libraries. For example, 6259135F8 is the identification number of an Incyte cDNA sequence, and BMARTXT06 is the cDNA library from which it is derived. Incyte cDNAs for which cDNA libraries are not indicated were derived from pooled cDNA libraries (e.g., 71899371V1). Alternatively, the identification numbers in column 5 may refer to GenBank cDNAs or ESTs (e.g., g1441460) which contributed to the assembly of the full length polynucleotide sequences. In addition, the identification numbers in column 5 may identify sequences derived from the ENSEMBL (The Sanger Centre, Cambridge, UK) database (*i.e.*, those sequences including the designation "ENST"). Alternatively, the identification numbers in column 5 may be derived from the NCBI RefSeq Nucleotide Sequence Records Database (*i.e.*, those sequences including the designation "NM" or "NT") or the NCBI RefSeq Protein Sequence Records (*i.e.*, those sequences including the designation "NP"). Alternatively, the identification numbers in column 5 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon stitching" algorithm. For example, FL_XXXXXX_N₁_N₂_YYYYY_N₃_N₄ represents a "stitched" sequence in which XXXXXX is the identification number of the cluster of sequences to which the algorithm was applied, and YYYYY is the number of the prediction generated by the algorithm, and N_{1,2,3...}, if present, represent specific exons that may have been manually edited during analysis (See Example V). Alternatively, the identification numbers in column 5 may refer to assemblages of exons brought together by an "exon-stretching" algorithm. For example, FLXXXXXX_gAAAAA_gBBBBB_1_N is the identification number of a "stretched" sequence, with XXXXXX being the Incyte project identification number, gAAAAA being the GenBank identification number of the human genomic sequence to which the "exon-stretching" algorithm was applied, gBBBBB being the GenBank identification number or NCBI RefSeq identification number of the nearest GenBank protein homolog, and N referring to specific exons (See Example V). In instances where a RefSeq sequence was used as a protein homolog for the "exon-stretching" algorithm, a

RefSeq identifier (denoted by "NM," "NP," or "NT") may be used in place of the GenBank identifier (*i.e.*, gBBBBB).

Alternatively, a prefix identifies component sequences that were hand-edited, predicted from genomic DNA sequences, or derived from a combination of sequence analysis methods. The

5 following Table lists examples of component sequence prefixes and corresponding sequence analysis methods associated with the prefixes (see Example IV and Example V).

Prefix	Type of analysis and/or examples of programs
GNN, GFG, ENST	Exon prediction from genomic sequences using, for example, GENSCAN (Stanford University, CA, USA) or FGENES (Computer Genomics Group, The Sanger Centre, Cambridge, UK).
GBI	Hand-edited analysis of genomic sequences.
FL	Stitched or stretched genomic sequences (see Example V).
INCY	Full length transcript and exon prediction from mapping of EST sequences to the genome. Genomic location and EST composition data are combined to predict the exons and resulting transcript.

10

In some cases, Incyte cDNA coverage redundant with the sequence coverage shown in
15 column 5 was obtained to confirm the final consensus polynucleotide sequence, but the relevant Incyte cDNA identification numbers are not shown.

Table 5 shows the representative cDNA libraries for those full length polynucleotide sequences which were assembled using Incyte cDNA sequences. The representative cDNA library is the Incyte cDNA library which is most frequently represented by the Incyte cDNA sequences
20 which were used to assemble and confirm the above polynucleotide sequences. The tissues and vectors which were used to construct the cDNA libraries shown in Table 5 are described in Table 6.

The invention also encompasses PKIN variants. A preferred PKIN variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the PKIN amino acid sequence, and which contains at least one functional or
25 structural characteristic of PKIN.

The invention also encompasses polynucleotides which encode PKIN. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:25-48, which encodes PKIN. The polynucleotide sequences of SEQ ID NO:25-48, as presented in the Sequence Listing, embrace the equivalent RNA sequences,

wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The invention also encompasses a variant of a polynucleotide sequence encoding PKIN. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding PKIN. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:25-48 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:25-48. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of PKIN.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding PKIN, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring PKIN, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode PKIN and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring PKIN under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding PKIN or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding PKIN and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode PKIN and PKIN derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding PKIN or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:25-48 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. (1987) *Methods Enzymol.* 152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in "Definitions."

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Applied Biosystems), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (Applied Biosystems), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

The nucleic acid sequences encoding PKIN may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) *PCR Methods Applic.* 2:318-322.)

Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) *Nucleic Acids Res.* 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) *PCR Methods Applic.* 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) *Nucleic Acids Res.* 19:3055-3060).

Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo

Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Applied Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode PKIN may be cloned in recombinant DNA molecules that direct expression of PKIN, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express PKIN.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter PKIN-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent Number

5,837,458; Chang, C.-C. et al. (1999) *Nat. Biotechnol.* 17:793-797; Christians, F.C. et al. (1999) *Nat. Biotechnol.* 17:259-264; and Cramer, A. et al. (1996) *Nat. Biotechnol.* 14:315-319) to alter or improve the biological properties of PKIN, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial" breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

In another embodiment, sequences encoding PKIN may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) *Nucleic Acids Symp. Ser.* 7:215-223; and Horn, T. et al. (1980) *Nucleic Acids Symp. Ser.* 7:225-232.) Alternatively, PKIN itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solution-phase or solid-phase techniques. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY, pp. 55-60; and Roberge, J.Y. et al. (1995) *Science* 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Applied Biosystems). Additionally, the amino acid sequence of PKIN, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) *Methods Enzymol.* 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, *supra*, pp. 28-53.)

In order to express a biologically active PKIN, the nucleotide sequences encoding PKIN or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding PKIN. Such elements may vary in their strength and specificity. Specific initiation signals

may also be used to achieve more efficient translation of sequences encoding PKIN. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding PKIN and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding PKIN and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding PKIN. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra; Ausubel, supra; Van Heeke, G. and S.M. Schuster (1989) *J. Biol. Chem.* 264:5503-5509; Engelhard, E.K. et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:3224-3227; Sandig, V. et al. (1996) *Hum. Gene Ther.* 7:1937-1945; Takamatsu, N. (1987) *EMBO J.* 6:307-311; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196; Logan, J. and T. Shenk (1984) *Proc. Natl. Acad. Sci. USA* 81:3655-3659; and Harrington, J.J. et al. (1997) *Nat. Genet.* 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) *Cancer Gen. Ther.* 5(6):350-356; Yu, M. et al. (1993) *Proc. Natl. Acad. Sci. USA* 90(13):6340-6344; Buller, R.M. et al. (1985) *Nature* 317(6040):813-815; McGregor, D.P. et al. (1994) *Mol. Immunol.* 31(3):219-226; and Verma, I.M. and N. Somia (1997) *Nature* 389:239-242.) The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding PKIN. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding PKIN can be achieved using a multifunctional *E. coli* vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPO11 plasmid (Life Technologies). Ligation of sequences encoding PKIN into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for *in vitro* transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of PKIN are needed, e.g. for the production of antibodies, vectors which direct high level expression of PKIN may be used. For example, vectors containing the strong, inducible SP6 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of PKIN. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast *Saccharomyces cerevisiae* or *Pichia pastoris*. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, *supra*; Bitter, G.A. et al. (1987) Methods Enzymol. 153:516-544; and Scorer, C.A. et al. (1994) Bio/Technology 12:181-184.)

Plant systems may also be used for expression of PKIN. Transcription of sequences encoding PKIN may be driven by viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., *The McGraw Hill Yearbook of Science and Technology* (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding PKIN may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses PKIN in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma

virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are
5 constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of PKIN in cell lines is preferred. For example, sequences encoding PKIN can be transformed into cell
10 lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the
15 introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk* and *apr* cells, respectively. (See, e.g., Wigler, M. et
20 al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981)
25 J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), β glucuronidase and its substrate β -glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to
30 quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding PKIN is inserted within a marker gene sequence, transformed cells containing

sequences encoding PKIN can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding PKIN under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

5 In general, host cells that contain the nucleic acid sequence encoding PKIN and that express PKIN may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

10 Immunological methods for detecting and measuring the expression of PKIN using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on PKIN is preferred, but a competitive
15 binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ.)

20 A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding PKIN include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding PKIN, or any fragments thereof, may be cloned into a vector
25 for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for
30 ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding PKIN may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence

and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode PKIN may be designed to contain signal sequences which direct secretion of PKIN through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding PKIN may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric PKIN protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of PKIN activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the PKIN encoding sequence and the heterologous protein sequence, so that PKIN may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, *supra*, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled PKIN may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, ³⁵S-methionine.

PKIN of the present invention or fragments thereof may be used to screen for compounds that specifically bind to PKIN. At least one and up to a plurality of test compounds may be screened for specific binding to PKIN. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

5 In one embodiment, the compound thus identified is closely related to the natural ligand of PKIN, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, e.g., Coligan, J.E. et al. (1991) Current Protocols in Immunology 1(2): Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which PKIN binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case, the
10 compound can be rationally designed using known techniques. In one embodiment, screening for these compounds involves producing appropriate cells which express PKIN, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing PKIN or cell membrane fractions which contain PKIN are then contacted with a test compound and binding, stimulation, or inhibition of activity of either PKIN or the compound is
15 analyzed.

An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the assay may comprise the steps of combining at least one test compound with PKIN, either in solution or affixed to a solid support, and detecting the binding of PKIN to the compound. Alternatively, the
20 assay may detect or measure binding of a test compound in the presence of a labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compound(s) may be free in solution or affixed to a solid support.

PKIN of the present invention or fragments thereof may be used to screen for compounds that modulate the activity of PKIN. Such compounds may include agonists, antagonists, or partial or
25 inverse agonists. In one embodiment, an assay is performed under conditions permissive for PKIN activity, wherein PKIN is combined with at least one test compound, and the activity of PKIN in the presence of a test compound is compared with the activity of PKIN in the absence of the test compound. A change in the activity of PKIN in the presence of the test compound is indicative of a compound that modulates the activity of PKIN. Alternatively, a test compound is combined with an in
30 vitro or cell-free system comprising PKIN under conditions suitable for PKIN activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of PKIN may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.

In another embodiment, polynucleotides encoding PKIN or their mammalian homologs may be “knocked out” in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Patent Number 5,175,383 and U.S. Patent Number 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999-2002; Wagner, K.U. et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.

Polynucleotides encoding PKIN may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al. (1998) Science 282:1145-1147).

Polynucleotides encoding PKIN can also be used to create “knockin” humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding PKIN is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress PKIN, e.g., by secreting PKIN in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).

THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of PKIN and human kinases. In addition, the expression of PKIN is closely associated with neurological, brain, immune system, diseased, developing, myometrium, smooth muscle cell, thyroid, nervous, reproductive, lung, gastrointestinal, developmental, tumorous, and cardiac tissues. Therefore,

PKIN appears to play a role in cancer, immune disorders, disorders affecting growth and development, cardiovascular diseases, and lipid disorders. In the treatment of disorders associated with increased PKIN expression or activity, it is desirable to decrease the expression or activity of PKIN. In the treatment of disorders associated with decreased PKIN expression or activity, it is
5 desirable to increase the expression or activity of PKIN.

Therefore, in one embodiment, PKIN or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PKIN.

Examples of such disorders include, but are not limited to, a cancer, such as adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of
10 the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus, leukemias such as multiple myeloma and lymphomas such as Hodgkin's disease; an immune disorder, such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing
15 spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's
20 thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral,
25 bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a growth and developmental disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including
adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in
30 particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus, renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental

retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Sydenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and

5 sensorineural hearing loss; a cardiovascular disease, such as arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, vascular tumors, and complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery, congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease,

10 degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, and complications of cardiac transplantation, congenital lung

15 anomalies, atelectasis, pulmonary congestion and edema, pulmonary embolism, pulmonary hemorrhage, pulmonary infarction, pulmonary hypertension, vascular sclerosis, obstructive pulmonary disease, restrictive pulmonary disease, chronic obstructive pulmonary disease, emphysema, chronic bronchitis, bronchial asthma, bronchiectasis, bacterial pneumonia, viral and mycoplasmal pneumonia, lung abscess, pulmonary tuberculosis, diffuse interstitial diseases, pneumoconioses, sarcoidosis, idiopathic

20 pulmonary fibrosis, desquamative interstitial pneumonitis, hypersensitivity pneumonitis, pulmonary eosinophilia bronchiolitis obliterans-organizing pneumonia, diffuse pulmonary hemorrhage syndromes, Goodpasture's syndromes, idiopathic pulmonary hemosiderosis, pulmonary involvement in collagen-vascular disorders, pulmonary alveolar proteinosis, lung tumors, inflammatory and noninflammatory pleural effusions, pneumothorax, pleural tumors, drug-induced lung disease, radiation

25 induced lung disease, and complications of lung transplantation; and a lipid disorder such as fatty liver, cholestasis, primary biliary cirrhosis, carnitine deficiency, carnitine palmitoyltransferase deficiency, myoadenylate deaminase deficiency, hypertriglyceridemia, lipid storage disorders such as Fabry's disease, Gaucher's disease, Niemann-Pick's disease, metachromatic leukodystrophy, adrenoleukodystrophy, GM₂ gangliosidosis, and ceroid lipofuscinosis, abetalipoproteinemia, Tangier

30 disease, hyperlipoproteinemia, diabetes mellitus, lipodystrophy, lipomatosis, acute panniculitis, disseminated fat necrosis, adiposis dolorosa, lipid adrenal hyperplasia, minimal change disease, lipomas, atherosclerosis, hypercholesterolemia, hypercholesterolemia with hypertriglyceridemia, primary hypoalphalipoproteinemia, hypothyroidism, renal disease, liver disease, lecithin:cholesterol

acyltransferase deficiency, cerebrotendinous xanthomatosis, sitosterolemia, hypocholesterolemia, Tay-Sachs disease, Sandhoff's disease, hyperlipidemia, hyperlipemia, lipid myopathies, and obesity.

In another embodiment, a vector capable of expressing PKIN or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PKIN including, but not limited to, those described above.

In a further embodiment, a composition comprising a substantially purified PKIN in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PKIN including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of PKIN may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PKIN including, but not limited to, those listed above.

In a further embodiment, an antagonist of PKIN may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of PKIN. Examples of such disorders include, but are not limited to, those cancer, immune disorders, disorders affecting growth and development, cardiovascular diseases, and lipid disorders described above. In one aspect, an antibody which specifically binds PKIN may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express PKIN.

In an additional embodiment, a vector expressing the complement of the polynucleotide encoding PKIN may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of PKIN including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of PKIN may be produced using methods which are generally known in the art. In particular, purified PKIN may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind PKIN. Antibodies to PKIN may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments

produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with PKIN or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluionic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to PKIN have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of PKIN amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to PKIN may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. USA 80:2026-2030; and Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) Proc. Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce PKIN-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.)

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

Antibody fragments which contain specific binding sites for PKIN may also be generated. For example, such fragments include, but are not limited to, $F(ab')_2$ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the $F(ab')_2$ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) Science 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between PKIN and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering PKIN epitopes is generally used, but a competitive binding assay may also be employed (Pound, *supra*).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for PKIN. Affinity is expressed as an association constant, K_a , which is defined as the molar concentration of PKIN-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The K_a determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple PKIN epitopes, represents the average affinity, or avidity, of the antibodies for PKIN. The K_a determined for a preparation of monoclonal antibodies, which are monospecific for a particular PKIN epitope, represents a true measure of affinity. High-affinity antibody preparations with K_a ranging from about 10^9 to 10^{12} L/mole are preferred for use in immunoassays in which the PKIN-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_a ranging from about 10^6 to 10^7 L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of PKIN, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington DC; Liddell, J.E. and A. Cryer (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of PKIN-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for

antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. supra.)

In another embodiment of the invention, the polynucleotides encoding PKIN, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene
5 expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding PKIN. Such technology is well known in the art, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding PKIN. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa NJ.)

10 In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J.E. et al. (1998) *J. Allergy Clin. Immunol.* 102(3):469-475; and Scanlon, K.J. et al. (1995)
15 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) *Blood* 76:271; Ausubel, supra; Uckert, W. and W. Walther (1994) *Pharmacol. Ther.* 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J.J. (1995) *Br. Med. Bull.* 51(1):217-225; Boado, R.J. et
20 al. (1998) *J. Pharm. Sci.* 87(11):1308-1315; and Morris, M.C. et al. (1997) *Nucleic Acids Res.* 25(14):2730-2736.)

In another embodiment of the invention, polynucleotides encoding PKIN may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-
25 linked inheritance (Cavazzana-Calvo, M. et al. (2000) *Science* 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R.M. et al. (1995) *Science* 270:475-480; Bordignon, C. et al. (1995) *Science* 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) *Cell* 75:207-216; Crystal, R.G. et al. (1995) *Hum. Gene Therapy* 6:643-666; Crystal, R.G. et al. (1995) *Hum. Gene Therapy* 6:667-703), thalassamias, familial
30 hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R.G. (1995) *Science* 270:404-410; Verma, I.M. and N. Somia (1997) *Nature* 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988)

Nature 335:395-396; Poeschla, E. et al. (1996) Proc. Natl. Acad. Sci. USA. 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in PKIN expression or regulation causes disease, the expression of

- 5 PKIN from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

In a further embodiment of the invention, diseases or disorders caused by deficiencies in PKIN are treated by constructing mammalian expression vectors encoding PKIN and introducing these vectors by mechanical means into PKIN-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R.A. and W.F. Anderson (1993) Annu. Rev. Biochem. 62:191-217; Ivics, Z. (1997) Cell 91:501-510; Boulay, J-L. and H. Récipon (1998) Curr. Opin. Biotechnol. 9:445-450).

- 15 Expression vectors that may be effective for the expression of PKIN include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX, PCR2-TOPOTA vectors (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). PKIN may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or β -actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551; Gossen, M. et al. (1995) Science 268:1766-1769; Rossi, F.M.V. and H.M. Blau (1998) Curr. Opin. Biotechnol. 9:451-456), commercially available in the T-REX plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the
- 20 FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V. and Blau, H.M. supra), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding PKIN from a normal individual.

- Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver
- 30 polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and A.J. Eb (1973) Virology 52:456-467), or by electroporation (Neumann, E. et al. (1982) EMBO J. 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to PKIN expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding PKIN under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus *cis*-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc. Natl. Acad. Sci. USA 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) J. Virol. 61:1647-1650; Bender, M.A. et al. (1987) J. Virol. 61:1639-1646; Adam, M.A. and A.D. Miller (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol. 72:8463-8471; Zufferey, R. et al. (1998) J. Virol. 72:9873-9880). U.S. Patent Number 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4⁺ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M.L. (1997) J. Virol. 71:4707-4716; Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. USA 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).

In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding PKIN to cells which have one or more genetic abnormalities with respect to the expression of PKIN. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M.E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Patent Number 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al. (1999) Annu. Rev. Nutr. 19:511-544 and Verma, I.M. and N. Somia (1997) Nature 18:389:239-242, both incorporated by reference herein.

In another alternative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding PKIN to target cells which have one or more genetic abnormalities with respect to the expression of PKIN. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing PKIN to cells of the central nervous system, for which HSV has a

tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) *Exp. Eye Res.* 169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Patent Number 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is hereby incorporated by reference. U.S. Patent Number 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W.F. et al. (1999) *J. Virol.* 73:519-532 and Xu, H. et al. (1994) *Dev. Biol.* 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.

In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver polynucleotides encoding PKIN to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K.-J. Li (1998) *Curr. Opin. Biotechnol.* 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for PKIN into the alphavirus genome in place of the capsid-coding region results in the production of a large number of PKIN-coding RNAs and the synthesis of high levels of PKIN in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S.A. et al. (1997) *Virology* 228:74-83). The wide host range of alphaviruses will allow the introduction of PKIN into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding PKIN.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding PKIN. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine,

and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding PKIN. Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased PKIN expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding PKIN may be therapeutically useful, and in the treatment of disorders associated with decreased PKIN expression or activity, a compound which specifically promotes expression of the polynucleotide encoding PKIN may be therapeutically useful.

At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding PKIN is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an in vitro cell-free or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding PKIN are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding PKIN. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide can be carried out, for example, using a Schizosaccharomyces pombe gene expression system (Atkins, D. et al. (1999) U.S. Patent No. 5,932,435; Arndt, G.M. et al. (2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M.L. et al. (2000) Biochem. Biophys. Res. Commun.

268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruice, T.W. et al. (1997) U.S. Patent No. 5,686,242; Bruice, T.W. et al. (2000) U.S. Patent No. 6,022,691).

5 Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat.

10 Biotechnol. 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

15 An additional embodiment of the invention relates to the administration of a composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins. Various formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA). Such compositions may consist of PKIN, antibodies to PKIN, and mimetics, agonists, antagonists, or inhibitors of PKIN.

20 The compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

25 Compositions for pulmonary administration may be prepared in liquid or dry powder form. These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar region of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, J.S. et al., U.S. Patent No. 5,997,848). Pulmonary delivery has the advantage of administration without
30 needle injection, and obviates the need for potentially toxic penetration enhancers.

Compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

Specialized forms of compositions may be prepared for direct intracellular delivery of macromolecules comprising PKIN or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of the macromolecule. Alternatively, PKIN or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S.R. et al. (1999) Science 285:1569-1572).

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example PKIN or fragments thereof, antibodies of PKIN, and agonists, antagonists or inhibitors of PKIN, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED_{50} (the dose therapeutically effective in 50% of the population) or LD_{50} (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD_{50}/ED_{50} ratio. Compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED_{50} with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1 μg to 100,000 μg , up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art.

Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

5 In another embodiment, antibodies which specifically bind PKIN may be used for the diagnosis of disorders characterized by expression of PKIN, or in assays to monitor patients being treated with PKIN or agonists, antagonists, or inhibitors of PKIN. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for PKIN include methods which utilize the antibody and a label to detect PKIN in human body
10 fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring PKIN, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of PKIN expression. Normal
15 or standard values for PKIN expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibodies to PKIN under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of PKIN expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation
20 between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding PKIN may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of PKIN may be correlated with
25 disease. The diagnostic assay may be used to determine absence, presence, and excess expression of PKIN, and to monitor regulation of PKIN levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding PKIN or closely related molecules may be used to identify nucleic acid sequences which encode PKIN. The specificity of the probe, whether it is made
30 from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding PKIN, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the PKIN encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:25-48 or from genomic sequences including promoters, enhancers, and introns of the PKIN gene.

5 Means for producing specific hybridization probes for DNAs encoding PKIN include the cloning of polynucleotide sequences encoding PKIN or PKIN derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a
10 variety of reporter groups, for example, by radionuclides such as ^{32}P or ^{35}S , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding PKIN may be used for the diagnosis of disorders associated with expression of PKIN. Examples of such disorders include, but are not limited to, a cancer, such as adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma,
15 teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus, leukemias such as multiple myeloma and lymphomas such as Hodgkin's disease; an immune disorder, such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress
20 syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's
25 syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer,
30 hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a growth and developmental disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma,

teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus, renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker

5 muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Sydenham's chorea and cerebral palsy, spina bifida, anencephaly,

10 craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss; a cardiovascular disease, such as arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, vascular tumors, and complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery, congestive heart failure, ischemic heart disease, angina pectoris,

15 myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, and complications of

20 cardiac transplantation, congenital lung anomalies, atelectasis, pulmonary congestion and edema, pulmonary embolism, pulmonary hemorrhage, pulmonary infarction, pulmonary hypertension, vascular sclerosis, obstructive pulmonary disease, restrictive pulmonary disease, chronic obstructive pulmonary disease, emphysema, chronic bronchitis, bronchial asthma, bronchiectasis, bacterial pneumonia, viral and mycoplasmal pneumonia, lung abscess, pulmonary tuberculosis, diffuse interstitial diseases,

25 pneumoconioses, sarcoidosis, idiopathic pulmonary fibrosis, desquamative interstitial pneumonitis, hypersensitivity pneumonitis, pulmonary eosinophilia bronchiolitis obliterans-organizing pneumonia, diffuse pulmonary hemorrhage syndromes, Goodpasture's syndromes, idiopathic pulmonary hemosiderosis, pulmonary involvement in collagen-vascular disorders, pulmonary alveolar proteinosis, lung tumors, inflammatory and noninflammatory pleural effusions, pneumothorax, pleural tumors, drug

30 induced lung disease, radiation-induced lung disease, and complications of lung transplantation; and a lipid disorder such as fatty liver, cholestasis, primary biliary cirrhosis, carnitine deficiency, carnitine palmitoyltransferase deficiency, myoadenylate deaminase deficiency, hypertriglyceridemia, lipid storage disorders such as Fabry's disease, Gaucher's disease, Niemann-Pick's disease, metachromatic leukodystrophy, adrenoleukodystrophy, GM₂ gangliosidosis, and ceroid lipofuscinosis,

abetalipoproteinemia, Tangier disease, hyperlipoproteinemia, diabetes mellitus, lipodystrophy, lipomatoses, acute panniculitis, disseminated fat necrosis, adiposis dolorosa, lipoid adrenal hyperplasia, minimal change disease, lipomas, atherosclerosis, hypercholesterolemia, hypercholesterolemia with hypertriglyceridemia, primary hypoalphalipoproteinemia, hypothyroidism, renal disease, liver disease, lecithin:cholesterol acyltransferase deficiency, cerebrotendinous xanthomatosis, sitosterolemia, hypocholesterolemia, Tay-Sachs disease, Sandhoff's disease, hyperlipidemia, hyperlipemia, lipid myopathies, and obesity. The polynucleotide sequences encoding PKIN may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered PKIN expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding PKIN may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding PKIN may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding PKIN in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of PKIN, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding PKIN, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding PKIN may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding PKIN, or a fragment of a polynucleotide complementary to the polynucleotide encoding PKIN, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences encoding PKIN may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding PKIN are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSSCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed *in silico* SNP (isSNP), are capable of identifying polymorphisms by comparing the sequence of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego CA).

Methods which may also be used to quantify the expression of PKIN include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) J. Immunol. Methods 159:235-244; Duplaa, C.

et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

5 In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described below. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene
10 function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and
15 display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.

In another embodiment, PKIN, fragments of PKIN, or antibodies specific for PKIN may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.

20 A particular embodiment relates to the use of the polynucleotides of the present invention to generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent Number
25 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The
30 resultant transcript image would provide a profile of gene activity.

Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

Transcript images which profile the expression of the polynucleotides of the present invention may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed

5 molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E.F. et al. (1999) *Mol. Carcinog.* 24:153-159; Steiner, S. and N.L. Anderson (2000) *Toxicol. Lett.* 112-113:467-471, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information

10 from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a

15 toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released February 29, 2000, available at <http://www.niehs.nih.gov/oc/news/toxchip.htm>.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed

20 gene sequences.

In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be

25 quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

Another particular embodiment relates to the use of the polypeptide sequences of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global

30 pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is

achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, *supra*). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.

A proteomic profile may also be generated using antibodies specific for PKIN to quantify the levels of PKIN expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) *Anal. Biochem.* 270:103-111; Mendoz, L.G. et al. (1999) *Biotechniques* 27:778-788). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.

Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N.L. and J. Seilhamer (1997) *Electrophoresis* 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the

test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the polypeptides of the present invention.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.) Various types of microarrays are well known and thoroughly described in DNA Microarrays: A Practical Approach, M. Schena, ed. (1999) Oxford University Press, London, hereby expressly incorporated by reference.

In another embodiment of the invention, nucleic acid sequences encoding PKIN may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP). (See, for example, Lander, E.S. and D. Botstein (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding PKIN on a

physical map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder and thus may further positional cloning efforts.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps.

5 Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the exact chromosomal locus is not known. This information is valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any
10 sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the instant invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, PKIN, its catalytic or immunogenic fragments, or
15 oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between PKIN and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds
20 having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with PKIN, or fragments thereof, and washed. Bound PKIN is then detected by methods well known in the art. Purified PKIN can also be coated directly onto plates for use in the aforementioned drug screening techniques.
25 Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding PKIN specifically compete with a test compound for binding PKIN. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more
30 antigenic determinants with PKIN.

In additional embodiments, the nucleotide sequences which encode PKIN may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

5 The disclosures of all patents, applications and publications, mentioned above and below and including U.S. Ser. No. 60/229,873, U.S. Ser. No. 60/231,357, U.S. Ser. No. 60/232,654, U.S. Ser. No. 60/234,902, U.S. Ser. No. 60/236,499, U.S. Ser. No. 60/238,389, and U.S. Ser. No. 60/240,542, are expressly incorporated by reference herein.

10 EXAMPLES

I. Construction of cDNA Libraries

Incye cDNAs were derived from cDNA libraries described in the LIFESEQ GOLD database (Incye Genomics, Palo Alto CA) and shown in Table 4, column 5. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in
15 phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA
20 purity. In some cases, RNA was treated with DNase. For most libraries, poly(A)+ RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

25 In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERScript plasmid system (Life Technologies), using

PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), PCDNA2.1 plasmid (Invitrogen, Carlsbad CA), PBK-CMV plasmid (Stratagene), PCR2-TOPOTA (Invitrogen), PCMV-ICIS (Stratagene), or pINCY (Incyte Genomics, Palo Alto CA), or derivatives thereof. Recombinant plasmids were transformed into competent *E. coli* cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5 α , DH10B, or ElectroMAX DH10B from Life Technologies.

II. Isolation of cDNA Clones

Plasmids obtained as described in Example I were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

III. Sequencing and Analysis

Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows. Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Applied Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII.

The polynucleotide sequences derived from Incyte cDNAs were validated by removing vector, linker, and poly(A) sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The Incyte cDNA sequences or translations thereof were then queried against a selection of public

5 databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM, and hidden Markov model (HMM)-based protein family databases such as PFAM. (HMM is a probabilistic approach which analyzes consensus primary structures of gene families. See, for example, Eddy, S.R. (1996) *Curr. Opin. Struct. Biol.* 6:361-365.) The queries were performed using programs based on BLAST, FASTA, BLIMPS, and HMMER.

10 The Incyte cDNA sequences were assembled to produce full length polynucleotide sequences. Alternatively, GenBank cDNAs, GenBank ESTs, stitched sequences, stretched sequences, or Genscan-predicted coding sequences (see Examples IV and V) were used to extend Incyte cDNA assemblages to full length. Assembly was performed using programs based on Phred, Phrap, and Consed, and cDNA assemblages were screened for open reading frames using programs based on

15 GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length polypeptide sequences. Alternatively, a polypeptide of the invention may begin at any of the methionine residues of the full length translated polypeptide. Full length polypeptide sequences were subsequently analyzed by querying against databases such as the GenBank protein databases (genpept), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and hidden

20 Markov model (HMM)-based protein family databases such as PFAM. Full length polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLUSTAL algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also

25 calculates the percent identity between aligned sequences.

Table 7 summarizes the tools, programs, and algorithms used for the analysis and assembly of Incyte cDNA and full length sequences and provides applicable descriptions, references, and threshold parameters. The first column of Table 7 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of

30 which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score or the lower the probability value, the greater the identity between two sequences).

The programs described above for the assembly and analysis of full length polynucleotide and polypeptide sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:25-48. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies are described in Table 4, column 4.

5 IV. Identification and Editing of Coding Sequences from Genomic DNA

Putative human kinases were initially identified by running the Genscan gene identification program against public genomic sequence databases (e.g., gbpri and gbhtg). Genscan is a general-purpose gene identification program which analyzes genomic DNA sequences from a variety of organisms (See Burge, C. and S. Karlin (1997) J. Mol. Biol. 268:78-94, and Burge, C. and S. Karlin
10 (1998) Curr. Opin. Struct. Biol. 8:346-354). The program concatenates predicted exons to form an assembled cDNA sequence extending from a methionine to a stop codon. The output of Genscan is a FASTA database of polynucleotide and polypeptide sequences. The maximum range of sequence for Genscan to analyze at once was set to 30 kb. To determine which of these Genscan predicted cDNA sequences encode human kinases, the encoded polypeptides were analyzed by querying against
15 PFAM models for human kinases. Potential human kinases were also identified by homology to Incyte cDNA sequences that had been annotated as human kinases. These selected Genscan-predicted sequences were then compared by BLAST analysis to the genpept and gbpri public databases. Where necessary, the Genscan-predicted sequences were then edited by comparison to the top BLAST hit from genpept to correct errors in the sequence predicted by Genscan, such as
20 extra or omitted exons. BLAST analysis was also used to find any Incyte cDNA or public cDNA coverage of the Genscan-predicted sequences, thus providing evidence for transcription. When Incyte cDNA coverage was available, this information was used to correct or confirm the Genscan predicted sequence. Full length polynucleotide sequences were obtained by assembling Genscan-predicted coding sequences with Incyte cDNA sequences and/or public cDNA sequences using the assembly
25 process described in Example III. Alternatively, full length polynucleotide sequences were derived entirely from edited or unedited Genscan-predicted coding sequences.

V. Assembly of Genomic Sequence Data with cDNA Sequence Data

"Stitched" Sequences

Partial cDNA sequences were extended with exons predicted by the Genscan gene
30 identification program described in Example IV. Partial cDNAs assembled as described in Example III were mapped to genomic DNA and parsed into clusters containing related cDNAs and Genscan exon predictions from one or more genomic sequences. Each cluster was analyzed using an algorithm based on graph theory and dynamic programming to integrate cDNA and genomic information, generating possible splice variants that were subsequently confirmed, edited, or extended to create a

full length sequence. Sequence intervals in which the entire length of the interval was present on more than one sequence in the cluster were identified, and intervals thus identified were considered to be equivalent by transitivity. For example, if an interval was present on a cDNA and two genomic sequences, then all three intervals were considered to be equivalent. This process allows unrelated but consecutive genomic sequences to be brought together, bridged by cDNA sequence. Intervals thus identified were then "stitched" together by the stitching algorithm in the order that they appear along their parent sequences to generate the longest possible sequence, as well as sequence variants. Linkages between intervals which proceed along one type of parent sequence (cDNA to cDNA or genomic sequence to genomic sequence) were given preference over linkages which change parent type (cDNA to genomic sequence). The resultant stitched sequences were translated and compared by BLAST analysis to the genpept and gbpr public databases. Incorrect exons predicted by Genscan were corrected by comparison to the top BLAST hit from genpept. Sequences were further extended with additional cDNA sequences, or by inspection of genomic DNA, when necessary.

"Stretched" Sequences

Partial DNA sequences were extended to full length with an algorithm based on BLAST analysis. First, partial cDNAs assembled as described in Example III were queried against public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases using the BLAST program. The nearest GenBank protein homolog was then compared by BLAST analysis to either Incyte cDNA sequences or GenScan exon predicted sequences described in Example IV. A chimeric protein was generated by using the resultant high-scoring segment pairs (HSPs) to map the translated sequences onto the GenBank protein homolog. Insertions or deletions may occur in the chimeric protein with respect to the original GenBank protein homolog. The GenBank protein homolog, the chimeric protein, or both were used as probes to search for homologous genomic sequences from the public human genome databases. Partial DNA sequences were therefore "stretched" or extended by the addition of homologous genomic sequences. The resultant stretched sequences were examined to determine whether it contained a complete gene.

VI. Chromosomal Mapping of PKIN Encoding Polynucleotides

The sequences which were used to assemble SEQ ID NO:25-48 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ ID NO:25-48 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 7). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Généthon were used to determine if any of the clustered sequences

had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO., to that map location.

Map locations are represented by ranges, or intervals, of human chromosomes. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Généthon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters. Human genome maps and other resources available to the public, such as the NCBI "GeneMap'99" World Wide Web site (<http://www.ncbi.nlm.nih.gov/genemap/>), can be employed to determine if previously identified disease genes map within or in proximity to the intervals indicated above.

VII. Analysis of Polynucleotide Expression

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, *supra*, ch. 7; Ausubel (1995) *supra*, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\text{BLAST Score} \times \text{Percent Identity}}{5 \times \text{minimum \{length(Seq. 1), length(Seq. 2)\}}}$$

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a

BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

Alternatively, polynucleotide sequences encoding PKIN are analyzed with respect to the tissue sources from which they were derived. For example, some full length sequences are assembled, at least in part, with overlapping Incyte cDNA sequences (see Example III). Each cDNA sequence is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following organ/tissue categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract. The number of libraries in each category is counted and divided by the total number of libraries across all categories. Similarly, each human tissue is classified into one of the following disease/condition categories: cancer, cell line, developmental, inflammation, neurological, trauma, cardiovascular, pooled, and other, and the number of libraries in each category is counted and divided by the total number of libraries across all categories. The resulting percentages reflect the tissue- and disease-specific expression of cDNA encoding PKIN. cDNA sequences and cDNA library/tissue information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA).

VIII. Extension of PKIN Encoding Polynucleotides

Full length polynucleotide sequences were also produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer was synthesized to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg^{2+} , $(NH_4)_2SO_4$,

and 2-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100 µl PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 µl of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 µl to 10 µl aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).

In like manner, full length polynucleotide sequences are verified using the above procedure or are used to obtain 5' regulatory sequences using the above procedure along with oligonucleotides designed for such extension, and an appropriate genomic library.

IX. Labeling and Use of Individual Hybridization Probes

5 Hybridization probes derived from SEQ ID NO:25-48 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μ Ci of
10 [γ -³²P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10⁷ counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase
15 I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate.
20 Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.

X. Microarrays

The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink-jet printing, See, e.g., Baldeschweiler, supra), mechanical
25 microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned technologies should be uniform and solid with a non-porous surface (Skena (1999), supra). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers. Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may
30 be produced using available methods and machines well known to those of ordinary skill in the art and may contain any appropriate number of elements. (See, e.g., Skena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645; Marshall, A. and J. Hodgson (1998) Nat. Biotechnol. 16:27-31.)

Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser desorption and mass spectrometry may be used for detection of hybridization. The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.

Tissue or Cell Sample Preparation

Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)⁺ RNA is purified using the oligo-(dT) cellulose method. Each poly(A)⁺ RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/ μ l oligo-(dT) primer (21mer), 1X first strand buffer, 0.03 units/ μ l RNase inhibitor, 500 μ M dATP, 500 μ M dGTP, 500 μ M dTTP, 40 μ M dCTP, 40 μ M dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)⁺ RNA with GEMBRIGHT kits (Incyte). Specific control poly(A)⁺ RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA. After incubation at 37°C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85°C to stop the reaction and degrade the RNA. Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and resuspended in 14 μ l 5X SSC/0.2% SDS.

Microarray Preparation

Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 μ g. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).

Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester PA), washed extensively in distilled water, and
5 coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C oven.

Array elements are applied to the coated glass substrate using a procedure described in US Patent No. 5,807,522, incorporated herein by reference. 1 μ l of the array element DNA, at an average concentration of 100 ng/ μ l, is loaded into the open capillary printing element by a high-speed robotic
10 apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford MA) for 30 minutes at 60°C followed by washes in 0.2%
15 SDS and distilled water as before.

Hybridization

Hybridization reactions contain 9 μ l of sample mixture consisting of 0.2 μ g each of Cy3 and Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer. The sample mixture is heated to 65°C for 5 minutes and is aliquoted onto the microarray surface and covered with
20 an 1.8 cm² coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 μ l of 5X SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60°C. The arrays are washed for 10 min at 45°C in a first wash buffer (1X SSC, 0.1% SDS), three times for 10 minutes each at 45°C in a second wash buffer (0.1X SSC), and dried.

Detection

Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide
30 containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8-cm array used in the present example is scanned with a resolution of 20 micrometers.

In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477,

Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood MA) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

XI. Complementary Polynucleotides

Sequences complementary to the PKIN-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring PKIN. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of PKIN. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the PKIN-encoding transcript.

XII. Expression of PKIN

Expression and purification of PKIN is achieved using bacterial or virus-based expression systems. For expression of PKIN in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac (tac)* hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3).

Antibiotic resistant bacteria express PKIN upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of PKIN in eukaryotic cells is achieved by infecting insect or mammalian cell

lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding PKIN by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, PKIN is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from PKIN at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch. 10 and 16). Purified PKIN obtained by these methods can be used directly in the assays shown in Examples XVI, XVII, XVIII, and XIX where applicable.

XIII. Functional Assays

PKIN function is assessed by expressing the sequences encoding PKIN at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include PCMV SPORT (Life Technologies) and PCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 μ g of recombinant vector are transiently transfected into

a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 μ g of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of PKIN on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding PKIN and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding PKIN and other genes of interest can be analyzed by northern analysis or microarray techniques.

XIV. Production of PKIN Specific Antibodies

PKIN substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the PKIN amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Applied Biosystems) using Fmoc chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, *supra*.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-PKIN activity by, for example, binding the peptide or PKIN to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

XV. Purification of Naturally Occurring PKIN Using Specific Antibodies

Naturally occurring or recombinant PKIN is substantially purified by immunoaffinity chromatography using antibodies specific for PKIN. An immunoaffinity column is constructed by covalently coupling anti-PKIN antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing PKIN are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of PKIN (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/PKIN binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and PKIN is collected.

XVI. Identification of Molecules Which Interact with PKIN

PKIN, or biologically active fragments thereof, are labeled with ^{125}I Bolton-Hunter reagent. (See, e.g., Bolton A.E. and W.M. Hunter (1973) *Biochem. J.* 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled PKIN, washed, and any wells with labeled PKIN complex are assayed. Data obtained using different concentrations of PKIN are used to calculate values for the number, affinity, and association of PKIN with the candidate molecules.

Alternatively, molecules interacting with PKIN are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989) *Nature* 340:245-246, or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech).

PKIN may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Patent No. 6,057,101).

XVII. Demonstration of PKIN Activity

Generally, protein kinase activity is measured by quantifying the phosphorylation of a protein substrate by PKIN in the presence of $[\gamma\text{-}^{32}\text{P}]\text{ATP}$. PKIN is incubated with the protein substrate, $^{32}\text{P}\text{-ATP}$, and an appropriate kinase buffer. The ^{32}P incorporated into the substrate is separated from free $^{32}\text{P}\text{-ATP}$ by electrophoresis and the incorporated ^{32}P is counted using a radioisotope counter.

- 5 The amount of incorporated ^{32}P is proportional to the activity of PKIN. A determination of the specific amino acid residue phosphorylated is made by phosphoamino acid analysis of the hydrolyzed protein.

In one alternative, protein kinase activity is measured by quantifying the transfer of gamma phosphate from adenosine triphosphate (ATP) to a serine, threonine or tyrosine residue in a protein substrate. The reaction occurs between a protein kinase sample with a biotinylated peptide substrate and gamma $^{32}\text{P}\text{-ATP}$. Following the reaction, free avidin in solution is added for binding to the biotinylated $^{32}\text{P}\text{-peptide}$ product. The binding sample then undergoes a centrifugal ultrafiltration process with a membrane which will retain the product-avidin complex and allow passage of free gamma $^{32}\text{P}\text{-ATP}$. The reservoir of the centrifuged unit containing the $^{32}\text{P}\text{-peptide}$ product as retentate is then counted in a scintillation counter. This procedure allows assay of any type of protein kinase sample, depending on the peptide substrate and kinase reaction buffer selected. This assay is provided in kit form (ASUA, Affinity Ultrafiltration Separation Assay, Transbio Corporation, Baltimore MD, U.S. Patent No. 5,869,275). Suggested substrates and their respective enzymes include but are not limited to: Histone H1 (Sigma) and p34^{cdc2}kinase, Annexin I, Angiotensin (Sigma) and EGF receptor kinase, Annexin II and *src* kinase, ERK1 & ERK2 substrates and MEK, and myelin basic protein and ERK (Pearson, J.D. et al. (1991) Methods Enzymol. 200:62-81).

In another alternative, protein kinase activity of PKIN is demonstrated in an assay containing PKIN, 50 μl of kinase buffer, 1 μg substrate, such as myelin basic protein (MBP) or synthetic peptide substrates, 1 mM DTT, 10 μg ATP, and 0.5 μCi $[\gamma\text{-}^{32}\text{P}]\text{ATP}$. The reaction is incubated at 30°C for 30 minutes and stopped by pipetting onto P81 paper. The unincorporated $[\gamma\text{-}^{32}\text{P}]\text{ATP}$ is removed by washing and the incorporated radioactivity is measured using a scintillation counter. Alternatively, the reaction is stopped by heating to 100°C in the presence of SDS loading buffer and resolved on a 12% SDS polyacrylamide gel followed by autoradiography. The amount of incorporated ^{32}P is proportional to the activity of PKIN.

30 In yet another alternative, adenylate kinase or guanylate kinase activity may be measured by the incorporation of ^{32}P from $[\gamma\text{-}^{32}\text{P}]\text{ATP}$ into ADP or GDP using a gamma radioisotope counter. The enzyme, in a kinase buffer, is incubated together with the appropriate nucleotide mono-phosphate substrate (AMP or GMP) and ^{32}P -labeled ATP as the phosphate donor. The reaction is incubated at 37°C and terminated by addition of trichloroacetic acid. The acid extract is neutralized and subjected

to gel electrophoresis to separate the mono-, di-, and triphosphonucleotide fractions. The diphosphonucleotide fraction is excised and counted. The radioactivity recovered is proportional to the enzyme activity.

In yet another alternative, other assays for PKIN include scintillation proximity assays (SPA), scintillation plate technology and filter binding assays. Useful substrates include recombinant proteins tagged with glutathione transferase, or synthetic peptide substrates tagged with biotin. Inhibitors of PKIN activity, such as small organic molecules, proteins or peptides, may be identified by such assays.

XVIII. Enhancement/Inhibition of Protein Kinase Activity

Agonists or antagonists of PKIN activation or inhibition may be tested using assays described in section XVII. Agonists cause an increase in PKIN activity and antagonists cause a decrease in PKIN activity.

XIX. Kinase Binding Assay

Binding of PKIN to a FLAG-CD44 cyt fusion protein can be determined by incubating PKIN to anti-PKIN-conjugated immunoaffinity beads followed by incubating portions of the beads (having 10-20 ng of protein) with 0.5 ml of a binding buffer (20 mM Tris-HCL (pH 7.4), 150 mM NaCl, 0.1% bovine serum albumin, and 0.05% Triton X-100) in the presence of ¹²⁵I-labeled FLAG-CD44cyt fusion protein (5,000 cpm/ng protein) at 4 °C for 5 hours. Following binding, beads were washed thoroughly in the binding buffer and the bead-bound radioactivity measured in a scintillation counter (Bourguignon, L.Y.W. et al. (2001) J. Biol. Chem. 276:7327-7336). The amount of incorporated ³²P is proportional to the amount of bound PKIN.

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Table 1

Incyte Project ID	Polypeptide SEQ ID NO:	Incyte Polypeptide ID	Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID
7312543	1	7312543CD1	25	7312543CB1
7477427	2	7477427CD1	26	7477427CB1
7481495	3	7481495CD1	27	7481495CB1
55053189	4	55053189CD1	28	55053189CB1
7474797	5	7474797CD1	29	7474797CB1
3296272	6	3296272CD1	30	3296272CB1
1989319	7	1989319CD1	31	1989319CB1
079284	8	079284CD1	32	079284CB1
5502218	9	5502218CD1	33	5502218CB1
55056054	10	55056054CD1	34	55056054CB1
7481989	11	7481989CD1	35	7481989CB1
55052990	12	55052990CD1	36	55052990CB1
7482377	13	7482377CD1	37	7482377CB1
7758364	14	7758364CD1	38	7758364CB1
5850001	15	5850001CD1	39	5850001CB1
7477062	16	7477062CD1	40	7477062CB1
7477207	17	7477207CD1	41	7477207CB1
4022651	18	4022651CD1	42	4022651CB1
7274927	19	7274927CD1	43	7274927CB1
7946584	20	7946584CD1	44	7946584CB1
8088078	21	8088078CD1	45	8088078CB1
2674269	22	2674269CD1	46	2674269CB1
7472409	23	7472409CD1	47	7472409CB1
7477484	24	7477484CD1	48	7477484CB1

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO:	Probability score	GenBank Homolog
1	7312543CD1	g4115429	9.00E-215	[Rattus norvegicus] serin/threonine protein kinase (Amano, M. et al. (1996) Science 271:648-650)
2	7477427CD1	g2736151	0	[Rattus norvegicus] myotonic dystrophy kinase-related (Jeung, T. et al. (1998) Mol. Cell. Biol. 18 (1), 130-140)
3	7481495CD1	g10945428	0	[fl][Homo sapiens] membrane-associated guanylate kinase MAGI3 (Wu, Y. et al. (2000) J. Biol. Chem. 275 (28), 21477-21485)
4	55053189CD1	g1360110	5.80E-73	[Plasmodium falciparum] mitogen-activated protein kinase 1, serine/threonine protein kinase (Doerig, C.M. et al. (1996) Gene 177 (1-2), 1-6)
		g4220888	5.30E-171	[Rattus norvegicus] extracellular signal-regulated kinase 7; ERK7 (Abe, M.K. et al. (1999) Mol. Cell. Biol. 19 (2), 1301-1312)
		g2131000	4.20E-70	[Leishmania mexicana] MAP-kinase homologue (Wiese, M. (1998) EMBO J. 17 (9), 2619-2628)
5	7474797CD1	g404634	2.60E-54	[Mus musculus] serine/threonine kinase (Bielke, W. et al. (1994) Gene 139 (2), 235-239)
6	3296272CD1	g6690020	1.60E-157	[Mus musculus] pantothenate kinase 1 beta (Rock, C.O. et al. (2000) J. Biol. Chem. 275 (2), 1377-1383)
7	1989319CD1	g6760436	9.20E-125	[Gallus gallus] gin-induced kinase (Xia, Y. et al. (2000) Biochem. Biophys. Res. Commun. 276 (2), 564-570)
8	79284CD1	g5757703	0	[Mus musculus] syntrophin-associated serine-threonine protein kinase (Lumeng, C. et al. (1999) Nat. Neurosci. 2 (7), 611-617)
9	5502218CD1	g8272557	0	[Rattus norvegicus] protein kinase WNK1 (Xu, B. et al. (2000) J. Biol. Chem. 275 (22), 16795-16801)

Table 2 (cont.)

Polyptide SEQ ID NO:	Incyte Polyptide ID	GenBank ID NO:	Probability score	GenBank Homolog
10	55056054CD1	g162787	1.80E-213	[Bos taurus] cAMP-dependent protein kinase II-beta catalytic (Wiemann, S. et al. (1991) J. Biol. Chem. 266, 5140-5145)
11	7481989CD1	g529073	8.20E-18	[Mus musculus] tyrosine-specific protein kinase (Kohmura, N. et al. (1994) Mol. Cell. Biol. 14 (10), 6915-6925)
12	55052990CD1	g10177211 g12005724	4.00E-21 0	[fl][Arabidopsis thaliana] protein kinase [5' incom][Homo sapiens] mixed lineage kinase MLK1
13	7482377CD1	g3851202	0	[Homo sapiens] MAGUK family member ZO-3 (Haskins, J. et al. (1998) J. Cell Biol. 141:199-208)
14	7758364CD1	g6716518	4.40E-266	[Mus musculus] doublecortin-like kinase (Burgess, H.A. et al. (1999) J. Neurosci. Res. 58 (4), 567-575)
15	5850001CD1	g6690020	9.90E-165	[Mus musculus] pantothenate kinase 1 beta (Rock, C.O. et al. (2000) J. Biol. Chem. 275 (2), 1377-1383)
16	7477062CD1	g4115429	7.90E-53	[Rattus norvegicus] serin/threonine protein kinase
17	7477207CD1	g12830335 g3136154	1.00E-130 1.10E-17	[5' incom][Homo sapiens] bA55008.2 (novel protein kinase) [Mus musculus] UNC-51-like kinase ULK1 (Kuroyanagi, H., et al. (1998) Genomics 51:76-85)
18	4022651CD1	g3217028	0	[Homo sapiens] putative serine/threonine protein kinase (Stanchi, F. et al. (2001) Yeast 18 (1), 69-80)
19	7274927CD1	g286232	3.10E-76	[Rattus norvegicus] nucleoside diphosphate kinase beta isoform (Shimada, N. et al. (1993) J. Biol. Chem. 268 (4), 2583-2589)
20	7946584CD1	g7161864	7.30E-148	[Mus musculus] serine/threonine protein kinase (Ruiz-Perez, V.L. et al. (2000) Nat. Genet. 24 (3), 283-286)
21	8088078CD1	g189992	1.20E-13	[Homo sapiens] protein kinase C-gamma (Coussens, L. et al. (1986) Science 233 (4766), 859-866)

Table 2 (cont.)

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO:	Probability score	GenBank Homolog
22	2674269CD1	g256855	5.60E-59	[Mus sp.] serine/threonine- and tyrosine-specific protein kinase, Nek1=NIMA cell cycle regulator homolog (Letwin, K. et al. (1992) EMBO J. 11 (10), 3521-3531)
23	7472409CD1	g256855	8.00E-64	[Mus sp.] serine/threonine- and tyrosine-specific protein kinase, Nek1=NIMA cell cycle regulator homolog (Letwin, K. et al. (1992) EMBO J. 11 (10), 3521-3531)
24	7477484CD1	g2459993	1.50E-153	[Mus musculus] apoptosis associated tyrosine kinase (Gaozza, E. et al. (1997) Oncogene 15:3127-35)

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
1	7312543CD1	424	S209 S257 S326 T150 T198 T215 T232 T285 T40 T418	N85	Eukaryotic protein kinase domain pkinae: Y53-V309 PROTEIN KINASE DOMAIN DM00004 JC1446 20-261: E54-R303 DM00004 P27448 58-297: L55-G304 DM00004 I48609 55-294: L55-G304 DM00004 Q05512 55-294: L55-G304 Tyrosine kinase catalytic site PR00109: Q128-P141, F164-L182, V234-A256 Protein kinase Ser/Thr active site domain Protein_Kinase_St: L170-L182 Protein kinase signatures and profile protein_kinase_tyr.prf: T150-G202 transmembrane domain: L228-T248	HMMER_PFAM BLAST_DOMO BLIMPS_PRINTS MOTIFS PROFILES SCAN HMMER

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
2	7477427CD1	1719	S167 S286 S344 S364 S369 S411 S459 S475 S507 S555 S616 S705 S750 S752 S781 S813 S877 S884 S917 S926 S940 S1532 T30 T423 T591 T624 T64 T691 T746 T780 T788 T959 T981 T999 Y358 S1142 T1172 T1242 S1283 S1406 S1607 S1651 S1271 S1306 T1492 S1517 S1532 S1622 S1643 S1680 S1700 T1712 Y1201 T1070	N560 N792 N854 N1629 N1688 N1691	Eukaryotic protein kinase domain pkinaase: F77-F343 Protein kinase C terminal domain pkinaase_C: S344-D372 PROTEIN KINASE DOMAIN DM00004 Q09013 83-336: I79-Q331 DM00004 S42867 75-498: I79-L226, V238-Y404, P1602-D1677 DM00004 I38133 90-369: E78-L226, V238-G330 DM00004 P53894 353-658: L80-G221, D205-Q331 Tyrosine kinase catalytic site PR00109: M154-S167, S191-M209, C263-E285 MYTONIC DYSTROPHY KINASE RELATED CDC42 BINDING KINASE PHORBOLESTER BINDING PD143271: R1592-P1719 PD011252: D833-P994 PD075023: E630-N713 PD150840: W1467-S1591 Phorbol ester/diacylglycerol binding domain DAG_PE-bind: H1000-C1049 Pleckstrin homology domain PH: T1070-K1188 Domain found in NIK1-like kinase, mouse citron CNH: K1215-K1499 Leucine Zipper: L772-L793, L779-L800, L786-L807	HMMER_PFAM HMMER_PFAM BLAST_DOMO BLIMPS_PRINTS BLAST_PRODUM HMMER_PFAM HMMER_PFAM HMMER_PFAM MOTIFS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
2					Protein kinase ATP binding domain Protein_Kinase_Atp: I83-K106 Protein kinase Ser/Thr active site domain Protein_Kinase_St: Y197-M209 Phorbol esters/DAG binding domain dag_pe_binding_domain.prf: C1013-A1071	MOTIFS MOTIFS PROFILESSCAN
3	7481495CD1	1125	S218 S227 S235 S278 S387 S388 S412 S572 S61 S66 S699 S785 S832 S889 S910 S949 S974 S987 S991 S1034 T102 T146 T190 T223 T224 T320 T365 T4 T417 T469 T520 T663 T668 T713 T805 T83 T868 Y303 Y353	N249 N274 N277 N487 N629	Guanylate kinase: T147-E243 Guanylate kinase protein BL00856: I143-I163 PROTEIN GUANYLATE KINASE MEMBRANEASSOCIATED ATROPHIN1 INTERACTING INVERTED PUTATIVE BAI1ASSOCIATED PD021703: M1-T146 PROTEIN GUANYLATE KINASE MEMBRANEASSOCIATED ATROPHIN1 INTERACTING INVERTED PAC PD029527: L326-Q379, E575-T663 Guanylate_Kinase: T146-I163 WW proline-rich motif binding domain WW: L295-P324, L341-P370 WW/rsp5/WWP domain BL01159: Y310-P324 WW domain signature PR00403: L295-M308, Y310-P324 Ww_Domain_1: W299-P324, W345-P370 PDZ domain found in signaling proteins PDZ: R410-G493, L576-G655, D724-K809, D851-E937, P1021-G1102	HMMER_PFAM BLIMPS_BLOCKS BLAST_PRODOM BLAST_PRODOM MOTIFS HMMER_PFAM BLIMPS_BLOCKS BLIMPS_PRINTS MOTIFS HMMER_PFAM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
3					PDZ domain PF00595: I1062-N1072 ATP/GTP binding site (P-loop) Atp_Gtp_A: G778-S785	BLIMPS_PPFAM MOTIFS
4	55053189CD1	500	S161 S192 S238 S294 S359 S403 S75 T150 T273 T3 T308 T57 Y89	N148	KINASE PROTEIN TRANSFERASE ATP BINDING SERINE/THREONINE PROTEIN PHOSPHORYLATION RECEPTOR TYROSINE PROTEIN PRECURSOR TRANSMEMBRANE PD000001:Y183-E301 Tyrosine kinase catalytic domain PR00109:F127-L145, V199-T221, T273-A295 Eukaryotic protein kinase domain pkinase: Y13-I299 Rgd R426-D428 Protein_Kinase_Atp L19-K42 Protein kinases signatures and profile protein_kinase_tyr.prf: H113-D164	BLAST_PRODOR BLIMPS_PRINTS HMMER_PPFAM MOTIFS MOTIFS PROFILES SCAN
5	7474797CD1	328	S18 S184 S38 S57 S62 T251 T95	N260	PROTEIN KINASE DOMAIN DM00004 P25389 22-275:E26-K280 Tyrosine kinase catalytic domain signature PR00109:L102-Q115, Y138-L156, S220-T242 Eukaryotic protein kinase domain pkinase: Y25-G293 Protein_Kinase_Atp I31-K54	BLAST_DOMO BLIMPS_PRINTS HMMER_PPFAM MOTIFS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
5					Protein_Kinase_St I144-L156 Protein_kinases_signatures_and_profile protein_kinase_tyr.prf: L124-Q177	MOTIFS PROFILESSCAN
6	3296272CD1	370	S10 S167 S230 S239 S26 S283 S285 S330 S44 S47 T209 T226 T244 T34	N103 N165, N368		
7	1989319CD1	1369	S1022 S1086 S1142 S1250 S1292 S1354 S146 S277 S307 S366 S464 S551 S592 S609 S674 S695 S877 T100 T1003 T1088 T134 T288 T391 T469 T585 T613 T653 T664 T84	N1339 N422 N607 N692 N693 N832	Protein_kinases_signatures_and_profile protein_kinase_tyr.prf: R136-G216 PROTEIN_KINASE_DOMAIN DM00004 P27448 58-297: R70-R305 DM00004 I48609 55-294: R70-R305 DM00004 Q05512 55-294: R70-R305 DM00004 JCI446 20-261: E67-M308 Tyrosine_kinase_catalytic_domain signature PR00109: T142-V155, F178-L196, V244-S266 Eukaryotic_protein_kinase_domain: Y66-M317 Protein_Kinase_ATP-binding_region signature: I72-K95 Serine/Threonine_protein_kinases_active-site_signature: I184-L196 SpScan_signal_cleavage: M1-G14	PROFILESSCAN BLAST_DOMO BLIMPS_PRINTS HMMER_PPFAM MOTIFS MOTIFS SPSCAN

Table 3 (cont.)

[illegible]

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
8			S768 S772 S840 S861 S886 S91 S927 S953 T1032 T1086 T127 T1277 T1450 T1470 T1568 T1575 T1712 T1718 T1786 T1798 T1811 T1827 T1945 T2083 T2144 T2160 T2171 T2181 T2235 T2322 T2362 T2397 T241 T378 T429 T445 T593 T679 T689 T695 T789 T880 T960 Y2185		Protein kinase signature protein_kinase_tyr.prf: F443-V523 Tyrosine kinase catalytic domain PRO0109: Y489-V507, V570-D592 PROTEIN KINASE DOMAIN DM00004 A54602 455-712: T378-G636 DM00004 S42867 75-498: I379-K522 DM08046 P05986 1-397: S374-K522, V549-D697 DM08046 P06244 1-396: D375-K522 PROTEIN KINASE SERINE/THREONINE KIN4 MICROTUBULE ASSOCIATED TESTIS SPECIFIC TESTISSPECIFIC MAST205 PD041650: K183-D375 MICROTUBULE ASSOCIATED TESTIS SPECIFIC SERINE/THREONINE PROTEIN KINASE 205KD MAST205 KINASE PD135564: M1-Y182 PD142315: H1151-A1412, P1969-P2107 PD182663: T725-N982 Atp_Gtp_A: A1841-T1848 Protein_Kinase_St: I495-V507	PROFILES SCAN BLIMPS_PRINTS BLAST_DOMO BLAST_PRODOR BLAST_PRODOR MOTIFS MOTIFS

Table 3 (cont.)

SEQ ID NO.	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
9	5502218CD1	2135	S1189 S1641 S1651 S1714 S174 S1765 S1790 S1814 S1818 S1874 S1888 S189 S1993 S1994 S2018 S2023 S2039 S231 S260 S29 S34 S363 S378 S469 S588 S679 S819 S843 S858 S863 S879 S929 S973 T1270 T1407 T160 T1682 T1723 T1881 T1998 T243 T258 T290 T308 T373 T436 T48 T60 T625 T73 T763 T850 T851 T868 T899 T91 Y1855 Y468	N1046 N1078 N1628 N1798 N1808 N1816 N1904 N2016 N2116 N27 N877 N89	Eukaryotic protein kinase domain pkinase: L221-F479 Protein kinase signature protein_kinase_tyr.prf: L324-S378 Tyrosine kinase catalytic domain PR00109: T301-K314, H339-I357, V403-C425, A448-I470 PROTEIN KINASE DOMAIN DM00004 S49611 39-259: I227-V447 DM00004 P51957 8-251: I227-I470 DM00004 Q05609 553-797: E226-C459 DM00004 P41892 11-249: I227-K471 Protein_Kinase_St: I345-I357	HMMER_PFAM PROFILES SCAN BLIMPS_PRINTS BLAST_DOMO MOTIFS
10	55056054CD1	398	S300 S373 S386 S62 T136 T326 T341 T37 T388 T43 T96 Y117	N47	Eukaryotic protein kinase domain pkinase: F91-F345 Protein kinase C terminal domain pkinase_C: A346-D377 Tyrosine kinase catalytic domain PR00109: M168-R181, Y204-I222, V267-D289	HMMER_PFAM HMMER_PFAM BLIMPS_PRINTS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
10					<p>PROTEIN KINASE DOMAIN</p> <p>DM00004 P00517 44-281: E92-G330</p> <p>DM00004 S19028 46-283: R93-G330</p> <p>DM00004 B35755 53-290: E92-G330</p> <p>DM08046 P06244 1-396: T82-I387</p> <p>CAMPDEPENDENT SERINE/THREONINE PKA</p> <p>PROTEIN KINASE BETA2CATALYTIC CBETA2</p> <p>TRANSFERASE ATPBINDING ALTERNATIVE SP</p> <p>PHOSPHORYLATION</p> <p>PD052800: M1-R61</p> <p>SERINE/THREONINE TYROSINEPROTEIN KINASE</p> <p>TRANSFERASE PHOSPHORYLATION</p> <p>TRANSMEMBRANE ATPBINDING RECEPTOR</p> <p>PD000001: T243-F287, K94-V171, M166-V239, R104-G174, D289-F345</p> <p>Protein_Kinase_Atp:</p> <p>L97-K120</p> <p>Protein_Kinase_St:</p> <p>L210-I222</p>	BLAST_DOMO
11	7481989CD1	929	<p>S147 S258 S292</p> <p>S298 S337 S482</p> <p>S595 S603 S612</p> <p>S642 S716 S845</p> <p>S916 T139 T186</p> <p>T293 T387 T394</p> <p>T426 T436 T48</p> <p>T822 Y312 Y402</p>	N594 N60	<p>Eukaryotic protein kinase domain</p> <p>pkinese:</p> <p>P652-P897</p> <p>Protein kinases signatures</p> <p>protein_kinase_tyr.prf:</p> <p>T753-K800</p> <p>Tyrosine kinase catalytic site</p> <p>PR00109: F767-L785, V829-A851, F877-L899</p> <p>PROTEIN KINASE DOMAIN</p> <p>DM00004 A56040 233-476: G655-P897</p> <p>DM00004 Q05609 553-797: Q656-P897</p> <p>DM00004 P51813 419-658: Q656-P897</p> <p>DM00004 S60612 419-658: Q656-P897</p> <p>Protein_Kinase_Atp:</p> <p>L658-K681</p>	<p>BLAST_PRODUM</p> <p>BLAST_PRODUM</p> <p>MOTIFS</p> <p>MOTIFS</p> <p>HMMER_PPFAM</p> <p>PROFILESSCAN</p> <p>BLIMPS_PRINTS</p> <p>BLAST_DOMO</p> <p>MOTIFS</p>

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
11					Protein_Kinase_St: L773-L785	MOTIFS
12	55052990CD1	1097	S1017 S1023 S1034 S118 S233 S286 S541 S569 S611 S618 S648 S715 S778 S789 S816 S822 S829 S842 S888 S89 S974 T1035 T1056 T1059 T1083 T112 T145 T304 T373 T404 T405 T446 T565 T72 T785 T892 T964 T970 Y335	N1015 N821 N870	Eukaryotic protein kinase domain pkinase: L144-L403 SH3 domain SH3: P55-R114 Protein kinase signature protein_kinase_tyr.prf: L242-T305 Receptor tyrosine kinase class II BL00239: E191-P238, L355-I399 Receptor tyrosine kinase class III BL00240: E300-V347, V347-I399 Tyrosine kinase catalytic domain PR00109: M220-S233, D258-I276, G311-I321, S330-I352, C374-F396 SH3 domain signature PR00452: P55-A65, D69-K84, D91-N100, R102-R114 PROTEIN KINASE DOMAIN DM00004 A53800 119-368: L146-F396 DM00004 I38044 100-349: L146-F396 DM00004 JC2363 126-356: W163-F396 ZIPPER MOTIF LEUCINE DM08113 I38044 392-721: R438-A749, P869-P893 KINASE DOMAIN SH3 MIXED LINEAGE SERINE/THREONINE WITH LEUCINE ZIPPER PD024997: I406-A749, F419-E833 PD034700: N855-R966, P934-P1022	HMER_PFAM HMER_PFAM PROFILESKAN BLIMPS_BLOCKS BLIMPS_BLOCKS BLIMPS_PRINTS BLIMPS_PRINTS BLAST_DOMO BLAST_DOMO BLAST_PRODOM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
12					SERINE/THREONINEPROTEIN TYROSINE KINASE TRANSFERASE ATPBINDING PHOSPHORYLATION RECEPTOR PRECURSOR TRANSMEMBRANE PD000001: L146-F222, W315-F349, L242-A317 Protein_Kinase_Atp: I150-K171 Protein_Kinase_St: I264-I276 signal_cleavage: M1-A17	BLAST_PRODOR MOTIFS MOTIFS SPSCAN
13	7482377CD1	928	S121 S147 S150 S155 S212 S258 S293 S298 S332 S336 S340 S347 S355 S368 S380 S422 S552 S600 S625 S659 S690 S726 S729 S744 S787 S802 S814 S865 S893 S914 S915 T14 T262 T353 T447 T468 T491 T506 T597 T672 T730 T779 T818 T826 T832 T840 T97 Y488	N256 N260 N445 N550 N755 N77 N95	Guanylate kinase Guanylate_kin: R628-S729 GUANYLATE KINASE DM00755 Q07157 628-788: E623-A780 DM00755 I38757 709-898: L670-W778 PDZ domain PDZ: T20-P101, S204-D280, R391-K471 GLGF DOMAIN DM00224 Q07157 1-94: M10-K99 DM00224 Q07157 402-488: P388-Q469 PDZ domain PF00595: I429-N439 Domain present in ZO-1 PF00791: I413-A451, L456-S498 TIGHT JUNCTION PROTEIN ZO2 ISOFORM ZO1 SH3 DOMAIN ALTERNATIVE SPLICING PD011344: R470-F626 PD021419: T730-D881 ZO3 PD068424: P101-Q222 PD072431: F284-V392 Leucine Zipper: L733-L754	BLAST_PRODOR HMMER_PFAM BLAST_DOMO HMMER_PFAM BLAST_DOMO BLIMPS_PFAM BLIMPS_PFAM BLAST_PRODOR BLAST_PRODOR MOTIFS

Table 3 (cont.)

SEQ ID NO.	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
13					Rgd: R507-D509	MOTIFS
14	7758364CD1	766	S109 S129 S134 S182 S23 S3 S312 S334 S347 S484 S532 S623 S67 S710 S724 S93 T133 T173 T331 T389 T416 T461 T488 T542 T666 T693 T739 T760	N164 N619 N681	Eukaryotic protein kinase domain pkinae: Y394-V651 Protein kinase signature protein_kinase_tyr.prf: D491-L548 Tyrosine kinase catalytic domain PR00109: M469-T482, Y505-V523, V572-E594 PROTEIN KINASE DOMAIN DM00004 S57347 21-266: V399-T641 DM00004 JU0270 16-262: I396-A642 DM00004 A44412 16-262: I396-A642 DM00004 P11798 15-261: I400-A642 LISSENCEPHALINX ISOFORM DOUBLECORTIN PD024506: I7-N322 Protein_Kinase_Atp: I400-K423 Protein_Kinase_St: I511-V523 signal_cleavage: M1-A56 PROTEIN T13D8.31 KINASE PANTOTHENATE TRANSFERASE D9719.34P CODED FOR BY C. ELEGANS PD018089: L93-L441 Tyrosine protein kinases specific active-site signature: A159-R208	HMMER_PFAM PROFILESKAN BLIMPS_PRINTS BLAST_DOMO BLAST_PRODUM MOTIFS MOTIFS SPSCAN BLAST_PRODUM PROFILESKAN
15	5850001CD1	447	S121 S124 S23 S246 S316 S320 S362 S428 S45 S80 T111 T204 T286 T306 T307 T321 T59	N180		
16	7477062CD1	348	S169 S19 S316 S99 T224 T28 T80 Y62			

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
16					PROTEIN KINASE DOMAIN DM08046 P06244 1-396: G3-W263 DM00004 B35755 53-290: E63-L267 DM00004 P22216 200-456: L68-S316 DM00004 P06245 72-308: V65-W263 KINASE PROTEIN TRANSFERASE ATP-BINDING SERINE/THREONINE PROTEIN PHOSPHORYLATION RECEPTOR TYROSINE PROTEIN PRECURSOR TRANSMEMBRANE PD000001: A225-F273, Q166-V191, Y62-R97 Tyrosine kinase catalytic domain PR00109: T137-Q150, Y173-V191, L244-P266 Eukaryotic protein kinase domain: Y62-R315 Protein kinases ATP-binding region signature: L68-K91 Serine/Threonine protein kinases active-site signature: L179-V191	BLAST_DOMO BLIMPS_PRINTS HMWPFAM MOTIFS MOTIFS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
17	7477207CD1	341	S100 S133 S180 S299 S31 S337 S59 T175 T185 T235 T255 T261	N141 N89	Eukaryotic protein kinase domain: Y8-L325 Tyrosine protein kinases specific active-site signature: T140-S200 PROTEIN KINASE DOMAIN DM00004 P39009 202-470: R110-L251 DM00004 Q02723 16-259: E104-V196 DM00004 P08414 44-285: V118-V196 DM00004 P23572 6-277: L115-K195 KINASE PROTEIN TRANSFERASE ATP-BINDING SERINE/THREONINE PROTEIN PHOSPHORYLATION RECEPTOR TYROSINE PROTEIN PRECURSOR TRANSMEMBRANE PD000001: F144-A236 Tyrosine kinase catalytic domain signature PR00109: M119-L132, F154-I172 transmembrane domain: A238-D258 Serine/Threonine protein kinases active-site signature: I160-I172 Protein kinases ATP-binding region signature: V14-K37 Protein kinases signatures and profile: E113-S166	HMMER_Pfam PROFILES SCAN BLAST_DOMO BLAST_PRODUM BLIMPS_PRINTS HMMER MOTIFS PROFILES SCAN
18	4022651CD1	664	S123 S166 S290 S320 S342 S383 S423 S431 S477 S485 S508 S541 S565 S615 S631 S95 T110 T256 T439 T447 T497 T590 T652 Y591			

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
18					PROTEIN KINASE DOMAIN DM00004 P34244 82-359:V36-T256 DM00004 JC1446 20-261:R16-L257 DM00004 P54645 17-258:L17-L257 DM00004 A53621 18-258:L17-L257	BLAST_DOMO
					HRPOP1 F15A2.6 PROTEIN, Protein Kinase PD039115: P278-N503, PD039117: W517-E623	BLAST_PRODUM
					Tyrosine kinase catalytic domain signature PR00109: L91-V104, F127-L145, A193-P215	BLIMPS_PRINTS
					Eukaryotic protein kinase domain: Y15-Y266	HMWER_PFAM
					Protein kinases ATP-binding region signature: L21-K44	MOTIFS
					Serine/Threonine protein kinases active-site signature: I133-L145	MOTIFS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
19	7274927CD1	177	S19 T111 T128		Nucleoside diphosphate kinases active site: N120-T168 NUCLEOSIDE DIPHOSPHATE KINASES DM00773 I39074 I19-168: E30-E177 DM00773 P48817 3-152: E30-E177 DM00773 P50590 1-150: E30-E177 DM00773 Q07661 1-148: E30-E177 KINASE DIPHOSPHATE NUCLEOSIDE TRANSFERASE NDK NDP ATP-BINDING PROTEIN I PRECURSOR PD001018: E30-E177 Nucleoside diphosphate kinases proteins BL00469: W103-L157 Nucleoside diphosphate kinases ND: E30-E177 Nucleoside diphosphate kinases active site: N140-V148 SpScan signal_cleavage: M1-G15	PROFILES SCAN BLAST_DOMO BLIMPS_BLOCKS HMMER_PFAM MOTIFS SPSCAN
20	7946584CD1	396	S193 S194 S230 S6 S89 T122 T212 T45 T5	N4 N43	Protein kinases signatures and profile: T122-E174 Eukaryotic protein kinase domain: F23-M281 PROTEIN KINASE DOMAIN DM00004 P54644 122-362: I25-S270 DM08046 P05986 1-397: D13-P300 DM00004 P28178 155-393: I25-R268 DM08046 P06244 1-396: F23-P300 Tyrosine kinase catalytic domain signature PR00109: V100-Q113, Y136-L154, V204-R226	PROFILES SCAN HMMER_PFAM BLAST_DOMO BLIMPS_PRINTS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
20					Protein kinases ATP-binding region signature: I29-K52 Serine/Threonine protein kinases active-site signature: I142-L154	MOTIFS
21	8088078CD1	614	S292 S295 S518 S525 S574 S578 T27 T389 T418 T499 T92	N309 N595 N598	C2 domain signature and profile: G39-V93 C2-DOMAIN DM00150 P05129 150-278: G39-L159 DM00150 P13677 186-313: G39-L159 PROTEIN KINASE C ALPHA DM04692 P05130 1-638: G39-G164 DM04692 A37237 1-676: G39-G164 C2 domain signature PR00360: Q66-L78, D95-P108 C2 domain C2: L52-S139 PDZ domain (Also known as DHR or GLGF). PDZ: Q199-M275 ATP/GTP-binding site motif A (P-loop): G395-S402	PROFILES SCAN BLAST_DOMO BLAST_DOMO BLIMPS_PRINTS HMMER_PPFAM HMMER_PPFAM
22	2674269CD1	484	S122 S179 S222 S248 S295 S422 S445 T111 T27 T437 T65		Eukaryotic protein kinase domain: L44-C282 PROTEIN KINASE DOMAIN DM00004 P51954 6-248: D50-P271 DM00004 P51957 8-251: V42-P271 DM00004 Q08942 22-269: D50-P271 DM00004 P51955 10-261: R47-P271 Tyrosine kinase catalytic domain PR00109: M104-Q117 H142-L160 S208-A230 Y251-L273 Protein kinases signatures and profile: I129-S182	MOTIFS HMMER_PPFAM BLAST_DOMO BLIMPS_PRINTS PROFILES SCAN

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
22					Serine/Threonine protein kinases active-site signature: I148-L160	MOTIFS
23	7472409CD1	460	S155 S198 S224 S271 S398 S421 S98 T41 T413 T87		Eukaryotic protein kinase domain: Y4-C258	HMMER_PFAM
					PROTEIN KINASE DOMAIN DM00004 P51954 6-248: R6-P247 DM00004 P51957 8-251: I7-P247 DM00004 Q08942 22-269: V9-P247 DM00004 P11837 13-285: I124-P247, V10-H120	BLAST_DOMO
					Tyrosine kinase catalytic domain PR00109: M80-Q93 H118-L136 S184-A206 Y227-L249	BLIMPS_PRINTS
					Protein kinases signatures and profile: I105-S158	PROFILES SCAN
					Protein kinases ATP-binding region signature: V10-K33	MOTIFS
					Serine/Threonine protein kinases active-site signature: I124-L136	MOTIFS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
24	7477484CD1	1413	S1016 S1082 S118 S1269 S1285 S1295 S355 S400 S413 S471 S528 S547 S608 S649 S746 S818 S96 T1003 T1041 T1350 T279 T339 T467 T834 T880 T968 T995 Y185 Y748	N1034 N1358	Tyrosine protein kinases specific active-site signature: Y262-L274 signal_cleavage: M1-A20 PROTEIN KINASE DOMAIN DM00004 S23008 273-531: Q137-S400 DM00004 P06213 1024-1282: L136-S400 DM00004 P15209 538-798: Q137-R398 DM00004 P08069 1000-1258: Q137-S400 APOPTOSIS ASSOCIATED TYROSINE KINASE KIAA0641 PROTEIN PD148361: P1080-P1376 APOPTOSIS ASSOCIATED TYROSINE KINASE PD059222: L56-Y135 Kinase Protein Domain PD00584: L136-G145 Tyrosine kinase catalytic domain PR00109: H256-L274 I305-L315 S331-H353 Y380-S402 M210-R223 Protein kinases signatures and profile: T242-E294 Receptor tyrosine kinase class II signature: R270-E317 signal peptide: M1-A20 Eukaryotic protein kinase domain: L133-L404 Protein kinases ATP-binding region signature: I139-K164	MOTIFS SPSCAN BLAST_DOMO BLAST_PRODOM BLIMPS_BLOCKS BLIMPS_PRINTS PROFILES SCAN PROFILES SCAN HMMER HMMER_PPFAM MOTIFS

Table 4

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragment(s)	Sequence Fragments	5' Position	3' Position
25	7312543CB1	2060	1-367, 1981- 2060, 1721-1882, 1406-1638, 625- 1129	GBI_g9101216_802181	961	1719
				5J1_8024094J1_edit	1	617
				55067455J1	1473	1716
				FL7312543	448	986
				71899371V1	1891	2060
				6259135F8 (BMARTXT06)		
				8024094J1 (BRADIE02)	920	1609
				7084221H1 (STOMTMR02)	3331	3859
				3081175H1 (BRAIUNT01)	5209	5518
				7341442H1 (COLNDIN02)	2311	2964
26	7477427CB1	5694	1807-4876, 1-869	6053208J1 (BRABDIR03)	4727	5119
				6051790H1 (BRABDIR03)	3609	4274
				452790T6 (TLYMNOT02)	1146	1795
				1340485F6 (COLNTUT03)	1	601
				6051790J1 (BRABDIR03)	4347	4900
				5048724H1 (BRSTNOT33)	1016	1275
				4954623H1 (ENDVUNT01)	504	787
				55099289J1	1599	2178
				g1441460	570	809
				6355285H1 (LJUNGDIS03)	828	1103
				2818149F6 (BRSTNOT14)	5251	5694

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragment(s)	Sequence Fragments	5' Position	3' Position
26				6800667F6 (COLENOT03) 6322587F7 (LUNGDI02) 5735737F6 (KIDCTMT01) 6771396J1 (BRAUNOR01) 6800667R6 (COLENOT03)	2049 3892 4818 3245 2727	2603 4570 5470 3857 3335
27	7481495CB1	3520	1-40, 2862-3520, 1622-1689, 607- 1074	71125065V1 71124933V1 71124726V1 55143095J1 6273371F8 (BRAIFEN03) 7289965F8 (BRAIFER06) GBI.g9755986_edit_1 GBI.g9755986_edit_3 71911787V1 6959111H1 (SKINDIA01) 71910755V1 2222335T6 (LUNGNOT18) 55053117J1 71911607V1	2970 2555 1649 1 2069 209 1151 498 280 1196	3520 3203 2196 476 2812 841 3394 1231 990 1852
28	55053189CB1	1988	1-1067			
29	7474797CB1	1822	1-470, 963-1217	GNN.g6850939_002 55078203J1 55078259J1 g3405101 8050406H1 (LUNGUS02) 3296272F6 (TLXJINT01)	738 135 1 1507 724 52	1734 920 917 1822 1394 723
30	3296272CB1	1814	1-34			

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragment(s)	Sequence Fragments	5' Position	3' Position
30				GNN.g7711609.edit1	124	1246
				8010594H1 (NOSEDIC02)	1	473
				4550262T1 (HELAUNT01)	1179	1814
				6766365H1 (BRAUNOR01)	3988	4381
				6771934J1 (BRAUNOR01)	1284	1867
31	1989319CB1	4381	1-606, 1171- 2589, 3359-3731, 4352-4381, 3137- 3182	7081255H1 (STOMTMR02)	1899	2467
				7074415H1 (BRAUTDR04)	7	546
				7233628H1 (BRAXTDR15)	3192	3760
				2972522F6 (HEAONOT02)	3805	4374
				3550738T6 (SYNONOT01)	3467	4338
				7689848H1 (PROSTME06)	1200	1856
				7643518H1 (SEMTDE01)	2454	3131
				55056624J1	191	833
				GNN.g7139740_000020 _002.edit	1	273
				6772392H1 (BRAUNOR01)	670	1296
				7641909J1 (SEMTDE01)	1390	2054
				7039379H1 (UTRSTMR02)	2393	2982
				5965355H1 (BRATNOT05)	2998	3635

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragment(s)	Sequence Fragments	5' Position	3' Position
32	079284CB1	7862	6343-7041, 1043- 1581, 1-453, 2297-6211	6558834H1 (BRAFNON02) 6957453H1 (BLADNOR01) 7030154F6 (BRAXTDR12) 2696941F6 (UTRSNOT12) 6993445H1 (BRAQTDR02) 6315055H1 (NERDTDN03) 7183303H1 (BONRFEC01) 55032462H1 1005113H1 (BRSTNOT03) 7034608H1 (SINTFER03) 55032462J1 92224546_CD 7740563H1 (THYMNOE01) 6943723H1 (FTUBTUR01) 7764524H1 (URETTUE01) 7030154R6 (BRAXTDR12) 6493861H1 (MIXDUNB01) 7764524J1 (URETTUE01) 55111711H1	6806 3532 3084 6628 2679 5981 5329 4893 2531 5826 4430 1221 4113 1062 545 2885 7457 350 1	7501 4226 3666 7209 3284 6672 5878 5540 2782 6570 5048 7714 4788 1416 1132 3416 7862 868 520

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragment(s)	Sequence Fragments	5' Position	3' Position
33	5502218CB1	7280	1-658, 1289- 3582, 6450-7280, 4416-5337	71172233V1	5856	6502
				7755001H1 (SPLNTUE01)	4757	5331
				71172416V1	5347	5905
				7143606H1 (LIVRDIT07)	2638	3173
				8262215J1 (MIXDUNL12)	4008	4571
				71728206V1	6354	7056
				1513828F6 (PANCTUT01)	1481	2005
				5504851F6 (BRADDIR01)	2190	2722
				71255229V1	2770	3388
				7099033H2 (BRAWTDRO2)	3321	3964
				7381635H1 (ENDMUNE01)	4401	5070
				6775620H1 (OVARDIR01)	1	576
				6773092H1 (BRAUNOR01)	4072	4748
				1852020T6 (LUNGFET03)	6862	7280
				71974333V1	823	1394
				6246863H1 (TESTNOT17)	1346	1961
				71174478V1	5283	5874
				7751827J1 (HEAONOE01)	1888	2490
				7733935J2 (COLDDIE01)	5932	6548
				6771926J1 (BRAUNOR01)	629	1285
				71088884V1	3416	4074

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragment(s)	Sequence Fragments	5' Position	3' Position
33				7437887H1 (ADRETUE02)	128	705
				7032601H1 (BRAXTDR12)	6540	7193
34	55056054CB1	1260	817-1260	6391212H1 (LUNPTMC01)	64	334
				GBI.g8516102_000009 _000010_000008.edit.	1	1260
				55076825J1	1	132
35	7481989CB1	3161	1-481, 1210-2220	70464274V1	2196	2774
				70467406V1	2110	2701
				7185326H1 (BONRFEC01)	793	1415
				7077190R8 (BRAUTDR04)	1	674
				70980877V1	1389	2032
				55013474H1 (GPCRDNV60)	1517	2149
				70464964V1	2517	3161
				71292191V1	518	1150
36	55052990CB1	3538	1-251, 1163- 1869, 2604-3538, 695-858	FL55052990_g4156209 _g758593	1	3294
				7580350H1 (BRAIFEC01)	3068	3538
37	7482377CB1	3047	1-1419, 3022- 3047	6931355H1 (SINITMR01)	1317	1950
				60203980U1	1971	2648
				5871544H1 (COLTDIT04)	2745	3043
				g2053163	2589	3047
				6821548H1 (SINTNOR01)	1691	2351
				7171378H1 (BRSTTMC01)	528	1120
				1428568F6 (SINTBST01)	2547	3019

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragment(s)	Sequence Fragments	5' Position	3' Position
37				1625022F6 (COLNPOT01)	1053	1538
				6822009J1 (SINTNOR01)	1	666
				8010427H1 (NOSEDIC02)	693	1191
38	7758364CB1	2667	2375-2667, 702- 1754, 1-178	7042389H1 (UTRSTMR02)	1	445
				6620147H1 (BRAUDIR01)	1777	2400
				55137902J1	89	943
				72053219V1	1961	2667
				55053087J1	909	1802
				7198790F8 (LUNGFER04)	1091	1812
39	5850001CB1	1719	1108-1719	1773374R6 (MENTUNON3)	1016	1417
				2746336T6 (LUNGTUT11)	1080	1719
				8081565H1 (BMARTXN03)	1	316
				2746336F6 (LUNGTUT11)	795	1320
				6768690J1 (BRAUNOR01)	324	914
				4403478H1 (PROSDIT01)	218	460
40	7477062CB1	1156	683-1156, 1-194, 472-644	8124387H1 (HEAONOC01)	55	692
				55149655J1	1	562
				GNN.g7191033_000008 _002.edit	108	1156
				982271H1 (TONGTUT01)	1044	1156
41	7477207CB1	1096	923-1096	6882293J1 (BRAHTR03)	1030	1096

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragment(s)	Sequence Fragments	5' Position	3' Position
41				55142304H1 GNN:g10045521_00000 3_004	1 65	782 1090
42	4022651CB1	2647	1-29, 2556-2647, 2233-2392, 795- 1365	6559541F8 (BRAFNON02) GBI:g9739340_000017 _000001_000005.edit 6149427H1 (BRANDIT03) 6559066F8 (BRAFNON02) 6951446H1 (BRAITDR02) 7228092H1 (BRAXTDR15) 7947344H1 (BRAENO02) 70581831V1 70590694V1 71928043V1 55071303H1 7338592T6 (SINTNON02) 6885143F6 (BRAHTDR03) g1482596 GBI:g10040007_14_ed it2 71113779V1 FL8088078_g9801056_ 000005_g6707837_1_1 -2 8088078F6 (BLADTUN02) GBI:g10040007_1_ed t	1619 1 2099 1356 676 621 79 1 884 250 537 1 754 388 -2 110 461	2410 178 2647 2049 1375 1060 645 700 864 1231 353 1594 960 981 160 1440 541 527 1845
43	7274927CB1	864	1-31, 822-864			
44	7946584CB1	1594	1-199, 1369-1594			
45	8088078CB1	1845	1-114, 1011-1845			

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragment(s)	Sequence Fragments	5' Position	3' Position
46	2674269CB1	1680	1-203, 991-1147	6248538F8	1288	1680
				(LUNPTUT02)		
				3156348F6	1125	1403
				(TLYMTXT02)		
				GBI.g7321523_edit	220	957
				55074191J1	1	217
				2674269H1	969	1213
47	7472409CB1	1528	1354-1528, 849-1005	(KIDNNOT19)		
				7990470H2	209	851
				(UTRCDIC01)		
				3926891H1	19	291
				(KIDNNOT19)		
				6248538F8	1146	1528
				(LUNPTUT02)		
48	7477484CB1	4988	4651-4742, 3382-4011, 1-491, 4429-4477, 1495-3210, 1074-1222, 4361-4388	3156348F6	983	1261
				(TLYMTXT02)		
				GBI.g7321523_edit	78	815
				2674269H1	827	1071
				(KIDNNOT19)		
				7990470H2	1	709
				(UTRCDIC01)		
48	7477484CB1	4988	4651-4742, 3382-4011, 1-491, 4429-4477, 1495-3210, 1074-1222, 4361-4388	7259537F6	2988	3998
				(BRAWNOC01)		
				4456665F8	2819	3339
				(HEAADIR01)		
				7087893H1	2095	2275
				(BRAUTDR03)		
				FL7477484_g9690314_g3327096_1_1-2	800	1040
48	7477484CB1	4988	4651-4742, 3382-4011, 1-491, 4429-4477, 1495-3210, 1074-1222, 4361-4388	6763489J1	965	1524
				(BRAUNOR01)		
				7226615H1	206	721
				(BRAXTDR15)		
48	7477484CB1	4988	4651-4742, 3382-4011, 1-491, 4429-4477, 1495-3210, 1074-1222, 4361-4388	6770515H1	1	510
				(BRAUNOR01)		

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragment(s)	Sequence Fragments	5' Position	3' Position
48				6979719H1 (BRAHTDR04)	4239	4801
				6770515R8 (BRAUNOR01)	1394	2240
				3825546H1 (BRAIHCT02)	4693	4988
				FL7477484_g9690314_ g3327096_1_5-6	1248	1845
				2570231T6 (HIPOAZT01)	4505	4955
				FL7477484_g9690314_ g3327096_1_15-16	3868	4333
				GNN.g9690314_008	247	4488

Table 5

Polynucleotide SEQ ID NO:	Incyte Project ID	Representative Library
25	7312543CB1	BRADIE02
26	7477427CB1	THYMNOR02
27	7481495CB1	BRAIFER06
28	55053189CB1	LUNGNOT18
29	7474797CB1	MIXDUNB01
30	3296272CB1	CERVNOT01
31	1989319CB1	BRAUNOR01
32	079284CB1	UTRSNOT12
33	5502218CB1	BRAUNOR01
34	55056054CB1	LUNPTMC01
35	7481989CB1	BLADNOT05
36	55052990CB1	BMARUNR02
37	7482377CB1	SINTNOR01
38	7758364CB1	LUNGFER04
39	5850001CB1	LUNGTUT11
40	7477062CB1	TONGTUT01
41	7477207CB1	SINTFEE02
42	4022651CB1	BRANDIT03
43	7274927CB1	MYEPTXT02
44	7946584CB1	BRAHTDR03
45	8088078CB1	ENDINOT02
46	2674269CB1	TYMTXT02
47	7472409CB1	TYMTXT02
48	7477484CB1	BRAUNOR01

Table 6

Library	Vector	Library Description
BLADNOT05	pINCY	Library was constructed using RNA isolated from bladder tissue removed from a 60-year-old Caucasian male during a radical cystectomy, prostatectomy, and vasectomy. Pathology for the associated tumor tissue indicated grade 3 transitional cell carcinoma. Carcinoma in-situ was identified in the dome and trigone. Patient history included tobacco use.
BMARUNR02	PIGEN	This random primed library was constructed using RNA isolated from an untreated SH-SY5Y cell line derived from bone marrow neuroblastoma tumor cells removed from a 4-year-old Caucasian female.
BRABDIE02	pINCY	This 5' biased random primed library was constructed using RNA isolated from diseased cerebellum tissue removed from the brain of a 57-year-old Caucasian male who died from a cerebrovascular accident. Serologies were negative. Patient history included Huntington's disease, emphysema, and tobacco abuse (3-4 packs per day, for 40 years).
BRAHTDR03	PCDNA2.1	This random primed library was constructed using RNA isolated from archaer cortex, anterior hippocampus tissue removed from a 55-year-old Caucasian female who died from cholangiocarcinoma. Pathology indicated mild meningeal fibrosis predominately over the convexities, scattered axonal spheroids in the white matter of the cingulate cortex and the thalamus, and a few scattered neurofibrillary tangles in the entorhinal cortex and the periaqueductal gray region. Pathology for the associated tumor tissue indicated well-differentiated cholangiocarcinoma of the liver with residual or relapsed tumor. Patient history included cholangiocarcinoma, post-operative Budd-Chiari syndrome, biliary ascites, hydrothorax, dehydration, malnutrition, oliguria and acute renal failure. Previous surgeries included cholecystectomy and resection of 85% of the liver.
BRAIFER06	PCDNA2.1	This random primed library was constructed using RNA isolated from brain tissue removed from a Caucasian male fetus who was stillborn with a hypoplastic left heart at 23 weeks' gestation. Serologies were negative.
BRANDIT03	pINCY	Library was constructed using RNA isolated from pineal gland tissue removed from a 79-year-old Caucasian female who died from pneumonia. Neuropathology indicated severe Alzheimer Disease, moderate to severe arteriosclerosis of the intracranial blood vessels, moderate cerebral amyloid angiopathy and infarctions involving the parieto-occipital lobes. There was atrophy of all lobes, caudate, putamen, amygdala, hippocampus, vermis, optic nerve, and the cerebral cortical white matter. There was cystic cavitation in the left medial occipital lobe, the right posterior parietal region, the right side insular cortex, and the right occipital and inferior parietal lobes. The ventricular system was severely dilated. Stains show numerous diffuse as well as neuritic amyloid plaques

Table 6 (cont.)

Library	Vector	Library Description
		<p>throughout all neocortical areas examined. There were numerous neurofibrillary tangles predominantly in the pyramidal cell neurons of layers 3 and 5, however, small interneurons in layers 3, 4, and 6 also contain tangles. The caudate and putamen contain large areas of mineralization and scattered neurofibrillary tangles. The amygdala was markedly gliotic containing numerous neurofibrillary, argyrophilic and ghost type tangles; and scattered cells with granulovacuolar degeneration and focal cells with Lewy-like body inclusions. The hippocampus contains marked gliosis with complete loss of pyramidal cell neurons in the CA1 region. Silver stained sections show numerous neuritic plaques and scattered neurofibrillary tangles within the dentate gyrus, CA2, and CA3 regions. The substantia nigra shows numerous neurofibrillary tangles in the periaqueductal grey region. Patient history included gastritis with bleeding, glaucoma, PVD, COPD, delayed onset tonic/clonic seizures, transient ischemic attacks, pseudophakia, and allergies to aspirin and clindamycin. Family history included Alzheimer disease.</p>
BRAUNOR01	pINCY	<p>This random primed library was constructed using RNA isolated from striatum, globus pallidus and posterior putamen tissue removed from an 81-year-old Caucasian female who died from a hemorrhage and ruptured thoracic aorta due to atherosclerosis. Pathology indicated moderate atherosclerosis involving the internal carotids, bilaterally; microscopic infarcts of the frontal cortex and hippocampus; and scattered diffuse amyloid plaques and neurofibrillary tangles, consistent with age. Grossly, the leptomeninges showed only mild thickening and hyalinization along the superior sagittal sinus. The remainder of the leptomeninges was thin and contained some congested blood vessels. Mild atrophy was found mostly in the frontal poles and lobes, and temporal lobes, bilaterally. Microscopically, there were pairs of Alzheimer type II astrocytes within the deep layers of the neocortex. There was increased satellitosis around neurons in the deep gray matter in the middle frontal cortex. The amygdala contained rare diffuse plaques and neurofibrillary tangles. The posterior hippocampus contained a microscopic area of cystic cavitation with hemosiderin-laden macrophages surrounded by reactive gliosis. Patient history included sepsis, cholangitis, post-operative atelectasis, pneumonia CAD, cardiomegaly due to left ventricular hypertrophy, splenomegaly, arteriolonephrosclerosis, nodular colloidal goiter, emphysema, CHF, hypothyroidism, and peripheral vascular disease.</p>
CERVNOT01	PSPORT1	<p>Library was constructed using RNA isolated from the uterine cervical tissue of a 35-year-old Caucasian female during a vaginal hysterectomy with dilation and curettage. Pathology indicated mild chronic cervicitis. Family history included atherosclerotic coronary artery disease and type II diabetes.</p>

Table 6 (cont.)

Library	Vector	Library Description
ENDINOT02	pINCY	The library was constructed using RNA isolated from treated iliac artery endothelial cells removed from a Black female. The cells were treated with TNF alpha 10ng/ml and IL-1 beta 10ng/ml for 20 hours.
LUNGFER04	PCDNA2.1	This random primed library was constructed using RNA isolated from lung tissue removed from a Caucasian male fetus who died from fetal demise.
LUNGNOT18	pINCY	Library was constructed using RNA isolated from left upper lobe lung tissue removed from a 66-year-old Caucasian female. Pathology for the associated tumor tissue indicated a grade 2 adenocarcinoma. Patient history included cerebrovascular disease, atherosclerotic coronary artery disease, and pulmonary insufficiency. Family history included a myocardial infarction and atherosclerotic coronary artery disease.
LUNGTUT11	pINCY	Library was constructed using RNA isolated from lung tumor tissue removed from the right lower lobe a 57-year-old Caucasian male during a segmental lung resection. Pathology indicated an infiltrating grade 4 squamous cell carcinoma. Multiple intrapulmonary peribronchial lymph nodes showed metastatic squamous cell carcinoma. Patient history included a benign brain neoplasm and tobacco abuse. Family history included spinal cord cancer, type II diabetes, cerebrovascular disease, and malignant prostate neoplasm.
LUNPTMC01	pINCY	This large size-fractionated library was constructed using RNA isolated from pleura tissue removed from a 58-year-old Caucasian female during segmental lung resection. Pathology for the matched tumor tissue indicated metastatic grade 4 leiomyosarcoma, forming a mass in the left lower lobe lung, with extension into the lumen of the pulmonary vein. Patient history included a malignant retroperitoneum neoplasm with metastasis to lung, an unspecified respiratory abnormality, cough, hyperlipidemia, paralytic polio, benign bladder neoplasm, normal delivery, benign hypertension, and tobacco abuse in remission. Family history included benign hypertension, hyperlipidemia skin cancer, and cerebrovascular disease.
MIXDUNB01	pINCY	Library was constructed using RNA isolated from myometrium removed from a 41-year-old Caucasian female during vaginal hysterectomy with a dilatation and curettage and untreated smooth muscle cells removed from the renal vein of a 57-year-old Caucasian male. Pathology indicated the myometrium and cervix were unremarkable. The endometrium was secretory and contained fragments of endometrial polyps. Benign endo- and ectocervical mucosa were identified in the endocervix. Pathology for the associated tumor tissue indicated uterine leiomyoma. Medical history included an unspecified menstrual disorder, ventral hernia, normal delivery, a benign ovarian neoplasm, and tobacco abuse.

Table 6 (cont.)

Library	Vector	Library Description
MYEPTXT02	pINCY	The library was constructed using RNA isolated from a treated K-562 cell line, derived from chronic myelogenous leukemia precursor cells removed from a 53-year-old female. The cells were treated with 1 micromolar PMA for 96 hours.
SINTFEE02	PCDNA2.1	This 5' biased random primed library was constructed using RNA isolated from small intestine tissue removed from a Caucasian male fetus who died from Patau's syndrome (trisomy 13) at 20-weeks' gestation. Serology was negative.
SINTNOR01	PCDNA2.1	This random primed library was constructed using RNA isolated from small intestine tissue removed from a 31-year-old Caucasian female during Roux-en-Y gastric bypass. Patient history included clinical obesity.
THYMNOR02	pINCY	The library was constructed using RNA isolated from thymus tissue removed from a 2-year-old Caucasian female during a thymectomy and patch closure of left atrioventricular fistula. Pathology indicated there was no gross abnormality of the thymus. The patient presented with congenital heart abnormalities. Patient history included double inlet left ventricle and a rudimentary right ventricle, pulmonary hypertension, cyanosis, subaortic stenosis, seizures, and a fracture of the skull base. Family history included reflux neuropathy.
TLYMTXT02	pINCY	Library was constructed using RNA isolated from CD4+ T cells obtained from a pool of donors. The cells were treated with CD3 antibodies.
TONGTUT01	PSPORT1	Library was constructed using RNA isolated from tongue tumor tissue obtained from a 36-year-old Caucasian male during a hemiglossectomy. Pathology indicated recurrent invasive grade 2 squamous-cell carcinoma.
UTRSNOT12	pINCY	Library was constructed using RNA isolated from uterine myometrial tissue removed from a 41-year-old Caucasian female during a vaginal hysterectomy with dilation and curettage. The endometrium was secretory and contained fragments of endometrial polyps. Benign endo- and ectocervical mucosa were identified in the endocervix. Pathology for the associated tumor tissue indicated uterine leiomyoma. Patient history included ventral hernia and a benign ovarian neoplasm.

Table 7

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) <i>J. Mol. Biol.</i> 215:403-410; Altschul, S.F. et al. (1997) <i>Nucleic Acids Res.</i> 25:3389-3402.	ESTs: Probability value= 1.0E-8 or less <i>Full Length sequences</i> : Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) <i>Proc. Natl. Acad. Sci. USA</i> 85:2444-2448; Pearson, W.R. (1990) <i>Methods Enzymol.</i> 183:63-98; and Smith, T.F. and M.S. Waterman (1981) <i>Adv. Appl. Math.</i> 2:482-489.	ESTs: fasta E value=1.06E-6 <i>Assembled ESTs</i> : fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value=1.0E-8 or less <i>Full Length sequences</i> : fastx score=100 or greater
BLIMPS	A BLocks IMProved Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S. and J.G. Henikoff (1991) <i>Nucleic Acids Res.</i> 19:6565-6572; Henikoff, J.G. and S. Henikoff (1996) <i>Methods Enzymol.</i> 266:88-105; and Attwood, T.K. et al. (1997) <i>J. Chem. Inf. Comput. Sci.</i> 37:417-424.	Probability value= 1.0E-3 or less
HMMER	An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM.	Krogh, A. et al. (1994) <i>J. Mol. Biol.</i> 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) <i>Nucleic Acids Res.</i> 26:320-322; Durbin, R. et al. (1998) <i>Our World View</i> , in a Nutshell, Cambridge Univ. Press, pp. 1-350.	PFAM hits: Probability value= 1.0E-3 or less <i>Signal peptide hits</i> : Score= 0 or greater

Table 7 (cont.)

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, M. et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221.	Normalized quality score ₂ GCG-specified "HIGH" value for that particular Prosite motif. Generally, score=1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M.S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies.	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12:431-439.	Score=3.5 or greater
TMAP	A program that uses weight matrices to delineate transmembrane segments on protein sequences and determine orientation.	Persson, B. and P. Argos (1994) J. Mol. Biol. 237:182-192; Persson, B. and P. Argos (1996) Protein Sci. 5:363-371.	
TMHMMER	A program that uses a hidden Markov model (HMM) to delineate transmembrane segments on protein sequences and determine orientation.	Sonnhammer, E.L. et al. (1998) Proc. Sixth Intl. Conf. on Intelligent Systems for Mol. Biol., Glasgow et al., eds., The Am. Assoc. for Artificial Intelligence Press, Menlo Park, CA, pp. 175-182.	
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. An isolated polypeptide selected from the group consisting of:

- 5 a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-24,
- b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-24,
- 10 c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, and
- d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24.

15 2. An isolated polypeptide of claim 1 selected from the group consisting of SEQ ID NO:1-24.

3. An isolated polynucleotide encoding a polypeptide of claim 1.

4. An isolated polynucleotide encoding a polypeptide of claim 2.

20 5. An isolated polynucleotide of claim 4 selected from the group consisting of SEQ ID NO:25-48.

25 6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.

7. A cell transformed with a recombinant polynucleotide of claim 6.

8. A transgenic organism comprising a recombinant polynucleotide of claim 6.

30 9. A method of producing a polypeptide of claim 1, the method comprising:

- a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and

- b) recovering the polypeptide so expressed.

10. A method of claim 9, wherein the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO:1-24.

5

11. An isolated antibody which specifically binds to a polypeptide of claim 1.

12. An isolated polynucleotide selected from the group consisting of:

10

- a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:25-48,
- b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:25-48,
- c) a polynucleotide complementary to a polynucleotide of a),
- 15 d) a polynucleotide complementary to a polynucleotide of b), and
- e) an RNA equivalent of a)-d).

15

13. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 12.

20

14. A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising:

25

- a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and
- b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

30

15. A method of claim 14, wherein the probe comprises at least 60 contiguous nucleotides.

16. A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising:

- a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
- b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

5

17. A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

18. A composition of claim 17, wherein the polypeptide has an amino acid sequence selected
10 from the group consisting of SEQ ID NO:1-24.

19. A method for treating a disease or condition associated with decreased expression of functional PKIN, comprising administering to a patient in need of such treatment the composition of claim 17.

15

20. A method of screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting agonist activity in the sample.

20

21. A composition comprising an agonist compound identified by a method of claim 20 and a pharmaceutically acceptable excipient.

22. A method for treating a disease or condition associated with decreased expression of
25 functional PKIN, comprising administering to a patient in need of such treatment a composition of claim 21.

23. A method of screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:

30

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting antagonist activity in the sample.

24. A composition comprising an antagonist compound identified by a method of claim 23 and a pharmaceutically acceptable excipient.

25. A method for treating a disease or condition associated with overexpression of functional PKIN, comprising administering to a patient in need of such treatment a composition of claim 24.

26. A method of screening for a compound that specifically binds to the polypeptide of claim 1, the method comprising:

- a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and
- b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.

27. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, the method comprising:

- a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,
- b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and
- c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.

28. A method of screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method comprising:

- a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,
- b) detecting altered expression of the target polynucleotide, and
- c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

29. A method of assessing toxicity of a test compound, the method comprising:

- a) treating a biological sample containing nucleic acids with the test compound,

- b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 12 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 12 or fragment thereof,
- c) quantifying the amount of hybridization complex, and
- d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

30. A diagnostic test for a condition or disease associated with the expression of PKIN in a biological sample, the method comprising:

- a) combining the biological sample with an antibody of claim 11, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex, and
- b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.

31. The antibody of claim 11, wherein the antibody is:

- a) a chimeric antibody,
- b) a single chain antibody,
- c) a Fab fragment,
- d) a F(ab')₂ fragment, or
- e) a humanized antibody.

32. A composition comprising an antibody of claim 11 and an acceptable excipient.

33. A method of diagnosing a condition or disease associated with the expression of PKIN in a subject, comprising administering to said subject an effective amount of the composition of claim 32.

34. A composition of claim 32, wherein the antibody is labeled.

35. A method of diagnosing a condition or disease associated with the expression of PKIN in a subject, comprising administering to said subject an effective amount of the composition of claim 34.

36. A method of preparing a polyclonal antibody with the specificity of the antibody of claim 11, the method comprising:

- a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, or an immunogenic fragment thereof, under conditions to elicit an antibody response,
- b) isolating antibodies from said animal, and
- c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24.

15

37. A polyclonal antibody produced by a method of claim 36.

38. A composition comprising the polyclonal antibody of claim 37 and a suitable carrier.

39. A method of making a monoclonal antibody with the specificity of the antibody of claim 11, the method comprising:

- a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24, or an immunogenic fragment thereof, under conditions to elicit an antibody response,
- b) isolating antibody producing cells from the animal,
- c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells,
- d) culturing the hybridoma cells, and
- e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24.

30

40. A monoclonal antibody produced by a method of claim 39.

41. A composition comprising the monoclonal antibody of claim 40 and a suitable carrier.

42. The antibody of claim 11, wherein the antibody is produced by screening a Fab expression library.

43. The antibody of claim 11, wherein the antibody is produced by screening a recombinant immunoglobulin library.

44. A method of detecting a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24 in a sample, the method comprising:

- a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and
- b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24 in the sample.

45. A method of purifying a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24 from a sample, the method comprising:

- a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and
- b) separating the antibody from the sample and obtaining the purified polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-24.

46. A microarray wherein at least one element of the microarray is a polynucleotide of claim 13.

47. A method of generating a transcript image of a sample which contains polynucleotides, the method comprising:

- a) labeling the polynucleotides of the sample,
- b) contacting the elements of the microarray of claim 46 with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and
- c) quantifying the expression of the polynucleotides in the sample.

48. An array comprising different nucleotide molecules affixed in distinct physical locations on a solid substrate, wherein at least one of said nucleotide molecules comprises a first oligonucleotide

or polynucleotide sequence specifically hybridizable with at least 30 contiguous nucleotides of a target polynucleotide, and wherein said target polynucleotide is a polynucleotide of claim 12.

49. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is
5 completely complementary to at least 30 contiguous nucleotides of said target polynucleotide.

50. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 60 contiguous nucleotides of said target polynucleotide.

10 51. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to said target polynucleotide.

52. An array of claim 48, which is a microarray.

15 53. An array of claim 48, further comprising said target polynucleotide hybridized to a nucleotide molecule comprising said first oligonucleotide or polynucleotide sequence.

54. An array of claim 48, wherein a linker joins at least one of said nucleotide molecules to said solid substrate.

20 55. An array of claim 48, wherein each distinct physical location on the substrate contains multiple nucleotide molecules, and the multiple nucleotide molecules at any single distinct physical location have the same sequence, and each distinct physical location on the substrate contains nucleotide molecules having a sequence which differs from the sequence of nucleotide molecules at
25 another distinct physical location on the substrate.

56. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:1.

57. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:2.

30 58. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:3.

59. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:4.

60. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:5.

61. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:6.

62. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:7.

63. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:8.

64. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:9.

65. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:10.

66. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:11.

67. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:12.

68. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:13.

69. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:14.

70. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:15.

71. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:16.

72. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:17.

73. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:18.

74. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:19.

75. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:20.

76. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:21.

77. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:22.

78. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:23.

79. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:24.

80. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:25.

81. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:26.

82. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:27.

83. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:28.

84. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:29.

85. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:30.

86. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:31.

87. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:32.

88. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:33.

89. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:34.

90. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:35.

91. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:36.

92. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:37.

93. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:38.

94. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:39.

95. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:40.

5 96. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:41.

97. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:42.

98. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:43.

10 99. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:44.

100. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:45.

15 101. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:46.

20 102. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:47.

103. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID
NO:48.

<110> INCYTE GENOMICS, INC.
BANDMAN, Olga
NGUYEN, Danniel B
WALIA, Narinder K.
HAFALIA, April J.A.
YAO, Monique G.
GANDHI, Ameena R.
GURURAJAN, Rajagopal
DING, Li
PATTERSON, Chandra
YUE, Henry
BAUGHN, Mariah R.
TRIBOULEY, Catherine M.
THORNTON, Michael
ELLIOTT, Vicki S.
LU, Yan
ISON, Craig H.
AU-YOUNG, Janice
TANG, Y. Tom
AZIMZAI, Yalda
BURRILL, John D.
MARCUS, Gregory A.
ZINGLER, Kurt A.
LU, Dyung Aina M.
LAL, Preeti G.
RAMKUMAR, Jayalaxmi
WARREN, Bridget A.
KEARNEY, Liam
POLICKY, Jennifer L.
THANGAVELU, Kavitha
BURFORD, Neil

<120> HUMAN KINASES

<130> PF-0209 PCT

<140> To Be Assigned

<141> Herewith

<150> 60/229,873; 60/231,357; 60/232,654; 60/234,902; 60/236,499;
60/238,389; 60/240,542

<151> 2000-08-31; 2000-09-08; 2000-09-14; 2000-09-22; 2000-09-29;
2000-10-06; 2000-10-13

<160> 48

<170> PERL Program

<210> 1

<211> 424

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7312543CD1

<400> 1

```

Met Ser Val Gly Cys Pro Glu Pro Glu Pro Pro Arg Ser Leu Thr
 1      5      10      15
Cys Cys Gly Pro Gly Thr Ala Pro Gly Pro Gly Ala Gly Val Pro
      20      25      30
Leu Leu Thr Glu Asp Met Gln Ala Leu Thr Leu Arg Thr Leu Ala
      35      40      45
Ala Ser Asp Val Thr Lys His Tyr Glu Leu Val Arg Glu Leu Gly
      50      55      60
Lys Gly Thr Tyr Gly Lys Val Asp Leu Val Val Tyr Lys Gly Thr
      65      70      75
Gly Thr Lys Met Ala Leu Lys Phe Val Asn Lys Ser Lys Thr Lys
      80      85      90
Leu Lys Asn Phe Leu Arg Glu Val Ser Ile Thr Asn Ser Leu Ser
      95     100     105
Ser Ser Pro Phe Ile Ile Lys Val Phe Asp Val Val Phe Glu Thr
     110     115     120
Glu Asp Cys Tyr Val Phe Ala Gln Glu Tyr Ala Pro Ala Gly Asp
     125     130     135
Leu Phe Asp Ile Ile Pro Pro Gln Val Gly Leu Pro Glu Asp Thr
     140     145     150
Val Lys Arg Cys Val Gln Gln Leu Gly Leu Ala Leu Asp Phe Met
     155     160     165
His Gly Arg Gln Leu Val His Arg Asp Ile Lys Pro Glu Asn Val
     170     175     180
Leu Leu Phe Asp Arg Glu Cys Arg Arg Val Lys Leu Ala Asp Phe
     185     190     195
Gly Met Thr Arg Arg Val Gly Cys Arg Val Lys Arg Val Ser Gly
     200     205     210
Thr Ile Pro Tyr Thr Ala Pro Glu Val Cys Gln Ala Gly Arg Ala
     215     220     225
Asp Gly Leu Ala Val Asp Thr Gly Val Asp Val Trp Ala Phe Gly
     230     235     240
Val Leu Ile Phe Cys Val Leu Thr Gly Asn Phe Pro Trp Glu Ala
     245     250     255
Ala Ser Gly Ala Asp Ala Phe Phe Glu Glu Phe Val Arg Trp Gln
     260     265     270
Arg Gly Arg Leu Pro Gly Leu Pro Ser Gln Trp Arg Arg Phe Thr
     275     280     285
Glu Pro Ala Leu Arg Met Phe Gln Arg Leu Leu Ala Leu Glu Pro
     290     295     300
Glu Arg Arg Gly Pro Ala Lys Glu Val Phe Arg Phe Leu Lys His
     305     310     315
Glu Leu Thr Ser Glu Leu Arg Arg Arg Pro Ser His Arg Ala Arg
     320     325     330
Lys Pro Pro Gly Asp Arg Pro Pro Ala Ala Gly Pro Leu Arg Leu
     335     340     345
Glu Ala Pro Gly Pro Leu Lys Arg Thr Val Leu Thr Glu Ser Gly
     350     355     360
Gly Gly Ser Arg Pro Ala Pro Pro Ala Val Gly Ser Val Pro Leu
     365     370     375
Pro Val Pro Val Pro Val Pro Val Pro Val Pro Val Pro Val Pro
     380     385     390
Glu Pro Gly Leu Ala Pro Gln Gly Pro Pro Gly Arg Thr Asp Gly
     395     400     405
Arg Ala Asp Lys Ser Lys Gly Gln Val Val Leu Ala Thr Ala Ile

```

	410		415		420
Glu Ile Cys Val					
<210> 2					
<211> 1719					
<212> PRT					
<213> Homo sapiens					
<220>					
<221> misc_feature					
<223> Incyte ID No: 7477427CD1					
<400> 2					
Met Ser Gly Glu Val Arg Leu Arg Gln Leu Glu Gln Phe Ile Leu					
1 5 10 15					
Asp Gly Pro Ala Gln Thr Asn Gly Gln Cys Phe Ser Val Glu Thr					
20 25 30					
Leu Leu Asp Ile Leu Ile Cys Leu Tyr Asp Glu Cys Asn Asn Ser					
35 40 45					
Pro Leu Arg Arg Glu Lys Asn Ile Leu Glu Tyr Leu Glu Trp Ala					
50 55 60					
Lys Pro Phe Thr Ser Lys Val Lys Gln Met Arg Leu His Arg Glu					
65 70 75					
Asp Phe Glu Ile Leu Lys Val Ile Gly Arg Gly Ala Phe Gly Glu					
80 85 90					
Val Ala Val Val Lys Leu Lys Asn Ala Asp Lys Val Phe Ala Met					
95 100 105					
Lys Ile Leu Asn Lys Trp Glu Met Leu Lys Arg Ala Glu Thr Ala					
110 115 120					
Cys Phe Arg Glu Glu Arg Asp Val Leu Val Asn Gly Asp Asn Lys					
125 130 135					
Trp Ile Thr Thr Leu His Tyr Ala Phe Gln Asp Asp Asn Asn Leu					
140 145 150					
Tyr Leu Val Met Asp Tyr Tyr Val Gly Gly Asp Leu Leu Thr Leu					
155 160 165					
Leu Ser Lys Phe Glu Asp Arg Leu Pro Glu Asp Met Ala Arg Phe					
170 175 180					
Tyr Leu Ala Glu Met Val Ile Ala Ile Asp Ser Val His Gln Leu					
185 190 195					
His Tyr Val His Arg Asp Ile Lys Pro Asp Asn Ile Leu Met Asp					
200 205 210					
Met Asn Gly His Ile Arg Leu Ala Asp Phe Gly Ser Cys Leu Lys					
215 220 225					
Leu Met Glu Asp Gly Thr Val Gln Ser Ser Val Ala Val Gly Thr					
230 235 240					
Pro Asp Tyr Ile Ser Pro Glu Ile Leu Gln Ala Met Glu Asp Gly					
245 250 255					
Lys Gly Arg Tyr Gly Pro Glu Cys Asp Trp Trp Ser Leu Gly Val					
260 265 270					
Cys Met Tyr Glu Met Leu Tyr Gly Glu Thr Pro Phe Tyr Ala Glu					
275 280 285					
Ser Leu Val Glu Thr Tyr Gly Lys Ile Met Asn His Lys Glu Arg					
290 295 300					
Phe Gln Phe Pro Ala Gln Val Thr Asp Val Ser Glu Asn Ala Lys					
305 310 315					

Asp	Leu	Ile	Arg	Arg	Leu	Ile	Cys	Ser	Arg	Glu	His	Arg	Leu	Gly	320	325	330
Gln	Asn	Gly	Ile	Glu	Asp	Phe	Lys	Lys	His	Pro	Phe	Phe	Ser	Gly	335	340	345
Ile	Asp	Trp	Asp	Asn	Ile	Arg	Asn	Cys	Glu	Ala	Pro	Tyr	Ile	Pro	350	355	360
Glu	Val	Ser	Ser	Pro	Thr	Asp	Thr	Ser	Asn	Phe	Asp	Val	Asp	Asp	365	370	375
Asp	Cys	Leu	Lys	Asn	Ser	Glu	Thr	Met	Pro	Pro	Pro	Thr	His	Thr	380	385	390
Ala	Phe	Ser	Gly	His	His	Leu	Pro	Phe	Val	Gly	Phe	Thr	Tyr	Thr	395	400	405
Ser	Ser	Cys	Val	Leu	Ser	Asp	Arg	Ser	Cys	Leu	Arg	Val	Thr	Ala	410	415	420
Gly	Pro	Thr	Ser	Leu	Asp	Leu	Asp	Val	Asn	Val	Gln	Arg	Thr	Leu	425	430	435
Asp	Asn	Asn	Leu	Ala	Thr	Glu	Ala	Tyr	Glu	Arg	Arg	Ile	Lys	Arg	440	445	450
Leu	Glu	Gln	Glu	Lys	Leu	Glu	Leu	Ser	Arg	Lys	Leu	Gln	Glu	Ser	455	460	465
Thr	Gln	Thr	Val	Gln	Ala	Leu	Gln	Tyr	Ser	Thr	Val	Asp	Gly	Pro	470	475	480
Leu	Thr	Ala	Ser	Lys	Asp	Leu	Glu	Ile	Lys	Asn	Leu	Lys	Glu	Glu	485	490	495
Ile	Glu	Lys	Leu	Arg	Lys	Gln	Val	Thr	Glu	Ser	Ser	His	Leu	Glu	500	505	510
Gln	Gln	Leu	Glu	Glu	Ala	Asn	Ala	Val	Arg	Gln	Glu	Leu	Asp	Asp	515	520	525
Ala	Phe	Arg	Gln	Ile	Lys	Ala	Tyr	Glu	Lys	Gln	Ile	Lys	Thr	Leu	530	535	540
Gln	Gln	Glu	Arg	Glu	Asp	Leu	Asn	Lys	Glu	Leu	Val	Gln	Ala	Ser	545	550	555
Glu	Arg	Leu	Lys	Asn	Gln	Ser	Lys	Glu	Leu	Lys	Asp	Ala	His	Cys	560	565	570
Gln	Arg	Lys	Leu	Ala	Met	Gln	Glu	Phe	Met	Glu	Ile	Asn	Glu	Arg	575	580	585
Leu	Thr	Glu	Leu	His	Thr	Gln	Lys	Gln	Lys	Leu	Ala	Arg	His	Val	590	595	600
Arg	Asp	Lys	Glu	Glu	Glu	Val	Asp	Leu	Val	Met	Gln	Lys	Val	Glu	605	610	615
Ser	Leu	Arg	Gln	Glu	Leu	Arg	Arg	Thr	Glu	Arg	Ala	Lys	Lys	Glu	620	625	630
Leu	Glu	Val	His	Thr	Glu	Ala	Leu	Ala	Ala	Glu	Ala	Ser	Lys	Asp	635	640	645
Arg	Lys	Leu	Arg	Glu	Gln	Ser	Glu	His	Tyr	Ser	Lys	Gln	Leu	Glu	650	655	660
Asn	Glu	Leu	Glu	Gly	Leu	Lys	Gln	Lys	Gln	Ile	Ser	Tyr	Ser	Pro	665	670	675
Gly	Val	Cys	Ser	Ile	Glu	His	Gln	Gln	Glu	Ile	Thr	Lys	Leu	Lys	680	685	690
Thr	Asp	Leu	Glu	Lys	Lys	Ser	Ile	Phe	Tyr	Glu	Glu	Glu	Leu	Ser	695	700	705
Lys	Arg	Glu	Gly	Ile	His	Ala	Asn	Glu	Ile	Lys	Asn	Leu	Lys	Lys	710	715	720
Glu	Leu	His	Asp	Ser	Glu	Gly	Gln	Gln	Leu	Ala	Leu	Asn	Lys	Glu	725	730	735

Ile Met Ile Leu Lys Asp Lys Leu Glu Lys Thr Arg Arg Glu Ser	740	745	750
Gln Ser Glu Arg Glu Glu Phe Glu Ser Glu Phe Lys Gln Gln Tyr	755	760	765
Glu Arg Glu Lys Val Leu Leu Thr Glu Glu Asn Lys Lys Leu Thr	770	775	780
Ser Glu Leu Asp Lys Leu Thr Thr Leu Tyr Glu Asn Leu Ser Ile	785	790	795
His Asn Gln Gln Leu Glu Glu Glu Val Lys Asp Leu Ala Asp Lys	800	805	810
Lys Glu Ser Val Ala His Trp Glu Ala Gln Ile Thr Glu Ile Ile	815	820	825
Gln Trp Val Ser Asp Glu Lys Asp Ala Arg Gly Tyr Leu Gln Ala	830	835	840
Leu Ala Ser Lys Met Thr Glu Glu Leu Glu Ala Leu Arg Asn Ser	845	850	855
Ser Leu Gly Thr Arg Ala Thr Asp Met Pro Trp Lys Met Arg Arg	860	865	870
Phe Ala Lys Leu Asp Met Ser Ala Arg Leu Glu Leu Gln Ser Ala	875	880	885
Leu Asp Ala Glu Ile Arg Ala Lys Gln Ala Ile Gln Glu Glu Leu	890	895	900
Asn Lys Val Lys Ala Ser Asn Ile Ile Thr Glu Cys Lys Leu Lys	905	910	915
Asp Ser Glu Lys Lys Asn Leu Glu Leu Leu Ser Glu Ile Glu Gln	920	925	930
Leu Ile Lys Asp Thr Glu Glu Leu Arg Ser Glu Lys Gly Ile Glu	935	940	945
His Gln Asp Ser Gln His Ser Phe Leu Ala Phe Leu Asn Thr Pro	950	955	960
Thr Asp Ala Leu Asp Gln Phe Glu Thr Val Asp Ser Thr Pro Leu	965	970	975
Ser Val His Thr Pro Thr Leu Arg Lys Lys Gly Cys Pro Gly Ser	980	985	990
Thr Gly Phe Pro Pro Lys Arg Lys Thr His Gln Phe Phe Val Lys	995	1000	1005
Ser Phe Thr Thr Pro Thr Lys Cys His Gln Cys Thr Ser Leu Met	1010	1015	1020
Val Gly Leu Ile Arg Gln Gly Cys Ser Cys Glu Val Cys Gly Phe	1025	1030	1035
Ser Cys His Ile Thr Cys Val Asn Lys Ala Pro Thr Thr Cys Pro	1040	1045	1050
Val Pro Pro Glu Gln Thr Lys Gly Pro Leu Gly Ile Asp Pro Gln	1055	1060	1065
Lys Gly Ile Gly Thr Ala Tyr Glu Gly His Val Arg Ile Pro Lys	1070	1075	1080
Pro Ala Gly Val Lys Lys Gly Trp Gln Arg Ala Leu Ala Ile Val	1085	1090	1095
Cys Asp Phe Lys Leu Phe Leu Tyr Asp Ile Ala Glu Gly Lys Ala	1100	1105	1110
Ser Gln Pro Ser Val Val Ile Ser Gln Val Ile Asp Met Arg Asp	1115	1120	1125
Glu Glu Phe Ser Val Ser Ser Val Leu Ala Ser Asp Val Ile His	1130	1135	1140
Ala Ser Arg Lys Asp Ile Pro Cys Ile Phe Arg Val Thr Ala Ser	1145	1150	1155

Gln	Leu	Ser	Ala	Ser	Asn	Asn	Lys	Cys	Ser	Ile	Leu	Met	Leu	Ala
				1160					1165					1170
Asp	Thr	Glu	Asn	Glu	Lys	Asn	Lys	Trp	Val	Gly	Val	Leu	Ser	Glu
				1175					1180					1185
Leu	His	Lys	Ile	Leu	Lys	Lys	Asn	Lys	Phe	Arg	Asp	Arg	Ser	Val
				1190					1195					1200
Tyr	Val	Pro	Lys	Glu	Ala	Tyr	Asp	Ser	Thr	Leu	Pro	Leu	Ile	Lys
				1205					1210					1215
Thr	Thr	Gln	Ala	Ala	Ala	Ile	Ile	Asp	His	Glu	Arg	Ile	Ala	Leu
				1220					1225					1230
Gly	Asn	Glu	Glu	Gly	Leu	Phe	Val	Val	His	Val	Thr	Lys	Asp	Glu
				1235					1240					1245
Ile	Ile	Arg	Val	Gly	Asp	Asn	Lys	Lys	Ile	His	Gln	Ile	Glu	Leu
				1250					1255					1260
Ile	Pro	Asn	Asp	Gln	Leu	Val	Ala	Val	Ile	Ser	Gly	Arg	Asn	Arg
				1265					1270					1275
His	Val	Arg	Leu	Phe	Pro	Met	Ser	Ala	Leu	Asp	Gly	Arg	Glu	Thr
				1280					1285					1290
Asp	Phe	Tyr	Lys	Leu	Ser	Glu	Thr	Lys	Gly	Cys	Gln	Thr	Val	Thr
				1295					1300					1305
Ser	Gly	Lys	Val	Arg	His	Gly	Ala	Leu	Thr	Cys	Leu	Cys	Val	Ala
				1310					1315					1320
Met	Lys	Arg	Gln	Val	Leu	Cys	Tyr	Glu	Leu	Phe	Gln	Ser	Lys	Thr
				1325					1330					1335
Arg	His	Arg	Lys	Phe	Lys	Glu	Ile	Gln	Val	Pro	Tyr	Asn	Val	Gln
				1340					1345					1350
Trp	Met	Ala	Ile	Phe	Ser	Glu	Gln	Leu	Cys	Val	Gly	Phe	Gln	Ser
				1355					1360					1365
Gly	Phe	Leu	Arg	Tyr	Pro	Leu	Asn	Gly	Glu	Gly	Asn	Pro	Tyr	Ser
				1370					1375					1380
Met	Leu	His	Ser	Asn	Asp	His	Thr	Leu	Ser	Phe	Ile	Ala	His	Gln
				1385					1390					1395
Pro	Met	Asp	Ala	Ile	Cys	Ala	Val	Glu	Ile	Ser	Ser	Lys	Glu	Tyr
				1400					1405					1410
Leu	Leu	Cys	Phe	Asn	Ser	Ile	Gly	Ile	Tyr	Thr	Asp	Cys	Gln	Gly
				1415					1420					1425
Arg	Arg	Ser	Arg	Gln	Gln	Glu	Leu	Met	Trp	Pro	Ala	Asn	Pro	Ser
				1430					1435					1440
Ser	Cys	Cys	Tyr	Asn	Ala	Pro	Tyr	Leu	Ser	Val	Tyr	Ser	Glu	Asn
				1445					1450					1455
Ala	Val	Asp	Ile	Phe	Asp	Val	Asn	Ser	Met	Glu	Trp	Ile	Gln	Thr
				1460					1465					1470
Leu	Pro	Leu	Lys	Lys	Val	Arg	Pro	Leu	Asn	Asn	Glu	Gly	Ser	Leu
				1475					1480					1485
Asn	Leu	Leu	Gly	Leu	Glu	Thr	Ile	Arg	Leu	Ile	Tyr	Phe	Lys	Asn
				1490					1495					1500
Lys	Met	Ala												

```

Ile Gln Ile Leu Lys Asp Leu Pro Met Asn Pro Arg Pro Gln Glu
    1580                      1585                      1590
Ser Arg Thr Val Phe Ser Gly Ser Val Ser Ile Pro Ser Ile Thr
    1595                      1600                      1605
Lys Ser Arg Pro Glu Pro Gly Arg Ser Met Ser Ala Ser Ser Gly
    1610                      1615                      1620
Leu Ser Ala Arg Ser Ser Ala Gln Asn Gly Ser Ala Leu Lys Arg
    1625                      1630                      1635
Glu Phe Ser Gly Gly Ser Tyr Ser Ala Lys Arg Gln Pro Met Pro
    1640                      1645                      1650
Ser Pro Ser Glu Gly Ser Leu Ser Ser Gly Gly Met Asp Gln Gly
    1655                      1660                      1665
Ser Asp Ala Pro Ala Arg Asp Phe Asp Gly Glu Asp Ser Asp Ser
    1670                      1675                      1680
Pro Arg His Ser Thr Ala Ser Asn Ser Ser Asn Leu Ser Ser Pro
    1685                      1690                      1695
Pro Ser Pro Val Ser Pro Arg Lys Thr Lys Ser Leu Ser Leu Glu
    1700                      1705                      1710
Ser Thr Asp Arg Gly Ser Trp Asp Pro
    1715

```

<210> 3

<211> 1125

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7481495CD1

<400> 3

```

Met Ser Lys Thr Leu Lys Lys Lys Lys His Trp Leu Ser Lys Val
    1          5          10          15
Gln Glu Cys Ala Val Ser Trp Ala Gly Pro Pro Gly Asp Phe Gly
    20          25          30
Ala Glu Ile Arg Gly Gly Ala Glu Arg Gly Glu Phe Pro Tyr Leu
    35          40          45
Gly Arg Leu Arg Glu Glu Pro Gly Gly Gly Thr Cys Tyr Val Val
    50          55          60
Ser Gly Lys Ala Pro Ser Pro Gly Asp Val Leu Leu Glu Val Asn
    65          70          75
Gly Thr Pro Val Ser Gly Leu Thr Asn Arg Asp Thr Leu Ala Val
    80          85          90
Ile Arg His Phe Arg Glu Pro Ile Arg Leu Lys Thr Val Lys Pro
    95          100         105
Gly Lys Val Ile Asn Lys Asp Leu Arg His Tyr Leu Ser Leu Gln
    110         115         120
Phe Gln Lys Gly Ser Ile Asp His Lys Leu Gln Gln Val Ile Arg
    125         130         135
Asp Asn Leu Tyr Leu Arg Thr Ile Pro Cys Thr Thr Arg Ala Pro
    140         145         150
Arg Asp Gly Glu Val Pro Gly Val Asp Tyr Asn Phe Ile Ser Val
    155         160         165
Glu Gln Phe Lys Ala Leu Glu Glu Ser Gly Ala Leu Leu Glu Ser
    170         175         180
Gly Thr Tyr Asp Gly Asn Phe Tyr Gly Thr Pro Lys Pro Pro Ala

```

	185		190		195
Glu Pro Ser Pro	Phe Gln Pro Asp Pro	Val Asp Gln Val Leu Phe			
	200		205		210
Asp Asn Glu Phe	Asp Ala Glu Ser Gln Arg	Lys Arg Thr Thr Ser			
	215		220		225
Val Ser Lys Met	Glu Arg Met Asp Ser	Ser Leu Pro Glu Glu Glu			
	230		235		240
Glu Asp Glu Asp	Lys Glu Ala Ile Asn Gly	Ser Gly Asn Ala Glu			
	245		250		255
Asn Arg Glu Arg	His Ser Glu Ser Ser	Asp Trp Met Lys Thr Val			
	260		265		270
Pro Ser Tyr Asn	Gln Thr Asn Ser Ser	Met Asp Phe Arg Asn Tyr			
	275		280		285
Met Met Arg Asp	Glu Thr Leu Glu Pro	Leu Pro Lys Asn Trp Glu			
	290		295		300
Met Ala Tyr Thr	Asp Thr Gly Met Ile	Tyr Phe Ile Asp His Asn			
	305		310		315
Thr Lys Thr Thr	Thr Trp Leu Asp Pro	Arg Leu Cys Lys Lys Ala			
	320		325		330
Lys Ala Pro Glu	Asp Cys Glu Asp Gly	Glu Leu Pro Tyr Gly Trp			
	335		340		345
Glu Lys Ile Glu	Asp Pro Gln Tyr Gly	Thr Tyr Tyr Val Asp His			
	350		355		360
Leu Asn Gln Lys	Thr Gln Phe Glu Asn	Pro Val Glu Glu Ala Lys			
	365		370		375
Arg Lys Lys Gln	Leu Gly Gln Val Glu	Ile Gly Ser Ser Lys Pro			
	380		385		390
Asp Met Glu Lys	Ser His Phe Thr Arg	Asp Pro Ser Gln Leu Lys			
	395		400		405
Gly Val Leu Val	Arg Ala Ser Leu Lys	Lys Ser Thr Met Gly Phe			
	410		415		420
Gly Phe Thr Ile	Ile Gly Gly Asp Arg	Pro Asp Glu Phe Leu Gln			
	425		430		435
Val Lys Asn Val	Leu Lys Asp Gly Pro	Ala Ala Gln Asp Gly Lys			
	440		445		450
Ile Ala Pro Gly	Asp Val Ile Val Asp	Ile Asn Gly Asn Cys Val			
	455		460		465
Leu Gly His Thr	His Ala Asp Val Val	Gln Met Phe Gln Leu Val			
	470		475		480
Pro Val Asn Gln	Tyr Val Asn Leu Thr	Leu Cys Arg Gly Tyr Pro			
	485		490		495
Leu Pro Asp Asp	Ser Glu Asp Pro Val	Val Asp Ile Val Ala Ala			
	500		505		510
Thr Pro Val Ile	Asn Gly Gln Ser Leu	Thr Lys Gly Glu Thr Cys			
	515		520		525
Met Asn Pro Gln	Asp Phe Lys Pro Gly	Ala Met Val Leu Glu Gln			
	530		535		540
Asn Gly Lys Ser	Gly His Thr Leu Thr	Gly Asp Gly Leu Asn Gly			
	545		550		555
Pro Ser Asp Ala	Ser Glu Gln Arg Val	Ser Met Ala Ser Ser Gly			
	560		565		570
Ser Ser Gln Pro	Glu Leu Val Thr Ile	Pro Leu Ile Lys Gly Pro			
	575		580		585
Lys Gly Phe Gly	Phe Ala Ile Ala Asp	Ser Pro Thr Gly Gln Lys			
	590		595		600
Val Lys Met Ile	Leu Asp Ser Gln Trp	Cys Gln Gly Leu Gln Lys			

	605		610		615
Gly Asp Ile Ile	Lys Glu Ile Tyr His	Gln Asn Val Gln Asn	Leu		
	620		625		630
Thr His Leu Gln	Val Val Glu Val Leu	Lys Gln Phe Pro Val	Gly		
	635		640		645
Ala Asp Val Pro	Leu Leu Ile Leu Arg	Gly Gly Pro Pro Ser	Pro		
	650		655		660
Thr Lys Thr Ala	Lys Met Lys Thr Asp	Lys Lys Glu Asn Ala	Gly		
	665		670		675
Ser Leu Glu Ala	Ile Asn Glu Pro Ile	Pro Gln Pro Met Pro	Phe		
	680		685		690
Pro Pro Ser Ile	Ile Arg Ser Gly Ser	Pro Lys Leu Asp Pro	Ser		
	695		700		705
Glu Val Tyr Leu	Lys Ser Lys Thr Leu	Tyr Glu Asp Lys Pro	Pro		
	710		715		720
Asn Thr Lys Asp	Leu Asp Val Phe Leu	Arg Lys Gln Glu Ser	Gly		
	725		730		735
Phe Gly Phe Arg	Val Leu Gly Gly Asp	Gly Pro Asp Gln Ser	Ile		
	740		745		750
Tyr Ile Gly Ala	Ile Ile Pro Leu Gly	Ala Ala Glu Lys Asp	Gly		
	755		760		765
Arg Leu Arg Ala	Ala Asp Glu Leu Met	Cys Ile Asp Gly Ile	Pro		
	770		775		780
Val Lys Gly Lys	Ser His Lys Gln Val	Leu Asp Leu Met Thr	Thr		
	785		790		795
Ala Ala Arg Asn	Gly His Val Leu Leu	Thr Val Arg Arg Lys	Ile		
	800		805		810
Phe Tyr Gly Glu	Lys Gln Pro Glu Asp	Asp Ser Ser Gln Ala	Phe		
	815		820		825
Ile Ser Thr Gln	Asn Gly Ser Pro Arg	Leu Asn Arg Ala Glu	Val		
	830		835		840
Pro Ala Arg Pro	Ala Pro Gln Glu Pro	Tyr Asp Val Val Leu	Gln		
	845		850		855
Arg Lys Glu Asn	Glu Gly Phe Gly Phe	Val Ile Leu Thr Ser	Lys		
	860		865		870
Asn Lys Pro Pro	Pro Gly Val Ile Pro	His Lys Ile Gly Arg	Val		
	875		880		885
Ile Glu Gly Ser	Pro Ala Asp Arg Cys	Gly Lys Leu Lys Val	Gly		
	890		895		900
Asp His Ile Ser	Ala Val Asn Gly Gln	Ser Ile Val Glu Leu	Ser		
	905		910		915
His Asp Asn Ile	Val Gln Leu Ile Lys	Asp Ala Gly Val Thr	Val		
	920		925		930
Thr Leu Thr Val	Ile Ala Glu Glu Glu	His His Gly Pro Pro	Ser		
	935		940		945
Gly Thr Asn Ser	Ala Arg Gln Ser Pro	Ala Leu Gln His Arg	Pro		
	950		955		960
Met Gly Gln Ser	Gln Ala Asn His Ile	Pro Gly Asp Arg Ser	Ala		
	965		970		975
Leu Glu Gly Glu	Ile Gly Lys Asp Val	Ser Thr Ser Tyr Arg	His		
	980		985		990
Ser Trp Ser Asp	His Lys His Leu Ala	Gln Pro Asp Thr Ala	Val		
	995		1000		1005
Ile Ser Val Val	Gly Ser Arg His Asn	Gln Asn Leu Gly Cys	Tyr		
	1010		1015		1020
Pro Val Glu Leu	Glu Arg Gly Pro Arg	Gly Phe Gly Phe Ser	Leu		

1025	1030	1035
Arg Gly Gly Lys Glu Tyr Asn Met Gly Leu Phe Ile Leu Arg Leu		
1040	1045	1050
Ala Glu Asp Gly Pro Ala Ile Lys Asp Gly Arg Ile His Val Gly		
1055	1060	1065
Asp Gln Ile Val Glu Ile Asn Gly Glu Pro Thr Gln Gly Ile Thr		
1070	1075	1080
His Thr Arg Ala Ile Glu Leu Ile Gln Ala Gly Gly Asn Lys Val		
1085	1090	1095
Leu Leu Leu Leu Arg Pro Gly Thr Gly Leu Ile Pro Asp His Gly		
1100	1105	1110
Leu Ala Pro Ser Gly Leu Cys Ser Tyr Val Lys Pro Glu Gln His		
1115	1120	1125

<210> 4

<211> 500

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 55053189CD1

<400> 4

Met Cys Thr Val Val Asp Pro Arg Ile Val Arg Arg Tyr Leu Leu		
1	5	10
Arg Arg Gln Leu Gly Gln Gly Ala Tyr Gly Ile Val Trp Lys Ala		
20	25	30
Val Asp Arg Arg Thr Gly Glu Val Val Ala Ile Lys Lys Ile Phe		
35	40	45
Asp Ala Phe Arg Asp Lys Thr Asp Ala Gln Arg Thr Phe Arg Glu		
50	55	60
Ile Thr Leu Leu Gln Glu Phe Gly Asp His Pro Asn Ile Ile Ser		
65	70	75
Leu Leu Asp Val Ile Arg Ala Glu Asn Asp Arg Asp Ile Tyr Leu		
80	85	90
Val Phe Glu Phe Met Asp Thr Asp Leu Asn Ala Val Ile Arg Lys		
95	100	105
Gly Gly Leu Leu Gln Asp Val His Val Arg Ser Ile Phe Tyr Gln		
110	115	120
Leu Leu Arg Ala Thr Arg Phe Leu His Ser Gly His Val Val His		
125	130	135
Arg Asp Gln Lys Pro Ser Asn Val Leu Leu Asp Ala Asn Cys Thr		
140	145	150
Val Lys Leu Cys Asp Phe Gly Leu Ala Arg Ser Leu Gly Asp Leu		
155	160	165
Pro Glu Gly Pro Glu Asp Gln Ala Val Thr Glu Tyr Val Ala Thr		
170	175	180
Arg Trp Tyr Arg Ala Pro Glu Val Leu Leu Ser Ser His Arg Tyr		
185	190	195
Thr Leu Gly Val Asp Met Trp Ser Leu Gly Cys Ile Leu Gly Glu		
200	205	210
Met Leu Arg Gly Arg Pro Leu Phe Pro Gly Thr Ser Thr Leu His		
215	220	225
Gln Leu Glu Leu Ile Leu Glu Thr Ile Pro Pro Pro Ser Glu Glu		

230	235	240
Asp Leu Leu Ala	Leu Gly Ser Gly Cys Arg Ala Ser Val Leu His	
245	250	255
Gln Leu Gly Ser	Arg Pro Arg Gln Thr Leu Asp Ala Leu Leu Pro	
260	265	270
Pro Asp Thr Ser	Pro Glu Ala Leu Asp Leu Leu Arg Arg Leu Leu	
275	280	285
Val Phe Ala Pro	Asp Lys Arg Leu Ser Ala Thr Gln Met Ile Leu	
290	295	300
Glu Cys Gly Gly	Ser Ser Gly Thr Ser Arg Glu Lys Gly Pro Glu	
305	310	315
Gly Val Ser Pro	Ser Gln Ala His Leu His Lys Pro Arg Ala Asp	
320	325	330
Pro Gln Leu Pro	Ser Arg Thr Pro Val Gln Gly Pro Arg Pro Arg	
335	340	345
Pro Gln Ser Ser	Pro Gly His Asp Pro Ala Glu His Glu Ser Pro	
350	355	360
Arg Ala Ala Lys	Asn Val Pro Arg Gln Asn Ser Ala Pro Leu Leu	
365	370	375
Gln Thr Ala Leu	Leu Gly Asn Gly Glu Arg Pro Pro Gly Ala Lys	
380	385	390
Glu Ala Pro Pro	Leu Thr Leu Ser Leu Val Lys Pro Ser Gly Arg	
395	400	405
Gly Ala Ala Pro	Ser Leu Thr Ser Gln Ala Ala Ala Gln Val Ala	
410	415	420
Asn Gln Ala Leu	Ile Arg Gly Asp Trp Asn Arg Gly Gly Gly Val	
425	430	435
Arg Val Ala Ser	Val Gln Gln Val Pro Pro Arg Leu Pro Pro Glu	
440	445	450
Ala Arg Pro Gly	Arg Arg Met Phe Ser Thr Ser Ala Leu Gln Gly	
455	460	465
Ala Gln Gly Gly	Ala Arg Ala Leu Leu Gly Gly Tyr Ser Gln Ala	
470	475	480
Tyr Gly Thr Val	Cys His Ser Ala Leu Gly His Leu Pro Leu Leu	
485	490	495
Glu Gly His His	Val	
500		

<210> 5

<211> 328

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7474797CD1

<400> 5

Met Gly Lys Gly Asp Val Leu Glu Ala Ala Pro Thr Thr Thr Ala	
1	5 10 15
Tyr His Ser Leu Met Asp Glu Tyr Gly Tyr Glu Val Gly Lys Ala	
	20 25 30
Ile Gly His Gly Ser Tyr Gly Ser Val Tyr Glu Ala Phe Tyr Thr	
	35 40 45
Lys Gln Lys Val Met Val Ala Val Lys Ile Ile Ser Lys Lys Lys	
	50 55 60

Ala	Ser	Asp	Asp	Tyr	Leu	Asn	Lys	Phe	Leu	Pro	Arg	Glu	Ile	Gln			
				65					70					75			
Val	Met	Lys	Val	Leu	Arg	His	Lys	Tyr	Leu	Ile	Asn	Phe	Tyr	Arg			
				80					85					90			
Ala	Ile	Glu	Ser	Thr	Ser	Arg	Val	Tyr	Ile	Ile	Leu	Glu	Leu	Ala			
				95					100					105			
Gln	Gly	Gly	Asp	Val	Leu	Glu	Trp	Ile	Gln	Arg	Tyr	Gly	Ala	Cys			
				110					115					120			
Ser	Glu	Pro	Leu	Ala	Gly	Lys	Trp	Phe	Ser	Gln	Leu	Thr	Leu	Gly			
				125					130					135			
Ile	Ala	Tyr	Leu	His	Ser	Lys	Ser	Ile	Val	His	Arg	Asp	Leu	Lys			
				140					145					150			
Leu	Glu	Asn	Leu	Leu	Leu	Asp	Lys	Trp	Glu	Asn	Val	Lys	Ile	Ser			
				155					160					165			
Asp	Phe	Gly	Phe	Ala	Lys	Met	Val	Pro	Ser	Asn	Gln	Pro	Val	Gly			
				170					175					180			
Cys	Ser	Pro	Ser	Tyr	Arg	Gln	Val	Asn	Cys	Phe	Ser	His	Leu	Ser			
				185					190					195			
Gln	Thr	Tyr	Cys	Gly	Ser	Phe	Ala	Tyr	Ala	Cys	Pro	Glu	Ile	Leu			
				200					205					210			
Arg	Gly	Leu	Pro	Tyr	Asn	Pro	Phe	Leu	Ser	Asp	Thr	Trp	Ser	Met			
				215					220					225			
Gly	Val	Ile	Leu	Tyr	Thr	Leu	Val	Val	Ala	His	Leu	Pro	Phe	Asp			
				230					235					240			
Asp	Thr	Asn	Leu	Lys	Lys	Leu	Leu	Arg	Glu	Thr	Gln	Lys	Glu	Val			
				245					250					255			
Thr	Phe	Pro	Ala	Asn	His	Thr	Ile	Ser	Gln	Glu	Cys	Lys	Asn	Leu			
				260					265					270			
Ile	Leu	Gln	Met	Val	Arg	Gln	Ala	Pro	Lys	Gly	Ala	Pro	Leu	Leu			
				275					280					285			
Asp	Ile	Ile	Lys	Asp	Phe	Trp	Gly	Val	Lys	Phe	Gln	Pro	Glu	Gln			
				290					295					300			
Pro	Pro	His	Glu	Ile	Arg	Leu	Leu	Glu	Ala	Met	Cys	Gln	Leu	Pro			
				305					310					315			
Asn	Pro	Pro	Lys	Gln	Pro	Gln	Ser	Leu	Gln	Ile	Ser	Pro					
				320					325								

<210> 6

<211> 370

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3296272CD1

<400> 6

Met	Lys	Ile	Lys	Asp	Ala	Lys	Lys	Pro	Ser	Phe	Pro	Trp	Phe	Gly			
1				5					10					15			
Met	Asp	Ile	Gly	Gly	Thr	Leu	Val	Lys	Leu	Ser	Tyr	Phe	Glu	Pro			
				20					25					30			
Ile	Asp	Ile	Thr	Ala	Glu	Glu	Glu	Gln	Glu	Glu	Val	Glu	Ser	Leu			
				35					40					45			
Lys	Ser	Ile	Arg	Lys	Tyr	Leu	Thr	Ser	Asn	Val	Ala	Tyr	Gly	Ser			
				50					55					60			
Thr	Gly	Ile	Arg	Asp	Val	His	Leu	Glu	Leu	Lys	Asp	Leu	Thr	Leu			

	65		70		75
Phe Gly Arg Arg Gly Asn Leu His Phe Ile Arg Phe Pro Thr Gln					
	80		85		90
Asp Leu Pro Thr Phe Ile Gln Met Gly Arg Asp Lys Asn Phe Ser					
	95		100		105
Thr Leu Gln Thr Val Leu Cys Ala Thr Gly Gly Gly Ala Tyr Lys					
	110		115		120
Phe Glu Lys Asp Phe Arg Thr Ile Gly Asn Leu His Leu His Lys					
	125		130		135
Leu Asp Glu Leu Asp Cys Leu Val Lys Gly Leu Leu Tyr Ile Asp					
	140		145		150
Ser Val Ser Phe Asn Gly Gln Ala Glu Cys Tyr Tyr Phe Ala Asn					
	155		160		165
Ala Ser Glu Pro Glu Arg Cys Gln Lys Met Pro Phe Asn Leu Asp					
	170		175		180
Asp Pro Tyr Pro Leu Leu Val Val Asn Ile Gly Ser Gly Val Ser					
	185		190		195
Ile Leu Ala Val His Ser Lys Asp Asn Tyr Lys Arg Val Thr Gly					
	200		205		210
Thr Ser Leu Gly Gly Gly Thr Tyr Thr Gly Phe Met Gln Leu Leu					
	215		220		225
Thr Gly Cys Glu Ser Phe Glu Glu Ala Leu Glu Met Ala Ser Lys					
	230		235		240
Gly Asp Ser Thr Gln Ala Asp Lys Leu Val Arg Asp Ile Tyr Gly					
	245		250		255
Gly Asp Tyr Glu Arg Phe Gly Leu Pro Gly Trp Ala Val Ala Ser					
	260		265		270
Ser Phe Gly Asn Met Ile Tyr Lys Glu Lys Arg Glu Ser Val Ser					
	275		280		285
Lys Glu Asp Leu Ala Arg Ala Thr Leu Val Thr Ile Thr Asn Asn					
	290		295		300
Ile Gly Ser Val Ala Arg Met Cys Ala Val Asn Glu Lys Ile Asn					
	305		310		315
Arg Val Val Phe Val Gly Asn Phe Leu Arg Val Asn Thr Leu Ser					
	320		325		330
Met Lys Leu Leu Ala Tyr Ala Leu Asp Tyr Trp Ser Lys Gly Gln					
	335		340		345
Leu Lys Ala Leu Phe Leu Glu His Glu Gly Tyr Phe Gly Ala Val					
	350		355		360
Gly Ala Leu Leu Gly Leu Pro Asn Phe Ser					
	365		370		

<210> 7

<211> 1369

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1989319CD1

<400> 7

Met Ala Ala Ala Ala Ala Ser Gly Ala Gly Gly Ala Ala Gly Ala			
1	5	10	15
Gly Thr Gly Gly Ala Gly Pro Ala Gly Arg Leu Leu Pro Pro Pro			
20	25	30	

Ala	Pro	Gly	Ser	Pro	Ala	Ala	Pro	Ala	Ala	Val	Ser	Pro	Ala	Ala	35	40	45
Gly	Gln	Pro	Arg	Pro	Pro	Ala	Pro	Ala	Ser	Arg	Gly	Pro	Met	Pro	50	55	60
Ala	Arg	Ile	Gly	Tyr	Tyr	Glu	Ile	Asp	Arg	Thr	Ile	Gly	Lys	Gly	65	70	75
Asn	Phe	Ala	Val	Val	Lys	Arg	Ala	Thr	His	Leu	Val	Thr	Lys	Ala	80	85	90
Lys	Val	Ala	Ile	Lys	Ile	Ile	Asp	Lys	Thr	Gln	Leu	Asp	Glu	Glu	95	100	105
Asn	Leu	Lys	Lys	Ile	Phe	Arg	Glu	Val	Gln	Ile	Met	Lys	Met	Leu	110	115	120
Cys	His	Pro	His	Ile	Ile	Arg	Leu	Tyr	Gln	Val	Met	Glu	Thr	Glu	125	130	135
Arg	Met	Ile	Tyr	Leu	Val	Thr	Glu	Tyr	Ala	Ser	Gly	Gly	Glu	Ile	140	145	150
Phe	Asp	His	Leu	Val	Ala	His	Gly	Arg	Met	Ala	Glu	Lys	Glu	Ala	155	160	165
Arg	Arg	Lys	Phe	Lys	Gln	Ile	Val	Thr	Ala	Val	Tyr	Phe	Cys	His	170	175	180
Cys	Arg	Asn	Ile	Val	His	Arg	Asp	Leu	Lys	Ala	Glu	Asn	Leu	Leu	185	190	195
Leu	Asp	Ala	Asn	Leu	Asn	Ile	Lys	Ile	Ala	Asp	Phe	Gly	Phe	Ser	200	205	210
Asn	Leu	Phe	Thr	Pro	Gly	Gln	Leu	Leu	Lys	Thr	Trp	Cys	Gly	Ser	215	220	225
Pro	Pro	Tyr	Ala	Ala	Pro	Glu	Leu	Phe	Glu	Gly	Lys	Glu	Tyr	Asp	230	235	240
Gly	Pro	Lys	Val	Asp	Ile	Trp	Ser	Leu	Gly	Val	Val	Leu	Tyr	Val	245	250	255
Leu	Val	Cys	Gly	Ala	Leu	Pro	Phe	Asp	Gly	Ser	Thr	Leu	Gln	Asn	260	265	270
Leu	Arg	Ala	Arg	Val	Leu	Ser	Gly	Lys	Phe	Arg	Ile	Pro	Phe	Phe	275	280	285
Met	Ser	Thr	Glu	Cys	Glu	His	Leu	Ile	Arg	His	Met	Leu	Val	Leu	290	295	300
Asp	Pro	Asn	Lys	Arg	Leu	Ser	Met	Glu	Gln	Ile	Cys	Lys	His	Lys	305	310	315
Trp	Met	Lys	Leu	Gly	Asp	Ala	Asp	Pro	Asn	Phe	Asp	Arg	Leu	Ile	320	325	330
Ala	Glu	Cys	Gln	Gln	Leu	Lys	Glu	Glu	Arg	Gln	Val	Asp	Pro	Leu	335	340	345
Asn	Glu	Asp	Val	Leu	Leu	Ala	Met	Glu	Asp	Met	Gly	Leu	Asp	Lys	350	355	360
Glu	Gln	Thr	Leu	Gln	Ser	Leu	Arg	Ser	Asp	Ala	Tyr	Asp	His	Tyr	365	370	375
Ser	Ala	Ile	Tyr	Ser	Leu	Leu	Cys	Asp	Arg	His	Lys	Arg	His	Lys	380	385	390
Thr	Leu	Arg	Leu	Gly	Ala	Leu	Pro	Ser	Met	Pro	Arg	Ala	Leu	Ala	395	400	405
Phe	Gln	Ala	Pro	Val	Asn	Ile	Gln	Ala	Glu	Gln	Ala	Gly	Thr	Ala	410	415	420
Met	Asn	Ile	Ser	Val	Pro	Gln	Val	Gln	Leu	Ile	Asn	Pro	Glu	Asn	425	430	435
Gln	Ile	Val	Glu	Pro	Asp	Gly	Thr	Leu	Asn	Leu	Asp	Ser	Asp	Glu	440	445	450

Gly	Glu	Glu	Pro	Ser	Pro	Glu	Ala	Leu	Val	Arg	Tyr	Leu	Ser	Met
				455					460					465
Arg	Arg	His	Thr	Val	Gly	Val	Ala	Asp	Pro	Arg	Thr	Glu	Val	Met
				470					475					480
Glu	Asp	Leu	Gln	Lys	Leu	Leu	Pro	Gly	Phe	Pro	Gly	Val	Asn	Pro
				485					490					495
Gln	Ala	Pro	Phe	Leu	Gln	Val	Ala	Pro	Asn	Val	Asn	Phe	Met	His
				500					505					510
Asn	Leu	Leu	Pro	Met	Gln	Asn	Leu	Gln	Pro	Thr	Gly	Gln	Leu	Glu
				515					520					525
Tyr	Lys	Glu	Gln	Ser	Leu	Leu	Gln	Pro	Pro	Thr	Leu	Gln	Leu	Leu
				530					535					540
Asn	Gly	Met	Gly	Pro	Leu	Gly	Arg	Arg	Ala	Ser	Asp	Gly	Gly	Ala
				545					550					555
Asn	Ile	Gln	Leu	His	Ala	Gln	Gln	Leu	Leu	Lys	Arg	Pro	Arg	Gly
				560					565					570
Pro	Ser	Pro	Leu	Val	Thr	Met	Thr	Pro	Ala	Val	Pro	Ala	Val	Thr
				575					580					585
Pro	Val	Asp	Glu	Glu	Ser	Ser	Asp	Gly	Glu	Pro	Asp	Gln	Glu	Ala
				590					595					600
Val	Gln	Arg	Tyr	Leu	Ala	Asn	Arg	Ser	Lys	Arg	His	Thr	Leu	Ala
				605					610					615
Met	Thr	Asn	Pro	Thr	Ala	Glu	Ile	Pro	Pro	Asp	Leu	Gln	Arg	Gln
				620					625					630
Leu	Gly	Gln	Gln	Pro	Phe	Arg	Ser	Arg	Val	Trp	Pro	Pro	His	Leu
				635					640					645
Val	Pro	Asp	Gln	His	Arg	Ser	Thr	Tyr	Lys	Asp	Ser	Asn	Thr	Leu
				650					655					660
His	Leu	Pro	Thr	Glu	Arg	Phe	Ser	Pro	Val	Arg	Arg	Phe	Ser	Asp
				665					670					675
Gly	Ala	Ala	Ser	Ile	Gln	Ala	Phe	Lys	Ala	His	Leu	Glu	Lys	Met
				680					685					690
Gly	Asn	Asn	Ser	Ser	Ile	Lys	Gln	Leu	Gln	Gln	Glu	Cys	Glu	Gln
				695					700					705
Leu	Gln	Lys	Met	Tyr	Gly	Gly	Gln	Ile	Asp	Glu	Arg	Thr	Leu	Glu
				710					715					720
Lys	Thr	Gln	Gln	Gln	His	Met	Leu	Tyr	Gln	Gln	Glu	Gln	His	His
				725					730					735
Gln	Ile	Leu	Gln	Gln	Gln	Ile	Gln	Asp	Ser	Ile	Cys	Pro	Pro	Gln
				740					745					750
Pro	Ser	Pro	Pro	Leu	Gln	Ala	Ala	Cys	Glu	Asn	Gln	Pro	Ala	Leu
				755					760					765
Leu	Thr	His	Gln	Leu	Gln	Arg	Leu	Arg	Ile	Gln	Pro	Ser	Ser	Pro
				770					775					780
Pro	Pro	Asn	His	Pro	Asn	Asn	His	Leu	Phe	Arg	Gln	Pro	Ser	Asn
				785					790					795
Ser	Pro	Pro	Pro	Met	Ser	Ser	Ala	Met	Ile	Gln	Pro	His	Gly	Ala
				800					805					810
Ala	Ser	Ser	Ser	Gln	Phe	Gln	Gly	Leu	Pro	Ser	Arg	Ser	Ala	Ile
				815					820					825
Phe	Gln	Gln	Gln	Pro	Glu	Asn	Cys	Ser	Ser	Pro	Pro	Asn	Val	Ala
				830					835					840
Leu	Thr	Cys	Leu	Gly	Met	Gln	Gln	Pro	Ala	Gln	Ser	Gln	Gln	Val
				845					850					855
Thr	Ile	Gln	Val	Gln	Glu	Pro	Val	Asp	Met	Leu	Ser	Asn	Met	Pro
				860					865					870

Gly	Thr	Ala	Ala	Gly	Ser	Ser	Gly	Arg	Gly	Ile	Ser	Ile	Ser	Pro	875	880	885
Ser	Ala	Gly	Gln	Met	Gln	Met	Gln	His	Arg	Thr	Asn	Leu	Met	Ala	890	895	900
Thr	Leu	Ser	Tyr	Gly	His	Arg	Pro	Leu	Ser	Lys	Gln	Leu	Ser	Ala	905	910	915
Asp	Ser	Ala	Glu	Ala	His	Ser	Leu	Asn	Val	Asn	Arg	Phe	Ser	Pro	920	925	930
Ala	Asn	Tyr	Asp	Gln	Ala	His	Leu	His	Pro	His	Leu	Phe	Ser	Asp	935	940	945
Gln	Ser	Arg	Gly	Ser	Pro	Ser	Ser	Tyr	Ser	Pro	Ser	Thr	Gly	Val	950	955	960
Gly	Phe	Ser	Pro	Thr	Gln	Ala	Leu	Lys	Val	Pro	Pro	Leu	Asp	Gln	965	970	975
Phe	Pro	Thr	Phe	Pro	Pro	Ser	Ala	His	Gln	Gln	Pro	Pro	His	Tyr	980	985	990
Thr	Thr	Ser	Ala	Leu	Gln	Gln	Ala	Leu	Leu	Ser	Pro	Thr	Pro	Pro	995	1000	1005
Asp	Tyr	Thr	Arg	His	Gln	Gln	Val	Pro	His	Ile	Leu	Gln	Gly	Leu	1010	1015	1020
Leu	Ser	Pro	Arg	His	Ser	Leu	Thr	Gly	His	Ser	Asp	Ile	Arg	Leu	1025	1030	1035
Pro	Pro	Thr	Glu	Phe	Ala	Gln	Leu	Ile	Lys	Arg	Gln	Gln	Gln	Gln	1040	1045	1050
Arg	Gln	Gln	Gln	Gln	Gln	Gln	Gln	Gln	Gln	Glu	Tyr	Gln	Glu		1055	1060	1065
Leu	Phe	Arg	His	Met	Asn	Gln	Gly	Asp	Ala	Gly	Ser	Leu	Ala	Pro	1070	1075	1080
Ser	Leu	Gly	Gly	Gln	Ser	Met	Thr	Glu	Arg	Gln	Ala	Leu	Ser	Tyr	1085	1090	1095
Gln	Asn	Ala	Asp	Ser	Tyr	His	His	His	Thr	Ser	Pro	Gln	His	Leu	1100	1105	1110
Leu	Gln	Ile	Arg	Ala	Gln	Glu	Cys	Val	Ser	Gln	Ala	Ser	Ser	Pro	1115	1120	1125
Thr	Pro	Pro	His	Gly	Tyr	Ala	His	Gln	Pro	Ala	Leu	Met	His	Ser	1130	1135	1140
Glu	Ser	Met	Glu	Glu	Asp	Cys	Ser	Cys	Glu	Gly	Ala	Lys	Asp	Gly	1145	1150	1155
Phe	Gln	Asp	Ser	Lys	Ser	Ser	Ser	Thr	Leu	Thr	Lys	Gly	Cys	His	1160	1165	1170
Asp	Ser	Pro	Leu	Leu	Leu	Ser	Thr	Gly	Gly	Pro	Gly	Asp	Pro	Glu	1175	1180	1185
Ser	Leu	Leu	Gly	Thr	Val	Ser	His	Ala	Gln	Glu	Leu	Gly	Ile	His	1190	1195	1200
Pro	Tyr	Gly	His	Gln	Pro	Thr	Ala	Ala	Phe	Ser	Lys	Asn	Lys	Val	1205	1210	1215
Pro	Ser	Arg	Glu	Pro	Val	Ile	Gly	Asn	Cys	Met	Asp	Arg	Ser	Ser	1220	1225	1230
Pro	Gly	Gln	Ala	Val	Glu	Leu	Pro	Asp	His	Asn	Gly	Leu	Gly	Tyr	1235	1240	1245
Pro	Ala	Arg	Pro	Ser	Val	His	Glu	His	His	Arg	Pro	Arg	Ala	Leu	1250	1255	1260
Gln	Arg	His	His	Thr	Ile	Gln	Asn	Ser	Asp	Asp	Ala	Tyr	Val	Gln	1265	1270	1275
Leu	Asp	Asn	Leu	Pro	Gly	Met	Ser	Leu	Val	Ala	Gly	Lys	Ala	Leu	1280	1285	1290

```

Ser Ser Ala Arg Met Ser Asp Ala Val Leu Ser Gln Ser Ser Leu
      1295                      1300                      1305
Met Gly Ser Gln Gln Phe Gln Asp Gly Glu Asn Glu Glu Cys Gly
      1310                      1315                      1320
Ala Ser Leu Gly Gly His Glu His Pro Asp Leu Ser Asp Gly Ser
      1325                      1330                      1335
Gln His Leu Asn Ser Ser Cys Tyr Pro Ser Thr Cys Ile Thr Asp
      1340                      1345                      1350
Ile Leu Leu Ser Tyr Lys His Pro Glu Val Ser Phe Ser Met Glu
      1355                      1360                      1365
Gln Ala Gly Val

```

<210> 8

<211> 2429

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 079284CD1

<400> 8

```

Met Gly Met Ser Asp Pro Asn Phe Trp Thr Val Leu Ser Asn Phe
  1          5          10          15
Thr Leu Pro His Leu Arg Ser Gly Asn Arg Leu Arg Arg Thr Gln
      20          25          30
Ser Cys Arg Thr Ser Asn Arg Lys Ser Leu Ile Gly Asn Gly Gln
      35          40          45
Ser Pro Ala Leu Pro Arg Pro His Ser Pro Leu Ser Ala His Ala
      50          55          60
Gly Asn Ser Pro Gln Asp Ser Pro Arg Asn Phe Ser Pro Ser Ala
      65          70          75
Ser Ala His Phe Ser Phe Ala Arg Arg Thr Asp Gly Arg Arg Trp
      80          85          90
Ser Leu Ala Ser Leu Pro Ser Ser Gly Tyr Gly Thr Asn Thr Pro
      95          100         105
Ser Ser Thr Val Ser Ser Ser Cys Ser Ser Gln Glu Lys Leu His
      110         115         120
Gln Leu Pro Tyr Gln Pro Thr Pro Asp Glu Leu His Phe Leu Ser
      125         130         135
Lys His Phe Cys Thr Thr Glu Ser Ile Ala Thr Glu Asn Arg Cys
      140         145         150
Arg Asn Thr Pro Met Arg Pro Arg Ser Arg Ser Leu Ser Pro Gly
      155         160         165
Arg Ser Pro Ala Cys Cys Asp His Glu Ile Ile Met Met Asn His
      170         175         180
Val Tyr Lys Glu Arg Phe Pro Lys Ala Thr Ala Gln Met Glu Glu
      185         190         195
Arg Leu Lys Glu Ile Ile Thr Ser Tyr Ser Pro Asp Asn Val Leu
      200         205         210
Pro Leu Ala Asp Gly Val Leu Ser Phe Thr His His Gln Ile Ile
      215         220         225
Glu Leu Ala Arg Asp Cys Leu Asp Lys Ser His Gln Gly Leu Ile
      230         235         240
Thr Ser Arg Tyr Phe Leu Glu Leu Gln His Lys Leu Asp Lys Leu

```


245	250	255
Leu Gln Glu Ala His Asp Arg Ser Glu	Ser Gly Glu Leu Ala Phe	
260	265	270
Ile Lys Gln Leu Val Arg Lys Ile Leu	Ile Val Ile Ala Arg Pro	
275	280	285
Ala Arg Leu Leu Glu Cys Leu Glu Phe	Asp Pro Glu Glu Phe Tyr	
290	295	300
Tyr Leu Leu Glu Ala Ala Glu Gly His	Ala Lys Glu Gly Gln Gly	
305	310	315
Ile Lys Thr Asp Ile Pro Arg Tyr Ile	Ile Ser Gln Leu Gly Leu	
320	325	330
Asn Lys Asp Pro Leu Glu Glu Met Ala	His Leu Gly Asn Tyr Asp	
335	340	345
Ser Gly Thr Ala Glu Thr Pro Glu Thr	Asp Glu Ser Val Ser Ser	
350	355	360
Ser Asn Ala Ser Leu Lys Leu Arg Arg	Lys Pro Arg Glu Ser Asp	
365	370	375
Phe Glu Thr Ile Lys Leu Ile Ser Asn	Gly Ala Tyr Gly Ala Val	
380	385	390
Tyr Phe Val Arg His Lys Glu Ser Arg	Gln Arg Phe Ala Met Lys	
395	400	405
Lys Ile Asn Lys Gln Asn Leu Ile Leu	Arg Asn Gln Ile Gln Gln	
410	415	420
Ala Phe Val Glu Arg Asp Ile Leu Thr	Phe Ala Glu Asn Pro Phe	
425	430	435
Val Val Ser Met Tyr Cys Ser Phe Glu	Thr Arg Arg His Leu Cys	
440	445	450
Met Val Met Glu Tyr Val Glu Gly Gly	Asp Cys Ala Thr Leu Met	
455	460	465
Lys Asn Met Gly Pro Leu Pro Val Asp	Met Ala Arg Met Tyr Phe	
470	475	480
Ala Glu Thr Val Leu Ala Leu Glu Tyr	Leu His Asn Tyr Gly Ile	
485	490	495
Val His Arg Asp Leu Lys Pro Asp Asn	Leu Leu Val Thr Ser Met	
500	505	510
Gly His Ile Lys Leu Thr Asp Phe Gly	Leu Ser Lys Val Gly Leu	
515	520	525
Met Ser Met Thr Thr Asn Leu Tyr Glu	Gly His Ile Glu Lys Asp	
530	535	540
Ala Arg Glu Phe Leu Asp Lys Gln Val	Cys Gly Thr Pro Glu Tyr	
545	550	555
Ile Ala Pro Glu Val Ile Leu Arg Gln	Gly Tyr Gly Lys Pro Val	
560	565	570
Asp Trp Trp Ala Met Gly Ile Ile Leu	Tyr Glu Phe Leu Val Gly	
575	580	585
Cys Val Pro Phe Phe Gly Asp Thr Pro	Glu Glu Leu Phe Gly Gln	
590	595	600
Val Ile Ser Asp Glu Ile Asn Trp Pro	Glu Lys Asp Glu Ala Pro	
605	610	615
Pro Pro Asp Ala Gln Asp Leu Ile Thr	Leu Leu Leu Arg Gln Asn	
620	625	630
Pro Leu Glu Arg Leu Gly Thr Gly Gly	Ala Tyr Glu Val Lys Gln	
635	640	645
His Arg Phe Phe Arg Ser Leu Asp Trp	Asn Ser Leu Leu Arg Gln	
650	655	660
Lys Ala Glu Phe Ile Pro Gln Leu Glu	Ser Glu Asp Asp Thr Ser	

	665		670		675
Tyr Phe Asp Thr	Arg Ser Glu Lys Tyr	His His Met Glu Thr	Glu		
	680		685		690
Glu Glu Asp Asp	Thr Asn Asp Glu Asp	Phe Asn Val Glu Ile	Arg		
	695		700		705
Gln Phe Ser Ser	Cys Ser His Arg Phe	Ser Lys Val Phe Ser	Ser		
	710		715		720
Ile Asp Arg Ile	Thr Gln Asn Ser Ala	Glu Glu Lys Glu Asp	Ser		
	725		730		735
Val Asp Lys Thr	Lys Ser Thr Thr	Leu Pro Ser Thr	Glu Thr	Leu	
	740		745		750
Ser Trp Ser Ser	Glu Tyr Ser Glu Met	Gln Gln Leu Ser Thr	Ser		
	755		760		765
Asn Ser Ser Asp	Thr Glu Ser Asn Arg	His Lys Leu Ser Ser	Gly		
	770		775		780
Leu Leu Pro Lys	Leu Ala Ile Ser Thr	Glu Gly Glu Gln Asp	Glu		
	785		790		795
Ala Ala Ser Cys	Pro Gly Asp Pro His	Glu Glu Pro Gly Lys	Pro		
	800		805		810
Ala Leu Pro Pro	Glu Glu Cys Ala Gln	Glu Glu Pro Glu Val	Thr		
	815		820		825
Thr Pro Ala Ser	Thr Ile Ser Ser Ser	Thr Leu Ser Val Gly	Ser		
	830		835		840
Phe Ser Glu His	Leu Asp Gln Ile Asn	Gly Arg Ser Glu Cys	Val		
	845		850		855
Asp Ser Thr Asp	Asn Ser Ser Lys Pro	Ser Ser Glu Pro Ala	Ser		
	860		865		870
His Met Ala Arg	Gln Arg Leu Glu Ser	Thr Glu Lys Lys Lys	Ile		
	875		880		885
Ser Gly Lys Val	Thr Lys Ser Leu Ser	Ala Ser Ala Leu Ser	Leu		
	890		895		900
Met Ile Pro Gly	Asp Met Phe Ala Val	Ser Pro Leu Gly Ser	Pro		
	905		910		915
Met Ser Pro His	Ser Leu Ser Ser Asp	Pro Ser Ser Ser Arg	Asp		
	920		925		930
Ser Ser Pro Ser	Arg Asp Ser Ser Ala	Ala Ser Ala Ser Pro	His		
	935		940		945
Gln Pro Ile Val	Ile His Ser Ser Gly	Lys Asn Tyr Gly Phe	Thr		
	950		955		960
Ile Arg Ala Ile	Arg Val Tyr Val Gly	Asp Ser Asp Ile Tyr	Thr		
	965		970		975
Val His His Ile	Val Trp Asn Val Glu	Glu Gly Ser Pro Ala	Cys		
	980		985		990
Gln Ala Gly Leu	Lys Ala Gly Asp Leu	Ile Thr Pro Ile Asn	Gly		
	995		1000		1005
Glu Pro Val His	Gly Leu Val His Thr	Glu Val Ile Glu Leu	Leu		
	1010		1015		1020
Leu Lys Ser Gly	Asn Lys Val Ser Ile	Thr Thr Thr Pro Phe	Glu		
	1025		1030		1035
Asn Thr Ser Ile	Lys Thr Gly Pro Ala	Arg Arg Asn Ser Tyr	Lys		
	1040		1045		1050
Ser Arg Met Val	Arg Arg Ser Lys Lys	Ser Lys Lys Lys Glu	Ser		
	1055		1060		1065
Leu Glu Arg Arg	Arg Ser Leu Phe Lys	Lys Leu Ala Lys Gln	Pro		
	1070		1075		1080
Ser Pro Leu Leu	His Thr Ser Arg Ser	Phe Ser Cys Leu Asn	Arg		

1085	1090	1095
Ser Leu Ser Ser Gly Glu Ser Leu Pro Gly Ser Pro Thr His Ser		
1100	1105	1110
Leu Ser Pro Arg Ser Pro Thr Pro Ser Tyr Arg Ser Thr Pro Asp		
1115	1120	1125
Phe Pro Ser Gly Thr Asn Ser Ser Gln Ser Ser Ser Pro Ser Ser		
1130	1135	1140
Ser Ala Pro Asn Ser Pro Ala Gly Ser Gly His Ile Arg Pro Ser		
1145	1150	1155
Thr Leu His Gly Leu Ala Pro Lys Leu Gly Gly Gln Arg Tyr Arg		
1160	1165	1170
Ser Gly Arg Arg Lys Ser Ala Gly Asn Ile Pro Leu Ser Pro Leu		
1175	1180	1185
Ala Arg Thr Pro Ser Pro Thr Pro Gln Pro Thr Ser Pro Gln Arg		
1190	1195	1200
Ser Pro Ser Pro Leu Leu Gly His Ser Leu Gly Asn Ser Lys Ile		
1205	1210	1215
Ala Gln Ala Phe Pro Ser Lys Met His Ser Pro Pro Thr Ile Val		
1220	1225	1230
Arg His Ile Val Arg Pro Lys Ser Ala Glu Pro Pro Arg Ser Pro		
1235	1240	1245
Leu Leu Lys Arg Val Gln Ser Glu Glu Lys Leu Ser Pro Ser Tyr		
1250	1255	1260
Gly Ser Asp Lys Lys His Leu Cys Ser Arg Lys His Ser Leu Glu		
1265	1270	1275
Val Thr Gln Glu Glu Val Gln Arg Glu Gln Ser Gln Arg Glu Ala		
1280	1285	1290
Pro Leu Gln Ser Leu Asp Glu Asn Val Cys Asp Val Pro Pro Leu		
1295	1300	1305
Ser Arg Ala Arg Pro Val Glu Gln Gly Cys Leu Lys Arg Pro Val		
1310	1315	1320
Ser Arg Lys Val Gly Arg Gln Glu Ser Val Asp Asp Leu Asp Arg		
1325	1330	1335
Asp Lys Leu Lys Ala Lys Val Val Val Lys Lys Ala Asp Gly Phe		
1340	1345	1350
Pro Glu Lys Gln Glu Ser His Gln Lys Ser His Gly Pro Gly Ser		
1355	1360	1365
Asp Leu Glu Asn Phe Ala Leu Phe Lys Leu Glu Glu Arg Glu Lys		
1370	1375	1380
Lys Val Tyr Pro Lys Ala Val Glu Arg Ser Ser Thr Phe Glu Asn		
1385	1390	1395
Lys Ala Ser Met Gln Glu Ala Pro Pro Leu Gly Ser Leu Leu Lys		
1400	1405	1410
Asp Ala Leu His Lys Gln Ala Ser Val Arg Ala Ser Glu Gly Ala		
1415	1420	1425
Met Ser Asp Gly Pro Val Pro Ala Glu His Arg Gln Gly Gly Gly		
1430	1435	1440
Asp Phe Arg Arg Ala Pro Ala Pro Gly Thr Leu Gln Asp Gly Leu		
1445	1450	1455
Cys His Ser Leu Asp Arg Gly Ile Ser Gly Lys Gly Glu Gly Thr		
1460	1465	1470
Glu Lys Ser Ser Gln Ala Lys Glu Leu Leu Arg Cys Glu Lys Leu		
1475	1480	1485
Asp Ser Lys Leu Ala Asn Ile Asp Tyr Leu Arg Lys Lys Met Ser		
1490	1495	1500
Leu Glu Asp Lys Glu Asp Asn Leu Cys Pro Val Leu Lys Pro Lys		

1505	1510	1515
Met Thr Ala Gly Ser His Glu Cys Leu Pro Gly Asn Pro Val Arg		
1520	1525	1530
Pro Thr Gly Gly Gln Gln Glu Pro Pro Pro Ala Ser Glu Ser Arg		
1535	1540	1545
Ala Phe Val Ser Ser Ser Thr His Ala Ala Gln Met Ser Ala Val Ser		
1550	1555	1560
Phe Val Pro Leu Lys Ala Leu Thr Gly Arg Val Asp Ser Gly Thr		
1565	1570	1575
Glu Lys Pro Gly Leu Val Ala Pro Glu Ser Pro Val Arg Lys Ser		
1580	1585	1590
Pro Ser Glu Tyr Lys Leu Glu Gly Arg Ser Val Ser Cys Leu Lys		
1595	1600	1605
Pro Ile Glu Gly Thr Leu Asp Ile Ala Leu Leu Ser Gly Pro Gln		
1610	1615	1620
Ala Ser Lys Thr Glu Leu Pro Ser Pro Glu Ser Ala Gln Ser Pro		
1625	1630	1635
Ser Pro Ser Gly Asp Val Arg Ala Ser Val Pro Pro Val Leu Pro		
1640	1645	1650
Ser Ser Ser Gly Lys Lys Asn Asp Thr Thr Ser Ala Arg Glu Leu		
1655	1660	1665
Ser Pro Ser Ser Leu Lys Met Asn Lys Ser Tyr Leu Leu Glu Pro		
1670	1675	1680
Trp Phe Leu Pro Pro Ser Arg Gly Leu Gln Asn Ser Pro Ala Val		
1685	1690	1695
Ser Leu Pro Asp Pro Glu Phe Lys Arg Asp Arg Lys Gly Pro His		
1700	1705	1710
Pro Thr Ala Arg Ser Pro Gly Thr Val Met Glu Ser Asn Pro Gln		
1715	1720	1725
Gln Arg Glu Gly Ser Ser Pro Lys His Gln Asp His Thr Thr Asp		
1730	1735	1740
Pro Lys Leu Leu Thr Cys Leu Gly Gln Asn Leu His Ser Pro Asp		
1745	1750	1755
Leu Ala Arg Pro Arg Cys Pro Leu Pro Pro Glu Ala Ser Pro Ser		
1760	1765	1770
Arg Glu Lys Pro Gly Leu Arg Glu Ser Ser Glu Arg Gly Pro Pro		
1775	1780	1785
Thr Ala Arg Ser Glu Arg Ser Ala Ala Arg Ala Asp Thr Cys Arg		
1790	1795	1800
Glu Pro Ser Met Glu Leu Cys Phe Pro Glu Thr Ala Lys Thr Ser		
1805	1810	1815
Asp Asn Ser Lys Asn Leu Leu Ser Val Gly Arg Thr His Pro Asp		
1820	1825	1830
Phe Tyr Thr Gln Thr Gln Ala Met Glu Lys Ala Trp Ala Pro Gly		
1835	1840	1845
Gly Lys Thr Asn His Lys Asp Gly Pro Gly Glu Ala Arg Pro Pro		
1850	1855	1860
Pro Arg Asp Asn Ser Ser Leu His Ser Ala Gly Ile Pro Cys Glu		
1865	1870	1875
Lys Glu Leu Gly Lys Val Arg Arg Gly Val Glu Pro Lys Pro Glu		
1880	1885	1890
Ala Leu Leu Ala Arg Arg Ser Leu Gln Pro Pro Gly Ile Glu Ser		
1895	1900	1905
Glu Lys Ser Glu Lys Leu Ser Ser Phe Pro Ser Leu Gln Lys Asp		
1910	1915	1920
Gly Ala Lys Glu Pro Glu Arg Lys Glu Gln Pro Leu Gln Arg His		

1925	1930	1935
Pro Ser Ser Ile Pro Pro Pro Pro Leu Thr Ala Lys Asp Leu Ser		
1940	1945	1950
Ser Pro Ala Ala Arg Gln His Cys Ser Ser Pro Ser His Ala Ser		
1955	1960	1965
Gly Arg Glu Pro Gly Ala Lys Pro Ser Thr Ala Glu Pro Ser Ser		
1970	1975	1980
Ser Pro Gln Asp Pro Pro Lys Pro Val Ala Ala His Ser Glu Ser		
1985	1990	1995
Ser Ser His Lys Pro Arg Pro Gly Pro Asp Pro Gly Pro Pro Lys		
2000	2005	2010
Thr Lys His Pro Asp Arg Ser Leu Ser Ser Gln Lys Pro Ser Val		
2015	2020	2025
Gly Ala Thr Lys Gly Lys Glu Pro Ala Thr Gln Ser Leu Gly Gly		
2030	2035	2040
Ser Ser Arg Glu Gly Lys Gly His Ser Lys Ser Gly Pro Asp Val		
2045	2050	2055
Phe Pro Ala Thr Pro Gly Ser Gln Asn Lys Ala Ser Asp Gly Ile		
2060	2065	2070
Gly Gln Gly Glu Gly Gly Pro Ser Val Pro Leu His Thr Asp Arg		
2075	2080	2085
Ala Pro Leu Asp Ala Lys Pro Gln Pro Thr Ser Gly Gly Arg Pro		
2090	2095	2100
Leu Glu Val Leu Glu Lys Pro Val His Leu Pro Arg Pro Gly His		
2105	2110	2115
Pro Gly Pro Ser Glu Pro Ala Asp Gln Lys Leu Ser Ala Val Gly		
2120	2125	2130
Glu Lys Gln Thr Leu Ser Pro Lys His Pro Lys Pro Ser Thr Val		
2135	2140	2145
Lys Asp Cys Pro Thr Leu Cys Lys Gln Thr Asp Asn Arg Gln Thr		
2150	2155	2160
Asp Lys Ser Pro Ser Gln Pro Ala Ala Asn Thr Asp Arg Arg Ala		
2165	2170	2175
Glu Gly Lys Lys Cys Thr Glu Ala Leu Tyr Ala Pro Ala Glu Gly		
2180	2185	2190
Asp Lys Leu Glu Ala Gly Leu Ser Phe Val His Ser Glu Asn Arg		
2195	2200	2205
Leu Lys Gly Ala Glu Arg Pro Ala Ala Gly Val Gly Lys Gly Phe		
2210	2215	2220
Pro Glu Ala Arg Gly Lys Gly Pro Gly Pro Gln Lys Pro Pro Thr		
2225	2230	2235
Glu Ala Asp Lys Pro Asn Gly Met Lys Arg Ser Pro Ser Ala Thr		
2240	2245	2250
Gly Gln Ser Ser Phe Arg Ser Thr Ala Leu Pro Glu Lys Ser Leu		
2255	2260	2265
Ser Cys Ser Ser Ser Phe Pro Glu Thr Arg Ala Gly Val Arg Glu		
2270	2275	2280
Ala Ser Ala Ala Ser Ser Asp Thr Ser Ser Ala Lys Ala Ala Gly		
2285	2290	2295
Gly Met Leu Glu Leu Pro Ala Pro Ser Asn Arg Asp His Arg Lys		
2300	2305	2310
Ala Gln Pro Ala Gly Glu Gly Arg Thr His Met Thr Lys Ser Asp		
2315	2320	2325
Ser Leu Pro Ser Phe Arg Val Ser Thr Leu Pro Leu Glu Ser His		
2330	2335	2340
His Pro Asp Pro Asn Thr Met Gly Gly Ala Ser His Arg Asp Arg		

2345	2350	2355
Ala Leu Ser Val Thr Ala Thr Val Gly Glu Thr Lys Gly Lys Asp		
2360	2365	2370
Pro Ala Pro Ala Gln Pro Pro Pro Ala Arg Lys Gln Asn Val Gly		
2375	2380	2385
Arg Asp Val Thr Lys Pro Ser Pro Ala Pro Asn Thr Asp Arg Pro		
2390	2395	2400
Ile Ser Leu Ser Asn Glu Lys Asp Phe Val Val Arg Gln Arg Arg		
2405	2410	2415
Gly Lys Glu Ser Leu Arg Ser Ser Pro His Lys Lys Ala Leu		
2420	2425	

<210> 9

<211> 2135

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5502218CD1

<400> 9

Met Ser Gly Gly Ala Ala Glu Lys Gln Ser Ser Thr Pro Gly Ser		
1	5	10
Leu Phe Leu Ser Pro Pro Ala Pro Ala Pro Lys Asn Gly Ser Ser		
	20	25
Ser Asp Ser Ser Val Gly Glu Lys Leu Gly Ala Ala Ala Ala Asp		
	35	40
Ala Val Thr Gly Arg Thr Glu Glu Tyr Arg Arg Arg Arg His Thr		
	50	55
Met Asp Lys Asp Ser Arg Gly Ala Ala Ala Thr Thr Thr Thr Thr		
	65	70
Glu His Arg Phe Phe Arg Arg Ser Val Ile Cys Asp Ser Asn Ala		
	80	85
Thr Ala Leu Glu Leu Pro Gly Leu Pro Leu Ser Leu Pro Gln Pro		
	95	100
Ser Ile Pro Ala Ala Val Pro Gln Ser Ala Pro Pro Glu Pro His		
	110	115
Arg Glu Glu Thr Val Thr Ala Thr Ala Thr Ser Gln Val Ala Gln		
	125	130
Gln Pro Pro Ala Ala Ala Ala Pro Gly Glu Gln Ala Val Ala Gly		
	140	145
Pro Ala Pro Ser Thr Val Pro Ser Ser Thr Ser Lys Asp Arg Pro		
	155	160
Val Ser Gln Pro Ser Leu Val Gly Ser Lys Glu Glu Pro Pro Pro		
	170	175
Ala Arg Ser Gly Ser Gly Gly Gly Ser Ala Lys Glu Pro Gln Glu		
	185	190
Glu Arg Ser Gln Gln Gln Asp Asp Ile Glu Glu Leu Glu Thr Lys		
	200	205
Ala Val Gly Met Ser Asn Asp Gly Arg Phe Leu Lys Phe Asp Ile		
	215	220
Glu Ile Gly Arg Gly Ser Phe Lys Thr Val Tyr Lys Gly Leu Asp		
	230	235
Thr Glu Thr Thr Val Glu Val Ala Trp Cys Glu Leu Gln Asp Arg		
	245	250
		255

Lys	Leu	Thr	Lys	Ser	Glu	Arg	Gln	Arg	Phe	Lys	Glu	Glu	Ala	Glu	
				260					265					270	
Met	Leu	Lys	Gly	Leu	Gln	His	Pro	Asn	Ile	Val	Arg	Phe	Tyr	Asp	
				275					280					285	
Ser	Trp	Glu	Ser	Thr	Val	Lys	Gly	Lys	Lys	Cys	Ile	Val	Leu	Val	
				290					295					300	
Thr	Glu	Leu	Met	Thr	Ser	Gly	Thr	Leu	Lys	Thr	Tyr	Leu	Lys	Arg	
				305					310					315	
Phe	Lys	Val	Met	Lys	Ile	Lys	Val	Leu	Arg	Ser	Trp	Cys	Arg	Gln	
				320					325					330	
Ile	Leu	Lys	Gly	Leu	Gln	Phe	Leu	His	Thr	Arg	Thr	Pro	Pro	Ile	
				335					340					345	
Ile	His	Arg	Asp	Leu	Lys	Cys	Asp	Asn	Ile	Phe	Ile	Thr	Gly	Pro	
				350					355					360	
Thr	Gly	Ser	Val	Lys	Ile	Gly	Asp	Leu	Gly	Leu	Ala	Thr	Leu	Lys	
				365					370					375	
Arg	Ala	Ser	Phe	Ala	Lys	Ser	Val	Ile	Gly	Thr	Pro	Glu	Phe	Met	
				380					385					390	
Ala	Pro	Glu	Met	Tyr	Glu	Glu	Lys	Tyr	Asp	Glu	Ser	Val	Asp	Val	
				395					400					405	
Tyr	Ala	Phe	Gly	Met	Cys	Met	Leu	Glu	Met	Ala	Thr	Ser	Glu	Tyr	
				410					415					420	
Pro	Tyr	Ser	Glu	Cys	Gln	Asn	Ala	Ala	Gln	Ile	Tyr	Arg	Arg	Val	
				425					430					435	
Thr	Ser	Gly	Val	Lys	Pro	Ala	Ser	Phe	Asp	Lys	Val	Ala	Ile	Pro	
				440					445					450	
Glu	Val	Lys	Glu	Ile	Ile	Glu	Gly	Cys	Ile	Arg	Gln	Asn	Lys	Asp	
				455					460					465	
Glu	Arg	Tyr	Ser	Ile	Lys	Asp	Leu	Leu	Asn	His	Ala	Phe	Phe	Gln	
				470					475					480	
Glu	Glu	Thr	Gly	Val	Arg	Val	Glu	Leu	Ala	Glu	Glu	Asp	Asp	Gly	
				485					490					495	
Glu	Lys	Ile	Ala	Ile	Lys	Leu	Trp	Leu	Arg	Ile	Glu	Asp	Ile	Lys	
				500					505					510	
Lys	Leu	Lys	Gly	Lys	Tyr	Lys	Asp	Asn	Glu	Ala	Ile	Glu	Phe	Ser	
				515					520					525	
Phe	Asp	Leu	Glu	Arg	Asp	Val	Pro	Glu	Asp	Val	Ala	Gln	Glu	Met	
				530					535					540	
Val	Glu	Ser	Gly	Tyr	Val	Cys	Glu	Gly	Asp	His	Lys	Thr	Met	Ala	
				545					550					555	
Lys	Ala	Ile	Lys	Asp	Arg	Val	Ser	Leu	Ile	Lys	Arg	Lys	Arg	Glu	
				560					565					570	
Gln	Arg	Gln	Leu	Val	Arg	Glu	Glu	Gln	Glu	Lys	Lys	Lys	Gln	Glu	
				575					580					585	
Glu	Ser	Ser	Leu	Lys	Gln	Gln	Val	Glu	Gln	Ser	Ser	Ala	Ser	Gln	
				590					595					600	
Thr	Gly	Ile	Lys	Gln	Leu	Pro	Ser	Ala	Ser	Thr	Gly	Ile	Pro	Thr	
				605					610					615	
Ala	Ser	Thr	Thr	Ser	Ala	Ser	Val	Ser	Thr	Gln	Val	Glu	Pro	Glu	
				620					625					630	
Glu	Pro	Glu	Ala	Asp	Gln	His	Gln	Gln	Leu	Gln	Tyr	Gln	Gln	Pro	
				635					640					645	
Ser	Ile	Ser	Val	Leu	Ser	Asp	Gly	Thr	Val	Asp	Ser	Gly	Gln	Gly	
				650					655					660	
Ser	Ser	Val	Phe	Thr	Glu	Ser	Arg	Val	Ser	Ser	Gln	Gln	Thr	Val	
				665					670					675	

Ser Tyr Gly Ser	Gln His Glu Gln Ala	His Ser Thr Gly Thr Val	680	685	690
Pro Gly His Ile	Pro Ser Thr Val Gln	Ala Gln Ser Gln Pro His	695	700	705
Gly Val Tyr Pro	Pro Ser Ser Val Ala	Gln Gly Gln Ser Gln Gly	710	715	720
Gln Pro Ser Ser	Ser Ser Leu Thr Gly	Val Ser Ser Ser Gln Pro	725	730	735
Ile Gln His Pro	Gln Gln Gln Gly Ile	Gln Gln Thr Ala Pro Pro	740	745	750
Gln Gln Thr Val	Gln Tyr Ser Leu Ser	Gln Thr Ser Thr Ser Ser	755	760	765
Glu Ala Thr Thr	Ala Gln Pro Val Ser	Gln Pro Gln Ala Pro Gln	770	775	780
Val Leu Pro Gln	Val Ser Ala Gly Lys	Gln Ser Thr Gln Gly Val	785	790	795
Ser Gln Val Ala	Pro Ala Glu Pro Val	Ala Val Ala Gln Pro Gln	800	805	810
Ala Thr Gln Pro	Thr Thr Leu Ala Ser	Ser Val Asp Ser Ala His	815	820	825
Ser Asp Val Ala	Ser Gly Met Ser Asp	Gly Asn Glu Asn Val Pro	830	835	840
Ser Ser Ser Gly	Arg His Glu Gly Arg	Thr Thr Lys Arg His Tyr	845	850	855
Arg Lys Ser Val	Arg Ser Arg Ser Arg	His Glu Lys Thr Ser Arg	860	865	870
Pro Lys Leu Arg	Ile Leu Asn Val Ser	Asn Lys Gly Asp Arg Val	875	880	885
Val Glu Cys Gln	Leu Glu Thr His Asn	Arg Lys Met Val Thr Phe	890	895	900
Lys Phe Asp Leu	Asp Gly Asp Asn Pro	Glu Glu Ile Ala Thr Ile	905	910	915
Met Val Asn Asn	Asp Phe Ile Leu Ala	Ile Glu Arg Glu Ser Phe	920	925	930
Val Asp Gln Val	Arg Glu Ile Ile Glu	Lys Ala Asp Glu Met Leu	935	940	945
Ser Glu Asp Val	Ser Val Glu Pro Glu	Gly Asp Gln Gly Leu Glu	950	955	960
Ser Leu Gln Gly	Lys Asp Asp Tyr Gly	Phe Ser Gly Ser Gln Lys	965	970	975
Leu Glu Gly Glu	Phe Lys Gln Pro Ile	Pro Ala Ser Ser Met Pro	980	985	990
Gln Gln Ile Gly	Ile Pro Thr Ser Ser	Leu Thr Gln Val Val His	995	1000	1005
Ser Ala Gly Arg	Arg Phe Ile Val Ser	Pro Val Pro Glu Ser Arg	1010	1015	1020
Leu Arg Glu Ser	Lys Val Phe Pro Ser	Glu Ile Thr Asp Thr Val	1025	1030	1035
Ala Ala Ser Thr	Ala Gln Ser Pro Gly	Met Asn Leu Ser His Ser	1040	1045	1050
Ala Ser Ser Leu	Ser Leu Gln Gln Ala	Phe Ser Glu Leu Arg Arg	1055	1060	1065
Ala Gln Met Thr	Glu Gly Pro Asn Thr	Ala Pro Pro Asn Phe Ser	1070	1075	1080
His Thr Gly Pro	Thr Phe Pro Val Val	Pro Pro Phe Leu Ser Ser	1085	1090	1095

Ile Ala Gly Val Pro Thr Thr Ala Ala Ala Thr Ala Pro Val Pro	1100	1105	1110
Ala Thr Ser Ser Pro Pro Asn Asp Ile Ser Thr Ser Val Ile Gln	1115	1120	1125
Ser Glu Val Thr Val Pro Thr Glu Glu Gly Ile Ala Gly Val Ala	1130	1135	1140
Thr Ser Thr Gly Val Val Thr Ser Gly Gly Leu Pro Ile Pro Pro	1145	1150	1155
Val Ser Glu Ser Pro Val Leu Ser Ser Val Val Ser Ser Ile Thr	1160	1165	1170
Ile Pro Ala Val Val Ser Ile Ser Thr Thr Ser Pro Ser Leu Gln	1175	1180	1185
Val Pro Thr Ser Thr Ser Glu Ile Val Val Ser Ser Thr Ala Leu	1190	1195	1200
Tyr Pro Ser Val Thr Val Ser Ala Thr Ser Ala Ser Ala Gly Gly	1205	1210	1215
Ser Thr Ala Thr Pro Gly Pro Lys Pro Pro Ala Val Val Ser Gln	1220	1225	1230
Gln Ala Ala Gly Ser Thr Thr Val Gly Ala Thr Leu Thr Ser Val	1235	1240	1245
Ser Thr Thr Thr Ser Phe Pro Ser Thr Ala Ser Gln Leu Ser Ile	1250	1255	1260
Gln Leu Ser Ser Ser Thr Ser Thr Pro Thr Leu Ala Glu Thr Val	1265	1270	1275
Val Val Ser Ala His Ser Leu Asp Lys Thr Ser His Ser Ser Thr	1280	1285	1290
Thr Gly Leu Ala Phe Ser Leu Ser Ala Pro Ser Ser Ser Ser Ser	1295	1300	1305
Pro Gly Ala Gly Val Ser Ser Tyr Ile Ser Gln Pro Gly Gly Leu	1310	1315	1320
His Pro Leu Val Ile Pro Ser Val Ile Ala Ser Thr Pro Ile Leu	1325	1330	1335
Pro Gln Ala Ala Gly Pro Thr Ser Thr Pro Leu Leu Pro Gln Val	1340	1345	1350
Pro Ser Ile Pro Pro Leu Val Gln Pro Val Ala Asn Val Pro Ala	1355	1360	1365
Val Gln Gln Thr Leu Ile His Ser Gln Pro Gln Pro Ala Leu Leu	1370	1375	1380
Pro Asn Gln Pro His Thr His Cys Pro Glu Val Asp Ser Asp Thr	1385	1390	1395
Gln Pro Lys Ala Pro Gly Ile Asp Asp Ile Lys Thr Leu Glu Glu	1400	1405	1410
Lys Leu Arg Ser Leu Phe Ser Glu His Ser Ser Ser Gly Ala Gln	1415	1420	1425
His Ala Ser Val Ser Leu Glu Thr Ser Leu Val Ile Glu Ser Thr	1430	1435	1440
Val Thr Pro Gly Ile Pro Thr Thr Ala Val Ala Pro Ser Lys Leu	1445	1450	1455
Leu Thr Ser Thr Thr Ser Thr Cys Leu Pro Pro Thr Asn Leu Pro	1460	1465	1470
Leu Gly Thr Val Ala Leu Pro Val Thr Pro Val Val Thr Pro Gly	1475	1480	1485
Gln Val Ser Thr Pro Val Ser Thr Thr Thr Ser Gly Val Lys Pro	1490	1495	1500
Gly Thr Ala Pro Ser Lys Pro Pro Leu Thr Lys Ala Pro Val Leu	1505	1510	1515

Pro Val Gly Thr Glu Leu Pro Ala Gly Thr Leu Pro Ser Glu Gln	1520	1525	1530
Leu Pro Pro Phe Pro Gly Pro Ser Leu Thr Gln Ser Gln Gln Pro	1535	1540	1545
Leu Glu Asp Leu Asp Ala Gln Leu Arg Arg Thr Leu Ser Pro Glu	1550	1555	1560
Met Ile Thr Val Thr Ser Ala Val Gly Pro Val Ser Met Ala Ala	1565	1570	1575
Pro Thr Ala Ile Thr Glu Ala Gly Thr Gln Pro Gln Lys Gly Val	1580	1585	1590
Ser Gln Val Lys Glu Gly Pro Val Leu Ala Thr Ser Ser Gly Ala	1595	1600	1605
Gly Val Phe Lys Met Gly Arg Phe Gln Val Ser Val Ala Ala Asp	1610	1615	1620
Gly Ala Gln Lys Glu Gly Lys Asn Lys Ser Glu Asp Ala Lys Ser	1625	1630	1635
Val His Phe Glu Ser Ser Thr Ser Glu Ser Ser Val Leu Ser Ser	1640	1645	1650
Ser Ser Pro Glu Ser Thr Leu Val Lys Pro Glu Pro Asn Gly Ile	1655	1660	1665
Thr Ile Pro Gly Ile Ser Ser Asp Val Pro Glu Ser Ala His Lys	1670	1675	1680
Thr Thr Ala Ser Glu Ala Lys Ser Asp Thr Gly Gln Pro Thr Lys	1685	1690	1695
Val Gly Arg Phe Gln Val Thr Thr Thr Ala Asn Lys Val Gly Arg	1700	1705	1710
Phe Ser Val Ser Lys Thr Glu Asp Lys Ile Thr Asp Thr Lys Lys	1715	1720	1725
Glu Gly Pro Val Ala Ser Pro Pro Phe Met Asp Leu Glu Gln Ala	1730	1735	1740
Val Leu Pro Ala Val Ile Pro Lys Lys Glu Lys Pro Glu Leu Ser	1745	1750	1755
Glu Pro Ser His Leu Asn Gly Pro Ser Ser Asp Pro Glu Ala Ala	1760	1765	1770
Phe Leu Ser Arg Asp Val Asp Asp Gly Ser Gly Ser Pro His Ser	1775	1780	1785
Pro His Gln Leu Ser Ser Lys Ser Leu Pro Ser Gln Asn Leu Ser	1790	1795	1800
Gln Ser Leu Ser Asn Ser Phe Asn Ser Ser Tyr Met Ser Ser Asp	1805	1810	1815
Asn Glu Ser Asp Ile Glu Asp Glu Asp Leu Lys Leu Glu Leu Arg	1820	1825	1830
Arg Leu Arg Asp Lys His Leu Lys Glu Ile Gln Asp Leu Gln Ser	1835	1840	1845
Arg Gln Lys His Glu Ile Glu Ser Leu Tyr Thr Lys Leu Gly Lys	1850	1855	1860
Val Pro Pro Ala Val Ile Ile Pro Pro Ala Ala Pro Leu Ser Gly	1865	1870	1875
Arg Arg Arg Arg Pro Thr Lys Ser Lys Gly Ser Lys Ser Ser Arg	1880	1885	1890
Ser Ser Ser Leu Gly Asn Lys Ser Pro Gln Leu Ser Gly Asn Leu	1895	1900	1905
Ser Gly Gln Ser Ala Ala Ser Val Leu His Pro Gln Gln Thr Leu	1910	1915	1920
His Pro Pro Gly Asn Ile Pro Glu Ser Gly Gln Asn Gln Leu Leu	1925	1930	1935

Gln Pro Leu Lys Pro Ser Pro Ser Ser Asp Asn Leu Tyr Ser Ala
 1940 1945 1950
 Phe Thr Ser Asp Gly Ala Ile Ser Val Pro Ser Leu Ser Ala Pro
 1955 1960 1965
 Gly Gln Gly Thr Ser Ser Thr Asn Thr Val Gly Ala Thr Val Asn
 1970 1975 1980
 Ser Gln Ala Ala Gln Ala Gln Pro Pro Ala Met Thr Ser Ser Arg
 1985 1990 1995
 Lys Gly Thr Phe Thr Asp Asp Leu His Lys Leu Val Asp Asn Trp
 2000 2005 2010
 Ala Arg Asp Ala Met Asn Leu Ser Gly Arg Arg Gly Ser Lys Gly
 2015 2020 2025
 His Met Asn Tyr Glu Gly Pro Gly Met Ala Arg Lys Phe Ser Ala
 2030 2035 2040
 Pro Gly Gln Leu Cys Ile Ser Met Thr Ser Asn Leu Gly Gly Ser
 2045 2050 2055
 Ala Pro Ile Ser Ala Ala Ser Ala Thr Ser Leu Gly His Phe Thr
 2060 2065 2070
 Lys Ser Met Cys Pro Pro Gln Gln Tyr Gly Phe Pro Ala Thr Pro
 2075 2080 2085
 Phe Gly Ala Gln Trp Ser Gly Thr Gly Gly Pro Ala Pro Gln Pro
 2090 2095 2100
 Leu Gly Gln Phe Gln Pro Val Gly Thr Ala Ser Leu Gln Asn Phe
 2105 2110 2115
 Asn Ile Ser Asn Leu Gln Lys Ser Ile Ser Asn Pro Pro Gly Ser
 2120 2125 2130
 Asn Leu Arg Thr Thr
 2135

<210> 10

<211> 398

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 55056054CD1

<400> 10

Met Ala Ala Tyr Arg Glu Pro Pro Cys Asn Gln Tyr Thr Gly Thr
 1 5 10 15
 Thr Thr Ala Leu Gln Lys Leu Glu Gly Phe Ala Ser Arg Leu Phe
 20 25 30
 His Arg His Ser Lys Gly Thr Ala His Asp Gln Lys Thr Ala Leu
 35 40 45
 Glu Asn Asp Ser Leu His Phe Ser Glu His Thr Ala Leu Trp Asp
 50 55 60
 Arg Ser Met Lys Glu Phe Leu Ala Lys Ala Lys Glu Asp Phe Leu
 65 70 75
 Lys Lys Trp Glu Asn Pro Thr Gln Asn Asn Ala Gly Leu Glu Asp
 80 85 90
 Phe Glu Arg Lys Lys Thr Leu Gly Thr Gly Ser Phe Gly Arg Val
 95 100 105
 Met Leu Val Lys His Lys Ala Thr Glu Gln Tyr Tyr Ala Met Lys
 110 115 120
 Ile Leu Asp Lys Gln Lys Val Val Lys Leu Lys Gln Ile Glu His

125	130	135
Thr Leu Asn Glu Lys Arg Ile Leu Gln	Ala Val Asn Phe Pro Phe	
140	145	150
Leu Val Arg Leu Glu Tyr Ala Phe Lys	Asp Asn Ser Asn Leu Tyr	
155	160	165
Met Val Met Glu Tyr Val Pro Gly Gly	Glu Met Phe Ser His Leu	
170	175	180
Arg Arg Ile Gly Arg Phe Ser Glu Pro	His Ala Arg Phe Tyr Ala	
185	190	195
Ala Gln Ile Val Leu Thr Phe Glu Tyr	Leu His Ser Leu Asp Leu	
200	205	210
Ile Tyr Arg Asp Leu Lys Pro Glu Asn	Leu Leu Ile Asp His Gln	
215	220	225
Gly Tyr Ile Gln Val Thr Asp Phe Gly	Phe Ala Lys Arg Val Lys	
230	235	240
Gly Arg Thr Trp Thr Leu Cys Gly Thr	Pro Glu Tyr Leu Ala Pro	
245	250	255
Glu Ile Ile Leu Ser Lys Gly Tyr Asn	Lys Ala Val Asp Trp Trp	
260	265	270
Ala Leu Gly Val Leu Ile Tyr Glu Met	Ala Ala Gly Tyr Pro Pro	
275	280	285
Phe Phe Ala Asp Gln Pro Ile Gln Ile	Tyr Glu Lys Ile Val Ser	
290	295	300
Gly Lys Val Arg Phe Pro Ser His Phe	Ser Ser Asp Leu Lys Asp	
305	310	315
Leu Leu Arg Asn Leu Leu Gln Val Asp	Leu Thr Lys Arg Phe Gly	
320	325	330
Asn Leu Lys Asn Gly Val Ser Asp Ile	Lys Thr His Lys Trp Phe	
335	340	345
Ala Thr Thr Asp Trp Ile Ala Ile Tyr	Gln Arg Lys Val Glu Ala	
350	355	360
Pro Phe Ile Pro Lys Phe Arg Gly Ser	Gly Asp Thr Ser Asn Phe	
365	370	375
Asp Asp Tyr Glu Glu Glu Asp Ile Arg	Val Ser Ile Thr Glu Lys	
380	385	390
Cys Ala Lys Glu Phe Gly Glu Phe		
395		

<210> 11

<211> 929

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7481989CD1

<400> 11

Met Glu Gly Asp Gly Val Pro Trp Gly	Ser Glu Pro Val Ser Gly
1	5 10 15
Pro Gly Pro Gly Gly Gly Gly Met Ile	Arg Glu Leu Cys Arg Gly
20	25 30
Phe Gly Arg Tyr Arg Arg Tyr Leu Gly	Arg Leu Arg Gln Asn Leu
35	40 45
Arg Glu Thr Gln Lys Phe Phe Arg Asp	Ile Lys Cys Ser His Asn
50	55 60

His	Thr	Cys	Leu	Ser	Ser	Leu	Thr	Gly	Gly	Gly	Gly	Ala	Glu	Arg	65	70	75
Gly	Pro	Ala	Gly	Asp	Val	Ala	Glu	Thr	Gly	Leu	Gln	Ala	Gly	Gln	80	85	90
Leu	Ser	Cys	Ile	Ser	Phe	Pro	Pro	Lys	Glu	Glu	Lys	Tyr	Leu	Gln	95	100	105
Gln	Ile	Val	Asp	Cys	Leu	Pro	Cys	Ile	Leu	Ile	Leu	Gly	Gln	Asp	110	115	120
Cys	Asn	Val	Lys	Cys	Gln	Leu	Leu	Asn	Leu	Leu	Leu	Gly	Val	Gln	125	130	135
Val	Leu	Pro	Thr	Thr	Lys	Leu	Gly	Ser	Glu	Glu	Ser	Cys	Lys	Leu	140	145	150
Arg	Arg	Leu	Arg	Phe	Thr	Tyr	Gly	Thr	Gln	Thr	Arg	Val	Ser	Leu	155	160	165
Ala	Leu	Pro	Gly	Gln	Tyr	Glu	Leu	Val	His	Thr	Leu	Val	Ala	His	170	175	180
Gln	Gly	Asn	Trp	Glu	Thr	Ile	Pro	Glu	Glu	Asp	Leu	Glu	Val	Gln	185	190	195
Glu	Asn	Asn	Glu	Asp	Ala	Ala	His	Val	Leu	Ala	Glu	Leu	Glu	Val	200	205	210
Thr	Met	His	His	Ala	Leu	Leu	Gln	Glu	Val	Asp	Val	Val	Val	Ala	215	220	225
Pro	Cys	Gln	Gly	Leu	Arg	Pro	Thr	Val	Asp	Val	Leu	Gly	Asp	Leu	230	235	240
Val	Asn	Asp	Phe	Leu	Pro	Val	Ile	Thr	Tyr	Ala	Leu	His	Lys	Asp	245	250	255
Glu	Leu	Ser	Glu	Arg	Asp	Glu	Gln	Glu	Leu	Gln	Glu	Ile	Arg	Lys	260	265	270
Tyr	Phe	Ser	Phe	Pro	Val	Phe	Phe	Phe	Lys	Val	Pro	Lys	Leu	Gly	275	280	285
Ser	Glu	Ile	Ile	Asp	Ser	Ser	Thr	Arg	Arg	Met	Glu	Ser	Glu	Arg	290	295	300
Ser	Pro	Leu	Tyr	Arg	Gln	Leu	Ile	Asp	Leu	Gly	Tyr	Leu	Ser	Ser	305	310	315
Ser	His	Trp	Asn	Cys	Gly	Ala	Pro	Gly	Gln	Asp	Thr	Lys	Ala	Gln	320	325	330
Ser	Met	Leu	Val	Glu	Gln	Ser	Glu	Lys	Leu	Arg	His	Leu	Ser	Thr	335	340	345
Phe	Ser	His	Gln	Val	Leu	Gln	Thr	Arg	Leu	Val	Asp	Ala	Ala	Lys	350	355	360
Ala	Leu	Asn	Leu	Val	His	Cys	His	Cys	Leu	Asp	Ile	Phe	Ile	Asn	365	370	375
Gln	Ala	Phe	Asp	Met	Gln	Arg	Asp	Leu	Gln	Ile	Thr	Pro	Lys	Arg	380	385	390
Leu	Glu	Tyr	Thr	Arg	Lys	Lys	Glu	Asn	Glu	Leu	Tyr	Glu	Ser	Leu	395	400	405
Met	Asn	Ile	Ala	Asn	Arg	Lys	Gln	Glu	Glu	Met	Lys	Asp	Met	Ile	410	415	420
Val	Glu	Thr	Leu	Asn	Thr	Met	Lys	Glu	Glu	Leu	Leu	Asp	Asp	Ala	425	430	435
Thr	Asn	Met	Glu	Phe	Lys	Asp	Val	Ile	Val	Pro	Glu	Asn	Gly	Glu	440	445	450
Pro	Val	Gly	Thr	Arg	Glu	Ile	Lys	Cys	Cys	Ile	Arg	Gln	Ile	Gln	455	460	465
Glu	Leu	Ile	Ile	Ser	Arg	Leu	Asn	Gln	Ala	Val	Ala	Asn	Lys	Leu	470	475	480

Ile Ser Ser Val	Asp Tyr Leu Arg	Glu Ser Phe Val	Gly Thr Leu	485	490	495
Glu Arg Cys Leu	Gln Ser Leu Glu Lys	Ser Gln Asp Val	Ser Val	500	505	510
His Ile Thr Ser	Asn Tyr Leu Lys Gln	Ile Leu Asn Ala	Ala Tyr	515	520	525
His Val Glu Val	Thr Phe His Ser Gly	Ser Ser Val Thr	Arg Met	530	535	540
Leu Trp Glu Gln	Ile Lys Gln Ile Ile	Gln Arg Ile Thr	Trp Val	545	550	555
Ser Pro Pro Ala	Ile Thr Leu Glu Trp	Lys Arg Lys Val	Ala Gln	560	565	570
Glu Ala Ile Glu	Ser Leu Ser Ala Ser	Lys Leu Ala Lys	Ser Ile	575	580	585
Cys Ser Gln Phe	Arg Thr Arg Leu Asn	Ser Ser His Glu	Ala Phe	590	595	600
Ala Ala Ser Leu	Arg Gln Leu Glu Ala	Gly His Ser Gly	Arg Leu	605	610	615
Glu Lys Thr Glu	Asp Leu Trp Leu Arg	Val Arg Lys Asp	His Ala	620	625	630
Pro Arg Leu Ala	Arg Leu Ser Leu Glu	Ser Arg Ser Leu	Gln Asp	635	640	645
Val Leu Leu His	Arg Lys Pro Lys Leu	Gly Gln Glu Leu	Gly Arg	650	655	660
Gly Gln Tyr Gly	Val Val Tyr Leu Cys	Asp Asn Trp Gly	Gly His	665	670	675
Phe Pro Cys Ala	Leu Lys Ser Val Val	Pro Pro Asp Glu	Lys His	680	685	690
Trp Asn Asp Leu	Ala Leu Glu Phe His	Tyr Met Arg Ser	Leu Pro	695	700	705
Lys His Glu Arg	Leu Val Asp Leu His	Gly Ser Val Ile	Asp Tyr	710	715	720
Asn Tyr Gly Gly	Gly Ser Ser Ile Ala	Val Leu Leu Ile	Met Glu	725	730	735
Arg Leu His Arg	Asp Leu Tyr Thr Gly	Leu Lys Ala Gly	Leu Thr	740	745	750
Leu Glu Thr Arg	Leu Gln Ile Ala Leu	Asp Val Val Glu	Gly Ile	755	760	765
Arg Phe Leu His	Ser Gln Gly Leu Val	His Arg Asp Ile	Lys Leu	770	775	780
Lys Asn Val Leu	Leu Asp Lys Gln Asn	Arg Ala Lys Ile	Thr Asp	785	790	795
Leu Gly Phe Cys	Lys Pro Glu Ala Met	Met Ser Gly Ser	Ile Val	800	805	810
Gly Thr Pro Ile	His Met Ala Pro Glu	Leu Phe Thr Gly	Lys Tyr	815	820	825
Asp Asn Ser Val	Asp Val Tyr Ala Phe	Gly Ile Leu Phe	Trp Tyr	830	835	840
Ile Cys Ser Gly	Ser Val Lys Leu Pro	Glu Ala Phe Glu	Arg Cys	845	850	855
Ala Ser Lys Asp	His Leu Trp Asn Asn	Val Arg Arg Gly	Ala Arg	860	865	870
Pro Glu Arg Leu	Pro Val Phe Asp Glu	Glu Cys Trp Gln	Leu Met	875	880	885
Glu Ala Cys Trp	Asp Gly Asp Pro Leu	Lys Arg Pro Leu	Leu Gly	890	895	900

Ile Val Gln Pro Met Leu Gln Gly Ile Met Asn Arg Leu Cys Lys
 905 910 915
 Ser Asn Ser Glu Gln Pro Asn Arg Gly Leu Asp Asp Ser Thr
 920 925

<210> 12

<211> 1097

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 55052990CD1

<400> 12

Met Glu Pro Ser Arg Ala Leu Leu Gly Cys Leu Ala Ser Ala Ala
 1 5 10 15
 Ala Ala Ala Pro Pro Gly Glu Asp Gly Ala Gly Ala Gly Ala Glu
 20 25 30
 Glu Glu Glu Glu Glu Glu Glu Glu Ala Ala Ala Ala Val Gly Pro
 35 40 45
 Gly Glu Leu Gly Cys Asp Ala Pro Leu Pro Tyr Trp Thr Ala Val
 50 55 60
 Phe Glu Tyr Glu Ala Ala Gly Glu Asp Glu Leu Thr Leu Arg Leu
 65 70 75
 Gly Asp Val Val Glu Val Leu Ser Lys Asp Ser Gln Val Ser Gly
 80 85 90
 Asp Glu Gly Trp Trp Thr Gly Gln Leu Asn Gln Arg Val Gly Ile
 95 100 105
 Phe Pro Ser Asn Tyr Val Thr Pro Arg Ser Ala Phe Ser Ser Arg
 110 115 120
 Cys Gln Pro Gly Gly Glu Asp Pro Ser Cys Tyr Pro Pro Ile Gln
 125 130 135
 Leu Leu Glu Ile Asp Phe Ala Glu Leu Thr Leu Glu Glu Ile Ile
 140 145 150
 Gly Ile Gly Gly Phe Gly Lys Val Tyr Arg Ala Phe Trp Ile Gly
 155 160 165
 Asp Glu Val Ala Val Lys Ala Ala Arg His Asp Pro Asp Glu Asp
 170 175 180
 Ile Ser Gln Thr Ile Glu Asn Val Arg Gln Glu Ala Lys Leu Phe
 185 190 195
 Ala Met Leu Lys His Pro Asn Ile Ile Ala Leu Arg Gly Val Cys
 200 205 210
 Leu Lys Glu Pro Asn Leu Cys Leu Val Met Glu Phe Ala Arg Gly
 215 220 225
 Gly Pro Leu Asn Arg Val Leu Ser Gly Lys Arg Ile Pro Pro Asp
 230 235 240
 Ile Leu Val Asn Trp Ala Val Gln Ile Ala Arg Gly Met Asn Tyr
 245 250 255
 Leu Leu Asp Glu Ala Ile Val Pro Ile Ile His Arg Asp Leu Lys
 260 265 270
 Ser Ser Asn Ile Leu Ile Leu Gln Lys Val Glu Asn Gly Asp Leu
 275 280 285
 Ser Asn Lys Ile Leu Lys Ile Thr Asp Phe Gly Leu Ala Arg Glu
 290 295 300
 Trp His Arg Thr Thr Lys Met Ser Ala Ala Gly Thr Tyr Ala Trp

	305		310		315
Met Ala Pro Glu Val	Ile Arg Ala Ser	Met Phe Ser Lys Gly Ser			
	320		325		330
Asp Val Trp Ser Tyr	Gly Val Leu Leu	Trp Glu Leu Leu Thr Gly			
	335		340		345
Glu Val Pro Phe Arg	Gly Ile Asp Gly	Leu Ala Val Ala Tyr Gly			
	350		355		360
Val Ala Met Asn Lys	Leu Ala Leu Pro	Ile Pro Ser Thr Cys Pro			
	365		370		375
Glu Pro Phe Ala Lys	Leu Met Glu Asp	Cys Trp Asn Pro Asp Pro			
	380		385		390
His Ser Arg Pro Ser	Phe Thr Asn Ile	Leu Asp Gln Leu Thr Thr			
	395		400		405
Ile Glu Glu Ser Gly	Phe Phe Glu Met	Pro Lys Asp Ser Phe His			
	410		415		420
Cys Leu Gln Asp Asn	Trp Lys His Glu	Ile Gln Glu Met Phe Asp			
	425		430		435
Gln Leu Arg Ala Lys	Glu Lys Glu Leu	Arg Thr Trp Glu Glu Glu			
	440		445		450
Leu Thr Arg Ala Ala	Leu Gln Gln Lys	Asn Gln Glu Glu Leu Leu			
	455		460		465
Arg Arg Arg Glu Gln	Glu Leu Ala Glu	Arg Glu Ile Asp Ile Leu			
	470		475		480
Glu Arg Glu Leu Asn	Ile Ile Ile His	Gln Leu Cys Gln Glu Lys			
	485		490		495
Pro Arg Val Lys Lys	Arg Lys Gly Lys	Phe Arg Lys Ser Arg Leu			
	500		505		510
Lys Leu Lys Asp Gly	Asn Arg Ile Ser	Leu Pro Ser Asp Phe Gln			
	515		520		525
His Lys Phe Thr Val	Gln Ala Ser Pro	Thr Met Asp Lys Arg Lys			
	530		535		540
Ser Leu Ile Asn Ser	Arg Ser Ser Pro	Pro Ala Ser Pro Thr Ile			
	545		550		555
Ile Pro Arg Leu Arg	Ala Ile Gln Leu	Thr Pro Gly Glu Ser Ser			
	560		565		570
Lys Thr Trp Gly Arg	Ser Ser Val Val	Pro Lys Glu Glu Gly Glu			
	575		580		585
Glu Glu Glu Lys Arg	Ala Pro Lys Lys	Lys Gly Arg Thr Trp Gly			
	590		595		600
Pro Gly Thr Leu Gly	Gln Lys Glu Leu	Ala Ser Gly Asp Glu Gly			
	605		610		615
Leu Lys Ser Leu Val	Asp Gly Tyr Lys	Gln Trp Ser Ser Ser Ala			
	620		625		630
Pro Asn Leu Val Lys	Gly Pro Arg Ser	Ser Pro Ala Leu Pro Gly			
	635		640		645
Phe Thr Ser Leu Met	Glu Met Glu Asp	Glu Asp Ser Glu Gly Pro			
	650		655		660
Gly Ser Gly Glu Ser	Arg Leu Gln His	Ser Pro Ser Gln Ser Tyr			
	665		670		675
Leu Cys Ile Pro Phe	Pro Arg Gly Glu	Asp Gly Asp Gly Pro Ser			
	680		685		690
Ser Asp Gly Ile His	Glu Glu Pro Thr	Pro Val Asn Ser Ala Thr			
	695		700		705
Ser Thr Pro Gln Leu	Thr Pro Thr Asn	Ser Leu Lys Arg Gly Gly			
	710		715		720
Ala His His Arg Arg	Cys Glu Val Ala	Leu Leu Gly Cys Gly Ala			

	725		730		735
Val Leu Ala Ala Thr Gly Leu Gly Phe Asp Leu Leu Glu Ala Gly					
	740		745		750
Lys Cys Gln Leu Leu Pro Leu Glu Glu Pro Glu Pro Pro Ala Arg					
	755		760		765
Glu Glu Lys Lys Arg Arg Glu Gly Leu Phe Gln Arg Ser Ser Arg					
	770		775		780
Pro Arg Arg Ser Thr Ser Pro Pro Ser Arg Lys Leu Phe Lys Lys					
	785		790		795
Glu Glu Pro Met Leu Leu Leu Gly Asp Pro Ser Ala Ser Leu Thr					
	800		805		810
Leu Leu Ser Leu Ser Ser Ile Ser Glu Cys Asn Ser Thr Arg Ser					
	815		820		825
Leu Leu Arg Ser Asp Ser Asp Glu Ile Val Val Tyr Glu Met Pro					
	830		835		840
Val Ser Pro Val Glu Ala Pro Pro Leu Ser Pro Cys Thr His Asn					
	845		850		855
Pro Leu Val Asn Val Arg Val Glu Arg Phe Lys Arg Asp Pro Asn					
	860		865		870
Gln Ser Leu Thr Pro Thr His Val Thr Leu Thr Thr Pro Ser Gln					
	875		880		885
Pro Ser Ser His Arg Arg Thr Pro Ser Asp Gly Ala Leu Lys Pro					
	890		895		900
Glu Thr Leu Leu Ala Ser Arg Ser Pro Ser Ser Asn Gly Leu Ser					
	905		910		915
Pro Ser Pro Gly Ala Gly Glu Ser Ser Ser Ser Phe Leu Phe Pro					
	920		925		930
Phe Phe Val Pro Pro Gln Gly Met Leu Lys Thr Pro Ser Pro Ser					
	935		940		945
Arg Asp Pro Gly Glu Phe Pro Arg Leu Pro Asp Pro Asn Val Val					
	950		955		960
Phe Pro Pro Thr Pro Arg Arg Trp Asn Thr Gln Gln Asp Ser Thr					
	965		970		975
Leu Glu Arg Pro Lys Thr Leu Glu Phe Leu Pro Arg Pro Arg Pro					
	980		985		990
Ser Ala Asn Arg Gln Arg Leu Asp Pro Trp Trp Phe Val Ser Pro					
	995		1000		1005
Ser His Ala Arg Ser Thr Ser Pro Ala Asn Ser Ser Ser Thr Glu					
	1010		1015		1020
Thr Pro Ser Asn Leu Asp Ser Cys Phe Ala Ser Ser Ser Ser Thr					
	1025		1030		1035
Val Glu Glu Arg Pro Gly Leu Pro Ala Leu Leu Pro Phe Gln Ala					
	1040		1045		1050
Gly Pro Leu Pro Pro Thr Glu Arg Thr Leu Leu Asp Leu Asp Ala					
	1055		1060		1065
Glu Gly Gln Ser Gln Asp Ser Thr Val Pro Leu Cys Arg Ala Glu					
	1070		1075		1080
Leu Asn Thr His Arg Pro Ala Pro Tyr Glu Ile Gln Gln Glu Phe					
	1085		1090		1095
Trp Ser					

<210> 13
 <211> 928
 <212> PRT
 <213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7482377CD1

<400> 13

Met	Ala	Val	Arg	Phe	Gln	Val	Ala	Asp	Met	Glu	Glu	Leu	Thr	Ile
1				5					10					15
Trp	Glu	Gln	His	Thr	Ala	Thr	Leu	Ser	Lys	Asp	Pro	Arg	Arg	Gly
				20					25					30
Phe	Gly	Ile	Ala	Ile	Ser	Gly	Gly	Arg	Asp	Arg	Pro	Gly	Gly	Ser
				35					40					45
Met	Val	Val	Ser	Asp	Val	Val	Pro	Gly	Gly	Pro	Ala	Glu	Gly	Arg
				50					55					60
Leu	Gln	Thr	Gly	Asp	His	Ile	Val	Met	Val	Asn	Gly	Val	Ser	Met
				65					70					75
Glu	Asn	Ala	Thr	Ser	Ala	Phe	Ala	Ile	Gln	Ile	Leu	Lys	Thr	Cys
				80					85					90
Thr	Lys	Met	Ala	Asn	Ile	Thr	Val	Lys	Arg	Pro	Arg	Arg	Ile	His
				95					100					105
Leu	Pro	Ala	Thr	Lys	Ala	Ser	Pro	Ser	Ser	Pro	Gly	Arg	Gln	Asp
				110					115					120
Ser	Asp	Glu	Asp	Asp	Gly	Pro	Gln	Arg	Val	Glu	Glu	Val	Asp	Gln
				125					130					135
Gly	Arg	Gly	Tyr	Asp	Gly	Asp	Ser	Ser	Ser	Gly	Ser	Gly	Arg	Ser
				140					145					150
Trp	Asp	Glu	Arg	Ser	Arg	Arg	Pro	Arg	Pro	Gly	Arg	Arg	Gly	Arg
				155					160					165
Ala	Gly	Ser	His	Gly	Arg	Arg	Ser	Pro	Gly	Gly	Gly	Ser	Glu	Ala
				170					175					180
Asn	Gly	Leu	Ala	Leu	Val	Ser	Gly	Phe	Lys	Arg	Leu	Pro	Arg	Gln
				185					190					195
Asp	Val	Gln	Met	Lys	Pro	Val	Lys	Ser	Val	Leu	Val	Lys	Arg	Arg
				200					205					210
Asp	Ser	Glu	Glu	Phe	Gly	Val	Lys	Leu	Gly	Ser	Gln	Ile	Phe	Ile
				215					220					225
Lys	His	Ile	Thr	Asp	Ser	Gly	Leu	Ala	Ala	Arg	His	Arg	Gly	Leu
				230					235					240
Gln	Glu	Gly	Asp	Leu	Ile	Leu	Gln	Ile	Asn	Gly	Val	Ser	Ser	Gln
				245					250					255
Asn	Leu	Ser	Leu	Asn	Asp	Thr	Arg	Arg	Leu	Ile	Glu	Lys	Ser	Glu
				260					265					270
Gly	Lys	Leu	Ser	Leu	Leu	Val	Leu	Arg	Asp	Arg	Gly	Gln	Phe	Leu
				275					280					285
Val	Asn	Ile	Pro	Pro	Ala	Val	Ser	Asp	Ser	Asp	Ser	Ser	Pro	Leu
				290					295					300
Glu	Asp	Ile	Ser	Asp	Leu	Ala	Ser	Glu	Leu	Ser	Gln	Ala	Pro	Pro
				305					310					315
Ser	His	Ile	Pro	Pro	Pro	Pro	Arg	His	Ala	Gln	Arg	Ser	Pro	Glu
				320					325					330
Ala	Ser	Gln	Thr	Asp	Ser	Pro	Val	Glu	Ser	Pro	Arg	Leu	Arg	Arg
				335					340					345
Glu	Ser	Ser	Val	Asp	Ser	Arg	Thr	Ile	Ser	Glu	Pro	Asp	Glu	Gln
				350					355					360
Arg	Ser	Glu	Leu	Pro	Arg	Glu	Ser	Ser	Tyr	Asp	Ile	Tyr	Arg	Val
				365					370					375
Pro	Ser	Ser	Gln	Ser	Met	Glu	Asp	Arg	Gly	Tyr	Ser	Pro	Asp	Thr

	380		385		390
Arg Val Val Arg	Phe Leu Lys Gly Lys	Ser Ile Gly Leu Arg	Leu		
	395		400		405
Ala Gly Gly Asn	Asp Val Gly Ile Phe	Val Ser Gly Val Gln	Ala		
	410		415		420
Gly Ser Pro Ala	Asp Gly Gln Gly Ile	Gln Glu Gly Asp Gln	Ile		
	425		430		435
Leu Gln Val Asn	Asp Val Pro Phe Gln	Asn Leu Thr Arg Glu	Glu		
	440		445		450
Ala Val Gln Phe	Leu Leu Gly Leu Pro	Pro Gly Glu Glu Met	Glu		
	455		460		465
Leu Val Thr Gln	Arg Lys Gln Asp Ile	Phe Trp Lys Met Val	Gln		
	470		475		480
Ser Arg Val Gly	Asp Ser Phe Tyr Ile	Arg Thr His Phe Glu	Leu		
	485		490		495
Glu Pro Ser Pro	Pro Ser Gly Leu Gly	Phe Thr Arg Gly Asp	Val		
	500		505		510
Phe His Val Leu	Asp Thr Leu His Pro	Gly Pro Gly Gln Ser	His		
	515		520		525
Ala Arg Gly Gly	His Trp Leu Ala Val	Arg Met Gly Arg Asp	Leu		
	530		535		540
Arg Glu Gln Glu	Arg Gly Ile Ile Pro	Asn Gln Ser Arg Ala	Glu		
	545		550		555
Gln Leu Ala Ser	Leu Glu Ala Ala Gln	Arg Ala Val Gly Val	Gly		
	560		565		570
Pro Gly Ser Ser	Ala Gly Ser Asn Ala	Arg Ala Glu Phe Trp	Arg		
	575		580		585
Leu Arg Gly Leu	Arg Arg Gly Ala Lys	Lys Thr Thr Gln Arg	Ser		
	590		595		600
Arg Glu Asp Leu	Ser Ala Leu Thr Arg	Gln Gly Arg Tyr Pro	Pro		
	605		610		615
Tyr Glu Arg Val	Val Leu Arg Glu Ala	Ser Phe Lys Arg Pro	Val		
	620		625		630
Val Ile Leu Gly	Pro Val Ala Asp Ile	Ala Met Gln Lys Leu	Thr		
	635		640		645
Ala Glu Met Pro	Asp Gln Phe Glu Ile	Ala Glu Thr Val Ser	Arg		
	650		655		660
Thr Asp Ser Pro	Ser Lys Ile Ile Lys	Leu Asp Thr Val Arg	Val		
	665		670		675
Ile Ala Glu Lys	Asp Lys His Ala Leu	Leu Asp Val Thr Pro	Ser		
	680		685		690
Ala Ile Glu Arg	Leu Asn Tyr Val Gln	Tyr Tyr Pro Ile Val	Val		
	695		700		705
Phe Phe Ile Pro	Glu Ser Arg Pro Ala	Leu Lys Ala Leu Arg	Gln		
	710		715		720
Trp Leu Ala Pro	Ala Ser Arg Arg Ser	Thr Arg Arg Leu Tyr	Ala		
	725		730		735
Gln Ala Gln Lys	Leu Arg Lys His Ser	Ser His Leu Phe Thr	Ala		
	740		745		750
Thr Ile Pro Leu	Asn Gly Thr Ser Asp	Thr Trp Tyr Gln Glu	Leu		
	755		760		765
Lys Ala Ile Ile	Arg Glu Gln Gln Thr	Arg Pro Ile Trp Thr	Ala		
	770		775		780
Glu Asp Gln Leu	Asp Gly Ser Leu Glu	Asp Asn Leu Asp Leu	Pro		
	785		790		795
His His Gly Leu	Ala Asp Ser Ser Ala	Asp Leu Ser Cys Asp	Ser		

800	805	810
Arg Val Asn Ser Asp Tyr Glu Thr Asp Gly Glu Gly Gly Ala Tyr		
815	820	825
Thr Asp Gly Glu Gly Tyr Thr Asp Gly Glu Gly Gly Pro Tyr Thr		
830	835	840
Asp Val Asp Asp Glu Pro Pro Ala Pro Ala Leu Ala Arg Ser Ser		
845	850	855
Glu Pro Val Gln Ala Asp Glu Ser Gln Ser Pro Arg Asp Arg Gly		
860	865	870
Arg Ile Ser Ala His Gln Gly Ala Gln Val Asp Ser Arg His Pro		
875	880	885
Gln Gly Gln Trp Arg Gln Asp Ser Met Arg Thr Tyr Glu Arg Glu		
890	895	900
Ala Leu Lys Lys Lys Phe Met Arg Val His Asp Ala Glu Ser Ser		
905	910	915
Asp Glu Asp Gly Tyr Asp Trp Gly Pro Ala Thr Asp Leu		
920	925	

<210> 14

<211> 766

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7758364CD1

<400> 14

Met Ala Ser Thr Arg Ser Ile Glu Leu Glu His Phe Glu Glu Arg		
1	5	10
Asp Lys Arg Pro Arg Pro Gly Ser Arg Arg Gly Ala Pro Ser Ser		
20	25	30
Ser Gly Gly Ser Ser Ser Ser Gly Pro Lys Gly Asn Gly Leu Ile		
35	40	45
Pro Ser Pro Ala His Ser Ala His Cys Ser Phe Tyr Arg Thr Arg		
50	55	60
Thr Leu Gln Ala Leu Ser Ser Glu Lys Lys Ala Lys Lys Ala Arg		
65	70	75
Phe Tyr Arg Asn Gly Asp Arg Tyr Phe Lys Gly Leu Val Phe Ala		
80	85	90
Ile Ser Ser Asp Arg Phe Arg Ser Phe Asp Ala Leu Leu Ile Glu		
95	100	105
Leu Thr Arg Ser Leu Ser Asp Asn Val Asn Leu Pro Gln Gly Val		
110	115	120
Arg Thr Ile Tyr Thr Ile Asp Gly Ser Arg Lys Val Thr Ser Leu		
125	130	135
Asp Glu Leu Leu Glu Gly Glu Ser Tyr Val Cys Ala Ser Asn Glu		
140	145	150
Pro Phe Arg Lys Val Asp Tyr Thr Lys Asn Ile Asn Pro Asn Trp		
155	160	165
Ser Val Asn Ile Lys Gly Gly Thr Ser Arg Ala Leu Ala Ala Ala		
170	175	180
Ser Ser Val Lys Ser Glu Val Lys Glu Ser Lys Asp Phe Ile Lys		
185	190	195
Pro Lys Leu Val Thr Val Ile Arg Ser Gly Val Lys Pro Arg Lys		
200	205	210

Ala Val Arg Ile	Leu Leu Asn Lys Lys	Thr Ala His Ser Phe	Glu
	215	220	225
Gln Val Leu Thr	Asp Ile Thr Glu Ala	Ile Lys Leu Asp Ser	Gly
	230	235	240
Val Val Lys Arg	Leu Cys Thr Leu Asp	Gly Lys Gln Val Thr	Cys
	245	250	255
Leu Gln Asp Phe	Phe Gly Asp Asp Asp	Val Phe Ile Ala Cys	Gly
	260	265	270
Pro Glu Lys Phe	Arg Tyr Ala Gln Asp	Asp Phe Val Leu Asp	His
	275	280	285
Ser Glu Cys Arg	Val Leu Lys Ser Ser	Tyr Ser Arg Ser Ser	Ala
	290	295	300
Val Lys Tyr Ser	Gly Ser Lys Ser Pro	Gly Pro Ser Arg Arg	Ser
	305	310	315
Lys Ser Pro Ala	Ser Val Asn Gly Thr	Pro Ser Ser Gln Leu	Ser
	320	325	330
Thr Pro Lys Ser	Thr Lys Ser Ser Ser	Ser Ser Pro Thr Ser	Pro
	335	340	345
Gly Ser Phe Arg	Gly Leu Lys Gln Ile	Ser Ala His Gly Arg	Ser
	350	355	360
Ser Ser Asn Val	Asn Gly Gly Pro Glu	Leu Asp Arg Cys Ile	Ser
	365	370	375
Pro Glu Gly Val	Asn Gly Asn Arg Cys	Ser Glu Ser Ser Thr	Leu
	380	385	390
Leu Glu Lys Tyr	Lys Ile Gly Lys Val	Ile Gly Asp Gly Asn	Phe
	395	400	405
Ala Val Val Lys	Glu Cys Ile Asp Arg	Ser Thr Gly Lys Glu	Phe
	410	415	420
Ala Leu Lys Ile	Ile Asp Lys Ala Lys	Cys Cys Gly Lys Glu	His
	425	430	435
Leu Ile Glu Asn	Glu Val Ser Ile Leu	Arg Arg Val Lys His	Pro
	440	445	450
Asn Ile Ile Met	Leu Val Glu Glu Met	Glu Thr Ala Thr Glu	Leu
	455	460	465
Phe Leu Val Met	Glu Leu Val Lys Gly	Gly Asp Leu Phe Asp	Ala
	470	475	480
Ile Thr Ser Ser	Thr Lys Tyr Thr Glu	Arg Asp Gly Ser Ala	Met
	485	490	495
Val Tyr Asn Leu	Ala Asn Ala Leu Arg	Tyr Leu His Gly Leu	Ser
	500	505	510
Ile Val His Arg	Asp Ile Lys Pro Glu	Asn Leu Leu Val Cys	Glu
	515	520	525
Tyr Pro Asp Gly	Thr Lys Ser Leu Lys	Leu Gly Asp Phe Gly	Leu
	530	535	540
Ala Thr Val Val	Glu Gly Pro Leu Tyr	Thr Val Cys Gly Thr	Pro
	545	550	555
Thr Tyr Val Ala	Pro Glu Ile Ile Ala	Glu Thr Gly Tyr Gly	Leu
	560	565	570
Lys Val Asp Ile	Trp Ala Ala Gly Val	Ile Thr Tyr Ile Leu	Leu
	575	580	585
Cys Gly Phe Pro	Pro Phe Arg Ser Glu	Asn Asn Leu Gln Glu	Asp
	590	595	600
Leu Phe Asp Gln	Ile Leu Ala Gly Lys	Leu Glu Phe Pro Ala	Pro
	605	610	615
Tyr Trp Asp Asn	Ile Thr Asp Ser Ala	Lys Glu Leu Ile Ser	Gln
	620	625	630

```

Met Leu Gln Val Asn Val Glu Ala Arg Cys Thr Ala Gly Gln Ile
      635      640      645
Leu Ser His Pro Trp Val Ser Asp Asp Ala Ser Gln Glu Asn Asn
      650      655      660
Met Gln Ala Glu Val Thr Gly Lys Leu Lys Gln His Phe Asn Asn
      665      670      675
Ala Leu Pro Lys Gln Asn Ser Thr Thr Thr Gly Val Ser Val Ile
      680      685      690
Met Asn Thr Ala Leu Asp Lys Glu Gly Gln Ile Phe Cys Ser Lys
      695      700      705
His Cys Gln Asp Ser Gly Arg Pro Gly Met Glu Pro Ile Ser Pro
      710      715      720
Val Pro Pro Ser Val Glu Glu Ile Pro Val Pro Gly Glu Ala Val
      725      730      735
Pro Ala Pro Thr Pro Pro Glu Ser Pro Thr Pro His Cys Pro Pro
      740      745      750
Ala Ala Pro Gly Gly Glu Arg Ala Gly Thr Trp Arg Arg His Arg
      755      760      765
Asp

```

<210> 15

<211> 447

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5850001CD1

<400> 15

```

Met Gly Ala Gly Arg Leu Gly Ala Pro Met Glu Arg His Gly Arg
  1      5      10      15
Ala Ser Ala Thr Ser Val Ser Ser Ala Gly Glu Gln Ala Ala Gly
      20      25      30
Asp Pro Glu Gly Arg Arg Gln Glu Pro Leu Arg Arg Arg Ala Ser
      35      40      45
Ser Ala Ser Val Pro Ala Val Gly Ala Ser Ala Glu Gly Thr Arg
      50      55      60
Arg Asp Arg Leu Gly Ser Tyr Ser Gly Pro Thr Ser Val Ser Arg
      65      70      75
Gln Arg Val Glu Ser Leu Arg Lys Lys Arg Pro Leu Phe Pro Trp
      80      85      90
Phe Gly Leu Asp Ile Gly Gly Thr Leu Val Lys Leu Val Tyr Phe
      95     100     105
Glu Pro Lys Asp Ile Thr Ala Glu Glu Glu Glu Glu Val Glu
     110     115     120
Ser Leu Lys Ser Ile Arg Lys Tyr Leu Thr Ser Asn Val Ala Tyr
     125     130     135
Gly Ser Thr Gly Ile Arg Asp Val His Leu Glu Leu Lys Asp Leu
     140     145     150
Thr Leu Cys Gly Arg Lys Gly Asn Leu His Phe Ile Arg Phe Pro
     155     160     165
Thr His Asp Met Pro Ala Phe Ile Gln Met Gly Arg Asp Lys Asn
     170     175     180
Phe Ser Ser Leu His Thr Val Phe Cys Ala Thr Gly Gly Gly Ala

```

	185		190		195
Tyr Lys Phe Glu	Gln Asp Phe Leu Thr	Ile Gly Asp Leu Gln	Leu		
	200		205		210
Cys Lys Leu Asp	Glu Leu Asp Cys Leu	Ile Lys Gly Ile Leu	Tyr		
	215		220		225
Ile Asp Ser Val	Gly Phe Asn Gly Arg	Ser Gln Cys Tyr Tyr	Phe		
	230		235		240
Glu Asn Pro Ala	Asp Ser Glu Lys Cys	Gln Lys Leu Pro Phe	Asp		
	245		250		255
Leu Lys Asn Pro	Tyr Pro Leu Leu Leu	Val Asn Ile Gly Ser	Gly		
	260		265		270
Val Ser Ile Leu	Ala Val Tyr Ser Lys	Asp Asn Tyr Lys Arg	Val		
	275		280		285
Thr Gly Thr Ser	Leu Gly Gly Gly Thr	Phe Phe Gly Leu Cys	Cys		
	290		295		300
Leu Leu Thr Gly	Cys Thr Thr Phe Glu	Glu Ala Leu Glu Met	Ala		
	305		310		315
Ser Arg Gly Asp	Ser Thr Lys Val Asp	Lys Leu Val Arg Asp	Ile		
	320		325		330
Tyr Gly Gly Asp	Tyr Glu Arg Phe Gly	Leu Pro Gly Trp Ala	Val		
	335		340		345
Ala Ser Ser Phe	Gly Asn Met Met Ser	Lys Glu Lys Arg Glu	Ala		
	350		355		360
Val Ser Lys Glu	Asp Leu Ala Arg Ala	Thr Leu Ile Thr Ile	Thr		
	365		370		375
Asn Asn Ile Gly	Ser Ile Ala Arg Met	Cys Ala Leu Asn Glu	Asn		
	380		385		390
Ile Asn Gln Val	Val Phe Val Gly Asn	Phe Leu Arg Ile Asn	Thr		
	395		400		405
Ile Ala Met Arg	Leu Leu Ala Tyr Ala	Leu Asp Tyr Trp Ser	Lys		
	410		415		420
Gly Gln Leu Lys	Ala Leu Phe Ser Glu	His Glu Gly Tyr Phe	Gly		
	425		430		435
Ala Val Gly Ala	Leu Leu Glu Leu Leu	Lys Ile Pro			
	440		445		

<210> 16

<211> 348

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7477062CD1

<400> 16

Met Pro Gly Lys	Gln Ser Glu Glu Gly	Pro Ala Glu Ala Gly	Ala
1	5	10	15
Ser Glu Asp Ser	Glu Glu Glu Gly Leu	Gly Gly Leu Thr Leu	Glu
	20	25	30
Glu Leu Gln Gln	Gly Gln Glu Ala Ala	Arg Ala Leu Glu Asp	Met
	35	40	45
Met Thr Leu Ser	Ala Gln Thr Leu Val	Arg Ala Glu Val Asp	Glu
	50	55	60
Leu Tyr Glu Glu	Val Arg Pro Leu Gly	Gln Gly Arg Tyr Gly	Arg
	65	70	75

Val	Leu	Leu	Val	Thr	His	Arg	Gln	Lys	Gly	Thr	Pro	Leu	Ala	Leu
				80					85					90
Lys	Gln	Leu	Pro	Lys	Pro	Arg	Thr	Ser	Leu	Arg	Gly	Phe	Leu	Tyr
				95					100					105
Glu	Phe	Cys	Val	Gly	Leu	Ser	Leu	Gly	Ala	His	Ser	Ala	Ile	Val
				110					115					120
Thr	Ala	Tyr	Gly	Ile	Gly	Ile	Glu	Ser	Ala	His	Ser	Tyr	Ser	Phe
				125					130					135
Leu	Thr	Glu	Pro	Val	Leu	His	Gly	Asp	Leu	Met	Ala	Phe	Ile	Gln
				140					145					150
Pro	Lys	Val	Gly	Leu	Pro	Gln	Pro	Ala	Val	His	Arg	Cys	Ala	Ala
				155					160					165
Gln	Leu	Ala	Ser	Ala	Leu	Glu	Tyr	Ile	His	Ala	Arg	Gly	Leu	Val
				170					175					180
Tyr	Arg	Asp	Leu	Lys	Pro	Glu	Asn	Val	Leu	Val	Cys	Asp	Pro	Ala
				185					190					195
Cys	Arg	Arg	Phe	Lys	Leu	Thr	Asp	Phe	Gly	His	Thr	Arg	Pro	Arg
				200					205					210
Gly	Thr	Leu	Leu	Arg	Leu	Ala	Gly	Pro	Pro	Ile	Pro	Tyr	Thr	Ala
				215					220					225
Pro	Glu	Leu	Cys	Ala	Pro	Pro	Pro	Leu	Pro	Glu	Gly	Leu	Pro	Ile
				230					235					240
Gln	Pro	Ala	Leu	Asp	Ala	Trp	Ala	Leu	Gly	Val	Leu	Leu	Phe	Cys
				245					250					255
Leu	Leu	Thr	Gly	Tyr	Phe	Pro	Trp	Asp	Arg	Pro	Leu	Ala	Glu	Ala
				260					265					270
Asp	Pro	Phe	Tyr	Glu	Asp	Phe	Leu	Ile	Trp	Gln	Ala	Ser	Gly	Gln
				275					280					285
Pro	Arg	Asp	Arg	Pro	Gln	Pro	Trp	Phe	Gly	Leu	Ala	Ala	Ala	Ala
				290					295					300
Asp	Ala	Leu	Leu	Arg	Gly	Leu	Leu	Asp	Pro	His	Pro	Arg	Arg	Arg
				305					310					315
Ser	Ala	Val	Ile	Ala	Ile	Arg	Glu	His	Leu	Gly	Arg	Pro	Trp	Arg
				320					325					330
Gln	Arg	Glu	Gly	Glu	Ala	Glu	Ala	Val	Gly	Ala	Val	Glu	Glu	Glu
				335					340					345
Ala	Gly	Gln												

<210> 17

<211> 341

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7477207CD1

<400> 17

Met	Val	Ser	Ser	Gln	Pro	Lys	Tyr	Asp	Leu	Ile	Arg	Glu	Val	Gly
1				5					10					15
Arg	Gly	Ser	Tyr	Gly	Val	Val	Tyr	Glu	Ala	Val	Ile	Arg	Lys	Thr
				20					25					30
Ser	Ala	Arg	Val	Ala	Val	Lys	Lys	Ile	Arg	Cys	His	Ala	Pro	Glu
				35					40					45
Asn	Val	Glu	Leu	Ala	Leu	Arg	Glu	Phe	Trp	Ala	Leu	Ser	Ser	Ile

	50		55		60
Lys Ser Gln His Pro Asn Val Ile His Leu Glu Glu Cys Ile Leu					
	65		70		75
Gln Lys Asp Gly Met Val Gln Lys Met Ser His Gly Ser Asn Ser					
	80		85		90
Ser Leu Tyr Leu Gln Leu Val Glu Thr Ser Leu Lys Gly Glu Ile					
	95		100		105
Ala Phe Asp Pro Arg Ser Ala Tyr Tyr Leu Trp Phe Val Met Asp					
	110		115		120
Phe Cys Asp Gly Gly Asp Met Asn Glu Tyr Leu Leu Ser Arg Lys					
	125		130		135
Pro Asn Arg Lys Thr Asn Thr Ser Phe Met Leu Gln Leu Ser Ser					
	140		145		150
Ala Leu Ala Phe Leu His Lys Asn Gln Ile Ile His Arg Asp Leu					
	155		160		165
Lys Pro Asp Asn Ile Leu Ile Ser Gln Thr Arg Leu Asp Thr Ser					
	170		175		180
Asp Leu Glu Pro Thr Leu Lys Val Ala Asp Phe Gly Leu Ser Lys					
	185		190		195
Val Cys Ser Ala Ser Gly Gln Asn Pro Glu Glu Pro Val Ser Val					
	200		205		210
Asn Lys Cys Phe Leu Ser Thr Ala Cys Gly Thr Asp Phe Tyr Met					
	215		220		225
Ala Pro Glu Val Trp Glu Gly His Tyr Thr Ala Lys Ala Asp Ile					
	230		235		240
Phe Ala Leu Gly Ile Ile Ile Trp Ala Met Leu Glu Arg Ile Thr					
	245		250		255
Phe Ile Asp Thr Glu Thr Lys Lys Glu Leu Leu Gly Ser Tyr Val					
	260		265		270
Lys Gln Gly Thr Glu Ile Val Pro Val Gly Glu Ala Leu Leu Glu					
	275		280		285
Asn Pro Lys Met Glu Leu Leu Ile Pro Val Lys Lys Lys Ser Met					
	290		295		300
Asn Gly Arg Met Lys Gln Leu Ile Lys Glu Met Leu Ala Ala Asn					
	305		310		315
Pro Gln Asp Arg Pro Asp Ala Phe Glu Leu Glu Leu Arg Leu Val					
	320		325		330
Gln Ile Ala Phe Lys Asp Ser Ser Trp Glu Thr					
	335		340		

<210> 18
 <211> 664
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 4022651CD1

<400> 18	
Met Ala Ser Ala Glu Thr Pro Gly Gln Trp Tyr Val Gly Pro Tyr	
1 5 10 15	
Arg Leu Glu Lys Thr Leu Gly Lys Gly Gln Thr Gly Leu Val Lys	
20 25 30	
Leu Gly Val His Cys Val Thr Cys Gln Lys Val Ala Ile Lys Ile	
35 40 45	

Val	Asn	Arg	Glu	Lys	Leu	Ser	Glu	Ser	Val	Leu	Met	Lys	Val	Glu
				50					55					60
Arg	Glu	Ile	Ala	Ile	Leu	Lys	Leu	Ile	Glu	His	Pro	His	Val	Leu
				65					70					75
Lys	Leu	His	Asp	Val	Tyr	Glu	Asn	Lys	Lys	Tyr	Leu	Tyr	Leu	Val
				80					85					90
Leu	Glu	His	Val	Ser	Gly	Gly	Glu	Leu	Phe	Asp	Tyr	Leu	Val	Lys
				95					100					105
Lys	Gly	Arg	Leu	Thr	Pro	Lys	Glu	Ala	Arg	Lys	Phe	Phe	Arg	Gln
				110					115					120
Ile	Ile	Ser	Ala	Leu	Asp	Phe	Cys	His	Ser	His	Ser	Ile	Cys	His
				125					130					135
Arg	Asp	Leu	Lys	Pro	Glu	Asn	Leu	Leu	Leu	Asp	Glu	Lys	Asn	Asn
				140					145					150
Ile	Arg	Ile	Ala	Asp	Phe	Gly	Met	Ala	Ser	Leu	Gln	Val	Gly	Asp
				155					160					165
Ser	Leu	Leu	Glu	Thr	Ser	Cys	Gly	Ser	Pro	His	Tyr	Ala	Cys	Pro
				170					175					180
Glu	Val	Ile	Arg	Gly	Glu	Lys	Tyr	Asp	Gly	Arg	Lys	Ala	Asp	Val
				185					190					195
Trp	Ser	Cys	Gly	Val	Ile	Leu	Phe	Ala	Leu	Leu	Val	Gly	Ala	Leu
				200					205					210
Pro	Phe	Asp	Asp	Asp	Asn	Leu	Arg	Gln	Leu	Leu	Glu	Lys	Val	Lys
				215					220					225
Arg	Gly	Val	Phe	His	Met	Pro	His	Phe	Ile	Pro	Pro	Asp	Cys	Gln
				230					235					240
Ser	Leu	Leu	Arg	Gly	Met	Ile	Glu	Val	Asp	Ala	Ala	Arg	Arg	Leu
				245					250					255
Thr	Leu	Glu	His	Ile	Gln	Lys	His	Ile	Trp	Tyr	Ile	Gly	Gly	Lys
				260					265					270
Asn	Glu	Pro	Glu	Pro	Glu	Gln	Pro	Ile	Pro	Arg	Lys	Val	Gln	Ile
				275					280					285
Arg	Ser	Leu	Pro	Ser	Leu	Glu	Asp	Ile	Asp	Pro	Asp	Val	Leu	Asp
				290					295					300
Ser	Met	His	Ser	Leu	Gly	Cys	Phe	Arg	Asp	Arg	Asn	Lys	Leu	Leu
				305					310					315
Gln	Asp	Leu	Leu	Ser	Glu	Glu	Glu	Asn	Gln	Glu	Lys	Met	Ile	Tyr
				320					325					330
Phe	Leu	Leu	Leu	Asp	Arg	Lys	Glu	Arg	Tyr	Pro	Ser	Gln	Glu	Asp
				335					340					345
Glu	Asp	Leu	Pro	Pro	Arg	Asn	Glu	Ile	Asp	Pro	Pro	Arg	Lys	Arg
				350					355					360
Val	Asp	Ser	Pro	Met	Leu	Asn	Arg	His	Gly	Lys	Arg	Arg	Pro	Glu
				365					370					375
Arg	Lys	Ser	Met	Glu	Val	Leu	Ser	Val	Thr	Asp	Gly	Gly	Ser	Pro
				380					385					390
Val	Pro	Ala	Arg	Arg	Ala	Ile	Glu	Met	Ala	Gln	His	Gly	Gln	Arg
				395					400					405
Ser	Arg	Ser	Ile	Ser	Gly	Ala	Ser	Ser	Gly	Leu	Ser	Thr	Ser	Pro
				410					415					420
Leu	Ser	Ser	Pro	Arg	Val	Thr	Pro	His	Pro	Ser	Pro	Arg	Gly	Ser
				425					430					435
Pro	Leu	Pro	Thr	Pro	Lys	Gly	Thr	Pro	Val	His	Thr	Pro	Lys	Glu
				440					445					450
Ser	Pro	Ala	Gly	Thr	Pro	Asn	Pro	Thr	Pro	Pro	Ser	Ser	Pro	Ser
				455					460					465

Val Gly Gly Val	Pro Trp Arg Ala Arg	Leu Asn Ser Ile Lys Asn	
	470	475	480
Ser Phe Leu Gly	Ser Pro Arg Phe His	Arg Arg Lys Leu Gln Val	
	485	490	495
Pro Thr Pro Glu	Glu Met Ser Asn Leu Thr	Pro Glu Ser Ser Pro	
	500	505	510
Glu Leu Ala Lys	Lys Ser Trp Phe Gly Asn	Phe Ile Ser Leu Glu	
	515	520	525
Lys Glu Glu Gln	Ile Phe Val Val Ile Lys	Asp Lys Pro Leu Ser	
	530	535	540
Ser Ile Lys Ala	Asp Ile Val His Ala Phe	Leu Ser Ile Pro Ser	
	545	550	555
Leu Ser His Ser	Val Ile Ser Gln Thr Ser	Phe Arg Ala Glu Tyr	
	560	565	570
Lys Ala Thr Gly	Gly Pro Ala Val Phe Gln	Lys Pro Val Lys Phe	
	575	580	585
Gln Val Asp Ile	Thr Tyr Thr Glu Gly Gly	Glu Ala Gln Lys Glu	
	590	595	600
Asn Gly Ile Tyr	Ser Val Thr Phe Thr Leu	Leu Ser Gly Pro Ser	
	605	610	615
Arg Arg Phe Lys	Arg Val Val Glu Thr Ile	Gln Ala Gln Leu Leu	
	620	625	630
Ser Thr His Asp	Pro Pro Ala Ala Gln His	Leu Ser Asp Thr Thr	
	635	640	645
Asn Cys Met Glu	Met Met Thr Gly Arg Leu	Ser Lys Cys Gly Ile	
	650	655	660
Ile Pro Lys Ser			

<210> 19

<211> 177

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7274927CD1

<400> 19

Met Val Leu Leu Ser Thr Leu Gly Ile Val Phe Gln Gly Glu Gly	
1 5 10 15	
Pro Pro Ile Ser Ser Cys Asp Thr Gly Thr Met Ala Asn Cys Glu	
20 25 30	
Arg Thr Phe Ile Ala Ile Lys Pro Asp Gly Val Gln Arg Gly Leu	
35 40 45	
Val Gly Glu Ile Ile Lys Arg Phe Glu Gln Lys Gly Phe Arg Leu	
50 55 60	
Val Gly Leu Lys Phe Met Gln Ala Ser Glu Asp Leu Leu Lys Glu	
65 70 75	
His Tyr Val Asp Leu Lys Asp Arg Pro Phe Phe Ala Gly Leu Val	
80 85 90	
Lys Tyr Met His Ser Gly Pro Val Val Ala Met Val Trp Glu Gly	
95 100 105	
Leu Asn Val Val Lys Thr Gly Arg Val Met Leu Gly Glu Thr Asn	
110 115 120	
Pro Ala Asp Ser Lys Pro Gly Thr Ile Arg Gly Asp Phe Cys Ile	

	125		130		135
Gln Val Gly Arg Asn	Ile Ile His Gly Ser Asp Ser Val Glu Ser				
	140		145		150
Ala Glu Lys Glu Ile Gly Leu Trp Phe	His Pro Glu Glu Leu Val				
	155		160		165
Asp Tyr Thr Ser Cys Ala Gln Asn Trp	Ile Tyr Glu				
	170		175		

<210> 20

<211> 396

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7946584CD1

<400> 20

Met Gly Ala Asn Thr Ser Arg Lys Pro Pro Val Phe Asp Glu Asn		
1 5 10 15		
Glu Asp Val Asn Phe Asp His Phe Glu Ile Leu Arg Ala Ile Gly		
20 25 30		
Lys Gly Ser Phe Gly Lys Val Cys Ile Val Gln Lys Asn Asp Thr		
35 40 45		
Lys Lys Met Tyr Ala Met Lys Tyr Met Asn Lys Gln Lys Cys Val		
50 55 60		
Glu Arg Asn Glu Val Arg Asn Val Phe Lys Glu Leu Gln Ile Met		
65 70 75		
Gln Gly Leu Glu His Pro Phe Leu Val Asn Leu Trp Tyr Ser Phe		
80 85 90		
Gln Asp Glu Glu Asp Met Phe Met Val Val Asp Leu Leu Leu Gly		
95 100 105		
Gly Asp Leu Arg Tyr His Leu Gln Gln Asn Val His Phe Lys Glu		
110 115 120		
Glu Thr Val Lys Leu Phe Ile Cys Glu Leu Val Met Ala Leu Asp		
125 130 135		
Tyr Leu Gln Asn Gln Arg Ile Ile His Arg Asp Met Lys Pro Asp		
140 145 150		
Asn Ile Leu Leu Asp Glu His Gly His Val His Ile Thr Asp Phe		
155 160 165		
Asn Ile Ala Ala Met Leu Pro Arg Glu Thr Gln Ile Thr Thr Met		
170 175 180		
Ala Gly Thr Lys Pro Tyr Met Ala Pro Glu Met Phe Ser Ser Arg		
185 190 195		
Lys Gly Ala Gly Tyr Ser Phe Ala Val Asp Trp Trp Ser Leu Gly		
200 205 210		
Val Thr Ala Tyr Glu Leu Leu Arg Gly Arg Arg Pro Tyr His Ile		
215 220 225		
Arg Ser Ser Thr Ser Ser Lys Glu Ile Val His Thr Phe Glu Thr		
230 235 240		
Thr Val Val Thr Tyr Pro Ser Ala Trp Ser Gln Glu Met Val Ser		
245 250 255		
Leu Leu Lys Lys Leu Leu Glu Pro Asn Pro Asp Gln Arg Phe Ser		
260 265 270		
Gln Leu Ser Asp Val Gln Asn Phe Pro Tyr Met Asn Asp Ile Asn		
275 280 285		

[illegible]

```
<210> 21
<211> 614
<212> PRT
<213> Homo sapiens
```

```
<220>  
<221> misc_feature  
<223> Incyte ID No: 8088078CD1
```

<400> 21

Met	Glu	Trp	Leu	Ser	Pro	Asp	Ile	Ala	Leu	Pro	Arg	Arg	Asp	Glu
1				5					10					15
Trp	Thr	Gln	Thr	Ser	Pro	Ala	Arg	Lys	Arg	Ile	Thr	His	Ala	Lys
				20					25					30
Val	Gln	Gly	Ala	Gly	Lys	Ser	Ile	Gly	Gln	Leu	Arg	Leu	Ser	Ile
				35					40					45
Asp	Ala	Gln	Asp	Arg	Val	Leu	Leu	Leu	His	Ile	Ile	Glu	Gly	Lys
				50					55					60
Gly	Leu	Ile	Ser	Lys	Gln	Pro	Gly	Thr	Cys	Asp	Pro	Tyr	Val	Lys
				65					70					75
Ile	Ser	Leu	Ile	Pro	Glu	Asp	Ser	Arg	Leu	Arg	His	Gln	Lys	Thr
				80					85					90
Gln	Thr	Val	Pro	Asp	Cys	Arg	Asp	Pro	Ala	Phe	His	Glu	His	Phe
				95					100					105
Phe	Phe	Pro	Val	Gln	Glu	Glu	Asp	Asp	Gln	Lys	Arg	Leu	Leu	Val
				110					115					120
Thr	Val	Trp	Asn	Arg	Ala	Ser	Gln	Ser	Arg	Gln	Ser	Gly	Leu	Ile
				125					130					135
Gly	Cys	Met	Ser	Phe	Gly	Val	Lys	Ser	Leu	Leu	Thr	Pro	Asp	Lys
				140					145					150
Glu	Ile	Ser	Gly	Trp	Tyr	Tyr	Leu	Leu	Gly	Glu	His	Leu	Gly	Arg
				155					160					165
Thr	Lys	His	Leu	Lys	Val	Ala	Arg	Arg	Arg	Leu	Arg	Pro	Leu	Arg
				170					175					180
Asp	Pro	Leu	Leu	Arg	Met	Pro	Gly	Gly	Gly	Asp	Thr	Glu	Asn	Gly
				185					190					195
Lys	Lys	Leu	Gln	Ile	Thr	Ile	Pro	Arg	Gly	Lys	Asp	Gly	Phe	Gly
				200					205					210
Phe	Thr	Ile	Cys	Cys	Asp	Ser	Pro	Val	Arg	Val	Gln	Ala	Val	Asp

	215		220		225
Ser Gly Gly Pro	Ala Glu Arg Ala Gly	Leu Gln Gln Leu Asp Thr			
	230		235		240
Val Leu Gln Leu	Asn Glu Arg Pro Val	Glu His Trp Lys Cys Val			
	245		250		255
Glu Leu Ala His	Glu Ile Arg Ser Cys	Pro Ser Glu Ile Ile Leu			
	260		265		270
Leu Val Trp Arg	Met Val Pro Gln Val	Lys Pro Gly Pro Asp Gly			
	275		280		285
Gly Val Leu Arg	Arg Ala Ser Cys Lys	Ser Thr His Asp Leu Gln			
	290		295		300
Ser Pro Pro Asn	Lys Arg Glu Lys Asn	Cys Thr His Gly Val Gln			
	305		310		315
Ala Arg Pro Glu	Gln Arg His Ser Cys	His Leu Val Cys Asp Ser			
	320		325		330
Ser Asp Gly Leu	Leu Leu Gly Gly Trp	Glu Arg Tyr Thr Glu Val			
	335		340		345
Ala Lys Arg Gly	Gly Gln His Thr Leu	Pro Ala Leu Ser Arg Ala			
	350		355		360
Thr Ala Pro Thr	Asp Pro Asn Tyr Ile	Ile Leu Ala Pro Leu Asn			
	365		370		375
Pro Gly Ser Gln	Leu Leu Arg Pro Val	Tyr Gln Glu Asp Thr Ile			
	380		385		390
Pro Glu Glu Ser	Gly Ser Pro Ser Lys	Gly Lys Ser Tyr Thr Gly			
	395		400		405
Leu Gly Lys Lys	Ser Arg Leu Met Lys	Thr Val Gln Thr Met Lys			
	410		415		420
Gly His Gly Asn	Tyr Gln Asn Cys Pro	Val Val Arg Pro His Ala			
	425		430		435
Thr His Ser Ser	Tyr Gly Thr Tyr Val	Thr Leu Ala Pro Lys Val			
	440		445		450
Leu Val Phe Pro	Val Phe Val Gln Pro	Leu Asp Leu Cys Asn Pro			
	455		460		465
Ala Arg Thr Leu	Leu Leu Ser Glu Glu	Leu Leu Leu Tyr Glu Gly			
	470		475		480
Arg Asn Lys Ala	Ala Glu Val Thr Leu	Phe Ala Tyr Ser Asp Leu			
	485		490		495
Leu Leu Phe Thr	Lys Glu Asp Glu Pro	Gly Arg Cys Asp Val Leu			
	500		505		510
Arg Asn Pro Leu	Tyr Leu Gln Ser Val	Lys Leu Gln Glu Gly Ser			
	515		520		525
Ser Glu Asp Leu	Lys Phe Cys Val Leu	Tyr Leu Ala Glu Lys Ala			
	530		535		540
Glu Cys Leu Phe	Thr Leu Glu Ala His	Ser Gln Glu Gln Lys Lys			
	545		550		555
Arg Val Cys Trp	Cys Leu Ser Glu Asn	Ile Ala Lys Gln Gln Gln			
	560		565		570
Leu Ala Ala Ser	Pro Pro Asp Ser Lys	Lys Leu His Pro Phe Gly			
	575		580		585
Ser Leu Gln Gln	Glu Met Gly Pro Val	Asn Ser Thr Asn Ala Thr			
	590		595		600
Gln Asp Arg Ser	Phe Thr Ser Pro Gly	Gln Thr Leu Ile Gly			
	605		610		

<210> 22

<211> 484

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2674269CD1

<400> 22

Met	Ser	Thr	Glu	Gly	Arg	Leu	Pro	Ser	Cys	Ser	Ala	Cys	Val	Lys	1	5	10	15
Gly	Glu	Leu	Arg	Val	Leu	Thr	Ser	Ala	Ala	Leu	Thr	Ser	Arg	Asp	20	25	30	
Gly	Pro	Arg	Pro	Cys	His	Val	Leu	Phe	Arg	Ile	Val	His	Leu	Cys	35	40	45	
Leu	Arg	Lys	Ala	Asp	Gln	Lys	Leu	Val	Ile	Ile	Lys	Gln	Ile	Pro	50	55	60	
Val	Glu	Gln	Met	Thr	Lys	Glu	Glu	Arg	Gln	Ala	Ala	Gln	Asn	Glu	65	70	75	
Cys	Gln	Val	Leu	Lys	Leu	Leu	Asn	His	Pro	Asn	Val	Ile	Glu	Tyr	80	85	90	
Tyr	Glu	Asn	Phe	Leu	Glu	Asp	Lys	Ala	Leu	Met	Ile	Ala	Met	Glu	95	100	105	
Tyr	Ala	Pro	Gly	Gly	Thr	Leu	Ala	Glu	Phe	Ile	Gln	Lys	Arg	Cys	110	115	120	
Asn	Ser	Leu	Leu	Glu	Glu	Thr	Ile	Leu	His	Phe	Phe	Val	Gln		125	130	135	
Ile	Leu	Leu	Ala	Leu	His	His	Val	His	Thr	His	Leu	Ile	Leu	His	140	145	150	
Arg	Asp	Leu	Lys	Thr	Gln	Asn	Ile	Leu	Leu	Asp	Lys	His	Arg	Met	155	160	165	
Val	Val	Lys	Ile	Gly	Asp	Phe	Gly	Ile	Ser	Lys	Ile	Leu	Ser	Ser	170	175	180	
Lys	Ser	Lys	Ala	Tyr	Thr	Val	Val	Gly	Thr	Pro	Cys	Tyr	Ile	Ser	185	190	195	
Pro	Glu	Leu	Cys	Glu	Gly	Lys	Pro	Tyr	Asn	Gln	Lys	Ser	Asp	Ile	200	205	210	
Trp	Ala	Leu	Gly	Cys	Val	Leu	Tyr	Glu	Leu	Ala	Ser	Leu	Lys	Arg	215	220	225	
Ala	Phe	Glu	Ala	Ala	Asn	Leu	Pro	Ala	Leu	Val	Leu	Lys	Ile	Met	230	235	240	
Ser	Gly	Thr	Phe	Ala	Pro	Ile	Ser	Asp	Arg	Tyr	Ser	Pro	Glu	Leu	245	250	255	
Arg	Gln	Leu	Val	Leu	Ser	Leu	Leu	Ser	Leu	Glu	Pro	Ala	Gln	Arg	260	265	270	
Pro	Pro	Leu	Ser	His	Ile	Met	Ala	Gln	Pro	Leu	Cys	Ile	Arg	Ala	275	280	285	
Leu	Leu	Asn	Leu	His	Thr	Asp	Val	Gly	Ser	Val	Arg	Met	Arg	Arg	290	295	300	
Pro	Val	Gln	Gly	Gln	Arg	Ala	Val	Leu	Gly	Gly	Arg	Val	Trp	Ala	305	310	315	
Pro	Ser	Gly	Ser	Thr	Gly	Gly	Leu	Arg	Gln	Arg	Glu	Thr	Trp	Gly	320	325	330	
Lys	Ser	Ser	Leu	Pro	Ala	Cys	Arg	Asn	Val	Arg	Arg	Val	Phe	Val	335	340	345	
Leu	Arg	Pro	Pro	Ser	Val	Leu	Gln	Gly	Arg	Glu	Val	Arg	Gly	Pro	350	355	360	

Gln	Gln	His	Arg	Glu	Gln	Asp	His	Gln	Cys	Pro	Leu	Gln	Arg	Tyr	365	370	375
Pro	Pro	Gly	Thr	Cys	Glu	Ala	Ser	His	Pro	Thr	Thr	Thr	Val	Val	380	385	390
Ser	Val	Cys	Leu	Gly	Trp	Trp	Ala	Gly	His	Pro	Pro	Ala	Ala	Ala	395	400	405
Asn	Ala	Gln	His	Arg	Gly	Gly	Pro	Gly	Gly	Ser	Trp	Ala	His	Ala	410	415	420
Glu	Ser	Arg	Arg	His	Ala	Leu	Trp	Ala	Ser	His	Pro	Val	Gly	Gly	425	430	435
Pro	Thr	Pro	Arg	Cys	Arg	Arg	Arg	Gln	Ser	Pro	Ser	Trp	Gly	Ser	440	445	450
Gly	Ala	Ala	Thr	Ala	Pro	Val	His	Leu	Ala	Phe	Pro	Gly	Gly	Pro	455	460	465
Val	Gly	Cys	Asp	His	Gln	Ala	Arg	Gly	Leu	Trp	Gly	Leu	Leu	His	470	475	480
Cys	Leu	Pro	Asp														

<210> 23

<211> 460

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472409CD1

<400> 23

Met	Glu	Lys	Tyr	Glu	Arg	Ile	Arg	Val	Val	Gly	Arg	Gly	Ala	Phe	1	5	10	15
Gly	Ile	Val	His	Leu	Cys	Leu	Arg	Lys	Ala	Asp	Gln	Lys	Leu	Val	20	25	30	
Ile	Ile	Lys	Gln	Ile	Pro	Val	Glu	Gln	Met	Thr	Lys	Glu	Glu	Arg	35	40	45	
Gln	Ala	Ala	Gln	Asn	Glu	Cys	Gln	Val	Leu	Lys	Leu	Leu	Asn	His	50	55	60	
Pro	Asn	Val	Ile	Glu	Tyr	Tyr	Glu	Asn	Phe	Leu	Glu	Asp	Lys	Ala	65	70	75	
Leu	Met	Ile	Ala	Met	Glu	Tyr	Ala	Pro	Gly	Gly	Thr	Leu	Ala	Glu	80	85	90	
Phe	Ile	Gln	Lys	Arg	Cys	Asn	Ser	Leu	Leu	Glu	Glu	Glu	Thr	Ile	95	100	105	
Leu	His	Phe	Phe	Val	Gln	Ile	Leu	Leu	Ala	Leu	His	His	Val	His	110	115	120	
Thr	His	Leu	Ile	Leu	His	Arg	Asp	Leu	Lys	Thr	Gln	Asn	Ile	Leu	125	130	135	
Leu	Asp	Lys	His	Arg	Met	Val	Val	Lys	Ile	Gly	Asp	Phe	Gly	Ile	140	145	150	
Ser	Lys	Ile	Leu	Ser	Ser	Lys	Ser	Lys	Ala	Tyr	Thr	Val	Val	Gly	155	160	165	
Thr	Pro	Cys	Tyr	Ile	Ser	Pro	Glu	Leu	Cys	Glu	Gly	Lys	Pro	Tyr	170	175	180	
Asn	Gln	Lys	Ser	Asp	Ile	Trp	Ala	Leu	Gly	Cys	Val	Leu	Tyr	Glu	185	190	195	
Leu	Ala	Ser	Leu	Lys	Arg	Ala	Phe	Glu	Ala	Ala	Asn	Leu	Pro	Ala				

200	205	210
Leu Val Leu Lys Ile Met Ser Gly Thr Phe Ala Pro Ile Ser Asp		
215	220	225
Arg Tyr Ser Pro Glu Leu Arg Gln Leu Val Leu Ser Leu Leu Ser		
230	235	240
Leu Glu Pro Ala Gln Arg Pro Pro Leu Ser His Ile Met Ala Gln		
245	250	255
Pro Leu Cys Ile Arg Ala Leu Leu Asn Leu His Thr Asp Val Gly		
260	265	270
Ser Val Arg Met Arg Arg Pro Val Gln Gly Gln Arg Ala Val Leu		
275	280	285
Gly Gly Arg Val Trp Ala Pro Ser Gly Ser Thr Gly Gly Leu Arg		
290	295	300
Gln Arg Glu Thr Trp Gly Lys Ser Ser Leu Pro Ala Cys Arg Asn		
305	310	315
Val Arg Arg Val Phe Val Leu Arg Pro Pro Ser Val Leu Gln Gly		
320	325	330
Arg Glu Val Arg Gly Pro Gln Gln His Arg Glu Gln Asp His Gln		
335	340	345
Cys Pro Leu Gln Arg Tyr Pro Pro Gly Thr Cys Glu Ala Ser His		
350	355	360
Pro Thr Thr Thr Val Val Ser Val Cys Leu Gly Trp Trp Ala Gly		
365	370	375
His Pro Pro Ala Ala Ala Asn Ala Gln His Arg Gly Gly Pro Gly		
380	385	390
Gly Ser Trp Ala His Ala Glu Ser Arg Arg His Ala Leu Trp Ala		
395	400	405
Ser His Pro Val Gly Gly Pro Thr Pro Arg Cys Arg Arg Arg Gln		
410	415	420
Ser Pro Ser Trp Gly Ser Gly Ala Ala Thr Ala Pro Val His Leu		
425	430	435
Ala Phe Pro Gly Gly Pro Val Gly Cys Asp His Gln Ala Arg Gly		
440	445	450
Leu Trp Gly Leu Leu His Cys Leu Pro Asp		
455	460	

<210> 24
 <211> 1413
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7477484CD1

<400> 24
 Met Pro Ala Pro Gly Ala Leu Ile Leu Leu Ala Ala Val Ser Ala
 1 5 10 15
 Ser Gly Cys Leu Ala Ser Pro Ala His Pro Asp Gly Phe Ala Leu
 20 25 30
 Gly Arg Ala Pro Leu Ala Pro Pro Tyr Ala Val Val Leu Ile Ser
 35 40 45
 Cys Ser Gly Leu Leu Ala Phe Ile Phe Leu Leu Leu Thr Cys Leu
 50 55 60
 Cys Cys Lys Arg Gly Asp Val Gly Phe Lys Glu Phe Glu Asn Pro
 65 70 75

Glu Gly Glu Asp Cys Ser Gly Glu Tyr Thr Pro Pro Ala Glu Glu	80	85	90
Thr Ser Ser Ser Gln Ser Leu Pro Asp Val Tyr Ile Leu Pro Leu	95	100	105
Ala Glu Val Ser Leu Pro Met Pro Ala Pro Gln Pro Ser His Ser	110	115	120
Asp Met Thr Thr Pro Leu Gly Leu Ser Arg Gln His Leu Ser Tyr	125	130	135
Leu Gln Glu Ile Gly Ser Gly Trp Phe Gly Lys Val Ile Leu Gly	140	145	150
Glu Ile Phe Ser Asp Tyr Thr Pro Ala Gln Val Val Val Lys Glu	155	160	165
Leu Arg Ala Ser Ala Gly Pro Leu Glu Gln Arg Lys Phe Ile Ser	170	175	180
Glu Ala Gln Pro Tyr Arg Ser Leu Gln His Pro Asn Val Leu Gln	185	190	195
Cys Leu Gly Leu Cys Val Glu Thr Leu Pro Phe Leu Leu Ile Met	200	205	210
Glu Phe Cys Gln Leu Gly Asp Leu Lys Arg Tyr Leu Arg Ala Gln	215	220	225
Arg Pro Pro Glu Gly Leu Ser Pro Glu Leu Pro Pro Arg Asp Leu	230	235	240
Arg Thr Leu Gln Arg Met Gly Leu Glu Ile Ala Arg Gly Leu Ala	245	250	255
His Leu His Ser His Asn Tyr Val His Ser Asp Leu Ala Leu Arg	260	265	270
Asn Cys Leu Leu Thr Ser Asp Leu Thr Val Arg Ile Gly Asp Tyr	275	280	285
Gly Leu Ala His Ser Asn Tyr Lys Glu Asp Tyr Tyr Leu Thr Pro	290	295	300
Glu Arg Leu Trp Ile Pro Leu Arg Trp Ala Ala Pro Glu Leu Leu	305	310	315
Gly Glu Leu His Gly Thr Phe Met Val Val Asp Gln Ser Arg Glu	320	325	330
Ser Asn Ile Trp Ser Leu Gly Val Thr Leu Trp Glu Leu Phe Glu	335	340	345
Phe Gly Ala Gln Pro Tyr Arg His Leu Ser Asp Glu Glu Val Leu	350	355	360
Ala Phe Val Val Arg Gln Gln His Val Lys Leu Ala Arg Pro Arg	365	370	375
Leu Lys Leu Pro Tyr Ala Asp Tyr Trp Tyr Asp Ile Leu Gln Ser	380	385	390
Cys Trp Arg Pro Pro Ala Gln Arg Pro Ser Ala Ser Asp Leu Gln	395	400	405
Leu Gln Leu Thr Tyr Leu Leu Ser Glu Arg Pro Pro Arg Pro Pro	410	415	420
Pro Pro Pro Pro Pro Pro Arg Asp Gly Pro Phe Pro Trp Pro Trp	425	430	435
Pro Pro Ala His Ser Ala Pro Arg Pro Gly Thr Leu Ser Ser Pro	440	445	450
Phe Pro Leu Leu Asp Gly Phe Pro Gly Ala Asp Pro Asp Asp Val	455	460	465
Leu Thr Val Thr Glu Ser Ser Arg Gly Leu Asn Leu Glu Cys Leu	470	475	480
Trp Glu Lys Ala Arg Arg Gly Ala Gly Arg Gly Gly Gly Ala Pro	485	490	495

Ala Trp Gln Pro	Ala Ser Ala Pro Pro	Ala Pro His Ala Asn Pro	500	505	510
Ser Asn Pro Phe	Tyr Glu Ala Leu Ser	Thr Pro Ser Val Leu Pro	515	520	525
Val Ile Ser Ala	Arg Ser Pro Ser Val	Ser Ser Glu Tyr Tyr Ile	530	535	540
Arg Leu Glu Glu	His Gly Ser Pro Pro	Glu Pro Leu Phe Pro Asn	545	550	555
Asp Trp Asp Pro	Leu Asp Pro Gly Val	Pro Ala Pro Gln Ala Pro	560	565	570
Gln Ala Pro Ser	Glu Val Pro Gln Leu	Val Ser Glu Thr Trp Ala	575	580	585
Ser Pro Leu Phe	Pro Ala Pro Arg Pro	Phe Pro Ala Gln Ser Ser	590	595	600
Ala Ser Gly Ser	Phe Leu Leu Ser Gly	Trp Asp Pro Glu Gly Arg	605	610	615
Gly Ala Gly Glu	Thr Leu Ala Gly Asp	Pro Ala Glu Val Leu Gly	620	625	630
Glu Arg Gly Thr	Ala Pro Trp Val Glu	Glu Glu Glu Glu Glu Glu	635	640	645
Glu Gly Ser Ser	Pro Gly Glu Asp Ser	Ser Ser Leu Gly Gly Arg	650	655	660
Leu Leu Ala Ala	Gly Arg Ala Gly Leu	Pro Gly Arg Leu Ala His	665	670	675
Gly Pro Pro Ala	Ser Ala Pro Pro Glu	Phe Leu Asp Pro Leu Met	680	685	690
Gly Ala Ala Ala	Pro Gln Tyr Pro Gly	Arg Gly Pro Pro Pro Ala	695	700	705
Pro Pro Pro Pro	Pro Pro Pro Pro Arg	Ala Pro Ala Asp Pro Ala	710	715	720
Ala Ser Pro Asp	Pro Pro Ser Ala Val	Ala Ser Pro Gly Ser Gly	725	730	735
Leu Ser Ser Pro	Gly Pro Lys Pro Gly	Asp Ser Gly Tyr Glu Thr	740	745	750
Glu Thr Pro Phe	Ser Pro Glu Gly Ala	Phe Pro Gly Gly Gly Ala	755	760	765
Ala Glu Glu Glu	Gly Val Pro Arg Pro	Arg Ala Pro Pro Glu Pro	770	775	780
Pro Asp Pro Gly	Ala Pro Arg Pro Pro	Pro Asp Pro Gly Pro Leu	785	790	795
Pro Leu Pro Gly	Pro Arg Glu Lys Pro	Thr Phe Val Val Gln Val	800	805	810
Ser Thr Glu Gln	Leu Leu Met Ser Leu	Arg Glu Asp Val Thr Arg	815	820	825
Asn Leu Leu Gly	Glu Lys Gly Ala Thr	Ala Arg Glu Thr Gly Pro	830	835	840
Arg Lys Ala Gly	Arg Gly Pro Gly Asn	Arg Glu Lys Val Pro Gly	845	850	855
Leu Asn Arg Asp	Pro Thr Val Leu Gly	Asn Gly Lys Gln Ala Pro	860	865	870
Ser Leu Ser Leu	Pro Val Asn Gly Val	Thr Val Leu Glu Asn Gly	875	880	885
Asp Gln Arg Ala	Pro Gly Ile Glu Glu	Lys Ala Ala Glu Asn Gly	890	895	900
Ala Leu Gly Ser	Pro Glu Arg Glu Glu	Lys Val Leu Glu Asn Gly	905	910	915

Glu Leu Thr Pro Pro Arg Arg Glu Glu Lys Ala Leu Glu Asn Gly	920	925	930
Glu Leu Arg Ser Pro Glu Ala Gly Glu Lys Val Leu Val Asn Gly	935	940	945
Gly Leu Thr Pro Pro Lys Ser Glu Asp Lys Val Ser Glu Asn Gly	950	955	960
Gly Leu Arg Phe Pro Arg Asn Thr Glu Arg Pro Pro Glu Thr Gly	965	970	975
Pro Trp Arg Ala Pro Gly Pro Trp Glu Lys Thr Pro Glu Ser Trp	980	985	990
Gly Pro Ala Pro Thr Ile Gly Glu Pro Ala Pro Glu Thr Ser Leu	995	1000	1005
Glu Arg Ala Pro Ala Pro Ser Ala Val Val Ser Ser Arg Asn Gly	1010	1015	1020
Gly Glu Thr Ala Pro Gly Pro Leu Gly Pro Ala Pro Lys Asn Gly	1025	1030	1035
Thr Leu Glu Pro Gly Thr Glu Arg Arg Ala Pro Glu Thr Gly Gly	1040	1045	1050
Ala Pro Arg Ala Pro Gly Ala Gly Arg Leu Asp Leu Gly Ser Gly	1055	1060	1065
Gly Arg Ala Pro Val Gly Thr Gly Thr Ala Pro Gly Gly Gly Pro	1070	1075	1080
Gly Ser Gly Val Asp Ala Lys Ala Gly Trp Val Asp Asn Thr Arg	1085	1090	1095
Pro Gln Pro Pro Pro Pro Pro Leu Pro Pro Pro Pro Glu Ala Gln	1100	1105	1110
Pro Arg Arg Leu Glu Pro Ala Pro Pro Arg Ala Arg Pro Glu Val	1115	1120	1125
Ala Pro Glu Gly Glu Pro Gly Ala Pro Asp Ser Arg Ala Gly Gly	1130	1135	1140
Asp Thr Ala Leu Ser Gly Asp Gly Asp Pro Pro Lys Pro Glu Arg	1145	1150	1155
Lys Gly Pro Glu Met Pro Arg Leu Phe Leu Asp Leu Gly Pro Pro	1160	1165	1170
Gln Gly Asn Ser Glu Gln Ile Lys Ala Arg Leu Ser Arg Leu Ser	1175	1180	1185
Leu Ala Leu Pro Pro Leu Thr Leu Thr Pro Phe Pro Gly Pro Gly	1190	1195	1200
Pro Arg Arg Pro Pro Trp Glu Gly Ala Asp Ala Gly Ala Ala Gly	1205	1210	1215
Gly Glu Ala Gly Gly Ala Gly Ala Pro Gly Pro Ala Glu Glu Asp	1220	1225	1230
Gly Glu Asp Glu Asp Glu Asp Glu Glu Glu Asp Glu Glu Ala Ala	1235	1240	1245
Ala Pro Gly Ala Ala Ala Gly Pro Arg Gly Pro Gly Arg Ala Arg	1250	1255	1260
Ala Ala Pro Val Pro Val Val Val Ser Ser Ala Asp Ala Asp Ala	1265	1270	1275
Ala Arg Pro Leu Arg Gly Leu Leu Lys Ser Pro Arg Gly Ala Asp	1280	1285	1290
Glu Pro Glu Asp Ser Glu Leu Glu Arg Lys Arg Lys Met Val Ser	1295	1300	1305
Phe His Gly Asp Val Thr Val Tyr Leu Phe Asp Gln Glu Thr Pro	1310	1315	1320
Thr Asn Glu Leu Ser Val Gln Ala Pro Pro Glu Gly Asp Thr Asp	1325	1330	1335

Pro Ser Thr Pro Pro Ala Pro Pro Thr Pro Pro His Pro Ala Thr
 1340 1345 1350
 Pro Gly Asp Gly Phe Pro Ser Asn Asp Ser Gly Phe Gly Gly Ser
 1355 1360 1365
 Phe Glu Trp Ala Glu Asp Phe Pro Leu Leu Pro Pro Pro Gly Pro
 1370 1375 1380
 Pro Leu Cys Phe Ser Arg Phe Ser Val Ser Pro Ala Leu Glu Thr
 1385 1390 1395
 Pro Gly Pro Pro Ala Arg Ala Pro Asp Ala Arg Pro Ala Gly Pro
 1400 1405 1410
 Val Glu Asn

<210> 25
 <211> 2060
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7312543CB1

<400> 25
 aagacagcaa gccccctacg gcaccgcaag gactccccct cctcagtctg ggcccccgcc 60
 ccaagaccta gaacgcagtg cccccaggcc gggattgcca gaacccccctc ccaagatccg 120
 gtcattacaa ctccacacct caagacaaga agaccagct cagaacgccc ctagatcagg 180
 ggatcccaat tcccccaaac tccggtacat agaaatccca aatctaggca gccggggaca 240
 gcaagagaca ctctcaccag caagaagcct cggggatccc ccccctaaag ctccaggact 300
 tgggcgactg agccccctggc ggcaccgctt gcacccccgt ccattggtcgt ggcgcctga 360
 gcccccgggg ccgggcagac gaagaccgcg acggcgccca ggccccctgc cgcggcgctcc 420
 ccgcggcccc agcccaggga gaagatgagc gtgggctgcc cagagcctga gccgccccgc 480
 tccctgacct gctgtgggccc ggggactgcc cctgggcctg gtgccggtgt gccccttctc 540
 actgaagaca tgcaggccct gactctccgc aactggccg ccagcgacgt caccaagcac 600
 tacgaactag tccgggagct gggcaaaggc acctatggga aggttgacct ggtggtctac 660
 aagggcacag gcacaaaaat ggcactgaag tttgtgaaca agagcaaaac caagctgaag 720
 aacttcctac gggaggtgag catcaccaac agcctctcct ccagccccct catcatcaag 780
 gtctttgacg tggcttttga gacagaggac tgctacgtct ttgccaggga gtacgcacct 840
 gctggggacc tgtttgacat catccctccc caggtggggc tccctgagga cacggtgaag 900
 cgctgtgtgc agcagctggg cctggcgctg gacttcatgc acgggcggca gctggtgcac 960
 cgcgacatca agcccagaaa cgtgctgctg ttcgaccgag agtgccgccc cgtaaagctg 1020
 gccgacttcg gcatgacgag ccgctggggc tgccgcgtca agcgcgtgag cggcaccatc 1080
 ccttacacgg cgctgaggt gtgccaggcg gcccgcgccc acgggctggc ggtggacacg 1140
 ggcgtggacg tgtgggcctt cggcgtgctc atcttctgcy tgctcaccgg caacttccc 1200
 tgggagggcg cgtcggggcg cgacgccttc ttcgaggagt tcgtgcgctg gcagcggggc 1260
 cgcctgcccg ggtgccttc gcagtggcgc cgcttcaccg agcccgcgct gcgcatgttc 1320
 cagcgcttac tggccctgga gcccgagcgc cgcggcccag ccaaggaggt gttccgcttc 1380
 ctcaagcacg agctcacgtc cgagctgcgc cgccggccct cgcaccgcgc gcgcaagccc 1440
 cccggggacc gccgcgccgc cgccgggcca ctgcgcctcg aggcgcctgg gccgtcaag 1500
 cggacggtgc tgaccgagag cggcgggcgg tcccggcccg cgccccccgc cgtcgggtcg 1560
 gtgcccttgc ccgtgccggt gccgggtgcca gtgcccgctc cgggtgcctgt gcccagagccc 1620
 ggcctagctc cccagggggc ccccgggcgg accgacggcc gcgcggacaa gagcaaaggg 1680
 caggtggtgc tggccacggc catcgagatc tgcgtctgag tctgcctcct ccgcgcctcg 1740
 gacccgggag cagcccgggc ccgccccgag ccggtgcccg gtgacgacgg tagggaatgg 1800
 agccacctcg ccgcggggca gggggcgag cggtagatct aggcagatcg cggcccgcca 1860
 cctggtccgt ccccgggggg cttggtgagg gggccacaca aagacccta gcgcggcctg 1920
 gtgagcgggg gcttgggcca gaggagccaa gccgcacaga cccgagaatt cggaggccac 1980

cacacaacac acacacacac acacacacac acacacacac acacacacac acacacgcca 2040
gagagcaagg gagctcttcg 2060

<210> 26

<211> 5694

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7477427CB1

<400> 26

```

tttttttgggt tttttaaaga agtgttgact ctctagttcg ttgtactttt aagtatgagt 60
tttattttaa tatacgactt aattgtattc ttttaaaaat gcattaagta tatattttat 120
ggtaatttta ccttcaaaat agatgtatat ggggtgaaatt gaagacgctt cagttaagt 180
aggttactgg tgtgttggat gtttaattca gcaccagcat tgcattgacag ttgtttgaat 240
aacaagtgggt ttatttttaa aaccatacct tttaaaattt aggttcagat aatagtaaaa 300
gtcatcataa taattttaaag gaaaaccagc agaaatcgaa gcaaacatgt ctggagaagt 360
gcgtttgagg cagttggagc agtttatttt ggacgggccc gctcagacca atgggcagt 420
cttcagtgtg gagacattac tggatatact catctgcctt tatgatgaat gcaataattc 480
tccattgaga agagagaaga acattctcga atacctagaa tgggctaaac catttacttc 540
taaagtgaag caaatgcatg tacatagaga agactttgaa atattaaagg tgattggctc 600
aggagctttt ggggagggtt ctgtagttaa actaaaaaat gcagataaag tgtttgccat 660
gaaaatattg aataaatggg aaatgctgaa aagagctgag acagcatgtt ttcgtgaaga 720
aagggatgta ttagtgaatg gagacaataa atggattaca accttgcact atgctttcca 780
ggatgacaat aacttatacc tggttatgga ttattatggt ggtggggatt tgcttactct 840
actcagcaaa tttgaagata gattgcctga agatatggct agattttact tggctgagat 900
ggatgatagc attgactcag ttcacagct acattatgta cacagagaca ttaaacctga 960
caatatactg atggatatga atggacatat tgggttagca gatttttggt cttgtctgaa 1020
gctgatggaa gatggaacgg ttcagtcctc agtggctgta ggaactccag attatatctc 1080
tcctgaaatc cttcaagcca tggagatgg aaaagggaga tatggacctg aatgtgactg 1140
gtggctcttg ggggtctgta tgtatgaaat gctttacgga gaaacaccat tttatgcaga 1200
atcgctgggt gagacatacg gaaaaatcat gaaccacaaa gagagggttc agtttccagc 1260
ccaagtgact gatgtgtctg aaaatgctaa ggatcttatt cgaaggctca tttgtagcag 1320
agaacatcga cttgggtcaaa atggaataga agactttaag aaacacccat ttttcagtgg 1380
aattgattgg gataatatc ggaactgtga agcaccttat attccagaag ttagtagccc 1440
aacagatata tcgaattttg atgtagatga tgattgttta aaaaattctg aaacgatgcc 1500
cccaccaaca catactgcat tttctggcca ccatctgcca tttgttggtt ttacatatac 1560
tagtagctgt gtactttctg atcggagctg ttttaagagt acggctgggt ccacctcact 1620
ggatcttgat gttaatgttc agaggactct agacaacaac ttagcaactg aagcttatga 1680
aagaagaatt aagcgcttg agcaagaaaa acttgaactc agtagaaaac ttcaagagtc 1740
aacacagact gtccaagctc tgcagtattc aactgttgat ggtccactaa cagcaagcaa 1800
agatttagaa ataaaaaact taaaagaaga aattgaaaaa ctaagaaaac aagtaacaga 1860
atcaagtcac ttggaacagc aacttgaaga agctaattgct gtgaggcaag aactagatga 1920
tgctttttag caaatcaagg cttatgaaaa acaaatcaaa acgttacaac aagaaagaga 1980
agatctaaat aaggaaactg tccaggctag tgagcgatta aaaaaccaat ccaaagagct 2040
gaaagacgca cactgtcaga ggaaactggc catgcaggaa ttcattggaga tcaatgagcg 2100
gctaacagaa ttgcacaccc aaaaacagaa acttgctcgc catgtccgag ataaggaaga 2160
agaggtggac ctggtgatgc aaaaagttga aagcttaagg caagaactgc gcagaacaga 2220
aagagccaaa aaagagctgg aagttcatac agaagctcta gctgctgaag catctaaaga 2280
caggaagcta cgtgaacaga gtgagcacta ttctaagcaa ctggaaaatg aattggaggg 2340
actgaagcaa aaacaaatta gttactcacc aggagtatgc agcatagaac atcagcaaga 2400
gataaccaa ctaaagactg atttggaaaa gaaaagtatc ttttatgaag aagaattatc 2460
taaaagagaa ggaatacatg caaatgaaat aaaaaatctt aagaaagaac tgcattgatt 2520
agaaggctcg caacttgctc tcaacaaaga aattatgatt ttaaaagaca aattggaaaa 2580

```

aaccagaaga	gaaagtcaaa	gtgaaaggga	ggaatttgaa	agtgagttca	aacaacaata	2640
tgaacgagaa	aaagtgttgt	taactgaaga	aaataaaaaag	ctgacgagtg	aacttgataa	2700
gcttactact	ttgtatgaga	acttaagtat	acacaaccag	cagttagaag	aagaggttaa	2760
agatctagca	gacaagaaag	aatcagttgc	acattgggaa	gccccaatca	cagaaataat	2820
tcagtggtgc	agcgatgaaa	aggatgcacg	agggtatctt	caggccttag	cttctaaaat	2880
gactgaagaa	ttggaggcat	taagaaattc	cagcttgggt	acacgagcaa	cagatatgcc	2940
ctggaaaatg	cgtcgttttg	cgaaactgga	tatgtcagct	agactggagt	tgcagtcggc	3000
tctggatgca	gaaataagag	ccaacaggc	catccaagaa	gagttgaata	aagttaaagc	3060
atctaataatc	ataacagaat	gtaaactaaa	agattcagag	agaagaact	tggaaactact	3120
ctcagaaatc	gaacagctga	taaaggacac	tgaagagctt	agatctgaaa	agggtataga	3180
gcaccaagac	tcacagcatt	ctttcttggc	atttttgaat	acgcctaccg	atgctctgga	3240
tcaatttgaa	actgtagact	ccactccact	ttcagttcac	acaccaacct	taaggaaaaa	3300
aggatgtcct	ggttcaactg	gctttccacc	taagcgcaag	actcaccagt	tttttgtaaa	3360
atcttttact	actcctacca	agtgtcatca	gtgtacctcc	ttgatgggtg	gtttaataag	3420
acagggctgt	tcatgtgaag	tgtgtggatt	ctcatgccat	ataacttgtg	taaacaaagc	3480
tccaaccact	tgtccagttc	ctcctgaaca	gacaaaagg	cccctgggta	tagatcctca	3540
gaaaggaata	ggaacagcat	atgaagggtca	tgtcaggatt	cctaagccag	ctggagtgaa	3600
gaaaggggtg	cagagagcac	tggctatagt	gtgtgacttc	aaactctttc	tgtacgatat	3660
tgtgaagga	aaagcatctc	agcccagtg	tgtcattagt	caagtgattg	acatgaggga	3720
tgaagaattt	tctgtgagtt	cagtcttggc	ttctgatgtt	atccatgcaa	gtcggaaaaga	3780
tataccctgt	atatttaggg	tcacagcttc	ccagctctca	gcatctaata	acaaatgttc	3840
aatcctgatg	ctagcagaca	ctgagaatga	gaagaataag	tgggtgggag	tgtgagtga	3900
attgcacaag	attttgaa	aaaacaaatt	cagagaccgc	tcagtctatg	ttcccaaaga	3960
ggcttatgac	agcactctac	ccctcattaa	aacaaccag	gcagccgcaa	tcatagatca	4020
tgaagaatt	gctttgggaa	acgaagaagg	gttatattgt	gtacatgtca	ccaaagatga	4080
aattattaga	gttggtgaca	ataagaagat	tcacagatt	gaactcattc	caaatgatca	4140
gcttggtgct	gtgatctcag	gacgaaatcg	tcatgtacga	ctttttccta	tgtcagcatt	4200
ggatgggcca	gagaccgatt	tttacaagct	gtcagaaact	aaaggggtgc	aaaccgtaac	4260
ttctggaaag	gtgcgccatg	gagctctcac	atgcctgtgt	gtggctatga	aaaggcaggt	4320
cctctgttat	gaactatttc	agagcaagac	ccgtcacaga	aaattttaaag	aaattcaagt	4380
cccatataat	gtccagtgga	tggcaatctt	cagtgaacaa	ctctgtgtgg	gattccagtc	4440
aggatttcta	agataccctt	tgaatggaga	aggaaatcca	tacagtatgc	tccattcaaa	4500
tgaccataca	ctatcattta	ttgcacatca	accaatggat	gctatctgcg	cagttgagat	4560
ctccagtaaa	gaatatctgc	tgtgttttaa	cagcattggg	atatacactg	actgccaggg	4620
ccgaagatct	agacaacagg	aattgatgtg	gccagcaaat	ccttccctct	gttggttaca	4680
tgcaccatat	ctctcgggtg	acagtgaaaa	tgcagttgat	atctttgatg	tgaactccat	4740
ggaatggatt	cagactcttc	ctctcaaaaa	ggttcgaccc	ttaaacaatg	aaggatcatt	4800
aaatctttta	gggttggaga	ccattagatt	aatatatttc	aaaaataaga	tggcagaagg	4860
ggacgaactg	gtagtacctg	aaacatcaga	taatagtcgg	aaacaaatgg	ttagaaacat	4920
taacaataag	cggcgttatt	ccttcagagt	cccagaagag	gaaaggatgc	agcagaggag	4980
ggaaatgcta	cgagatccag	aaatgagaaa	taaattaatt	tctaatacaa	ctaattttaa	5040
tcacatagca	cacatgggtc	ctggagatgg	aatacagatc	ctgaaagatc	tgcccatgaa	5100
ccctcggcct	caggaaagtc	ggacagtatt	cagtggctca	gtcagtattc	catctatcac	5160
caaattcccgc	cctgagccag	gccgtccat	gagtgttagc	agtggccttg	cagcaaggtc	5220
atccgcacag	aatggcagcg	cattaaagag	ggaattctct	ggaggaagct	acagtgccaa	5280
gcggcagccc	atgccctccc	cgtcagaggg	ctctttgtcc	tctggaggca	tggaccaagg	5340
aagtgatgcc	ccagcgaggg	actttgacgg	agaggactct	gactctccga	ggcattccac	5400
agcttccaac	agttccaacc	taagcagccc	cccaagccca	gtttcaccce	gaaaaaccaa	5460
gagcctctcc	ctggagagca	ctgaccgcgg	gagctgggac	ccgtgagctg	cctcagcact	5520
gggacctctc	gctctccgct	ccctgccact	cgcctcctct	cactttcatc	tcttccctcc	5580
acctcgctg	ctcggcctga	aagccaccag	gggctggcag	cagtagcagg	acagggattc	5640
aggagttctg	acgacacgac	tctcagatcc	acgccccagc	taacagcaaa	acaa	5694

<210> 27

<211> 3520

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7481495CB1

<400> 27

```
cggggcccga gggcgcccc gggcgcccc ggggggtctc ccccatggtg cagcgggggtt 60
cgggatgtcg aagacgctga agaagaagaa gcactggctc agcaagggtgc aggagtgcgc 120
cgtgtccttg gccgggcccc cgggcgactt cggcgcgagg atcccgggtg gcgcggagcg 180
tggcgagttc ccctacctgg gggcggtccg cgaggagccc ggcgggggca cctgctacgt 240
cgtctcgggc aaggcgccca gcccaggcga tgtgctgctg gaggtaaacg ggacgcctgt 300
cagcgggctc accaaccggg acaccctggc tgtcatccgc cacttccgcg agcccatccg 360
tctcaagact gtgaaaccag gcaaagtcac taataaagat ttgcggcatt acctaagtct 420
tcagtttcaa aaaggatcaa ttgaccacaa actgcagcaa gtgatcagag ataattctta 480
cttgagaacc attccatgca ctacaagggc ccccagggat ggagaagtac caggagtggg 540
ttataatttc atttccgttg aacagttcaa agcactggaa gagagtggag cattgttaga 600
aagtgggaca tatgatggaa acttctatgg aactcccaag cctccagcag aaccagccc 660
ttttcagcca gatccagttg atcaagtcct ctttgataat gagtttgatg cagaatctca 720
aagaaaacga acgacatctg tcagcaagat ggaaagaatg gatagctctc ttcctgaaga 780
ggaagaagat gaggacaagg aagctattaa tggcagtggg aacgcagaaa acagagagag 840
gcattctgag tcactctgact ggatgaagac tgttccaagt tacaaccaa ccaatagctc 900
catggacttt agaaattata tgatgagaga tgagactctg gaaccactgc caaaaactg 960
ggaaatggcc tacactgaca cagggatgat ctacttcatt gaccacaata ccaagacaac 1020
cacctggttg gatcctcgtc tttgtaagaa agccaaagcc cctgaagact gtgaagatgg 1080
agagcttctt tatggctggg agaaaataga ggacctcag tatgggacat actatgttga 1140
tcaccttaac cagaaaaccc agtttgaaaa tccagtggag gaagccaaaa ggaaaaagca 1200
gttaggacag gttgaaattg ggtcttcaaa accagatatg gaaaaatcac acttcacaag 1260
agatccatcc cagcttaaaag gtgtccttgt tcgagcatca ctgaaaaaaa gcacaatggg 1320
atltggtttt actattattg gtggagatag acctgatgag ttcctacaag tgaaaaatgt 1380
gctgaaagat ggtcccgag ctcaggatgg gaaaattgca ccaggcgatg ttattgtaga 1440
catcaatggc aactgtgtcc tcggtcacac tcatgcagat gttgtccaga tgtttcaatt 1500
ggtacctgtc aatcagtatg taaacctcac tttatgtcgt ggttatccac ttcctgatga 1560
cagtgaagat cctgttggtg acattgttgc tgctaccctc gtcattcaatg gacagtcatt 1620
aaccaagggg gagacttgca tgaatcctca ggattttaag ccaggagcaa tggttcttga 1680
gcagaatgga aaatcgggac acactttgac tgggtgatggc ctcaatggac catcagatgc 1740
aagtgagcag agagtatcca tggcatcgtc aggcagctcc cagcctgaac tagtgactat 1800
ccctttgatt aagggcccta aagggttttg gtttgcaatt gctgacagcc ctactggaca 1860
gaagggtgaa atgatactgg atagtcagtg gtgtcaaggc cttcagaaaag gagatataat 1920
taaggaaata taccatcaaa atgtgcagaa tttaacacat ctccaagtgg tagagggtct 1980
aaagcagttt ccagtaggtg ctgatgtacc attgtttatc ttaagaggag gtcctccttc 2040
accaaccaa actgccaaaa tgaaaacaga taaaaggaa aatgcaggaa gtttgaggc 2100
cataaatgag cctattcttc agcctatgcc tttccaccg agcattatca ggtcaggatc 2160
ccaaaattg gatccttctg aggtctacct gaaatctaag acttttatatg aagataaacc 2220
accaaacacc aaagatttgg atgtttttct tcgaaaacaa gagtccagggt ttggcttcag 2280
ggtgctagga ggagatggac ctgaccagtc tatatatatt ggggctatta ttcccctggg 2340
agcagctgag aaagatggtc ggctccgcgc agctgatgaa ctaatgtgca ttgatggaat 2400
tctgttaaaa gggaaatcac acaacaagt cttggacctc atgacaactg ctgctcgaaa 2460
tggccatgtg ttactaactg tcagacggaa gatcttctat ggagaaaaac aaccggagga 2520
cgacagctct caggccttca tttcaacgca gaatggatct ccccgctga accgggcaga 2580
ggtcccagcc aggcctgcac cccaggagcc ctatgatgtt gtcttgcaac gaaaagaaaa 2640
tgaaggattt ggctttgtca tcttcacctc caaaaacaaa ccacctccag gagttattcc 2700
tcataaaatt ggccgagtc tagaaggaag tccggctgac cgctgtggaa aactgaaagt 2760
tggagatcat atctctgcag tgaatgggca gtccattgtt gaactgtctc atgataacat 2820
tgttcagctg atcaaagatg ctggtgtcac cgtcacacta acggtcattg ctgaagaaga 2880
gcatcatggt ccaccatcag gaacaaactc agccaggcaa agcccagccc tgcagcacag 2940
```



```

gccccatggga cagtcacagg ccaaccacat acctggggac agaagtgtccc tagaaggtga 3000
aatttgaaaa gatgtctcca cttcttacag acattcttgg tcagaccaca agcaccttgc 3060
acagcctgac accgcagtaa tttcagttgt aggcagtcgg cacaatcaga accttggttg 3120
ttatccagta gagctggaga gaggcccccg gggctttgga ttcagcctcc gaggggggaa 3180
ggagtacaac atggggctgt tcatccttcg tcttgctgaa gatggtcctg ccatcaaaga 3240
tggcagaatt catgttgggtg accagattgt tgaaatcaat ggggaacctc cacaaggaat 3300
cacacatact cgagcaattg agctcattca ggctgggtgga aataaagttc ttcttctttt 3360
gaggccaggga actggcttga tacctgacca tgggttgggt ccttccgggtc tgtgctccta 3420
cgtgaaaccc gagcaacatt aaggctttca gggcttttct tggcttttcc ttaaaaagac 3480
ttggtaaatt tgcattgtct gtaaatactt ttcttctttt 3520

```

<210> 28

<211> 1988

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 55053189CB1

<400> 28

```

acagcaatga cttgttcttg gttcaaagca cgatttagca aagctgtaca aactgttgag 60
tctactccac cactgagtaa aacaaaaact tttgacgtgc ctactctctc tttgatctct 120
cgaatacact caagtctctc gttctgcacg gtgaagggtc cactgcatcc agctatatca 180
taaaggaaat tcttcagtat tacttttcca tttctgtaa ggccaacttc aggggtggaac 240
tgtgctccat ataacttttt agattcattt gctatgacct ctggccgcca tgtgcaccgt 300
agtggaccct cgcattgtcc ggagatacct actcaggcgg cagctcgggc agggggccca 360
tggcattgtg tgggaaggcag tggaccggag gactgggtgag gtcgtggcca tcaagaaaat 420
ctttgatgct tttagggata agacagatgc ccagagaaca ttccgggaaa tcacgctcct 480
ccaggagttt ggggaccatc ccaacatcat cagcctcctt gacgtgatcc gggcagagaa 540
cgacagggac atttacctgg tgtttgagtt tatggacact gacctgaacg cagtcatecg 600
gaagggcggc ctgctgcagg acgtccacgt gcgtccatc ttctaccagc tctgcgggc 660
cacccggttc ctccactcgg ggcacgttgt gcaccgggac cagaagccgt ccaatgtgct 720
cctggatgcc aactgcacag tgaagctgtg tgactttggc ctggcccgtt ccctgggcga 780
cctccctgag gggcctgagg accaggccgt gacagagtac gtggccacac gctggtaccg 840
agcaccggag gtgctgctct cttcgcaccg atacaccctt ggggtggaca tgtggagtct 900
gggctgtatc ctgggggaga tgctgcgggg gagaccctt ttccccggca cgtccaccct 960
ccaccagctg gagctgatcc tggagaccat cccaccgcca tctgaggagg acctcctggc 1020
tctcggtcca ggctgcggtg cctctgtgct gcaccagctg ggggtccggc caccagagac 1080
gctggatgcc ctctaccgc cagacacctc ccagaggcc ttggacctcc ttaggcgact 1140
cctggtgttc gccccggaca agcggttaag cgcgaccag atgaccttg agtgtggagg 1200
cagcagcggc acctcgagag agaagggtgc ggagggtgtc tccccagcc aggcacacct 1260
gcacaaaccc agagccgacc ctacagctgc ttctaggaca cctgtgcagg gtcccagacc 1320
caggccccag agcagcccag gccatgaccc tgccaggcac gagtcccccc gtgcagccaa 1380
gaacgttccc aggcagaact ccgctccccct gctccaaact gctctcctag ggaatgggga 1440
aaggccccct ggggcgaagg aagcgcccc cttgacactc tcgctggtga agccaagcgg 1500
gaggggagct gcgcctctcc tgacctccca ggctgcggct cagggtggca accaggccct 1560
gatccggggt gactggaacc ggggcggtgg ggtgagggtg gccagcgtac aacaggctcc 1620
tccccggctt cctccggagg cccggccccg ccggaggatg ttcagcacct ctgccttgca 1680
gggtgcccag gggggtgcca gggctttgct tggaggctac tccaagcct acgggactgt 1740
ctgccactcg gcactgggac acctgcccct gctggagggg caccatgtgt gagccgccct 1800
actcccttca cctggccctc tgttctctgc ccagccctt cccagaccc ctctccagtc 1860
tcttgacccc cttagccctc cctgctttgc ctggcccggt gaagttccag ggagcttgcc 1920
cgggtctcct cgggggagca gatgaggggc ctgccccgc cccactgact tctccaata 1980
aagtcate
1988

```

<210> 29
 <211> 1822
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7474797CB1

<400> 29
 caagggtggtg actgagggga acaaaaccaa gaaaggtgga ctaagggagt tacccaacgt 60
 gggagggccc tcggggaaag agagaagttc ccaaggcaac aatgttccgt gtttggtttt 120
 ttttgagagc ggagtcctgc tctggtcgcc caggcctggg agtgcagtgg cgggatctcg 180
 gctcactgca agctctgcct cccaggttca cgccattctc ctgcctcagc ctccccaagt 240
 agctggggac tacaggcgcc cgccactacg cccggctaatt tttttgtatt tttagtagag 300
 acgggggtttc accgttttag cggggatggt ctcgatctcc tgacctcgtg atccgccccg 360
 ctcggcctcc caaagtgctg ggattacagg cgtgagccac cgcgcccggc cgcacttcat 420
 tctcaagttt tgtggccaac gatggatagg aggtggattg tgatgtattc ggaacatggg 480
 accttgagga gtccgtaac caaaaggaga aagtaacaac agccagtgga gacaaaaaga 540
 actgcttctc tttctttccc cctccaagtt cctagtggag ggctgagtc agcatcccag 600
 actcgtgtga ctatataggc aagcatttgg ggacctactt cactttgata ccctagcctt 660
 cagcagctca aggtgttggc ctttggatag gaggttcca agtagtaaag ctccctgctc 720
 tcagcaagcc caacaccatg gggaaggag atgtcttaga ggcagcacca accaccacag 780
 cctaccattc cctcatggat gaatatggtt atgaggtggg caaggccatt ggccatggct 840
 cctatgggtc ggtatatgag gctttctaca caaagcagaa ggttatggtg gcagtaaga 900
 tcctctcaaa gaagaaggcc tctgatgact atcttaacaa gttcctgccc cgtgaaatac 960
 aggtaatgaa agtcttgccg cacaagtacc tcatcaactt ctatcgggcc attgagagca 1020
 catctcgagt atacatcatt ctggaactgg ctcagggtgg tgatgtcctt gaatggatcc 1080
 agcgctacgg ggctgctct gagcccttg ctggcaagtg gttctcccag ctgacctgg 1140
 gcattgcta cctgcacagc aagagcatcg tgcaccggga cttaaagttg gagaacctgt 1200
 tgctggacaa gtgggagaat gtgaagatat cagactttgg ctttgccaag atggtgcctt 1260
 ctaaccagcc tgtgggttgt agcccttctt accgccaagt gaactgcttt tcccacctca 1320
 gccagactta ctgtggcagc tttgcttacg cttgccaga gatcttacga ggcttgccct 1380
 acaacccttt cctgtctgac acctggagca tgggcgtcat cctttacact ctagtggctg 1440
 cccatctgcc ctttgatgac accaatctca aaaagctgct aagagagact cagaaggagg 1500
 tcactttccc agctaaccat accatctccc aggagtgcga gaacctgatc ctccagatgg 1560
 tacgccaagc ccctaagggg gcccccttt tggacatcat caaggatttc tgggggggtca 1620
 agttccagcc tgagcaaccc ccccatgaga tcaggctgct tgaggccatg tgccagctcc 1680
 ccaaccccc taaacagccc caatccttgc aaatttcgcc ctgaaaatgg ctgagggagg 1740
 ggggtaaaaa aggagcaaaa caggaggttt tgggctaata atctttttta ccaaaaataa 1800
 atttaagttt gatttagttt cc 1822

<210> 30
 <211> 1814
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 3296272CB1

<400> 30
 ggggcctcgc cgcgcgcca gccacctccg gagtcgccgc ctctgctctc agtgccccgg 60
 atcggaggcc gtccatcgcc cctcgggccg acgcatgaa gatcaaagat gccaagaaac 120
 cctctttccc atggtttggc atggacattg ggggaactct agtaaagctc tcgtactttg 180
 aacctattga tatcacagca gaggaagagc aagaagaagt tgagagttaa aaaagtattc 240

```

ggaaatattt gacttctaac gtggcatatg gatccaccgg cattcgggat gtacaccttg 300
aactgaaaga ttttaacactt tttggccgaa gaggggaactt gcactttatc aggtttccaa 360
cccaggacct gcctactttt atccaaatgg gaagagataa aaactttctca acattgcaga 420
cgggtgctatg tgctacagga ggtggtgctt acaagtttga aaaagatttt cgcaaatg 480
gaaacctcca cctgcacaaa ctggatgaac ttgactgcct tgtaaagggc ttgctgtata 540
tagactctgt cagtttcaat ggacaagccg agtgctatta ttttgctaact gcctcagaac 600
ctgagcgatg ccaaaaagatg ccttttaacc tggatgatcc ctatccactg cttgtagtga 660
acattggctc aggagtcagt attttagcag tccattccaa agacaactat aaacgagtga 720
ctgggacaag tcttgagggg ggtacctata ctgggtttat gcagttattg actggctgtg 780
aaagttttga agaggctctt gaaatggcat ccaaagggtga tagcacacaa gctgacaagc 840
tggtccgtga tatttatgga ggagattatg aaagatttgg tttgccaggt tgggctgtag 900
catctagttt tgggaatatg atttataagg agaagcgaga atctgttagt aaagaagatc 960
tggcaagagc tacttttagt actatcacca ataacattgg ttctgtggca cgaatgtgtg 1020
ctgttaatga gaaaataaac agagttgtct ttgttggaaa ctttttacgt gtcaataacc 1080
tctcaatgaa acttttggca tatgcactgg attactggctc aaaagggtcaa ctaaaagcat 1140
tgtttctaga acatgagggg tactttggag cagttgggtgc acttcttggg ctgccaaatt 1200
tcagctaaag catcaggtct ctctctctgc taataaatgt catccaagag gaactaaaac 1260
cagaggcatt attactgcat tgtttgtcac tgggaaccaa aggataaaaag agtagcataa 1320
gctgctgaat gttgccatat taaaggagag aacttggtaa cgtgaagtat ttctcattga 1380
aatgctttcc cttttgtata tagccagtggt taaatcctta aatgcaatac agcctctgat 1440
tattgagctt cctcttaaaa agattttttt attttatgta gccaacattg cagtactgta 1500
tgctcaaaaa caaatcttaa agtatcggaa ctgttttagct tatgaaaata atcgactctg 1560
aatatttgtt acaagtctgt tttatgtgtt ttgattacta gtgagcagaa aataacatac 1620
cctgtattca aaattactga aatggcaatc aaagatgatc atttttatgt gatttttagaa 1680
atgttaaggc aatactacta attattgtag gtttttttaa cgtatcaccc aaagcatgta 1740
tgtgatcttt ccccatagat atctttttct caaatgccat aattaactga aatactatta 1800
ttaaatattg taga 1814

```

<210> 31

<211> 4381

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1989319CB1

<400> 31

```

atggcggcgg cggcggcgag cggagctggc ggggctgccg gggccgggac tgggggagcc 60
gggcccgcgg gccgcctgct gcctccgccc gcgcgggggt cccagccgc ccccgctgcc 120
gtgtcccttg cggcgggcca gccgcgtccc ccagcccggg cctccgcggg acccatgccc 180
gccggtatcg gctactacga gatcgaccgc accatcggca agggcaactt cgcgggtggc 240
aagcgggcca cgcacctcgt caccaaggcc aaggttgcta tcaagatcat agataagacc 300
cagctggatg aagaaaactt gaagaagatt ttccgggaag ttcaaattat gaagatgctt 360
tgccaccccc atatcatcag gctctaccag gttatggaga cagaacggat gatttatctg 420
gtgacagaat atgctagtgg aggggaaata tttgaccacc tgggtggcca tggtagaatg 480
gcagaaaagg aggcacgtcg gaagttcaaa cagatcgtca cagctgtcta tttttgtcac 540
tgtcggaaaca ttgttcatcg tgatttaaaa gctgaaaatt tacttctgga tgccaatctg 600
aatatcaaaa tagcagattt tggtttcagt aacctcttca ctctgggca gctgtgaag 660
acctgggtgtg gcagccctcc ctatgctgca cctgaactct ttgaaggaaa agaatatgat 720
gggcccacaa tggacatctg gagccttggg gttgtcctct acgtgcttgt gtgcggtgcc 780
ctgccatttg atggaagcac actgcagaat ctgcgggccc gcgtgctgag tggaaagttc 840
cgcaccccat tttttatgtc cacagaatgt gagcatttga tccgccatat gttggtgtta 900
gatcccaata agcgcctctc catggagcag atctgcaagc acaagtggat gaagctaggg 960
gacgccgatc ccaactttga caggttaata gctgaatgcc aacaactaaa ggaagaaaga 1020
cagggtggacc ccctgaatga ggatgtcctc ttggccatgg aggacatggg actggacaaa 1080

```

gaacagacac tgcagtcatt aagatcagat gcctatgatc actatagtgc aatctacagc 1140
 ctgctgtgtg atcgacataa gagacataaa accctgcgtc tcggagcact tcctagcatg 1200
 ccccgagccc tggcctttca agcaccagtc aatatccagg cggagcaggc aggtactgct 1260
 atgaacatca gcgttcccca ggtgcagctg atcaaccagg agaaccaaat tgtggagccg 1320
 gatgggacac tgaatttggg cagtgatgag ggtgaagagc cttccctga agcattggtg 1380
 cgctatttgt caatgaggag gcacacagtg ggtgtggctg acccacgcac ggaagtattg 1440
 gaagatctgc agaagctcct acctggcttt cctggagtca acccccaggc tccattcctg 1500
 caggtggccc ctaatgtgaa cttcatgcac aacctgttgc ctatgcaaaa cttgcaacca 1560
 accgggcaac ttgagtacaa ggagcagtc ctctacagc cgccacgct acagctgttg 1620
 aatggaatgg gcccccttgg ccggagggca tcagatggag gagccaacat ccaactgcat 1680
 gccagcagc tgcgtgaagcg ccacgggga cctctccgc ttgtcaccat gacaccagca 1740
 gtgccagcag ttacccctgt ggacgaggag agctcagacg gggagccaga ccaggaagct 1800
 gtgcagaggt acttggcaaa taggtccaaa agacatacac tggccatgac caaccctaca 1860
 gctgagatcc caccggacct acaacggcag ctaggacagc agcctttccg tccccgggtc 1920
 tggcctcctc acctggtacc tgatcagcat cgctctacct acaaggactc caacactctg 1980
 cacctcccta cggagcggtt ctcccctgtg cgccggttct cagatggggc tgcgagcatc 2040
 caggccttca aagctcacct ggaaaaaatg ggcaacaaca gcagcatcaa acagctgcag 2100
 caggagtgtg agcagctgca gaagatgtac ggggggcaga ttgatgaaag aacctggag 2160
 aagaccagc agcagcatat gttataccag caggagcagc accatcaaat tctccagcaa 2220
 caaattcaag actctatctg tctcctcag ccctctccac ctcttcaggc tgcagtgtgaa 2280
 aatcagccag cctcctttac ccctcagctc cagagggtta ggattcagcc ttcaagccca 2340
 ccccccaacc accccaacaa ccctctcttc aggcagccca gtaatagtcc tcccccatg 2400
 agcagtgcga tgatccagcc tcacggggct gcctctctt cccagtttca aggtttacct 2460
 tcccgcagtg caatctttca gcagcaacct gagaactgtt cctctctcc caacgtggca 2520
 ttaacctgct tgggtatgca gcagcctgct cagtcacagc aggtcaccat ccaagtccaa 2580
 gagcctgtt acatgctcag caacatgcc aagcagctg ggcacagctg caggctccag tgggcgggc 2640
 atctccatca gcccagtgct tggtcagatg cagatgcagc accgtaccaa cctgatggcc 2700
 accctcagct atgggcaccg tcccttgtcc aagcagctga gtgctgacag tgcagaggct 2760
 cacagcttga acgtgaatcg gttctccct gctaactacg accaggcgca ttacacccc 2820
 catctgtttt cggaccagtc ccgggggttc cccagcagct acagcccttc aacaggagtg 2880
 ggggttctct caacccaagc cctgaaagtc cctccacttg accaattccc cacttccct 2940
 cccagtgcac atcagcagcc gccacactat accacgtcgg cactacagca ggccctgctg 3000
 tctccacgc cgcagacta tacaagacac cagcaggtac cccacatcct tcaaggactg 3060
 ctttctcccc ggcattcgct caccggccac tcggacatcc ggctgcccc aacagagttt 3120
 gcacagctca ttaaaggca gcagcaacaa cggcagcagc agcagcaaca gcagcaacag 3180
 caagaatacc aggaactgtt caggcacatg aaccaagggg atgcggggag tctggctccc 3240
 agccttgggg gacagagcat gacagagcgc caggctttat cttatcaaaa tgcgtactct 3300
 tatcaccatc acaccagccc ccagcatctg ctacaaatca gggcacaaga atgtgtctca 3360
 caggcttct caccaccccc gcccacggg tatgctcacc agccggcact gatgcattca 3420
 gagagcatgg aggaggactg ctctgtgtgag ggggccaagg atggcttcca agacagtaag 3480
 agttcaagta cattgaccaa aggttgccat gacagccctc tgctcttgag taccggtgga 3540
 cctggggacc ctgaatcttt gctaggaact gtgagtcag cccaagaatt ggggatacat 3600
 ccctatgggt atcagccaac tgctgcattc agtaaaaata aggtgccag cagagagcct 3660
 gtcataggga actgcatgga tagaagttct ccaggacaag cagtggagct gccggtcac 3720
 aatgggctcg ggtacccagc acgcccctcc gtccatgagc accacaggcc cggggccctc 3780
 cagagacacc acacgatcca gaacagcgac gatgcttatg tacagctgga taacttgcca 3840
 ggaatgagtc tcgtggctgg gaaagcactt agctctgccc ggatgttggg tgcagttctc 3900
 agtcagtctt cgctcatggg cagccagcag tttcaggatg gggaaaatga ggaatgtggg 3960
 gcaagcctgg gaggtcatga gcaccagac ctgagtgatg gcagccagca tttaaactcc 4020
 tcttgctatc catctacgtg tattacagac attctgtctc gctacaagca cccgaagtc 4080
 tcttcagca tggagcaggc aggcgtgtaa caagaacag agagttttgt gtacagcttg 4140
 ggaatgaaaa ggttgattgt aaaccacag tatctagcag cgttggtgca aattgccctt 4200
 gtgtttctct ccacccaaaa tatcacagct gctttctcct ctttgggttc atccgtgtgc 4260
 tgttcttttg ggttctgaga gggttttgcc atgtttgctt gtatgaccaa gtcaccaagg 4320
 aaataaacag gaaggaaatc catgttctcc atcttttgtg aaagtatatt tgagttgggtg 4380
 g 4381

<210> 32
<211> 7862
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 079284CB1

<400> 32
atccccacaga cagcgcctttg agcagaacgc acggctcaac tcatgtaatt actgtttata 60
gctggccgag cctgactagg agagggcaga cccgagaggg aatcagtttc cccgaccttt 120
gagaggaggg tgtgtgttaa ttaaaggcta ggacgggacg ggtactttctc agacatgctc 180
caagttgttc ttgagatcac agttcccatc acattttctc tggagggagt gagtagataa 240
ttgggatttt ttttttattt ttggccttgt ctttcttctc tttttttacc tctccccatt 300
ttagtcatat ggccttgaac ccacagtga tgaagagag aaagaaatgg gtatgtctga 360
ccccaatttt tggactgtgc tctcaactt tactttgcct catttgagga gtgggaacag 420
gcttcggcga acacaaagt gccaacaag caaccgaaa agcttaatag gcaatgggca 480
gtcaccagca ttgcctcgac cacactcacc tctctctgct catgcaggaa atagccctca 540
agatagtcca agaaatttct ccccagtg ctcagcccat ttttcatttg cacggaggac 600
tgatggacgc cgctggctgt tggcttctct ccttctctc ggctatggga caaacacacc 660
cagctctacg gtctcttcat cctgttctc ccaggagaag ttgcatcagt taccatacca 720
accaacacca gacgagttac acttcttctc aaaacatttc tgtaccaccg aaagcatcgc 780
cactgagaac agatgcagga acacgccgat gcgccccgt tcccgaagtc tgagccctgg 840
acgttctccc gcctgctgtg accatgaaat aattatgatg aaccatgtct acaaagaaag 900
gttcccaaag gctacagctc agatggaaga acgtctaaag gaaattatca ccagctactc 960
tctgacaac gttctaccct tagcagatgg agtgcttagt ttcactcacc accagattat 1020
tgaactggct cgagattgct tggataaatc ccaccagggc ctcatcacct cagcatactt 1080
ccttgaatta cagcacaaat tagataagtt gctacaggag gctcatgatc gttcagaaag 1140
tggagaattg gcatttatta aacaactagt tcgaaagatc ctaattgtta ttgcccgc 1200
tgctcgggta ttagagtgcc tgggaatttg tccggaagaa ttttactacc tattggaagc 1260
agcagaaggc catgccaaag aaggacaggg tattaaaacc gacattccca ggtacatcat 1320
tagccaactg ggactcaata aggatccctt ggaagaaatg gctcatttgg gaaactacga 1380
tagtgggaca gcagaaacac cagaaacaga tgaatcagtg agtagctcta atgcctccct 1440
gaaacttoga aggaaacctc gggaaagtga ttttgaaacg attaaattga ttagcaatgg 1500
agcctatggg gcagtctact ttgttcggca taaagaatcc cggcagaggt ttgccatgaa 1560
gaagattaat aaacagaacc tcatccttcg aaaccagatc cagcaggcct ttgtggagcg 1620
ggatatectg acttttgcag aaaaccctt tgttgcagc atgtattgct ctttgaac 1680
aaggcgccac ttgtgcatgg tcatggaata tgtggaaggg ggagactgtg ctactttaat 1740
gaaaaacatg ggctctctcc ctgttgatat ggccagaatg tactttgctg agacggtctt 1800
ggccttggaa tatttacata attatggaat tgtacacagg gatttgaaac cagacaactt 1860
gttggttacc tccatggggc acataaagct gacagatttt ggattatcta aggtgggact 1920
aatgagcatg actaccaacc tttacgaggg tcatattgag aaggatgcta gagagttcct 1980
ggataaacag gtctgtggca cacctgaata cattgcacca gaagtgattc tgaggcaggg 2040
ttatggaaag ccggtggact ggtgggcat ggggattatc ctctatgaat ttctggttg 2100
atgctgcca ttctttggg atactccaga ggagctattt ggacaagtca tcagtgatga 2160
gatcaactgg cctgagaagg atgaggcacc cccactgat gcccaggatc tgattacctt 2220
actcctcagg cagaatccc tggagaggct gggaaacaggt ggtgcatatg aagtcaaaca 2280
gcatcgattc ttccgttctt tagactggaa cagtttgctg agacagaagg cagaatttat 2340
tccccactg gaatctgagg atgacacaag ttattttgat actcggctctg agaagtatca 2400
tcatatggaa acggaggaag aagatgacac aaatgatgaa gactttaatg tggaaataag 2460
gcagttttct tcatgttcac acaggttttc aaaagttttc agcagtatag atcgaatcac 2520
tcagaattca gcagaagaga aggaagactc tgtggacaaa accaaaagca ccacctgcc 2580
atccacagaa acactgagct ggagttcaga atattctgaa atgcaacagc tatcaacatc 2640
caactcttca gatactgaaa gcaacagaca taaactcagt tctggcctac ttcccaact 2700
ggctatttca acagagggag agcaagatga agctgcctcc tggcctggag acccccatga 2760

ggagccagga	aagccagccc	ttcctcctga	agagtgtgcc	caggaggagc	ctgagggtcac	2820
caccccagcc	agcaccatca	gcagctccac	cctgtcagtt	ggcagttttt	cagagcactt	2880
ggatcagata	aatggacgaa	gcgagtgtgt	ggacagtaca	gataattcct	caaagccatc	2940
cagtgaaccc	gcttctcaca	tggctcggca	gcgattagaa	agcacagaaa	aaaagaaaat	3000
ctcggggaaa	gtcacaaaagt	ccctctctgc	cagtgtctct	tccctcatga	tcccaggaga	3060
tatgtttgtc	gtttcccttc	tgggaagtcc	aatgtctccc	cattccctgt	cctcggaccc	3120
ttcttcttca	cgagattcct	ctcccagccg	agattcctca	gcagcttctg	ccagtccaca	3180
tcagccgatt	gtgatccaca	gttcggggaa	gaactacggc	tttaccatcc	gagccatccg	3240
ggtgtatgtg	ggagacagtg	acatctatac	agtgcaccat	atcgtctgga	atgtagaaga	3300
aggaagtccg	gcatgccagg	caggactgaa	ggctggagat	cttaccatcc	ccatcaatgg	3360
agaaccagtg	catggacttg	tccacacaga	agttatagaa	ctcctactga	agagtgggaa	3420
taagggtgtca	atcactacta	ccccatttga	aaacacatca	atcaaaactg	gaccagccag	3480
gagaaacagc	tataagagcc	ggatggtgag	gcggagcaag	aaatccaaga	agaaagaaag	3540
tctcgaaagg	aggagatctc	ttttcaaaaa	gctagccaag	cagccttctc	ctttactcca	3600
caccagccga	agtttctcct	gcttgaacag	atccctgtca	tcgggtgaga	gcctcccagg	3660
ttccccact	catagcttgt	ctccccggtc	tccaacacca	agctaccgct	ccaccctga	3720
cttcccatct	ggtactaatt	cctcccagag	cagctccctt	agttctagt	cccccaattc	3780
cccagcaggg	tccgggcaca	tccggcccag	cactctccac	ggtcttgcac	ccaaactcgg	3840
cgggcagcgg	taccggtccg	gaaggcgaaa	gtccgcgggc	aacatcccac	tgtccccgct	3900
ggcccggacg	ccctctccaa	ccccgcaacc	cacctccccg	cagcggtcac	catcccctct	3960
tctggggacac	tcactgggca	attccaagat	cgcgcaagcc	tttcccagca	agatgcactc	4020
cccgccacc	atcgtcagac	acatcgtgag	gcccaagagt	gcggagcccc	ccagggtcccc	4080
gctgtcaag	cgcgtgcagt	ccgaggagaa	gctgtcggcc	tcttacggca	gtgacaagaa	4140
gcacctgtgc	tcccgcaagc	acagcctgga	ggtgacccaa	gaggaggtgc	agcgggagca	4200
gtcccagcgg	gaggcgccgc	tgcagagcct	ggatgagaac	gtgtgcgacg	tgccgcgct	4260
cagccgcgcc	cggccagtgg	agcaaggctg	cctgaaacgc	ccagtctccc	ggaagggtggg	4320
ccgcccaggag	tctgtggacg	acctggaccg	cgacaagctg	aaggccaagg	tgggtggtgaa	4380
gaaagcagac	ggcttcccag	agaaacagga	atcccaccag	aaatcccattg	gaccgcgggag	4440
tgatttgga	aacttttgctc	tgtttaagct	ggaagagaga	gagaagaaag	tctatccgaa	4500
ggctgtggaa	aggtcaagta	cttttgaaaa	caaagcgtct	atgcaggagg	cgccaccgct	4560
gggcagcctg	ctgaaggatg	ctcttcacaa	gcaggccagc	gtgcgcgcca	gcgaggtgtgc	4620
gatgtcggat	ggcccgggtgc	ctgcggagca	ccgccagggt	ggcggggact	tcagaggggc	4680
ccccgctcct	ggcaccctcc	aggatggtct	ctgccactcc	ctcyacaggg	gcatctcttg	4740
gaagggggaa	ggcacggaga	agtcctccca	ggccaaggag	cttctccgat	gtgaaaagtt	4800
agacagcaag	ctggccaaca	tcgattacct	ccgaaagaaa	atgtcacttg	aggacaaaga	4860
ggacaacctc	tgccctgtgc	tgaagcccaa	gatgacagct	ggctcccacg	aatgcctgcc	4920
agggaaacca	gtccgaccca	cgggtgggca	gcaggagccc	ccgccggctt	ctgagagccg	4980
agcttttgtc	agcagcaccc	atgcagctca	gatgagtgcc	gtctcttttg	ttccccca	5040
ggccttaaca	ggccgggtgg	acagtggaa	ggagaagcct	ggcttggttg	ctcctgagtc	5100
ccctgttagg	aagagccctt	ccgagtataa	gctggaagg	aggtctgtct	catgcctgaa	5160
gccgatcgag	ggcactcttg	acattgctct	cctgtccgga	cctcaggcct	ccaagacaga	5220
actgccttcc	ccagagtctg	cacagagccc	cagcccaagt	ggtgacgtga	gggcctctgt	5280
gccaccagtt	ctccccagca	gcagtgggaa	aaagaacgat	accaccagt	caagagagct	5340
ttctccttcc	agcttaaaga	tgaataaatc	ctacctgctg	gagccttggt	tcctgcccc	5400
cagccgaggt	ctccagaatt	caccagcagt	ttccctgcct	gaccagagt	tcaagaggga	5460
caggaaaggt	ccccatccta	ctgccaggag	ccctggaaca	gtcatggaaa	gcaatcccca	5520
acagagagag	ggcagctccc	ctaaacacca	agaccacacc	actgacccca	agcttctgac	5580
ctgcctgggg	cagaacctcc	acagccctga	cctggccagg	ccacgctgcc	cgctcccacc	5640
tgaagcttcc	ccctcaagg	agaagccagg	cctgagggaa	tcgtctgaaa	gaggccctcc	5700
cacagccaga	agcgagcgct	ctgctgcgag	ggctgacaca	tgcagagagc	cctccatgga	5760
actgtgcttt	ccagaaactg	cgaaaaccag	tgacaactcc	aaaaatctcc	tctctgtggg	5820
aaggacccac	ccagatttct	atacacagac	ccaggccatg	gagaaagcat	ggcgccggg	5880
tgggaaaacg	aaccacaaag	atggcccagg	tgaggcgagg	cccccgccca	gagacaactc	5940
ctctctgcac	tcagctggaa	ttccctgtga	gaaggagctg	ggcaagggtga	ggcgtggcgt	6000
ggaaccaag	cccgaagcgc	ttcttgccag	gcggtctctg	cagccacctg	gaattgagag	6060
tgagaagagt	gaaaagctct	ccagtttccc	atctttgcag	aaagatggtg	ccaaggaacc	6120

```

tgaaaggaag gagcagcctc tacaaaggca tcccagcagc atccctccgc cccctctgac 6180
ggccaaagac ctgtccagcc cggtgccag gcagcattgc agttcccca gccacgcttc 6240
tggcagagag ccggggggcca agcccagcac tgcagagccc agctcgagcc cccaggaccc 6300
tcccagcct gttgctgcgc acagtgaag cagcagccac aagccccggc ctggccctga 6360
cccgggccct ccaaagacta agcaccgcc cgggtccctc tcctctcaga aaccaagtgt 6420
cggggccaca aagggcaaag agcctgccac tcaatccctc ggtggctcta gcagagagg 6480
gaagggccac agtaagagt ggccggatgt gtttcctgct accccaggct cccagaacaa 6540
agccagcgat gggattggcc agggagaagg tgggcccctc gtcccactgc aactgacag 6600
ggctcctcta gacgccaagc cacaaccac cagtgggtgg cggccccctg aggtgctgga 6660
gaagcctgtg catttgccaa ggccgggaca cccagggcct agtgagccag cggaccagaa 6720
actgtccgct gttggtgaaa agcaaaccct gtctccaaag caccccaac catccactgt 6780
gaaagattgc ccacacctgt gcaaacagac agacaacaga cagacagaca aaagccccgag 6840
tcagccggcc gccaacaccg acagaagggc ggaagggaag aaatgcactg aagcacttta 6900
tgctccagca gagggcgaca agctcgaggc cggcctttcc tttgtgcata gcgagaaccg 6960
gttgaaaggc gcggagcggc cagccgcggg ggtggggaag ggcttccctg aggccagagg 7020
gaaaggggcc ggtccccaga agccaccgac ggaggcagac aagcccaatg gcatgaaacg 7080
gtccccctca gccactgggc agagttcttt ccgatccacg gccctcccgg aaaagtctct 7140
gagctgctcc tccagcttcc ctgaaaccag ggccggagtt agagaggcct ctgcagccag 7200
cagcgacacc tcttctgcca aggcgcgcgg gggcatgctg gagcttccag ccccagcaa 7260
cagggaccat aggaaggctc agcctgccgg ggaggggcga acccacatga caaagagtga 7320
ctccctgccc tccttcggg tctccacctt gcctctggag tcacaccacc ccgacccaaa 7380
caccatgggc ggggcccagc accgggacag ggctctctcg gtgactgcca ccgtagggga 7440
aaccaaaggg aaggaccctg cccagccca gcctcccca gctaggaaac agaacgtggg 7500
cagagacgtg accaagccat cccagcccc aaacactgac cgcctcatct ctctttctaa 7560
tgagaaggac tttgtggtac ggcagaggcg ggggaaagag agtttgcgta gcagccctca 7620
caaaaaggcc ttgtaacggg gagggcccag gggcaggact gtggagaccg gtcctgaacg 7680
ggcgactgtg tcttgactac ctttcaaaac cagcactgtg tgggaatgtc cgccaggcag 7740
agctcggagc ctcatgtaga caggggagag agaaagacaa agagggggacc ttcttccaga 7800
tgccctccca gttgtaaccg gtaaaactgt taccagatag tgtttgtaca aaaaaaaaaa 7860
aa

```

<210> 33

<211> 7280

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5502218CB1

<400> 33

```

tcggcgagcg gcggcagtgg gagccgcgtc cgccgcatcc gcctcgactc ggtgccggcc 60
cctggccctc ccctcatgac tgcgggcgct ctgctgccac cgcccgcccg gccgcccgtc 120
gccgcaggat ggatgcggac cgtgcggcgc taacccccgt ggctcagctc ccgaatcgcc 180
cgcttcgag ccctcctcgt gagccgcagc agcctcggtg ccagcccccg ccgcagctgg 240
gcccagcggg ccgcctgtcc ctcgttgcgg ctgtcggtg ctgagtgagg cgtcgtccgg 300
gtcggcgcgga acccgcccgg ccgcggttcc ctgcagacct ctgcgcgggc ggtcggccc 360
ttcacgccct ttctgttcac gaatccgagc ccgctcgctt ctctccagcg aaccgaccat 420
gtctggcggc gccgcagaga agcagagcag cactcccggt tcctgttcc tctcgccgcc 480
ggctcctgcc cccaagaatg gctccagctc cgattcctcc gtgggggaga aactgggagc 540
cgcgcccgcc gagctgtgga ccggcaggac cgaggagtag aggcgcgcgc gccacactat 600
ggacaaggac agccgtgggg cggccgcgac cactaccacc actgagcacc gcttcttccg 660
ccggagcgtc atctgcgact ccaatgccac tgcactggag ctcccgccg ttctctttc 720
cctgccccag cccagcatcc ccgcggctgt cccgcagagt gctccaccgg agccccaccg 780
ggaagagacc gtgaccgcca ccgccacttc ccaggtagcc cagcagcctc cagccgctgc 840
cgccccctggg gaacaggccg tcgcggggcc tgccccctcg actgtcccca gcagtaccag 900

```

caaagaccgc	ccagtgtccc	agcctagcct	tgtggggagc	aaagaggagc	cgccgcgggc	960
gagaagtggc	agcggcgccg	gcagcgccaa	ggagccacag	gaggaacgga	gccagcagca	1020
ggatgatata	gaagagctgg	agaccaaggc	cgtgggaatg	tctaacgatg	gccgctttct	1080
caagtttgac	atcgaaatcg	gcagaggctc	ctttaagacg	gtctacaaag	gtctggacac	1140
tgaaccacc	gtggaagtgc	cctgggtgtg	actgcaggat	cgaaaattaa	caaagtctga	1200
gaggcagaga	tttaaagaag	aagctgaaat	gttaaaagg	cttcagcatc	ccaatattgt	1260
tagattttat	gattcctggg	aatccacagt	aaaaggaaa	aagtgcattg	ttttggtagc	1320
tgaacttatg	acgtctggaa	cacttaaaac	gtatctgaaa	aggtttaaag	tgatgaagat	1380
caaagttcta	agaagctggg	gccgtcagat	ccttaaagg	cttcagtttc	ttcatactcg	1440
aactccacct	atcattcacc	gcgatcttaa	atgtgacaac	atctttatca	ccggccctac	1500
tggtctcagtc	aagattggag	acctcggctc	ggcaaccctg	aagcgggctt	cttttgccaa	1560
gagtgtgata	ggtaccccag	agttcatggc	ccctgagatg	tatgaggaga	aatatgatga	1620
atccgttgac	gtttatgctt	ttgggatgtg	catgcttgag	atggctacat	ctgaatatcc	1680
ttactcggag	tgccaaaatg	ctgcgcagat	ctaccgtcgc	gtgaccagtg	gggtgaagcc	1740
agccagtttt	gacaaagtag	caattcctga	agtgaaggaa	attattgaag	gatgcatacg	1800
acaaaacaaa	gatgaaagat	attccatcaa	agaccttttg	aaccatgcct	tcttccaaga	1860
ggaaacagga	gtacgggtag	aattagcaga	agaagatgat	ggagaaaaaa	tagccataaa	1920
attatggcta	cgtattgaag	atattaagaa	attaaaggga	aaatacaaa	ataatgaagc	1980
tattgagttt	tcttttgatt	tagagagaga	tgtcccagaa	gatgttgcac	aagaaatggt	2040
agagtctggg	tatgtctgtg	aaggtgatca	caagaccatg	gctaaagcta	tcaaagacag	2100
agtatcatta	attaagagga	aacgagagca	gcggcagttg	gtacgggagg	agcaagaaaa	2160
aaaaaagcag	gaagagagca	gtctcaaaca	gcaggtagaa	caatccagtg	cttcccagac	2220
aggaatcaag	cagctccctt	ctgctagcac	cggcatacct	actgcttcta	ccacttcagc	2280
ttcagtttct	acacaagtag	aacctgaaga	acctgaggca	gatcaacatc	aacaactaca	2340
gtaccagcaa	ccagtatata	ctgtgttatc	tgatgggacg	gttgacagtg	gtcagggatc	2400
ctctgtcttc	acagaatctc	gagtgaagca	ccaacagaca	gtttcatatg	gttcccaaca	2460
tgaacaggca	cattctacag	gcacagtcct	agggcatata	ccttctactg	tccaagcata	2520
gtctcagccc	catgggggat	atccaccctc	aagtgtggca	caggggcaga	gccagggtca	2580
gccatectca	agtagcttaa	caggggtttc	atcttcccaa	cccatacaac	atcctcagca	2640
gcagggaata	cagcagacag	cccctcctca	acagacagtg	cagtattcac	tttcacagac	2700
atcaacctcc	agtgaggcca	ctactgcaca	gccagtgaat	caacctcaag	ctccacaagt	2760
cttgccctcaa	gtatcagctg	gaaaacagag	tactcaggga	gtctctcagg	ttgtctctgc	2820
agagccagtt	gcagtagcac	agccccaagc	taccagcccg	accacttttg	cttctctgtt	2880
agacagtgca	cattcagatg	ttgcttcagg	tatgagtgat	ggcaatgaga	acgtcccatc	2940
ttccagtggg	aggcatgaag	gaagaactac	aaaacggcat	taccgaaaat	ctgtaaggag	3000
tcgctctcga	catgaaaaaa	cttcacgccc	aaaattaaga	attttgaaatg	tttcaataaa	3060
aggagaccga	gtagtagaat	gtcaattaga	gactcataat	aggaaaatgg	ttacattcaa	3120
atttgacctt	gatggtgaca	accccgagga	gatagcaaca	attatggtga	acaatgactt	3180
tattctagca	atagagagag	agtcgtttgt	ggatcaagtg	cgagaaatta	ttgaaaaagc	3240
tgatgaaatg	ctcagtggag	atgtcagtgt	ggaaccagag	ggtgatcagg	gattggagag	3300
ttacaaggga	aaggatgact	atggcttttc	aggttctcag	aaattggaag	gagagttcaa	3360
acaaccaatt	cctgcgtctt	ccatgccaca	gcaaataagg	attcctacca	gttctttaac	3420
tcaagttggt	cattctgcgg	gaaggcggtt	tatagtgaat	cctgtgccag	aaagccgatt	3480
acgagaatca	aaagttttcc	ccagtgaat	aacagatata	gttgctgcct	ctacagctca	3540
gagccctgga	atgaacttgt	ctcactctgc	atcatccctt	agtctacaac	aggccttttc	3600
tgaacttaga	cgtgcccaaa	tgacagaagg	acccaataca	gcacctcaa	actttagtca	3660
tacaggacca	acatttccag	tagtacctcc	tttcttaagt	agcattgctg	gagtcccaac	3720
cacagcagca	gccacagcac	cagtccctgc	aacaagcagc	cctcctaagt	acatttccac	3780
atcagtaatt	cagtctgagg	ttacagtgcc	cactgaagag	gggattgctg	gagttgccac	3840
cagcacaggt	gtggttaact	caggtgggtc	ccccatacca	cctgtgtctg	aatcaccagt	3900
actttccagc	gtagtttcaa	gtatcacaat	acctgcagtt	gtctcaatat	ctactacatc	3960
cccgtcactt	caagtcccca	catccacatc	tgagatcggt	gtttctagta	cagcactgta	4020
tccttcagta	acagtttcag	caacttcagc	ctctgcaggg	ggcagtactg	ctaccccagg	4080
tcctaagcct	ccagctgtag	tatctcagca	ggcagcaggc	agcactactg	tgggagccac	4140
attaacatca	gtttctacca	ccacttcatt	cccaagcaca	gcttcacagc	tgtccattca	4200
gcttagcagc	agtacttcta	ctcctacttt	agctgaaacc	gtggtagtta	gcgcacactc	4260


```

actagataag acatctcata gcagtacaac tggattggct ttctccctct ctgcaccatc 4320
ttcctcttcc tctcctggag caggagtgtc tagttatatt tctcagcctg gtgggctgca 4380
tcctttgggtc attccatcag tgatagcttc tactcctatt cttccccaag cagcaggacc 4440
tactttctaca cctttattac cccaagtacc tagtatccca cccttgggtac agcctgtttgc 4500
caatgtgcct gctgtacagc agacactaat tcatagtcag cctcaaccag ctttgcttcc 4560
caaccagccc catactcatt gtctgaagt agattctgat acacaaccca aagctcctgg 4620
aattgatgac ataaagactc tagaagaaaa gctgcggtct ctgttcagtg aacacagctc 4680
atctggagct cagcatgcct ctgtctcact ggagacctca ctagtcatag agagcactgt 4740
cacaccaggc atcccaacta ctgctgttgc accaagcaaa ctctgactt ctaccacaag 4800
tacttgctta ccaccaacca atttaccact aggaacagtt gctttgccag ttaccaccag 4860
ggtcacacct gggcaagttt ctaccccagt cagcactact acatcaggag tgaaacctgg 4920
aactgctccc tccaagccac ctctaactaa ggtcccggtg ctgccagtgg gtactgaact 4980
tccagcaggt actctacca gcgagcagct gccacctttt ccaggacctt ctctaaccaca 5040
gtcccagcaa cctctagagg atcttgatgc tcaattgaga agaacttta gtccagagat 5100
gatcacagtg acttctgctg ttgggtcctgt gtccatggcg gctccaacag caatcacaga 5160
agcaggaaca cagcctcaga aggggtgttt tcaagtcaaa gaaggccctg tcctagcaac 5220
tagttcagga gctgggtgttt ttaagatggg acgatttcag gttttctgtt cagcagacgg 5280
tgcccagaaa gagggtaaaa ataagtcaga agatgcaaag tctgttcatt ttgaatccag 5340
cacctcagag tcctcagtgc tatcaagtag tagtccagag agtaccttgg tgaaaccaga 5400
gccgaatggc ataaccatcc ctggtatctc ttcagatgtg ccagagagtg cccacaaaac 5460
tactgcctca gaggcaaagt cagacactgg gcagcctacc aagggtggac gttttcaggt 5520
gacaactaca gcaaacaaag tgggtcgttt ctctgtatca aaaactgagg acaagatcac 5580
tgacacaaag aaagaaggac cagtggcatc tcctcctttt atggatttgg aacaagctgt 5640
tcttctctgt gtgataccaa agaaagagaa gcctgaactg tcagagcctt cacatctaaa 5700
tgggcccgtc tctgaccggg aggccgcttt ttttaagtagg gatgtggatg atgggtccgg 5760
tagtccacac tcgccccatc agctgagctc aaagagcctt cctagccaga atctaagtca 5820
aagccttagt aattcattta actcctctta catgagtagc gacaatgagt cagatatcga 5880
agatgaagac ttaaagttag agctgcgacg actacgagat aaacatctca aagagattca 5940
ggacctgagc agtcgccaga agcatgaaat tgaatctttg tataccaaac tgggcaaggt 6000
gccccctgct gttattatct cccagctgc tcccccttca gggagaagac gacgaccac 6060
taaaagcaaa ggcagcaaat ctagtcgaag cagttccttg ggggaataaaa gccccagct 6120
ttcaggtaac ctgtctggtc agagtgcagc ttcagtcctg cacccccagc agacctcca 6180
ccctcctggc aacatcccag agtccgggca gaatcagctg ttacagcccc ttaagccatc 6240
tcctccagct gacaacctct attcagcctt caccagtgtg ggtgccattt cagtaccaag 6300
cctttctgct ccaggtaag gaaccagcag cacaacact gttggggcaa cagtgaacag 6360
ccaagccgcc caagctcagc ctctgccc atcagctcagc aggaagggca cattcacaga 6420
tgacttgac aagtgtgtag acaattgggc ccgagatgcc atgaatctct caggcaggag 6480
aggaagcaaa gggcacatga attatgaggg ccctggaatg gcaaggaagt tctctgcacc 6540
tgggcaactg tgcattctca tgacctgaa cctgggtggc tctgccccca tctctgcagc 6600
atcagctacc tctctaggtc acttcaccaa gtctatgtgc cccccacagc agtatggctt 6660
tccagctacc ccatttggtg ctcaatggag tgggacgggt ggcccagcac cacagccact 6720
tggccagttc caacctgtgg gaactgcctc cttgcagaat ttcaacatca gcaatttgca 6780
gaaatccatc agcaaccccc caggctccaa cctgcggacc acttagacct agagacatta 6840
actgaataga tctgggggca ggagatggaa tgctgagggg gtgggtgggg gtgggaagta 6900
gcctatatac taactactag tgctgcattt aactggttat ttcttgccag aggggaatgt 6960
ttttaatact gcattgagcc ctcaaatgg agagtctccc ccgtccagc tattggaatg 7020
ggagaggaag gaaagaacag cttttttgtc aaggggcagc ttcagaccat gctttcctgt 7080
ttatctatac tcagtaatga ggatgagggc taggaaagtc ttgttcataa ggaagctgga 7140
gaactcaatg taaaatcaaa ccatctgta atttcgagt ggtggagctc ttgcttttgg 7200
tacatgcct gaatccctca ctccctcaag aatccgaacc acaggacaaa aaccacctac 7260
tgggctctct cctaccctgc

```

<210> 34
 <211> 1260
 <212> DNA
 <213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 55056054CB1

<400> 34

```

gaagttgtga gctccttctg gaaacatttg cagttacatt aagtaaagtg taaatgcaca 60
tgaatggcag cttatagaga accaccttgt aaccagtata caggtacaac tacagctctt 120
cagaaattgg aagggttttg tagccgggta tttcatagac actctaaagg tactgcacat 180
gatcagaaaa cagctctgga aaatgacagc cttcatttct ctgaacatac tgccttatgg 240
gacagatcaa tgaaagagtt tctagccaaa gccaaagaag acttttttgaa aaaatgggag 300
aatccaactc agaataatgc cggacttgaa gattttgaaa ggaaaaaaac ccttgggaaca 360
ggttcatttg gaagagtcac gttggtaaaa cacaaagcca ctgaacagta ttatgccatg 420
aagatccttag ataagcagaa ggttggttaa ctgaagcaaa tagagcatac tttgaatgag 480
aaaagaatat tacaggcagc gaatttttct ttccttggtc gactggagta tgcttttaag 540
gataattcta atttatacat ggttatggaa tatgtccctg ggggtgaaat gttttcacat 600
ctaagaagaa ttggaagggt cagtgagccc catgcacggg tctatgcagc tcagatagtg 660
ctaacattcg agtacctcca ttcactagac ctcactctaca gagatctaaa acctgaaaat 720
ctcttaattg accatcaagg ctatatccag gtcacagact ttgggtttgc caaaagagtt 780
aaaggcagaa cttggacatt atgtggaact ccagagtatt tggctccaga aataattctc 840
agcaagggtc acaataaggc agtggatttg tgggcattag gagtgctaata ctatgaaatg 900
gcagctggct atccccatt ctttgcagac caaccaattc agatttatga aaagattgtt 960
tctggaaagg tccgattccc atcccacttc agttcagatc tcaaggacct tctacggaac 1020
ctgctgcagg tggatttgac caagagattt ggaaatctaa agaattggtg cagtgatata 1080
aaaactcaca agtggtttgc cagcacagat tggattgcta tttaccagag gaaggttgaa 1140
gtccattca taccaaagtt tagaggctct ggagatacca gcaactttga tgactatgaa 1200
gaagaagata tccgtgtctc tataacagaa aaatgtgcaa aagaatttgg tgaattttaa 1260

```

<210> 35

<211> 3161

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7481989CB1

<400> 35

```

gcggccgggg accgagccgc aaagacagag cgggcagagg cgatggaggg cgacgggggtg 60
ccatggggca gcgagcccgt ctcgggtccc ggcccggcg gcggcggaat gatccgcgag 120
ctgtgccggg gcttcggcgc ctaccgcccg tacctgggac ggctgcgaca gaacctgcgc 180
gagaccaga agttcttccg cgacatcaag tgcctccaca accacacttg tctctcctcc 240
ctcacgggcg gcggcggggc cgagcgcggc cctgcaggcg atgtcgccga aaccgggctg 300
caggcgggcc aactgagctg catttccttc ccacctaagg aagagaagta cctccagcag 360
attgtggact gcctcccttg catactgac ctcggccagg attgtaacgt caagtgccag 420
ctgttgaatc tgctgttggg ggtgcagggt cttcccacca ccaagctggg cagtgaggag 480
agctgtaagc ttcgggcct cgccttcacc tatgggactc agactcgggt cagcctggcg 540
ctccctggac agtatgaact agtgcacacg ctggttgctc atcagggcaa ctgggagacc 600
atccctgagg aggatctgga ggtccaagag aacaatgagg atgtctctca tgttttagcg 660
gaactggagg taacgatgca ccatgctctc ttacaggaag tggacgttgt ggtagacca 720
tgccaaggcc tccggccac agtggatgtt ctgggtgact tggatgaatga tttcttgctc 780
gtgataacct atgactcca caaagatgaa ctctctgaga gggatgagca agagcttcag 840
gaaatccgaa agtatttctc ctttcctgta ttcttttca aagtgccgaa actgggctcg 900
gagataatag actcctcaac caggagaatg gagagcgaaa gatcacgct ttatcgccag 960
ctaattgacc tgggctatct gagcagcagc cactggaact gtggggctcc tggccaggat 1020
actaaagctc agagcatgtt ggtggaacag agtgaaaagc tgagacactt gagcacattt 1080
tctcaccagg tgttacagac tcgcctggtg gatgcagcca aggcctgaa cctggtgcac 1140

```

```

tgccactgcc ttgacatctt tattaaccag gcatttgaca tgcagcggga cctgcagatc 1200
actcccaaac gtctggaata tactcgaaaa aaggagaatg agttgtatga atcattgatg 1260
aatattgcc aaccgaaagca ggaggaaatg aaggatatga ttgttgagac acttaatacc 1320
atgaaggagg aacttctgga tgatgctact aacatggagt ttaaagacgt cattgtccct 1380
gagaatggag aaccagtagg caccagagag atcaaatgct gcatccgaca gatccaggaa 1440
ctcatcatct cccgacttaa tcaggcagtg gctaataagc tgatcagctc agtggattac 1500
ctgagggaaa gcttcgtcgg aaccctggaa cgatgtctgc agagcctgga gaagtctcag 1560
gatgtctcag ttcacatcac cagtaattat ctcaaacaga tcttaaatgc tgcctatcat 1620
gttgaagtca cgtttcactc agggctcgtca gttacaagga tgctatggga gcaaatcaaa 1680
cagatcatcc agcgcacac atgggtgagc ccacctgcca tcaactctgga atggaagagg 1740
aaggtggccc aggaagccat tgagagcctc agcgcctcca aattggctaa gagcatttgc 1800
agccaattcc ggactcggct caatagtctc caccaggctt ttgcagcctc cttgcccagc 1860
ctggaagctg gccactcagg ccggttagag aaaacggaa atctatggct gaggggttcgg 1920
aaagatcatg ctccccgcct ggccccgcct tctctggaaa gccgttcttt acaggatgtc 1980
ttgcttcatc gtaaacctaa actgggacag gaactgggccc ggggccagta tgggtgtgga 2040
tacctgtgtg acaactgggg aggacacttt ccttgtgccc tcaaatcagt tgtccctcca 2100
gatgagaagc actggaatga tctggctttg gaatttcaat atatgaggtc tctgccgaag 2160
catgagcgat tgggtgatct ccattggttca gtcattgact acaactatgg tgggtggctcc 2220
agcattgctg tgctctcat tatggagcgg ctacaccggg atctctacac agggctgaag 2280
gctgggctga ccttgagac acgtttgcag atagcactag atgtggtgga gggaatccgc 2340
ttcctgcaca gccagggact tgtccatcgt gatatacaac tgaaaaatgt gctgctggat 2400
aagcagaacc gtgccaagat cactgactta ggattctgca agccagaggc catgatgtca 2460
ggcagcattg tggggacacc aatccatatt gcccctgaac ttttcacagg gaagtacgat 2520
aattccgtgg atgtctacgc ttttgggaatt cttttctggt atatctgctc aggtctgtc 2580
aagctccctg aggcatttga gaggtgtgct agcaaagacc atctctggaa caatgtgcgg 2640
aggggggctc gcccagaacg tcttcctgtg tttgatgagg agtgctggca gttgatggaa 2700
gcctgttggg atggcgaccc cttgaagagg cctctcttgg gcattgtcca gcccatgctc 2760
cagggcacat tgaatcggct ctgcaagtcc aattctgagc agccaaacag aggactagat 2820
gattctactt gaaagccaag acctttctct ttcactctct agttatttcc tccccctca 2880
ccttttggcc atggggagaa tttgacattt attcactata ggacacactc ccaagggaac 2940
tgggtgcttg tgggaaactt ggaacccttc ccaggcaggg atgactcctg gacagtgaag 3000
agttgaatga ctgagcatat tcagcagctc actgaagcgc ccagctatcc ctttagcaaa 3060
aaagtgtctc agatgtgtaa aagctgagga atgtggtgtt ctggcttcac aaatgaaaag 3120
gaggcagatg ttaccattgt cttttcactg tatatacttc t 3161

```

<210> 36

<211> 3538

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 55052990CB1

<400> 36

```

atggagccct ccagagcgct tctcggctgc ctacgagcgc ccgcccgtgc cggcccgcgc 60
ggggaggatg gagcaggggc cggggccgag gaggaggagg aggaggagga ggaggcggcg 120
gcggcggtgg gcccggggga gctgggctgc gacgcgccgc tgccctactg gacggcctg 180
ttcgagtacg aggcggcggg cgaggacgag ctgaccctgc ggctgggcca cgtgggtggag 240
gtgctgtcca aggactcgca ggtgtccggc gacgagggct ggtggaccgg gcagctgaac 300
cagcgggtgg gcatcttccc cagcaactac gtgacccgc gcagcgcctt ctccagccgc 360
tgccagcccg gcggcgagga cccagttgc taccgcccga ttcagttgtt agaaattgat 420
tttgcgagc tcaccttgga agagattatt ggcacgggg gctttgggaa ggtctatcgt 480
gctttctgga taggggatga ggttgctgtg aaagcagctc gccacgacc tgatgaggac 540
atcagccaga ccatagagaa tgttcgcca gaggccaa tcttcgcat gctgaagcac 600
cccaacatca ttgccctaag aggggtatgt ctgaaggagc ccaacctctg cttgggtcatg 660

```

```

gagtttgtctc gtggaggacc tttgaataga gtgttatctg ggaaaaggat tccccagac 720
atcctgggtga attgggctgt gcagattgcc agagggatga actacttact tgatgaggca 780
attgttccca tcatccaccg cgaccttaag tccagcaaca tattgatcct ccagaagggtg 840
gagaatggag acctgagcaa caagattctg aagatcactg attttggcct ggctcgggaa 900
tggcaccgaa ccaccaagat gagtgcggca gggacgtatg cttggatggc acccgaagtc 960
atccgggcct ccatgttttc caaaggcagt gatgtgtgga gctatggggt gctacttttg 1020
gagttgtctga ctgggtgaggt gccctttcga ggcattgatg gcttagcagt cgcttatgga 1080
gtggccatga acaaactcgc ccttcctatt ccttctacgt gcccagaacc ttttgccaaa 1140
ctcatggaag actgctggaa tctgatccc cactcacgac catctttcac gaatatcctg 1200
gaccagctaa ccaccataga ggagtctggt ttctttgaaa tgcccaagga ctcttccac 1260
tgcttcgagg acaactggaa acacgagatt caggagatgt ttgaccaact cagggccaaa 1320
gaaaaggaaac ttgcacacct ggaggaggag ctgacgcggg ctgcaactgca gcagaagaac 1380
caggaggaaac tgctgcggcg tcgggagcag gagctggccg agcgggagat tgacatcctg 1440
gaacgggagc tcaacatcat catccaccag ctgtgccagg agaagccccg ggtgaagaaa 1500
cgcaagggca agttcaggaa gagccggctg aagctcaagg atggcaaccg catcagcctc 1560
ccttctgatt tccagcaca gttcacgggt caggcctccc ctaccatgga taaaaggaa 1620
agtcttatca acagccgtc cagtcctcct gcaagcccca ccatcattcc tcgccttcga 1680
gccatccagt tgacaccagg tgaaagcagc aaaacctggg gcaggagctc agtcgtccca 1740
aaggaggaa gggaggagga ggagaagagg gccccaaaga agaagggacg gacgtggggg 1800
ccagggacgc ttggtcagaa ggagcttgcc tcgggagatg aaggcctcaa gtccctggta 1860
gatggatata agcagtggtc gtccagtgcc cccaacctgg tgaaggggcc aaggagtagc 1920
ccggccctgc cagggttcac cagccttatg gagatggagg atgaggacag tgaaggccca 1980
gggagtggag agagtgcct acagcattca ccagccagt cctacctctg tatccattc 2040
cctcgtggag aggatggcga tggccctcc agtgatggaa tccatgagga gccacccca 2100
gtcaactcgg ccacagtag cctcagctg acgccaacca acagcctcaa gcggggcggt 2160
gcccaccacc gccgctgcga ggtggctctg ctcggtctgt gggctgttct ggcagccaca 2220
ggcctagggg ttgacttgct ggaagctggc aagtgccagc tgcttcccct ggaggagcct 2280
gagccaccag cccgggagga gaagaaaaga cgggagggtc tttttcagag gtccagccgt 2340
cctcgtcgga gcaccagccc cccatcccga aagcttttca agaaggagga gcccatgctg 2400
ttgctaggag acccctctgc ctccctgacg ctgctctccc tctcctccat ctccgagtgc 2460
aactccacac gctccctgct gcgctccgac agcgatgaaa ttgtcgtgta tgagatgcca 2520
gtcagcccag tcgaggcccc tcccctgagt ccatgtacct acaaccccct ggtcaatgtc 2580
cgagtagagc gcttcaaacg agatcctaac caatctctga ctcccacca tgtcaccctc 2640
accaccccct cgcagcccag cagtcaccgg cggactcctt ctgatggggc ccttaagcca 2700
gagactctcc tagccagcag gagcccctcc agcaatgggt tgagcccag tctggagca 2760
ggtgagtctt ctctctctt tctctttcct ttctttgtgc ctctcaggg aatgttgaa 2820
acccccagtc ccagccgaga ccaggtgaa ttccccgctc tcctgacct caatgtggtc 2880
ttcccccaa cccaaggcg ctggaacact cagcaggact ctaccttga gagaccag 2940
actctggagt ttctgectcg gccgcgtcct tctgccaacc ggcaacggct ggaccttgg 3000
tggtttgtgt ccccagcca tgcccgcagc acctcccag ccaacagctc cagcacagag 3060
acgcccagca acctggactc ctgctttgct agcagtagca gcaactgtag ggagcggcct 3120
ggacttccag cctgctccc gttccaggca gggccgctgc ccccgactga gcggacgctc 3180
ctggacctgg atcgagagg gcagagtcag gacagaccg tgccgctgtg cagagcggaa 3240
ctgaacacac acaggcctgc cccttatgag atccagcagg agttctggtc ttagcacgaa 3300
aaggattggg gcgggcaagg gggacagcca gcggagatga ggggagctgg cgggcacagc 3360
cctttctcag ggttggaacc cctgagatcc agccctactt cttgcaacta taatgcactt 3420
tgaagatgga agggatggaa acagggccac ttcagagggt ctctgcct gcagggcctt 3480
tctaccgctg tccactggag gggctgtggc catcagctct ggctgtgtag gggaggag 3538

```

<210> 37

<211> 3047

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7482377CB1

<400> 37

```

aagccccgtg tgactctcct cagccactcc cccagccccg ggtggggggcc gattgactgt 60
ttccagggacc ccctcgggta ggggggctgg agagccccc a ggtggaccat ggcgggtgaga 120
ttccagggtgg ctgacatgga ggagctgacc atcttgggaac agcacacggc cacactgtcc 180
aaggaccccc gccggggcctt tggcattgag atctctggag gccgagaccg gcccggtgga 240
tccatgggttg tatctgacgt ggtacctgga gggccggcgg agggcaggct acagacaggc 300
gaccacattg tcatggtgaa cgggggtttcc atggagaatg ccacctccgc gtttgccatt 360
cagatactca agacctgcac caagatggcc aacatcacag tgaaacgtcc ccggaggatc 420
cacctgcccc ccaccaaagc cagccccctc agcccagggc gccaggactc ggatgaagac 480
gatgggcccc agcgggtgga ggaggtggac cagggccggg gctatgacgg cgactcatcc 540
agtggctccg gccgctcctg ggacgagcgc tcccgcgggc cgaggcctgg tcgccggggc 600
cgggcccggca gccatgggag taggagccca ggtggtggct ctgaggccaa cgggctggcc 660
ctggtgtccg gctttaagcg gctgccacgg caggacgtgc agatgaagcc tgtgaagtca 720
gtgctggtga agaggagaga cagcgaagag tttggcgta agctgggcag tcagatcttc 780
atcaagcaca ttacagattc gggcctggct gcccggcacc gtgggctgca ggaaggagat 840
ctcattctac agatcaaacg ggtgtctagc cagaacctgt cactgaacga cccccggcga 900
ctgattgaga agtcagaagg gaagctaagc ctgctggtgc tgagagatcg tgggcagttc 960
ctggtgaaca ttccgcctgc tgtcagtgac agcgacagct cgccattgga ggacatctcg 1020
gacctgcct cggagctatc gcaggcacca ccattcccac tcccaccacc accccggcat 1080
gctcagcggg gccccgaggg cagccagacc gactctcccg tggagagtcc ccggcttcgg 1140
cgggaaagt cagtagattc cagaaccatc tcggaaccag atgagcaacg gtcagagttg 1200
cccagggaaa gcagctatga catctacaga gtgccagca gtcagagcat ggaggatcgt 1260
gggtacagcc ccgacacgcg tgtggtccgc ttctcaagg gcaagagcat cgggctgcgg 1320
ctggcagggg gcaatgacgt gggcatcttc gtgtccgggg tgacggcggg cagcccggcc 1380
gacgggcagg gcatccagg gggagatcag attctgcagg tgaatgacgt gccattccag 1440
aacctgacac gggaggaggc agtgcagttc ctgctggggc tgccaccagg cgaggagatg 1500
gagctggtga cgcagcggaa gcaggacatt ttctggaaaa tgggtgcagtc ccgctgggt 1560
gactccttct acatccgcac tcactttgag ctggagccca gtccgcctgc tggcctgggc 1620
ttcacccgtg gcgacgtctt ccaegtgtcg gacacgtgac accccggccc cgggcagagc 1680
cacgcacgag gaggccactg gctggcggtg cgcattgggtc gtgacctgcg ggagcaagag 1740
cggggcatca ttcccaacca gagcagggcg gagcagctgg ccagcctgga agctgccag 1800
agggccgtgg gagtcggggc cggctcctcc gcgggctcca atgctcgggc cgagttcttg 1860
cggctgcggg gtctgcgtcg aggagccaag aagaccactc agcggagccg tgaggacctc 1920
tcagctctga cccgacaggg ccgtaccccg ccctacgaac gagtgggtgt gcgagaagcc 1980
agtttcaagc gcccggtagt gacctgaggc cccgtggccg acattgctat gcagaagttg 2040
actgctgaga tgcttgacca gtttgaaatc gcagagactg tgtccaggac cgacagcccc 2100
tccaagatca tcaaaactaga caccgtgcgg gtgattgcag aaaaagacaa gcatgcgtc 2160
ctggatgtga cccctccgc catcgagcgc ctcaactatg tgcagtacta cccattgtg 2220
gtcttcttca tcccagagag ccggccggcc ctcaaggcac tgcgccagtg gctggcgcc 2280
gcctcccgcc gcagacccc tgccctctac gcacaagccc agaagctgcg aaaacacagc 2340
agccacctct tcaagaccac catccctctg aatggcacga gtgacacctg gtaccaggag 2400
ctcaaggcca tcatcgaga gcagcagacg cgtaccacag gcctggccga cagctccgct 2520
gatggctcct tggaggacaa cctagacctc cctaccacag gcctggccga cagctccgct 2580
gacctcagct gcgacagccg cgttaacagc gactacgaga cggacggcga gggcggcgcg 2640
tacacggatg gcgagggcta cacagacggc gagggggggc cctacacgga tgtggatgat 2640
gagcccccg ctccagccct ggcccggctc tcggagcccg tgacggcaga tgagtcagg 2700
agcccagggg atcgtgggag aatctcggtc catcaggggg cccaggtgga cagccgccac 2760
ccccagggac agtggcgaca ggacagcatg cgaacctatg aacgggaagc cctgaagaaa 2820
aagtttatgc gactacatga tgcggagtc tccgatgaag acggctatga ctgggggtccg 2880
gccactgacc tgtgacctct cgaaggctgc cagctggctc gtcctccttc tccctccctg 2940
gggctgggac tcagtttccc atacagaacc cacaacctta cctccctccg cctggtcttt 3000
aataaacaga gtattttcac agcaaaaaaa aaaaaaaa aaaaaaa 3047

```

<210> 38

<211> 2667

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7758364CB1

<400> 38

```
tttagctgag ggcgcggggcg ggtcgggtcc tccgcgggtc ctcggcccca cctgcgcgga 60
gagggcggga tgccagagcc aggtgtcccg gcgcgttaag ggccctcgca gtcagacgtc 120
cctgcaccgg cgctcgcacc cttagtcggc ccggaacgtc tttttgcgga cgccctcgga 180
gcagccgcga tggccagcac caggagtatc gagctggagc actttgagga acgggacaaa 240
aggccgcggc cgggggtcgcg gagagggggc cccagctcct ccggggggcag cagcagctcg 300
ggccccaagg ggaacgggct catccccagt ccggcgcaca gtgcccactg cagcttctac 360
cgcacgcgga ccctgcaggc cctcagctcg gagaagaagg ccaagaaggc gcgcttctac 420
cggaacgggg accgctactt caagggcctg gtgtttgcca tctccagcga ccgcttccgg 480
tccttcgatg cgctcctcat agagctcacc cgctccctgt cggacaacgt gaacctgccc 540
caggggtgtc gcactatcta caccatcgac ggcagccgga aggtcaccag cctggacgag 600
ctgctggaag gtgagagtta cgtgtgtgca tccaatgaac catttcgtaa agtcgattac 660
acaaaaata ttaatccaaa ctggtctgtg aacatcaagg gtgggacatc ccgagcgctg 720
gctgctgcct cctctgtgaa aagtgaagta aaagaaagta aagatttcat caaacccaag 780
ttagtgactg tgattcgaag tggagtgaag cctagaaaaag ccgtgcggat ccttctgaat 840
aaaaagactg ctcatctcct tgaacaagtc ttaacagata tcaccgaagc cattaacta 900
gactcaggag tcgtcaagag gctctgcacc ctggatggaa agcaggttac ttgtctgcaa 960
gacttttttg gtgatgacga tgtttttatt gcatgtggac cagaaaaatt tcgttatgcc 1020
caagatgact ttgtcctgga tcatagttaa tgtcgtgtcc tgaagtcac tttattctga 1080
tcctcagctg ttaagtattc tggatccaaa agccctgggc cctctcgacg cagcaaatca 1140
ccagcttcag ttaatggaac tcccagcagc caactttcta ctctaaatc tacgaaatcc 1200
tccagttcct ctccaactag tccaggaagt ttcagaggat taaagcagat ttctgctcat 1260
ggcagatcct ctccaatgt aaacggtgga cctgagcttg accgttgcac aagtcctgaa 1320
ggtgtgaatg gaaacagatg ctctgaatca tcaactcttc ttgagaaata caaaattgga 1380
aaggtcattg gtgatggcaa ttttgagta gtcaaagagt gtatagacag gtccactgga 1440
aaggagtttg ccctaaagat tatagacaaa gccaaatgtt gtggaaagga acacctgatt 1500
gagaatgaag tgtcaatact gcgccgagtg aaacatccca atatcattat gctggctcag 1560
gagatggaaa cagcaactga gctctttctg gtgatggaat tgggtcaaagg tggagatctc 1620
tttgatgcaa ttaactcgtc gaccaagtac actgagagag atggcagtg catggtgtac 1680
aacttagcca atgccctcag gtatctccat ggcctcagca tcgtgcacag agacatcaaa 1740
ccagagaatc tcttggtgtg tgaatatcct gatggaacca agtctttgaa actgggagac 1800
tttgggcttg cgactgtggt agaaggccct ttatacacag tctgtggcac acccacttat 1860
gtggctccag aaatcattgc tgaactggc tatggcctga aggtggacat ttgggcagct 1920
ggtgtgatca catacatact tctctgtgga tccccaccat tccgaagtga gaacaatctc 1980
caggaagatc tcttcgacca gatcttggt gggaaagctg agtttcgggc cccctactgg 2040
gataacatca cggaactctg caaggaatta atcagtcaaa tgcttcaggt aaatggtgaa 2100
gctcgggtga ccgcgggaca aatcctgagt caccctggg .tgtcagatga tgcctcccag 2160
gagaataaca tgcaagctga ggtgacaggt aaactaaaac agcactttaa taatgcgctc 2220
cccaaacaga acagcactac caccggggtc tccgtcatca tgaacacggc tctagataag 2280
gaggggcaga ttttctgcag caagcactgt caagacagcg gcaggcctgg gatggagccc 2340
atctctccag ttctccctc agtggaggag atccctgtgc ctggggaagc agtcccggcc 2400
cccacccctc cggaatctcc cacccccac tgtcctcccg ctgcccggg tgggtgagcg 2460
gcaggaacct ggcgcgcca ccgagactga gcctcctgca gacgggcgaa gccgcctgct 2520
gcagccagg aagccagccc tctgctcggc ctgcgggcc tccctgctgc aggcctccct 2580
ctcttcaccg cctgcgcctg agttcgcggg tctcgcgag gccgcctggg aaccggagcc 2640
tggcgtgccg gagcctggcc tgggtgct 2667
```

<210> 39

<211> 1719

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5850001CB1

<400> 39

```
gcgaggagg cgagaaggaa tccgacgctg gggggccttg tcgggcggca gcgactgctg 60
ctgcggatgg gagcggggccg gctcggcgcg cccatggagc gccacggcag ggcttccgcc 120
acctcgcgtc cgtcggctgg ggagcaggcg gccggggacc ccgaaggcg gcggcaggag 180
ccactgcggc gccgggagag cagcgcgctg gtgcccgcgg tcggggcctc ggctgagggc 240
acgaggcggg atcgactggg ctcttacagc ggccccacct cggctctccc ccagcgcgtc 300
gaaagcctga ggaaaaagcg gccgcttttt ccatggtttg gactggatat cggtggaact 360
ctggtcaagc tggatatatt tgaacccaaa gacatcactg ctgaagaaga agaggaagaa 420
gtggaaagtc ttaaaagcat tcggaagtac ctgacctcca atgtggctta tgggtctaca 480
ggcattcggg acgtgcacct cgagctgaag gacctgactc tgtgtggacg caaaggcaat 540
ctgcacttta tacgctttcc cactcatgac atgcctgctt ttattcaa atggcagagat 600
aaaaacttct cgagtctcca cactgtcttt tgtgccactg gaggtggagc gtacaaattt 660
gagcaggatt ttctcacaat aggtgatctt cagctttgca aactggatga actagattgc 720
ttgatcaaag gaattttata cattgactca gtccgattca atggacggtc acagtgcctat 780
tactttgaaa accctgctga ttctgaaaag tgcagaagt taccatttga tttgaaaaat 840
ccgtatcctc tgcttctggg gaacattggc tcaggggtta gcatcttagc agtatattcc 900
aaagataatt acaaacgggt cacaggctact agtcttggag gaggaacttt ttttggtctc 960
tgctgtcttc ttactggctg taccactttt gaagaagctc ttgaaatggc atctcgtgga 1020
gatagcacca aagtggataa actagtacga gatatttatg gaggggacta tgagaggttt 1080
ggactgccag gctgggctgt ggcttcaagc tttggaaaca tgatgagcaa ggagaagcga 1140
gaggctgtca gtaaagagga cctggccaga gcgactttga tcaccatcac caacaacatt 1200
ggctcaatag caagaatgtg tgcccttaat gaaaacatta accagggtgg atttgttgg 1260
aatttcttga gaattaatac gatcgccatg cggcttttgg catatgcttt ggattattgg 1320
tccaaggggc agttgaaagc acttttttct gaacacgagg gttatttttg agctgttgg 1380
gcactccttg agctgttgaa gatcccgctg tcattacctg gggagggggt cctgaaacct 1440
tccacaatgg gatctgtgga ctttcatttt tttaagagac ttactcaatt tcatgactgt 1500
actacctgaa acaaagttag aaaggacagg tgtatttttc taagtcatca agataaatcc 1560
ttaagaattc agtctaaatt agcaaccagg aaggaaaaat atattaaaaa caacaaaaaa 1620
gtggcacatg tccaggcagt gtgaggattt gctgtatata agttgcctgc tttgtatttt 1680
tgaaatctct gcatcactca ttggaagtgc ttctgaagt 1719
```

<210> 40

<211> 1156

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7477062CB1

<400> 40

```
agtcggggcg gggctcttgc cctaggcagg cctctgctgg catgagccct aagtgccggg 60
cactgaccac agccggcagc cggagggtca ggagggcctt ggaggagaga tgcccgccaa 120
acagtctgag gaagggcccg cggaggcagg ggcttcggag gacagcgagg aggagggtct 180
gggcggcctg acattagagg agctccagca gggccaggag gctgcccgcg cgctggagga 240
catgatgacg ctgagtgtc agaccctgg ccgagccgag gtggacgagc tctacgagga 300
agtgcgtccc ctgggcccagg gtcgctatgg ccgcgtcctt ctggtcaccc atcgctcagaa 360
aggcacaccc ctggcactga agcagctccc gaaacccgc acgtccctcc gtggcttctc 420
```

```

gtacgagttc tgtgtggggc tctcgctggg cgcgcaactca gccatcgtga cggcctacgg 480
cattggcatc gagtgcggac actcctacag ctctctgacg gagcccgtec tgcacgggga 540
cctcatggcc ttcattccagc ccaaggtggg cctcccgag cccgcggtgc accgctgcgc 600
cgcccgagctg gcctccgccc tggagtacat ccacgcccgc ggcttgggtg accgggacct 660
gaagccggag aacgtcctgg tgtgcgacct ggcttggcgg cgcttcaagc tgaccgactt 720
cggccacacg aggcctcgcg ggacgctgct gcgctggcc gggccgcca tcccctacac 780
ggcccccgag ctctgcgcgc ccccgccgct ccccgagggc ctgcccattc agcccgccct 840
ggacgcctgg gcgctgggcg tctgtctctt ctgcctcttc acgggctaact tcccctggga 900
ccggccccctg gccgaggccg accccttcta cgaggacttc ctcatctggc aggcgtcggg 960
ccagcccccg gaccgccttc agccctggtt cggcctggcc gccgcggccg acgcgcttct 1020
gcgggggctg ctggaccctc acccccgaag gaggagcgct gtgatcgcca tcaggagaca 1080
cctggggcgc ccctggaggc agcgggaggg cgaggcgagg gcagtgggag cgggtggaaga 1140
ggaggctggg cagtga

```

1156

<210> 41

<211> 1096

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7477207CB1

<400> 41

```

ggcctgcaga gcccatgaga gggagaagcg gcagcgtcta ccctgagaaa cctcgacctt 60
gaagatggtg agtagccagc caaagtacga tctaatacgg gaggtaggcc gaggtagtta 120
cgggtgtgtg tatgaagcag tcatacagaaa gacctctgca cgggtggcag tgaagaaaat 180
tcgatgtcac gcacctgaaa atgttgaact agcccttcgt gagttctggg cactaagcag 240
tatcaagagc caacatccaa atgtgattca cttggaggaa tgcatectac aaaaggatgg 300
gatggtgcaa aagatgtccc acggctctaa ttcttccctt tatttacagc ttgtagaaac 360
ttcattaaaa ggagaaattg cttttgatcc cagaagcgcc tattatttgt ggtttgtgat 420
ggatttttgt gacggaggag atatgaatga gtatctgttg tccaggaaac ccaatcgtaa 480
aactaacacc agcttcatgc ttcagctgag cagtgccttg gctttcttgc ataaaaacca 540
gatcatccac cgagatctta agcctgataa catectgatt tctcaaacca ggttgatac 600
cagtgacttg gaacctaccc tcaaagtggc tgatttttgt ctaagtaaag tttgttcagc 660
ctctgggcag aaccagaag aacctgtcag tgtaaacaag tgtttccttt ccacagcatg 720
tggaacagat ttttacatgg ctctgaagt ttgggaagga cattacacag caaaagctga 780
catctttgct ctggggatta tcatctgggc aatgctggaa aggatcacat tcatagacac 840
agagacaaaag aagggaactct tggggagtta tgtaaaacaa ggaactgaga ttgtgcctgt 900
tggggaggca cttctggaaa atcccataat ggaacttctc attcctgtga agaaaaaatc 960
tatgaatggg cgaatgaaac aactgattaa ggaatgctg gctgcaaacc ctcaggatcg 1020
tccagatgct tttgaactag aactcagatt agtacaaatt gcatttaaag atagcagctg 1080
ggaaacgtga cacata

```

1096

<210> 42

<211> 2647

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 4022651CB1

<400> 42

```

atggcctcag ccgagacccc aggccaatgg tatgttgggc cctaccggct ggagaagacg 60
ctgggcaagg ggcagacagg tctggtgaag ctgggggttc actgcgtcac ctgccagaag 120

```



```

gtggccatca agatcgtcaa ccgtgagaag ctcagcgagt cgggtgctgat gaaggtggag 180
cgggagatcg cgatcctgaa gctcattgag cacccccacg tcctaaagct gcacgacgtt 240
tatgaaaaca aaaaatatatt gtacctggtg ctagaacacg tgtcaggtgg tgagctcttc 300
gactacctgg tgaagaaggg gaggtgacg cctaaggagg ctcggaagtt cttccggcag 360
atcatctctg cgctggactt ctgccacagc cactccatat gccacaggga tctgaaacct 420
gaaaacctcc tgctggacga gaagaacaac atccgcacg cagacttttg catggcgctc 480
ctgcaggttg gcgacagcct gttggagacc agctgtgggt cccccacta cgectgcccc 540
gaggtgatcc ggggggagaa gtatgacggc cggaaggcgg acgtgtggag ctggggcgtc 600
atcctgttcg ccttgctggt gggggctctg cccttcgacg atgacaactt gcgacagctg 660
ctggagaagg tgaagcgggg cgtgttccac atgccgact ttatcccgcc cgactgccag 720
agtctgctac ggggcatgat cgaggtggac gccgcacgcc gcctcacgct agagcacatt 780
cagaaacaca tatggtatat agggggcaag aatgagcccg aaccagagca gcccattcct 840
cgcaaggtgc agatccgctc gctgccacg ctggaggaca tcgaccccga cgtgctggac 900
agcatgcact cactgggctg cttccgagac cgcaacaagc tgctgcagga cctgctgtcc 960
gaggaggaga accaggagaa gatgatttac ttctctctcc tggaccggaa agaaaggtag 1020
ccgagccagg aggatgagga cctgcccccc cggaacgaga tagaccctcc ccggaagcgt 1080
gtggactccc cgatgctgaa ccggcacggc aagcggcggc cagaacgcaa atccatggag 1140
gtgctcagcg tgacggacgg cggtccccc gtgctgcgc ggcgggccat tgagatggcc 1200
cagcacggcc agaggtctcg gtccatcagc ggtgcctcct caggcctttc caccagccca 1260
ctcagcagcc cccgggtgac ccctcaccct tcaccaaggg gcagtcctct cccaccccc 1320
aaggggacac ctgtccacac gccaaaggag agcccggctg gcacgcccac cccacgccc 1380
ccgtccagcc ccagcgctcg aggggtgccc tggagggcgc ggctcaactc catcaagaac 1440
agctttcttg gctcaccctg cttccaccgc cggaaactgc aagttccgac gccggaggag 1500
atgtccaacc tgacaccaga gtcgtcccca gagctggcga agaagtcctg gtttgggaac 1560
ttcatcagcc tggagaagga ggagcagatc ttctgtgtca tcaaagacaa acctctgagc 1620
tccatcaagg ctgacatcgt gcacgccttc ctgtcgattc ccagtctcag ccacagcgtc 1680
atctccaaa cgagcttcg ggcgagtag aagggcacgg gggggccagc cgtgttccag 1740
aagccggtca agttccaggt tgatatcacc tacacggagg gtggggaggc gcagaaggag 1800
aacggcatct actccgtcac cttcacctg ctctcaggcc ccagccgtcg cttcaaggag 1860
gtggtggaga ccatccaggc ccagctgctg agcacacacg acccgctgc ggcccagcac 1920
ttgtcagaca ccactaactg tatggaaatg atgacggggc ggctttccaa atgtggaatt 1980
atcccgaaaa gttaacatgt cacctccacg agggcctcct ctgtgaccga aggcagctgc 2040
tgcggaaccc cctccctcc gctcctgctg ttgtgcccgc gcagtgaggc ccagcccagc 2100
gccccgtcca ccccgcgga gctcctcgcc tcagctccgc acggcccgtg ggaggaaggc 2160
caggctcggg ggagcctcct ccagcccggc cgacccggac tcccggtcac ctgaccctc 2220
agcaagaaca gcctgcctgg tggcctctc gggccaggac ccccggtggg caacgtagcc 2280
acaggaacag gccccgtcca ccgctccac gccgcacctg gaggcctcct cgcaggcccc 2340
tgccccgccc tccctggcgc cgcgggctc cgtgtagtct tggcctcctc aggctgcctc 2400
ccgtcctctc gtctcaccgc cgcctccctt gcctcatctg gggcggtgtt gggctctggc 2460
gctcctctct ggctgaggtg gaaacagaga caccctgcgg caccagagcc ttcccagcag 2520
gccaggccgc tgggtggga tcagtgttat ttatttgccg ttttaattta tggattctcc 2580
gcacctctgt tcaggaagg gcggcgcca catccctgc cgtctgcgcg tctcaggcag 2640
tggggggg
2647

```

<210> 43

<211> 864

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7274927CB1

<400> 43

```

ggcgcgctttc ggggtgctggc ggctgcagcc ggagttcaaa cctaagcagc tggaagggcc 60
ctgtggctag gtaccataga gtctctacac aggactaaat cagcctggtg tgcaggggag 120

```

```

gcagacacac aaacagaaaa ttggactaca gtgctaagat gctgtaagaa gaggttaact 180
aaaggacagg aagatggggc caagagatgg tgctactgtc tacttttaggg atcgtctttc 240
aaggcgaggg gcctcctatc tcaagctgtg atacaggaac catggccaac tgtgagcgta 300
ccttcattgc gatcaaacca gatgggggtcc agcgggggtct tgtgggagag attatcaagc 360
gttttgagca gaaaggattc cgccttggtg gtctgaaatt catgcaagct tccgaagatc 420
ttctcaagga acactacggt gacctgaagg accgtccatt ctttgccggc ctggtgaaat 480
acatgcactc agggccggtg gttgccatgg tctgggaggg gctgaatgtg gtgaagacgg 540
gccgagtcac gtcgggggag accaaccctg cagactccaa gcctgggacc atccgtggag 600
acttctgcat acaagtgtgc aggaacatta tacatggcag tgattctgtg gagagtgcag 660
agaaggagat cggcttgtgg ttccaccctg aggaactggg agattacacg agctgtgctc 720
agaactggat ctatgaatga caggagggca gaccacattg cttttcacat ccatttcccc 780
tccttcccat gggcagagga ccaggctgta ggaaatctag ttatttacag gaaggggagc 840
cactagtctt aagcgccgca cccc

```

864

<210> 44

<211> 1594

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7946584CB1

<400> 44

```

gcggagacgc ccgctggcaa gcagatcctg cctccttccc tggccaagga gccgcccctc 60
cggggtagct gtgcgctggg cggcgctcgg accccttggc agccgcaggt gcctccccag 120
cccagcccag cttagtccag cgcagcccag cccagcccag cccggcgctc gcagcctccg 180
ccgcttccgg gcagataggt gccttttctt ctccttggc cttaggttc ttctcttagt 240
ccctgttccc tggatgaaag catcgctccg agcctcatgg gaggaatgaa ggaagaatgc 300
agactagata tccaactaag gcttcgggac atgttttgag cgaagatggg tgtttctgctc 360
cggatagtat aaatcgagga tccaggtctg ggcagattca accatgggag ccaacacttc 420
aagaaaacca ccagtgtttg atgaaaatga agatgtcaac tttgaccact ttgaaatttt 480
gcgagccatt gggaaaggca gttttgggaa ggtctgcatt gtacagaaga atgataccaa 540
gaagatgtac gcaatgaagt acatgaataa acaaaagtgc gtggagcgca atgaagtgcag 600
aaatgtcttc aaggaaactc agatcatgca gggctctggg caccctttcc tgggttaattt 660
gtggtattcc ttccaagatg aggaagacat gttcatggg gtggacctcc tgctgggtgg 720
agacctgcgt tatcacctgc aacagaacgt ccacttcaag gaagaaacag tgaagctctt 780
catctgtgag ctggtcatgg ccctggacta cctgcagaac cagcgcatca ttcacaggga 840
tatgaagcct gacaatattt tacttgacga acatgggcac gtgcacatca cagatttcaa 900
cattgctgcg atgctgcca gggagacaca gattaccacc atggctggca ccaagcctta 960
catggcacct gagatgttca gctccagaaa aggagcaggc tattcctttg ctgttgactg 1020
gtggtccctg ggagtgcgg catatgaact gctgagaggg cggagaccgt atcatattcg 1080
ctccagtact tccagcaagg aaattgtaca cagttttgag acgactgttg taacttacct 1140
ttctgcctgg tcacaggaaa tgggtgtcact tcttaaaaag ctactcgaac ctaatccaga 1200
ccaacgattt tctcagttat ctgatgtcca gaacttccc tatatgaatg atataaactg 1260
ggatgcagtt tttcagaaga ggctcattcc aggtttcatt cctaataaag gcaggctgaa 1320
ttgtgatcct acctttgaac ttgaggaaat gattttggag tccaaacctc tacataagaa 1380
aaaaaagcgt ctggcaaga aggagaagga tataggaaa tgcgattctt ctacagacatg 1440
tcttcttcaa gagcaccttg actctgtcca gaaggagttc ataattttca acagagaaaa 1500
agtaaacagg gactttaaca aaagacaacc aaatctagcc ttggaacaaa ccaaagacct 1560
acaaggtgag gatggtcaga ataacaactt gtaa

```

1594

<210> 45

<211> 1845

<212> DNA

<213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 8088078CB1

<400> 45
 atggagtggtc taagccctga tategctctg cccagaagag atgagtggtc tcaaacttct 60
 ccagccagga agaggatcac gcatgccaaa gtccagggtg caggtaagtc catcggtcag 120
 ctgaggctgt ccattgatgc ccaggaccgg gtctctgctgc ttcacattat agaaggtaaa 180
 ggcctgatca gcaaacagcc tggcacctgt gatccgtatg tgaagatttc tttgatccct 240
 gaagatagta gactacgcca ccagaagacg cagaccgttc cagactgcag agaccgggt 300
 ttccacgagc acttcttctt tcctgtccaa gaggaggatg atcagaagcg tctcttggtt 360
 actgtgtgga acagggccag ccagtccaga gagatcagtg tcattggctg catgagcttt 420
 ggggtgaagt ctctcctgac tccagacaag gagatcagtg gttggtacta cctcctaggg 480
 gagcacctgg gccggacca gacattgaag gtggccaggc ggcgactgcg gccgctgaga 540
 gaccgcgtgc tgagaatgcc aggaggtggg gacactgaga atgggaagaa actacagatc 600
 accatcccga ggggaaagga cggctttggc ttcaccatct gctgcgactc tccagttcga 660
 gtccaggccg tggattccgg gggctccggc gaacgggcag ggctgcagca gctggacacg 720
 gtgctgcagc tgaatgagag gcctgtggag cactggaaat gtgtggagct ggcccacgag 780
 atccggagct gcccagtgat gatcatccta ctctgtgtgc gcatgggtccc ccagggtcaag 840
 ccaggaccag atggcggggt cctgcggcgg gcctcctgca agtcgacaca tgacctccag 900
 tcacccccca acaaacggga gaagaactgc acccatgggg tccaggcacg gcctgagcag 960
 cgccacagct gccacctggt atgtgacagc tctgatgggc tgctgctcgg cggctgggag 1020
 cgctacaccg aggtggccaa gcgcgggggc cagcacaccc tgctgcact gtcccgtgcc 1080
 actgccccca ccgaccccaa ctacatcatc ctggccccgc tgaatcctgg gagccagctg 1140
 ctccggcctg tgtaccagga ggataccatc cccgaagaat cagggagtc cagtaaaggg 1200
 aagtcctaca caggcctggg gaagaagtcc cggctgatga agacagtgc gaccatgaag 1260
 ggccacggga actacccaaa ctgcccgggt gtgaggccgc atgccacgca ctcaagctat 1320
 ggcacctacg tcacctggc ccccaaagtc ctggtgttcc ctgtctttgt tcagcctcta 1380
 gatctctgta atcctgccc gacctcctg ctgtcagagg agctgctgct gtatgaaggg 1440
 aggaacaagg ctgccgaggt gacactgttt gcctattcgg acctgctgct cttaccaag 1500
 gaggacgagc ctggcgcgtg cgacgtcctt aggaaccccc tctacctcca gagtgtgaag 1560
 ctgcaggaag gttcttcaga agacctgaaa ttctgcgtgc tctatctagc agagaaggca 1620
 gagtgtcttat tcacttttga agcgactcg caggagcaga agaagagagt gtgctggtgc 1680
 ctgtcggaga acatcgccaa gcagcaacag ctggcagcat ccccccgga cagcaagaaa 1740
 ctccaccctt tcggctctct ccagcaggag atggggcggg tcaactcaac caatgccacc 1800
 caggatagaa gctttacctc accaggacag actctgattg gctga 1845

<210> 46
 <211> 1680
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2674269CB1

<400> 46
 gctcatttgc gcgaaccgc ggtctttcct tctccccttg atgctttcag gtactgacct 60
 actaccgccc ccatcttccc ccatgggaag atgagcactg agggcagatt accctcctgc 120
 agcgcgtgtg tgaaagggga gttgagagt ctgacgagcg cggcgctcac tagtcgggac 180
 ggcccagagc cgtgtcatgt cctcttcagg attgtgcacc tgtgcctgcg aaaggctgac 240
 cagaagctgg tgatcatcaa gcagattcca gtggaacaga tgaccaagga agagcggcag 300
 gcagcccaga atgagtgcc ggtcctcaag ctgctcaacc accccaatgt cattgagtac 360
 tacgagaact tcctggaaga caaagccctt atgatcgcca tggaatatgc accaggcggc 420
 actctggctg agttcatcca aaagcgtgt aattccctgc tggaggagga gaccatcctg 480
 cacttcttgc tgcagatcct gcttgactg catcatgtgc acaccacct catcctgcac 540

```

cgagacctca agaccagaa catcctgctt gacaaacacc gcatggctgt caagatcggt 600
gatttcggca tctccaagat ccttagcagc aagagcaagg cctacacggg ggtgggtacc 660
ccatgctata tctccctga gctgtgtgag ggcaagccct acaaccagaa gagtgcacatc 720
tgggcccctg gctgtgtcct ctacgagctg gccagcctca agagggttt cgaggctgcg 780
aacttgccag cactggtgct gaagatcatg agtggcacct ttgcacctat ctctgaccgg 840
tacagccctg agcttcgcca gctggctctg agtctactca gcctggagcc tgcccagcgg 900
ccaccactca gccacatcat ggacacagccc ctctgcatcc gtgcctcct caacctccac 960
accgacgtgg gcagtgtccg catgcgaggg cctgtgcagg gacagcgagc ggtcctgggc 1020
ggcaggggtgt gggcaccagc tgggagcaca ggaggtctga ggcagagggg aacctggggc 1080
aagtcctccc ttctgtcatg taggaatgtc aggagggtct ttgtccttag gccccatct 1140
gtcctgcagg gcagagaagt ccgtggcccc cagcaacaca gggagcagga ccaccagtgt 1200
ccgctgcaga ggtatcccc ggggacctgt gaggccagcc atcccaccac cactgtcgtc 1260
agtgtatgcc tggggtgggt ggctgggcac cccctgcgg ctgccaatgc tcaacacaga 1320
ggtgtccag gtggcagctg ggcgacgca gaaagccggc gtcacgcgct ctgggctct 1380
catcctgtgg gaggccccac ccctaggtgc aggcggaggc agtctccttc ctggggcagt 1440
ggagcagcca cagccccagt tcatctcgcg ttctctggag ggccagtcgg gtgtgacct 1500
caagcacgtg gcctgtgggg acttcttcac tgcctgcctg actgacagag gcatcatcat 1560
gacattcggc agcggcagca atgggtgcct aggccatggc agcctcactg acatcagcca 1620
gccaccatt gtggaggctt tgctgggcta tgaaatgggt caggtggcct gtggggcctc 1680

```

<210> 47

<211> 1528

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472409CB1

<400> 47

```

gtgaaactct aagaaatgag atggagaagt acgagcggat ccgagtgggt gggagagggt 60
ccttcgggat tgtgcacctg tgcctgcgaa aggtgacca gaagctgggt atcatcaagc 120
agattccagt ggaacagatg accaaggaag agcggcaggc agcccagaat gagtgccagg 180
tctcaagct gctcaaccac cccaatgtca ttgagtacta cgagaacttc ctggaagaca 240
aagcccttat gatcgccatg gaatatgcac caggcggcac tctggctgag ttcacccaaa 300
agcgtgttaa ttccctgctg gaggaggaga ccatcctgca ctctctcgtg cagatcctgc 360
ttgcaactga tcatgtgcac acccacctca tctgcaccg agacctcaag acccagaaca 420
tctgtcttga caaacaccgc atggctcgta agatcggtga ttctggcatc tccaagatcc 480
ttagcagcaa gagcaaggcc tacacggtgg tgggtacccc atgtatatc tcccctgagc 540
tgtgtgaggg caagccctac aaccagaaga gtgacatctg ggccctgggc tgtgtcctct 600
acgagctggc cagcctcaag agggctttcg aggtgcgaa cttgccagca ctggtgctga 660
agatcatgag tggcacctt gcacctatct ctgaccggtg cagccctgag cttcgccagc 720
tggctctgag tctactcagc ctggagcctg ccagcggcc accactcagc cacatcatgg 780
cacagccct ctgcatcctg gccctcctca acctccacac cgacgtgggc agtgtccgca 840
tgccgaggcc tgtgcagggg cagcgagcgg tcctgggcgg cagggtgtgg gcaccagtg 900
ggagcacagg aggtctgagg cagaggggaaa cctggggcaa gtctccctt cctgcatgta 960
ggaatgtcag gagggtcttt gtcttaggc ccccatctgt cctgcagggc agagaagtcc 1020
gtggccccc gcaacacagg gagcaggacc accagtgtcc gctgcagagg tatccccgg 1080
ggacctgtga ggccagccat cccaccacca ctgtcgtcag tgtatgcctg ggggtgggtgg 1140
ctgggcaccc ccctgcggct gccaatgtct aacacagagg tgggtccagg ggcagctggg 1200
cgcacgcaga aagccggcgt cagcgcctct gggcgtctca tctgtggga ggccccacc 1260
ctaggtgcag gcggaggcag tctccttct ggggcagtgg agcagccaca gcccagttc 1320
atctcgcgtt tcttgaggg ccagtcgggt gtgacctca agcacgtggc ctgtggggac 1380
ttcttactg cctgcctgac tgacagaggg atcatcatga cattcggcag cggcagcaat 1440
gggtgcctag gccatggcag cctcactgac atcagccagc ccaccattgt ggaggctttg 1500
ctgggctatg aaatggtgca ggtggcct

```

1528

<210> 48
<211> 4988
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7477484CB1

<400> 48

```
ccggctcccc agcatctctc ctctgtccgc ctctccatcc ctccatccgt ctgtcccttc 60
aaagaggggg aggggggtac ctgagccagc aagcagcccc tccctcccc tgctctgct 120
ctcctgcccc tctcctgggc cgggaggagg ccaggctcgc cgggtcccca tggctggggg 180
ctgagggccc gccccccct cctccccagc cgccaccacc tccacctccc tgccatcctc 240
gacaagatgc ctgcccccg cgccctcctc ctcccttgccg ccgtctccgc ctccggctgc 300
ctggcgctcc cggcccaccc cgatggatcc gccctgggccc gggctcctct ggctcctccc 360
tacgctgtgg tctcatttc ctgctccggc ctgctggcct tcatcttct cctcctcacc 420
tgtctgtgct gcaaacgggg cgatgtcggc ttcaaggaat ttgagaacct tgaaggggag 480
gactgctccg gggagtacac tccccctgcg gaggagacct cctcctcaca gtcgctgcct 540
gatgtctaca ttctcccgt ggctgaggtc tccctgccaa tgctgcccc gcagccttca 600
cactcagaca tgaccacccc cctgggcctt agccggcagc acctgagcta cctgcaggag 660
attgggagtg gctggtttgg gaaggtgatc ctgggagaga tttctccga ctacaccccc 720
gcccaggtgg tggatgaagga gctccgagcc agcgcggggc ccctggagca acgcaagtcc 780
atctcggaag cacagccgta caggagcctg cagcaccaca atgtcctcca gtgcctgggt 840
ctgtgcgtgg agacgctgcc gttctctgct attatggagt tctgtcaact gggggacctg 900
aagcgttacc tccgagccca gcggccccc gagggcctgt cccctgagct acccctcga 960
gacctgcgga cgctgcagag gatgggcctg gagatgcgcc gcgggctggc gcacctgcct 1020
tcccacaact acgtgcacag cgacctggcc ctgcgcaact gcctgctgac ctctgacctg 1080
accgtgcgca tcggagacta cgggctggcc cacagcaact acaaggagga ctactacctg 1140
acccagagc gcctgtggat cccactgcgc tgggcggcgc ccgagctcct cggggagctg 1200
cacgggacct tcatgggtgg ggaccagagc cgcgagagca acatctggtc cctgggggtg 1260
accctgtggg agctgtttga gtttggggcc cagccctacc gccacctgtc agacgaggag 1320
gtcctcgctc tctggttccg ccagcagcat gtgaagctgg cccggccgag gctcaagctg 1380
ccttacgcgg actactggta tgacattctt cagtctctgt ggcggccacc tgccagcgc 1440
ccttcagcct ctgatctcca attgcagctc acctacttgc tctccgagcg gcctcccccg 1500
ccccacgcgc cgccaccccc accccgagac ggtcccttcc cctggccctg gccccctgca 1560
cacagtgcgc cccgcccggg gacctctcc tcaccgttcc ccctactgga tggcttccct 1620
ggagccgacc ccgacgatgt gctcacggtc accgagagta gccgcggcct caacctcgag 1680
tgctctgtgg agaaggcccc gcgtggggcc ggccggggtg ggggggcacc tgctggcag 1740
ccggcgctcg ccccccgcc cccccacgcc aaccctcca accctttcta cgaggcgctg 1800
tccacgcca gcgtgctgcc tgtcatcagc gccgcagcc cctccgtgag cagcgagtac 1860
tacatccgct tggaggagca cggctccct cctgagcccc tcttcccaaa cgactgggac 1920
ccctggacc caggagtgc cgccctcag gcccccagg cccctccga ggtccccag 1980
ctggtgtccg agacctgggc ctccccctc ttccctgcgc ccgggccctt cccagcccag 2040
tcctcagcgt caggcagctt cctgctgagc ggctgggacc ccgagggccg gggcgccggg 2100
gagacctgg cgggagaccc tgccgaggtc ttgggggagc gggggaccgc cccgtgggtg 2160
gaagaagaag aggaggagga ggagggcagc tccccagggg aagacagcag cagccttga 2220
ggacgactcc tcgctgcggg cagagcgggg ctccctggcc gacttgccca tggccccccc 2280
gcctcgcccc ccccgaggtt tctggacccc ctcatggggg cggcgggcgc ccagtacccc 2340
gggcgggggc cacctccgc tcccccccc ccgcgcgac ctctcgggc ccccgcgac 2400
ccggccgct ccccgaccc ccttcggcc gtggccagtc ccggttcagg cctctcgctg 2460
ccgggcccc aagccggggg cagcggtac gagaccgaga ccccttttcc cccagaggga 2520
gccttcccag gtgggggggc ggccgaggag gaaggggtcc ctcgcccgcg ggtcccccc 2580
gagccacccg acccaggagc gcccggcca cctccagacc cgggtccgct cccactccc 2640
gggccccggg agaagccgac ctctgtggt caagtgcga cggaacagct gctgatgtcc 2700
ctgcgggagg atgtgacaag gaacctcctg ggggagaagg gggcgacagc cggggagaca 2760
```

```

ggacccagga aggcggggag agggcccggg aacagagaga aagtcccggg cctgaacagg 2820
gacccgacag tcctgggcaa cgggaaacaa gcccgaagcc tgagcctccc agtgaacggg 2880
gtgacagtgc tggagaacgg ggaccagaga gcccagggca tggaggagaa ggcggcggag 2940
aatggggccc tggggtcccc cgagagagaa gagaaagtgc tggagaatgg ggagctgaca 3000
cccccaagga gggaggagaa agcgctggag aatggggagc tgagggtccc agaggccggg 3060
gagaaggtgc tggatgaatgg gggcctgaca cccccaaga gcgaggacaa ggtgtcagag 3120
aatggggggc tgagattccc caggaacacg gagaggccac cagagactgg gccttgagag 3180
gccccagggc cctgggagaa gacgcccag agttggggtc cagccccac gatcggggag 3240
ccagccccag agacctctct ggagagagcc cctgcaccca gcgcagtggg ctctcccg 3300
aacggcgggg agacagcccc tggccccctt ggcccagccc ccaagaacgg gacgctggaa 3360
ccggggaccg agaggagagc ccccgagact gggggggcgc cgagagcccc aggggctggg 3420
aggctggacc tcgggagtgg gggccgagcc ccagtgggca cggggacggc cccggcggc 3480
ggccccgga gcggcgtgga cgcaaaggcc ggatgggtag acaacacgag gccgcagcca 3540
ccgcccac cgtgccacc gccaccggag gcacagccga ggaggctgga gccagcggc 3600
ccgagagcca ggcggagggt ggcccccgag ggagagcccg gggccccaga cagcaggggc 3660
ggcgagaca cggcactcag cggagacggg gacccccca agcccagag gaaggggccc 3720
gagatgccac gactattctt ggacttggga cccctcagg ggaacagcga gcagatcaaa 3780
gccaggctct cccggctctc gctggcgctg ccgcccgtca cgctcacgcc attcccggg 3840
ccggggccgc ggcggccccc gtgggagggc gcggacggcg gggcggtgg cggggaggcc 3900
ggcgggcg ggcggccggg gccggcgag gaggacgggg aggacgagga cgaggacgag 3960
gaggaggacg aggaggcggc ggcggcgggc gcggcgggc ggcggcggg cccggggagg 4020
gcgcgagcag ccccggtgcc cgtcgtgggt agcagcgccg acgcggacgc ggcccggc 4080
ctgcgggggc tgctcaagtc tccgcgggg gccgacgagc cagaggacag cgagctggag 4140
aggaagcgca agatggtctc cttccacggg gacgtgaccg tctacctct cgaccaggag 4200
acgccaacca acgagctgag cgtccaggg ccccccagg gggacacgga cccgtcaacg 4260
cctccagcgc ccccgacacc tcccacccc gccaccccg gagatgggtt tccagcaac 4320
gacagcggct ttggaggcag ttctgagtgg gcggaggatt tccccctct ccccccctca 4380
ggccccccgc tgtgcttctc ccgcttctcc gtctcgctg cgctggagac cccggggcca 4440
cccgccccgg ccccgacgc ccggcccgca ggcccgtgg agaattgatt cccgaagac 4500
ccgaccccg tgcacctca gaagaggggt tgagaatgga atcctctgtg gatgacggcg 4560
ccactgccac caccgcagac gccgcctctg gggaggcccc cgaggctggg ccctccccct 4620
cccactcccc taccatgtgc caaacgggag gccccgggccc cccgcccccc agccccccag 4680
atggctcccc tgacccccct gacccctcg gagccaaatg aggcaggaat ccccccgccc 4740
ctccatagag agcgccttt ctcggaactg aactgaactc ttttgggct ggagccccctc 4800
gacacagcgg aggtccctcc tcacccactc ctggcccaag acaggggccc caggcttcgg 4860
ggacccggac cccccatttc gcgtctcccc tttccctccc cagcccggcc cctggagggg 4920
cctctgggtt aaaccttcgc gtggcatttt cacattattt aaaaaagaca aaaacaactt 4980
tttgagg

```

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
7 March 2002 (07.03.2002)

PCT

(10) International Publication Number
WO 02/018557 A3(51) International Patent Classification⁷: **C12N 15/54**,
9/12, 15/63, 5/10, A01K 67/027, C12P 21/02, C07K
16/40, C12Q 1/68, A61K 38/45, C12Q 1/48, G01N 33/573

(21) International Application Number: PCT/US01/27219

(22) International Filing Date: 31 August 2001 (31.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/229,873	31 August 2000 (31.08.2000)	US
60/231,357	8 September 2000 (08.09.2000)	US
60/232,654	14 September 2000 (14.09.2000)	US
60/234,902	22 September 2000 (22.09.2000)	US
60/236,499	29 September 2000 (29.09.2000)	US
60/238,389	6 October 2000 (06.10.2000)	US
60/240,542	13 October 2000 (13.10.2000)	US

(71) Applicant (*for all designated States except US*): **INCYTE GENOMICS, INC.** [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BANDMAN, Olga** [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). **NGUYEN, Danniell, B.** [US/US]; 1403 Ridgewood Drive, San Jose, CA 95118 (US). **WALIA, Narinder, K.** [US/US]; 890 David Street, #205, San Leandro, CA 94577 (US). **HAFALIA, April, J., A.** [US/US]; 2227 Calle de Primavera, Santa Clara, CA 95054 (US). **YAO, Monique, G.** [US/US]; 111 Frederick Court, Mountain View, CA 94043 (US). **GANDHI, Ameena, R.** [US/US]; 837 Roble Avenue #1, Menlo Park, CA 94025 (US). **GURURAJAN, Rajagopal** [IN/US]; 5591 Dent Avenue, San Jose, CA 95118 (US). **DING, Li** [CN/US]; 3353 Alma Street #146, Palo Alto, CA 94306 (US). **PATTERSON, Chandra** [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). **YUE, Henry** [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). **BAUGHN, Mariah, R.** [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). **TRIBOULEY, Catherine, M.** [FR/US]; 1121 Tennessee Street #5, San Francisco, CA 94107 (US). **THORNTON, Michael** [US/US]; 9 Medway Road, Woodside, CA 94062-2612 (US). **ELLIOTT, Vicki, S.** [US/US]; 3770Polton Place Way, San Jose, CA 95121 (US). **LU, Yan** [CN/US]; 3885 Corrina Way, Palo Alto, CA 94303 (US). **ISON, Craig, H.** [US/US]; 1242 Weathersfield Way, San Jose, CA 95118 (US). **AU-YOUNG, Janice** [US/US]; 233 Golden Eagle Lane, Brisbane, CA 94005 (US). **TANG, Y., Tom** [US/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). **AZIMZAI, Yalda** [US/US]; 5518 Boulder Canyon Drive, Castro Valley, CA 94552 (US). **BURRILL, John, D.** [US/US]; 650 Emerald Hill Road, Redwood City, CA 94061 (US). **MARCUS, Gregory, A.** [US/US]; 73 Maple Way, San Carlos, CA 94070 (US). **ZINGLER, Kurt, A.** [US/US]; 723 Ashbury Street #C, San Francisco, CA 94117 (US). **LU, Dyung, Aina, M.** [US/US]; 233 Coy Drive, San Jose, CA 95123 (US). **LAL, Preeti, G.** [IN/US]; P.O. Box 5142, Santa Clara, CA 95056 (US). **RAMKUMAR, Jayalaxmi** [IN/US]; 34359 Maybird Circle, Fremont, CA 94555 (US). **WARREN, Bridget, A.** [US/US]; 10130 Parkwood Drive #2, Cupertino, CA 95014 (US). **KEARNEY, Liam** [IR/US]; 50 Woodside Avenue, San Francisco, CA 94127 (US). **POLICKY, Jennifer, L.** [US/US]; 1511 Jarvis Court, San Jose, CA 95118 (US). **THANGAVELU, Kavitha** [IN/US]; 1950 Montecito Avenue #23, Mountain View, CA 94043 (US). **BURFORD, Neil** [GB/US]; 105 Wildwood Circle, Durham, CT 06422 (US).(74) Agents: **HAMLET-COX, Diana et al.**; Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

[Continued on next page]

(54) Title: HUMAN KINASES

(57) Abstract: The invention provides human kinases (PKIN) and polynucleotides which identify and encode PKIN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of PKIN.

WO 02/018557 A3



(88) Date of publication of the international search report:
12 December 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No

PL, US 01/27219

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/54 C12N9/12 C12N15/63 C12N5/10 A01K67/027
 C12P21/02 C07K16/40 C12Q1/68 A61K38/45 C12Q1/48
 G01N33/573

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

SEQUENCE SEARCH, EPO-Internal, WPI Data, PAJ, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE SWALL [Online] 1 May 1999 (1999-05-01) NARA, K.: "Serine/threonine protein kinase (EC 2.7.1.)" retrieved from EBI, accession no. Q9Z335 Database accession no. Q9Z335 XP002198514	1-4,13
Y		1-4, 6-11, 13-20, 23, 26-56,80
X	the whole document -& DATABASE EM_R0 [Online] EMBL; 8 January 1999 (1999-01-08) NARA, K.: "Rattus norvegicus sbk mRNA for serine/threonine protein kinase" retrieved from EBI, accession no. AB010154 Database accession no. AB010154 -/--	1-4,13

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

13 May 2002

Date of mailing of the international search report

2.5. 09. 2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

CEDER O.

INTERNATIONAL SEARCH REPORT

Int. Patent Application No

PL 1, US 01/27219

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>XP002198515 the whole document ---</p> <p>US 6 096 308 A (CORLEY NEIL C ET AL) 1 August 2000 (2000-08-01)</p> <p>abstract ---</p>	<p>1-4, 6-11, 13-20, 23, 26-56,80</p>
X	<p>DATABASE WPI Section Ch, Week 200022 Derwent Publications Ltd., London, GB; Class B04, AN 2000-249682 XP002198516 -& JP 2000 060571 A (MITSUBISHI CHEM CORP) , 29 February 2000 (2000-02-29)</p>	<p>1-4,6,7, 9-11, 13-20, 23, 26-45,56</p>
A	<p>the whole document especially Seq Id Nos 1 and 2 abstract ---</p>	<p>5,12,80</p>
A	<p>US 5 817 479 A (HAWKINS PHILLIP R ET AL) 6 October 1998 (1998-10-06) abstract column 8, line 19 - line 44 column 4, line 65 -column 5, line 23 ---</p>	<p>1-20,23, 26-56,80</p>
A	<p>WO 00 08180 A (MARKEN JOHN S ;ANDERSON DIRK M (US); BIRD TIMOTHY A (US); IMMUNEX) 17 February 2000 (2000-02-17) abstract; claims page 6, line 14 - line 27 ---</p>	<p>1-20,23, 26-45, 56,80</p>
A	<p>HANES J ET AL: "CHARACTERIZATION BY CDNA CLONING OF TWO NEW HUMAN PROTEIN KINASES. EVIDENCE BY SEQUENCE COMPARISON OF A NEW FAMILY OF MAMMALIAN PROTEIN KINASES" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 244, 1994, pages 665-672, XP002064038 ISSN: 0022-2836 ---</p>	
P,X	<p>WO 01 38503 A (PLOWMAN GREGORY D ;CLARY DOUGLAS (US); SUGEN INC (US); WHYTE DAVID) 31 May 2001 (2001-05-31) page 3 page 117, last line page 239, line 16 - line 21 page 258, line 1 - line 10 page 282, line 6 - line 17 page 326, line 3 - line 5 claims; figures 1X,,2I ---</p>	<p>1-20,23, 26-45, 56,80</p>

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PL, US 01/27219

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 01 88148 A (APPLERA CORP) 22 November 2001 (2001-11-22) Seq Id Nos 1 and 2 abstract; claims -----	1-20,23, 26-56,80

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-55 partially and 56 and 80 completely

An isolated polypeptide and the polynucleotide encoding it and their uses, where the polypeptide and polynucleotide are respectively Seq Id Nos 1 and 25.

2. Claims: 1-55 partially and 57 and 81 completely

An isolated polypeptide and the polynucleotide encoding it and their uses, where the polypeptide and polynucleotide are respectively Seq Id Nos 2 and 26.

3. Claims: 1-55 partially and 58 and 82 completely

An isolated polypeptide and the polynucleotide encoding it and their uses, where the polypeptide and polynucleotide are respectively Seq Id Nos 3 and 27.

4. Claims: 1-55 partially and 59 and 83 completely

An isolated polypeptide and the polynucleotide encoding it and their uses, where the polypeptide and polynucleotide are respectively Seq Id Nos 4 and 28.

5. Claims: 1-55 partially and 60 and 84 completely

An isolated polypeptide and the polynucleotide encoding it and their uses, where the polypeptide and polynucleotide are respectively Seq Id Nos 5 and 29.

6. Claims: 1-55 partially and 61 and 85 completely⁵

An isolated polypeptide and the polynucleotide encoding it and their uses, where the polypeptide and polynucleotide are respectively Seq Id Nos 6 and 30.

7. Claims: 1-55 partially and 62 and 86 completely

An isolated polypeptide and the polynucleotide encoding it and their uses, where the polypeptide and polynucleotide are respectively Seq Id Nos 7 and 31.

8. Claims: 1-55 partially and 63 and 87 completely

An isolated polypeptide and the polynucleotide encoding it

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

and their uses, where the polypeptide and polynucleotide are respectively Seq Id Nos 8 and 32.

9. Claims: 1-55 partially and 64 and 88 completely

An isolated polypeptide and the polynucleotide encoding it and their uses, where the polypeptide and polynucleotide are respectively Seq Id Nos 9 and 33.

10. Claims: 1-55 partially and 65 and 89 completely

An isolated polypeptide and the polynucleotide encoding it and their uses, where the polypeptide and polynucleotide are respectively Seq Id Nos 10 and 34.

11. Claims: 1-55 partially and 66 and 90 completely

An isolated polypeptide and the polynucleotide encoding it and their uses, where the polypeptide and polynucleotide are respectively Seq Id Nos 11 and 35.

12. Claims: 1-55 partially and 67 and 91 completely

An isolated polypeptide and the polynucleotide encoding it and their uses, where the polypeptide and polynucleotide are respectively Seq Id Nos 12 and 36.

13. Claims: 1-55 partially and 68 and 92 completely

An isolated polypeptide and the polynucleotide encoding it and their uses, where the polypeptide and polynucleotide are respectively Seq Id Nos 13 and 37.

14. Claims: 1-55 partially and 69 and 93 completely

An isolated polypeptide and the polynucleotide encoding it and their uses, where the polypeptide and polynucleotide are respectively Seq Id Nos 14 and 38.

15. Claims: 1-55 partially and 70 and 94 completely

An isolated polypeptide and the polynucleotide encoding it and their uses, where the polypeptide and polynucleotide are respectively Seq Id Nos 15 and 39.

16. Claims: 1-55 partially and 71 and 95 completely

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

An isolated polypeptide and the polynucleotide encoding it and their uses, where the polypeptide and polynucleotide are respectively Seq Id Nos 16 and 40.

17. Claims: 1-55 partially and 72 and 96 completely

An isolated polypeptide and the polynucleotide encoding it and their uses, where the polypeptide and polynucleotide are respectively Seq Id Nos 17 and 41.

18. Claims: 1-55 partially and 73 and 97 completely

An isolated polypeptide and the polynucleotide encoding it and their uses, where the polypeptide and polynucleotide are respectively Seq Id Nos 18 and 42.

19. Claims: 1-55 partially and 74 and 98 completely

An isolated polypeptide and the polynucleotide encoding it and their uses, where the polypeptide and polynucleotide are respectively Seq Id Nos 19 and 43.

20. Claims: 1-55 partially and 75 and 99 completely

An isolated polypeptide and the polynucleotide encoding it and their uses, where the polypeptide and polynucleotide are respectively Seq Id Nos 20 and 44.

21. Claims: 1-55 partially and 76 and 100 completely

An isolated polypeptide and the polynucleotide encoding it and their uses, where the polypeptide and polynucleotide are respectively Seq Id Nos 21 and 45.

22. Claims: 1-55 partially and 77 and 101 completely

An isolated polypeptide and the polynucleotide encoding it and their uses, where the polypeptide and polynucleotide are respectively Seq Id Nos 22 and 46.

23. Claims: 1-55 partially and 78 and 102 completely

An isolated polypeptide and the polynucleotide encoding it and their uses, where the polypeptide and polynucleotide are respectively Seq Id Nos 23 and 47.

24. Claims: 1-55 partially and 79 and 103 completely

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

An isolated polypeptide and the polynucleotide encoding it and their uses, where the polypeptide and polynucleotide are respectively Seq Id Nos 24 and 48.

INTERNATIONAL SEARCH REPORT

national application No.
PCT/US 01/27219

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: -
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: 21, 22, 24, 25
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-55 partially and 56 and 80 completely

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

Continuation of Box I.1

Although claims 19, 22 and 25 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Although claims 33 and 35 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

Rule 39.1(iv) PCT - Diagnostic method practised on the human or animal body

Continuation of Box I.2

Claims Nos.: 21, 22, 24, 25

Claims 21, 22, 24 and 25 refer to agonists/antagonists of the polypeptide of claim 1, identified by a method of claim 20/23, without giving a true technical characterization. Moreover, no such compounds are specifically defined in the description. It is only indicated that they "may include proteins" (such as antibodies), nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of PKIN either by directly interacting with PKIN or by acting on components of the biological pathway in which PKIN participates." (page 18 lines 18-20; page 19 lines 19-22). In consequence the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT). No search can be carried out for such claims whose wording is, in fact, a mere recitation of the results to be achieved.

Claim 8 has only been searched as far as it relates to non-human transgenic organisms.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT
information on patent family members

Int. Application No
PCT/US 01/27219

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6096308	A	01-08-2000	US 6194186 B1	27-02-2001
			AU 1456899 A	15-06-1999
			CA 2310565 A1	03-06-1999
			EP 1040187 A2	04-10-2000
			JP 2001524309 T	04-12-2001
			WO 9927080 A2	03-06-1999

JP 2000060571	A	29-02-2000	NONE	

US 5817479	A	06-10-1998	NONE	

WO 0008180	A	17-02-2000	AU 5254399 A	28-02-2000
			CA 2305308 A1	17-02-2000
			EP 1032687 A2	06-09-2000
			JP 2002524048 T	06-08-2002
			WO 0008180 A2	17-02-2000
			US 6387676 B1	14-05-2002

WO 0138503	A	31-05-2001	AU 1926001 A	04-06-2001
			EP 1240194 A2	18-09-2002
			WO 0138503 A2	31-05-2001

WO 0188148	A	22-11-2001	US 2002103116 A1	01-08-2002
			US 2002064851 A1	30-05-2002
			AU 7291001 A	26-11-2001
			WO 0188148 A2	22-11-2001
